id	sid	tid	token	lemma	pos
fnp-2627	1	1	top	top	ADJ
fnp-2627	1	2	ten	ten	NUM
fnp-2627	1	3	discoveries	discovery	NOUN
fnp-2627	1	4	of	of	ADP
fnp-2627	1	5	the	the	DET
fnp-2627	1	6	year	year	NOUN
fnp-2627	1	7	:	:	PUNCT
fnp-2627	1	8	neuromuscular	neuromuscular	ADJ
fnp-2627	1	9	disease	disease	NOUN
fnp-2627	1	10	feel	feel	VERB
fnp-2627	1	11	free	free	ADJ
fnp-2627	1	12	to	to	PART
fnp-2627	1	13	add	add	VERB
fnp-2627	1	14	comments	comment	NOUN
fnp-2627	1	15	by	by	ADP
fnp-2627	1	16	clicking	click	VERB
fnp-2627	1	17	these	these	DET
fnp-2627	1	18	icons	icon	NOUN
fnp-2627	1	19	on	on	ADP
fnp-2627	1	20	the	the	DET
fnp-2627	1	21	sidebar	sidebar	NOUN
fnp-2627	1	22	>	>	X
fnp-2627	1	23	free	free	PROPN
fnp-2627	1	24	neuropathology	neuropathology	NOUN
fnp-2627	1	25	1:4	1:4	NUM
fnp-2627	1	26	(	(	PUNCT
fnp-2627	1	27	2020	2020	NUM
fnp-2627	1	28	)	)	PUNCT
fnp-2627	1	29	review	review	VERB
fnp-2627	1	30	top	top	ADJ
fnp-2627	1	31	ten	ten	NUM
fnp-2627	1	32	discoveries	discovery	NOUN
fnp-2627	1	33	of	of	ADP
fnp-2627	1	34	the	the	DET
fnp-2627	1	35	year	year	NOUN
fnp-2627	1	36	:	:	PUNCT
fnp-2627	1	37	neuromuscular	neuromuscular	ADJ
fnp-2627	1	38	disease	disease	NOUN
fnp-2627	1	39	marta	marta	PROPN
fnp-2627	1	40	margeta	margeta	PROPN
fnp-2627	1	41	department	department	PROPN
fnp-2627	1	42	of	of	ADP
fnp-2627	1	43	pathology	pathology	PROPN
fnp-2627	1	44	,	,	PUNCT
fnp-2627	1	45	university	university	PROPN
fnp-2627	1	46	of	of	ADP
fnp-2627	1	47	california	california	PROPN
fnp-2627	1	48	,	,	PUNCT
fnp-2627	1	49	san	san	PROPN
fnp-2627	1	50	francisco	francisco	PROPN
fnp-2627	1	51	,	,	PUNCT
fnp-2627	1	52	ca	ca	PROPN
fnp-2627	1	53	,	,	PUNCT
fnp-2627	1	54	usa	usa	PROPN
fnp-2627	1	55	corresponding	corresponding	PROPN
fnp-2627	1	56	author	author	NOUN
fnp-2627	1	57	:	:	PUNCT
fnp-2627	1	58	marta	marta	PROPN
fnp-2627	1	59	margeta	margeta	PROPN
fnp-2627	1	60	·	·	PUNCT
fnp-2627	1	61	ucsf	ucsf	PROPN
fnp-2627	1	62	pathology	pathology	PROPN
fnp-2627	1	63	,	,	PUNCT
fnp-2627	1	64	box	box	PROPN
fnp-2627	1	65	0511	0511	NUM
fnp-2627	1	66	·	·	PUNCT
fnp-2627	2	1	513	513	NUM
fnp-2627	2	2	parnassus	parnassus	PROPN
fnp-2627	2	3	ave	ave	PROPN
fnp-2627	2	4	.	.	PROPN
fnp-2627	2	5	,	,	PUNCT
fnp-2627	2	6	hsw-514	hsw-514	NOUN
fnp-2627	2	7	·	·	PUNCT
fnp-2627	2	8	san	san	PROPN
fnp-2627	2	9	francisco	francisco	PROPN
fnp-2627	2	10	,	,	PUNCT
fnp-2627	2	11	ca	ca	PROPN
fnp-2627	2	12	94143	94143	NUM
fnp-2627	2	13	·	·	PUNCT
fnp-2627	3	1	usa	usa	PROPN
fnp-2627	3	2	marta.margeta@ucsf.edu	marta.margeta@ucsf.edu	PROPN
fnp-2627	3	3	submitted	submit	VERB
fnp-2627	3	4	:	:	PUNCT
fnp-2627	3	5	15	15	NUM
fnp-2627	3	6	january	january	PROPN
fnp-2627	3	7	2020	2020	NUM
fnp-2627	3	8	accepted	accept	VERB
fnp-2627	3	9	:	:	PUNCT
fnp-2627	3	10	21	21	NUM
fnp-2627	3	11	january	january	NOUN
fnp-2627	3	12	2020	2020	NUM
fnp-2627	3	13	published	publish	VERB
fnp-2627	3	14	:	:	PUNCT
fnp-2627	4	1	23	23	NUM
fnp-2627	4	2	january	january	NOUN
fnp-2627	4	3	2020	2020	NUM
fnp-2627	4	4	https://doi.org/10.17879/freeneuropathology-2020-2627	https://doi.org/10.17879/freeneuropathology-2020-2627	VERB
fnp-2627	4	5	keywords	keyword	NOUN
fnp-2627	4	6	:	:	PUNCT
fnp-2627	4	7	anterior	anterior	ADJ
fnp-2627	4	8	horn	horn	NOUN
fnp-2627	4	9	disease	disease	NOUN
fnp-2627	4	10	,	,	PUNCT
fnp-2627	4	11	congenital	congenital	ADJ
fnp-2627	4	12	myopathy	myopathy	ADJ
fnp-2627	4	13	,	,	PUNCT
fnp-2627	4	14	inflammatory	inflammatory	ADJ
fnp-2627	4	15	myopathy	myopathy	ADJ
fnp-2627	4	16	,	,	PUNCT
fnp-2627	4	17	muscular	muscular	ADJ
fnp-2627	4	18	dystrophy	dystrophy	NOUN
fnp-2627	4	19	,	,	PUNCT
fnp-2627	4	20	neuropathy	neuropathy	ADJ
fnp-2627	4	21	,	,	PUNCT
fnp-2627	4	22	radiculopathy	radiculopathy	ADJ
fnp-2627	4	23	,	,	PUNCT
fnp-2627	4	24	rna	rna	NOUN
fnp-2627	4	25	-	-	PUNCT
fnp-2627	4	26	seq	seq	NOUN
fnp-2627	4	27	,	,	PUNCT
fnp-2627	4	28	gene	gene	NOUN
fnp-2627	4	29	therapy	therapy	NOUN
fnp-2627	4	30	abstract	abstract	ADV
fnp-2627	4	31	this	this	DET
fnp-2627	4	32	review	review	NOUN
fnp-2627	4	33	highlights	highlight	VERB
fnp-2627	4	34	ten	ten	NUM
fnp-2627	4	35	important	important	ADJ
fnp-2627	4	36	advances	advance	NOUN
fnp-2627	4	37	in	in	ADP
fnp-2627	4	38	the	the	DET
fnp-2627	4	39	neuromuscular	neuromuscular	ADJ
fnp-2627	4	40	disease	disease	NOUN
fnp-2627	4	41	field	field	NOUN
fnp-2627	4	42	that	that	PRON
fnp-2627	4	43	either	either	CCONJ
fnp-2627	4	44	were	be	AUX
fnp-2627	4	45	first	first	ADV
fnp-2627	4	46	reported	report	VERB
fnp-2627	4	47	in	in	ADP
fnp-2627	4	48	2019	2019	NUM
fnp-2627	4	49	,	,	PUNCT
fnp-2627	4	50	or	or	CCONJ
fnp-2627	4	51	have	have	AUX
fnp-2627	4	52	reached	reach	VERB
fnp-2627	4	53	a	a	DET
fnp-2627	4	54	broad	broad	ADJ
fnp-2627	4	55	consensus	consensus	NOUN
fnp-2627	4	56	during	during	ADP
fnp-2627	4	57	that	that	DET
fnp-2627	4	58	year	year	NOUN
fnp-2627	4	59	.	.	PUNCT
fnp-2627	5	1	the	the	DET
fnp-2627	5	2	overarching	overarching	ADJ
fnp-2627	5	3	topics	topic	NOUN
fnp-2627	5	4	include	include	VERB
fnp-2627	5	5	(	(	PUNCT
fnp-2627	5	6	i	i	NOUN
fnp-2627	5	7	)	)	PUNCT
fnp-2627	5	8	new	new	ADJ
fnp-2627	5	9	/	/	SYM
fnp-2627	5	10	emerging	emerge	VERB
fnp-2627	5	11	diseases	disease	NOUN
fnp-2627	5	12	;	;	PUNCT
fnp-2627	5	13	(	(	PUNCT
fnp-2627	5	14	ii	ii	NOUN
fnp-2627	5	15	)	)	PUNCT
fnp-2627	5	16	advances	advance	NOUN
fnp-2627	5	17	in	in	ADP
fnp-2627	5	18	understanding	understanding	NOUN
fnp-2627	5	19	of	of	ADP
fnp-2627	5	20	disease	disease	NOUN
fnp-2627	5	21	etiology	etiology	NOUN
fnp-2627	5	22	and	and	CCONJ
fnp-2627	5	23	pathogenesis	pathogenesis	NOUN
fnp-2627	5	24	;	;	PUNCT
fnp-2627	5	25	(	(	PUNCT
fnp-2627	5	26	iii	iii	X
fnp-2627	5	27	)	)	PUNCT
fnp-2627	5	28	diagnostic	diagnostic	ADJ
fnp-2627	5	29	advances	advance	NOUN
fnp-2627	5	30	;	;	PUNCT
fnp-2627	5	31	and	and	CCONJ
fnp-2627	5	32	(	(	PUNCT
fnp-2627	5	33	iv	iv	X
fnp-2627	5	34	)	)	PUNCT
fnp-2627	5	35	therapeutic	therapeutic	ADJ
fnp-2627	5	36	advances	advance	NOUN
fnp-2627	5	37	.	.	PUNCT
fnp-2627	6	1	within	within	ADP
fnp-2627	6	2	this	this	DET
fnp-2627	6	3	broad	broad	ADJ
fnp-2627	6	4	framework	framework	NOUN
fnp-2627	6	5	,	,	PUNCT
fnp-2627	6	6	the	the	DET
fnp-2627	6	7	individual	individual	ADJ
fnp-2627	6	8	disease	disease	NOUN
fnp-2627	6	9	entities	entity	NOUN
fnp-2627	6	10	that	that	PRON
fnp-2627	6	11	are	be	AUX
fnp-2627	6	12	discussed	discuss	VERB
fnp-2627	6	13	in	in	ADP
fnp-2627	6	14	more	more	ADJ
fnp-2627	6	15	detail	detail	NOUN
fnp-2627	6	16	include	include	VERB
fnp-2627	6	17	myoglobinopathy	myoglobinopathy	ADJ
fnp-2627	6	18	,	,	PUNCT
fnp-2627	6	19	popdc3	popdc3	NOUN
fnp-2627	6	20	-	-	PUNCT
fnp-2627	6	21	mutated	mutate	VERB
fnp-2627	6	22	limb	limb	NOUN
fnp-2627	6	23	-	-	PUNCT
fnp-2627	6	24	girdle	girdle	NOUN
fnp-2627	6	25	muscular	muscular	ADJ
fnp-2627	6	26	dystrophy	dystrophy	NOUN
fnp-2627	6	27	,	,	PUNCT
fnp-2627	6	28	neuromuscular	neuromuscular	ADJ
fnp-2627	6	29	adverse	adverse	ADJ
fnp-2627	6	30	events	event	NOUN
fnp-2627	6	31	associated	associate	VERB
fnp-2627	6	32	with	with	ADP
fnp-2627	6	33	the	the	DET
fnp-2627	6	34	immune	immune	ADJ
fnp-2627	6	35	checkpoint	checkpoint	NOUN
fnp-2627	6	36	inhibition	inhibition	NOUN
fnp-2627	6	37	therapy	therapy	NOUN
fnp-2627	6	38	,	,	PUNCT
fnp-2627	6	39	neuroglial	neuroglial	ADJ
fnp-2627	6	40	stem	stem	NOUN
fnp-2627	6	41	cell	cell	NOUN
fnp-2627	6	42	-	-	PUNCT
fnp-2627	6	43	derived	derive	VERB
fnp-2627	6	44	inflammatory	inflammatory	ADJ
fnp-2627	6	45	pseudotumor	pseudotumor	NOUN
fnp-2627	6	46	of	of	ADP
fnp-2627	6	47	the	the	DET
fnp-2627	6	48	spinal	spinal	ADJ
fnp-2627	6	49	cord	cord	NOUN
fnp-2627	6	50	and	and	CCONJ
fnp-2627	6	51	spinal	spinal	ADJ
fnp-2627	6	52	cord	cord	NOUN
fnp-2627	6	53	roots	root	NOUN
fnp-2627	6	54	,	,	PUNCT
fnp-2627	6	55	acute	acute	ADJ
fnp-2627	6	56	flaccid	flaccid	ADJ
fnp-2627	6	57	myelitis	myelitis	NOUN
fnp-2627	6	58	,	,	PUNCT
fnp-2627	6	59	congenital	congenital	ADJ
fnp-2627	6	60	myopathies	myopathy	NOUN
fnp-2627	6	61	,	,	PUNCT
fnp-2627	6	62	idiopathic	idiopathic	ADJ
fnp-2627	6	63	inflammatory	inflammatory	ADJ
fnp-2627	6	64	myopathies	myopathy	NOUN
fnp-2627	6	65	(	(	PUNCT
fnp-2627	6	66	with	with	ADP
fnp-2627	6	67	particular	particular	ADJ
fnp-2627	6	68	emphasis	emphasis	NOUN
fnp-2627	6	69	on	on	ADP
fnp-2627	6	70	immune	immune	NOUN
fnp-2627	6	71	-	-	PUNCT
fnp-2627	6	72	mediated	mediate	VERB
fnp-2627	6	73	necrotizing	necrotizing	NOUN
fnp-2627	6	74	myopathies	myopathy	NOUN
fnp-2627	6	75	and	and	CCONJ
fnp-2627	6	76	sporadic	sporadic	ADJ
fnp-2627	6	77	inclusion	inclusion	NOUN
fnp-2627	6	78	body	body	NOUN
fnp-2627	6	79	myositis	myositis	PROPN
fnp-2627	6	80	)	)	PUNCT
fnp-2627	6	81	,	,	PUNCT
fnp-2627	6	82	spinal	spinal	ADJ
fnp-2627	6	83	muscular	muscular	ADJ
fnp-2627	6	84	atrophy	atrophy	NOUN
fnp-2627	6	85	,	,	PUNCT
fnp-2627	6	86	and	and	CCONJ
fnp-2627	6	87	duchenne	duchenne	VERB
fnp-2627	6	88	muscular	muscular	ADJ
fnp-2627	6	89	dystrophy	dystrophy	NOUN
fnp-2627	6	90	.	.	PUNCT
fnp-2627	7	1	in	in	ADP
fnp-2627	7	2	addition	addition	NOUN
fnp-2627	7	3	,	,	PUNCT
fnp-2627	7	4	the	the	DET
fnp-2627	7	5	review	review	NOUN
fnp-2627	7	6	highlights	highlight	VERB
fnp-2627	7	7	several	several	ADJ
fnp-2627	7	8	diagnostic	diagnostic	ADJ
fnp-2627	7	9	advances	advance	NOUN
fnp-2627	7	10	(	(	PUNCT
fnp-2627	7	11	such	such	ADJ
fnp-2627	7	12	as	as	ADP
fnp-2627	7	13	diagnostic	diagnostic	ADJ
fnp-2627	7	14	rna	rna	NOUN
fnp-2627	7	15	sequencing	sequencing	NOUN
fnp-2627	7	16	and	and	CCONJ
fnp-2627	7	17	development	development	NOUN
fnp-2627	7	18	of	of	ADP
fnp-2627	7	19	digital	digital	ADJ
fnp-2627	7	20	diagnostic	diagnostic	ADJ
fnp-2627	7	21	tools	tool	NOUN
fnp-2627	7	22	)	)	PUNCT
fnp-2627	7	23	that	that	PRON
fnp-2627	7	24	will	will	AUX
fnp-2627	7	25	likely	likely	ADV
fnp-2627	7	26	have	have	VERB
fnp-2627	7	27	a	a	DET
fnp-2627	7	28	significant	significant	ADJ
fnp-2627	7	29	impact	impact	NOUN
fnp-2627	7	30	on	on	ADP
fnp-2627	7	31	the	the	DET
fnp-2627	7	32	overall	overall	ADJ
fnp-2627	7	33	neuromuscular	neuromuscular	ADJ
fnp-2627	7	34	disease	disease	NOUN
fnp-2627	7	35	field	field	NOUN
fnp-2627	7	36	going	go	VERB
fnp-2627	7	37	forward	forward	ADV
fnp-2627	7	38	.	.	PUNCT
fnp-2627	8	1	abbreviations	abbreviation	NOUN
fnp-2627	8	2	aav	aav	PROPN
fnp-2627	8	3	,	,	PUNCT
fnp-2627	8	4	adeno	adeno	NOUN
fnp-2627	8	5	-	-	PUNCT
fnp-2627	8	6	associated	associate	VERB
fnp-2627	8	7	virus	virus	NOUN
fnp-2627	8	8	;	;	PUNCT
fnp-2627	8	9	afm	afm	PROPN
fnp-2627	8	10	,	,	PUNCT
fnp-2627	8	11	acute	acute	ADJ
fnp-2627	8	12	flaccid	flaccid	ADJ
fnp-2627	8	13	myelitis	myelitis	NOUN
fnp-2627	8	14	;	;	PUNCT
fnp-2627	8	15	ai	ai	VERB
fnp-2627	8	16	,	,	PUNCT
fnp-2627	8	17	artificial	artificial	ADJ
fnp-2627	8	18	intelligence	intelligence	NOUN
fnp-2627	8	19	;	;	PUNCT
fnp-2627	8	20	asm	asm	NOUN
fnp-2627	8	21	,	,	PUNCT
fnp-2627	8	22	antisynthetase	antisynthetase	NOUN
fnp-2627	8	23	syndrome	syndrome	NOUN
fnp-2627	8	24	-	-	PUNCT
fnp-2627	8	25	associated	associate	VERB
fnp-2627	8	26	myositis	myositis	NOUN
fnp-2627	8	27	;	;	PUNCT
fnp-2627	8	28	aso	aso	PROPN
fnp-2627	8	29	,	,	PUNCT
fnp-2627	8	30	antisense	antisense	NOUN
fnp-2627	8	31	oligonucleotide	oligonucleotide	NOUN
fnp-2627	8	32	;	;	PUNCT
fnp-2627	8	33	casa	casa	PROPN
fnp-2627	8	34	,	,	PUNCT
fnp-2627	8	35	chaperone	chaperone	NOUN
fnp-2627	8	36	-	-	PUNCT
fnp-2627	8	37	assisted	assist	VERB
fnp-2627	8	38	selective	selective	ADJ
fnp-2627	8	39	autophagy	autophagy	NOUN
fnp-2627	8	40	;	;	PUNCT
fnp-2627	8	41	dm	dm	NUM
fnp-2627	8	42	,	,	PUNCT
fnp-2627	8	43	dermatomyositis	dermatomyositis	PROPN
fnp-2627	8	44	;	;	PUNCT
fnp-2627	8	45	dmd	dmd	NOUN
fnp-2627	8	46	,	,	PUNCT
fnp-2627	8	47	duchenne	duchenne	ADJ
fnp-2627	8	48	muscular	muscular	ADJ
fnp-2627	8	49	dystrophy	dystrophy	NOUN
fnp-2627	8	50	;	;	PUNCT
fnp-2627	8	51	ema	ema	PROPN
fnp-2627	8	52	,	,	PUNCT
fnp-2627	8	53	european	european	PROPN
fnp-2627	8	54	medicines	medicine	NOUN
fnp-2627	8	55	agency	agency	NOUN
fnp-2627	8	56	;	;	PUNCT
fnp-2627	8	57	ev	ev	NOUN
fnp-2627	8	58	,	,	PUNCT
fnp-2627	8	59	enterovirus	enterovirus	NOUN
fnp-2627	8	60	;	;	PUNCT
fnp-2627	8	61	fda	fda	PROPN
fnp-2627	8	62	,	,	PUNCT
fnp-2627	8	63	federal	federal	ADJ
fnp-2627	8	64	drug	drug	NOUN
fnp-2627	8	65	administration	administration	NOUN
fnp-2627	8	66	;	;	PUNCT
fnp-2627	8	67	hmgcr	hmgcr	NOUN
fnp-2627	8	68	,	,	PUNCT
fnp-2627	8	69	3	3	NUM
fnp-2627	8	70	-	-	PUNCT
fnp-2627	8	71	hydroxy-3	hydroxy-3	NUM
fnp-2627	8	72	-	-	PUNCT
fnp-2627	8	73	methylglutaryl	methylglutaryl	ADJ
fnp-2627	8	74	-	-	PUNCT
fnp-2627	8	75	coa	coa	NOUN
fnp-2627	8	76	reductase	reductase	NOUN
fnp-2627	8	77	;	;	PUNCT
fnp-2627	8	78	ifn	ifn	PROPN
fnp-2627	8	79	,	,	PUNCT
fnp-2627	8	80	interferon	interferon	ADJ
fnp-2627	8	81	;	;	PUNCT
fnp-2627	8	82	iim	iim	PROPN
fnp-2627	8	83	,	,	PUNCT
fnp-2627	8	84	idiopathic	idiopathic	ADJ
fnp-2627	8	85	inflammatory	inflammatory	ADJ
fnp-2627	8	86	myopathy	myopathy	NOUN
fnp-2627	8	87	;	;	PUNCT
fnp-2627	8	88	imnm	imnm	PROPN
fnp-2627	8	89	,	,	PUNCT
fnp-2627	8	90	immune	immune	NOUN
fnp-2627	8	91	-	-	PUNCT
fnp-2627	8	92	mediated	mediate	VERB
fnp-2627	8	93	necrotizing	necrotizing	NOUN
fnp-2627	8	94	myopathy	myopathy	NOUN
fnp-2627	8	95	;	;	PUNCT
fnp-2627	8	96	irae	irae	NOUN
fnp-2627	8	97	,	,	PUNCT
fnp-2627	8	98	immune	immune	NOUN
fnp-2627	8	99	-	-	PUNCT
fnp-2627	8	100	related	relate	VERB
fnp-2627	8	101	adverse	adverse	ADJ
fnp-2627	8	102	event	event	NOUN
fnp-2627	8	103	secondary	secondary	ADJ
fnp-2627	8	104	to	to	ADP
fnp-2627	8	105	immune	immune	ADJ
fnp-2627	8	106	checkpoint	checkpoint	NOUN
fnp-2627	8	107	inhibition	inhibition	NOUN
fnp-2627	8	108	;	;	PUNCT
fnp-2627	8	109	irmg	irmg	NOUN
fnp-2627	8	110	,	,	PUNCT
fnp-2627	8	111	myasthenia	myasthenia	PROPN
fnp-2627	8	112	gravis	gravis	NOUN
fnp-2627	8	113	secondary	secondary	ADJ
fnp-2627	8	114	to	to	ADP
fnp-2627	8	115	immune	immune	ADJ
fnp-2627	8	116	checkpoint	checkpoint	NOUN
fnp-2627	8	117	inhibition	inhibition	NOUN
fnp-2627	8	118	;	;	PUNCT
fnp-2627	8	119	irmyositis	irmyositis	NOUN
fnp-2627	8	120	,	,	PUNCT
fnp-2627	8	121	inflammatory	inflammatory	ADJ
fnp-2627	8	122	myopathy	myopathy	ADJ
fnp-2627	8	123	secondary	secondary	ADJ
fnp-2627	8	124	to	to	ADP
fnp-2627	8	125	immune	immune	ADJ
fnp-2627	8	126	checkpoint	checkpoint	NOUN
fnp-2627	8	127	inhibition	inhibition	NOUN
fnp-2627	8	128	;	;	PUNCT
fnp-2627	8	129	irneuropathy	irneuropathy	ADJ
fnp-2627	8	130	,	,	PUNCT
fnp-2627	8	131	immune	immune	NOUN
fnp-2627	8	132	-	-	PUNCT
fnp-2627	8	133	mediated	mediate	VERB
fnp-2627	8	134	neuropathy	neuropathy	ADJ
fnp-2627	8	135	secondary	secondary	ADJ
fnp-2627	8	136	to	to	ADP
fnp-2627	8	137	immune	immune	ADJ
fnp-2627	8	138	checkpoint	checkpoint	NOUN
fnp-2627	8	139	inhibition	inhibition	NOUN
fnp-2627	8	140	;	;	PUNCT
fnp-2627	8	141	mhc	mhc	NOUN
fnp-2627	8	142	,	,	PUNCT
fnp-2627	8	143	major	major	ADJ
fnp-2627	8	144	histocompatibility	histocompatibility	NOUN
fnp-2627	8	145	complex	complex	NOUN
fnp-2627	8	146	;	;	PUNCT
fnp-2627	8	147	mngs	mng	NOUN
fnp-2627	8	148	,	,	PUNCT
fnp-2627	8	149	metagenomic	metagenomic	ADJ
fnp-2627	8	150	next	next	ADJ
fnp-2627	8	151	generation	generation	NOUN
fnp-2627	8	152	sequencing	sequencing	NOUN
fnp-2627	8	153	;	;	PUNCT
fnp-2627	8	154	msa	msa	PROPN
fnp-2627	8	155	,	,	PUNCT
fnp-2627	8	156	myositis	myositis	NOUN
fnp-2627	8	157	-	-	PUNCT
fnp-2627	8	158	specific	specific	ADJ
fnp-2627	8	159	antibodies	antibody	NOUN
fnp-2627	8	160	;	;	PUNCT
fnp-2627	8	161	mxa	mxa	NOUN
fnp-2627	8	162	,	,	PUNCT
fnp-2627	8	163	myxovirus	myxovirus	NOUN
fnp-2627	8	164	resistance	resistance	NOUN
fnp-2627	8	165	protein	protein	NOUN
fnp-2627	8	166	a	a	PRON
fnp-2627	8	167	;	;	PUNCT
fnp-2627	8	168	nm	nm	ADJ
fnp-2627	8	169	,	,	PUNCT
fnp-2627	8	170	nemaline	nemaline	ADJ
fnp-2627	8	171	myopathy	myopathy	ADJ
fnp-2627	8	172	;	;	PUNCT
fnp-2627	8	173	nmd	nmd	NUM
fnp-2627	8	174	,	,	PUNCT
fnp-2627	8	175	neuromuscular	neuromuscular	ADJ
fnp-2627	8	176	disease	disease	NOUN
fnp-2627	8	177	;	;	PUNCT
fnp-2627	8	178	n	n	CCONJ
fnp-2627	8	179	-	-	PUNCT
fnp-2627	8	180	scipt	scipt	NOUN
fnp-2627	8	181	,	,	PUNCT
fnp-2627	8	182	neuroglial	neuroglial	ADJ
fnp-2627	8	183	stem	stem	NOUN
fnp-2627	8	184	cell	cell	NOUN
fnp-2627	8	185	-	-	PUNCT
fnp-2627	8	186	derived	derive	VERB
fnp-2627	8	187	inflammatory	inflammatory	ADJ
fnp-2627	8	188	pseudotumor	pseudotumor	NOUN
fnp-2627	8	189	;	;	PUNCT
fnp-2627	8	190	pm	pm	NOUN
fnp-2627	8	191	,	,	PUNCT
fnp-2627	8	192	polymyositis	polymyositis	PROPN
fnp-2627	8	193	;	;	PUNCT
fnp-2627	8	194	rna	rna	PROPN
fnp-2627	8	195	-	-	PUNCT
fnp-2627	8	196	seq	seq	NOUN
fnp-2627	8	197	,	,	PUNCT
fnp-2627	8	198	transcriptome	transcriptome	ADJ
fnp-2627	8	199	analysis	analysis	NOUN
fnp-2627	8	200	(	(	PUNCT
fnp-2627	8	201	rna	rna	NOUN
fnp-2627	8	202	sequencing	sequencing	NOUN
fnp-2627	8	203	)	)	PUNCT
fnp-2627	8	204	;	;	PUNCT
fnp-2627	8	205	sibm	sibm	NOUN
fnp-2627	8	206	,	,	PUNCT
fnp-2627	8	207	sporadic	sporadic	ADJ
fnp-2627	8	208	inclusion	inclusion	NOUN
fnp-2627	8	209	body	body	NOUN
fnp-2627	8	210	myositis	myositis	NOUN
fnp-2627	8	211	;	;	PUNCT
fnp-2627	8	212	sma	sma	NOUN
fnp-2627	8	213	,	,	PUNCT
fnp-2627	8	214	spinal	spinal	ADJ
fnp-2627	8	215	muscular	muscular	ADJ
fnp-2627	8	216	atrophy	atrophy	NOUN
fnp-2627	8	217	;	;	PUNCT
fnp-2627	8	218	srp	srp	PROPN
fnp-2627	8	219	,	,	PUNCT
fnp-2627	8	220	signal	signal	ADJ
fnp-2627	8	221	recognition	recognition	NOUN
fnp-2627	8	222	particle	particle	NOUN
fnp-2627	8	223	;	;	PUNCT
fnp-2627	8	224	temra	temra	NOUN
fnp-2627	8	225	cells	cell	NOUN
fnp-2627	8	226	,	,	PUNCT
fnp-2627	8	227	terminally	terminally	ADV
fnp-2627	8	228	differentiated	differentiate	VERB
fnp-2627	8	229	effector	effector	NOUN
fnp-2627	8	230	memory	memory	NOUN
fnp-2627	8	231	t	t	NOUN
fnp-2627	8	232	cells	cell	NOUN
fnp-2627	8	233	;	;	PUNCT
fnp-2627	8	234	wes	wes	PROPN
fnp-2627	8	235	,	,	PUNCT
fnp-2627	8	236	whole	whole	ADJ
fnp-2627	8	237	exome	exome	NOUN
fnp-2627	8	238	sequencing	sequence	VERB
fnp-2627	8	239	introduction	introduction	NOUN
fnp-2627	8	240	2019	2019	NUM
fnp-2627	8	241	was	be	AUX
fnp-2627	8	242	an	an	DET
fnp-2627	8	243	exciting	exciting	ADJ
fnp-2627	8	244	year	year	NOUN
fnp-2627	8	245	for	for	ADP
fnp-2627	8	246	the	the	DET
fnp-2627	8	247	neuromuscular	neuromuscular	ADJ
fnp-2627	8	248	disease	disease	NOUN
fnp-2627	8	249	(	(	PUNCT
fnp-2627	8	250	nmd	nmd	NOUN
fnp-2627	8	251	)	)	PUNCT
fnp-2627	8	252	field	field	NOUN
fnp-2627	8	253	,	,	PUNCT
fnp-2627	8	254	with	with	ADP
fnp-2627	8	255	important	important	ADJ
fnp-2627	8	256	developments	development	NOUN
fnp-2627	8	257	on	on	ADP
fnp-2627	8	258	multiple	multiple	ADJ
fnp-2627	8	259	fronts	front	NOUN
fnp-2627	8	260	and	and	CCONJ
fnp-2627	8	261	in	in	ADP
fnp-2627	8	262	many	many	ADJ
fnp-2627	8	263	different	different	ADJ
fnp-2627	8	264	disease	disease	NOUN
fnp-2627	8	265	categories	category	NOUN
fnp-2627	8	266	.	.	PUNCT
fnp-2627	9	1	in	in	ADP
fnp-2627	9	2	this	this	DET
fnp-2627	9	3	review	review	NOUN
fnp-2627	9	4	paper	paper	NOUN
fnp-2627	9	5	,	,	PUNCT
fnp-2627	9	6	i	i	PRON
fnp-2627	9	7	will	will	AUX
fnp-2627	9	8	summarize	summarize	VERB
fnp-2627	9	9	ten	ten	NUM
fnp-2627	9	10	2019	2019	NUM
fnp-2627	9	11	nmd	nmd	NOUN
fnp-2627	9	12	discoveries	discovery	NOUN
fnp-2627	9	13	that	that	PRON
fnp-2627	9	14	i	i	PRON
fnp-2627	9	15	consider	consider	VERB
fnp-2627	9	16	to	to	PART
fnp-2627	9	17	be	be	AUX
fnp-2627	9	18	most	most	ADV
fnp-2627	9	19	important	important	ADJ
fnp-2627	9	20	and/or	and/or	CCONJ
fnp-2627	9	21	interesting	interesting	ADJ
fnp-2627	9	22	;	;	PUNCT
fnp-2627	9	23	they	they	PRON
fnp-2627	9	24	are	be	AUX
fnp-2627	9	25	grouped	group	VERB
fnp-2627	9	26	in	in	ADP
fnp-2627	9	27	four	four	NUM
fnp-2627	9	28	different	different	ADJ
fnp-2627	9	29	“	"	PUNCT
fnp-2627	9	30	discovery	discovery	NOUN
fnp-2627	9	31	clusters	cluster	NOUN
fnp-2627	9	32	”	"	PUNCT
fnp-2627	9	33	and	and	CCONJ
fnp-2627	9	34	listed	list	VERB
fnp-2627	9	35	in	in	ADP
fnp-2627	9	36	no	no	DET
fnp-2627	9	37	particular	particular	ADJ
fnp-2627	9	38	order	order	NOUN
fnp-2627	9	39	.	.	PUNCT
fnp-2627	10	1	(	(	PUNCT
fnp-2627	10	2	like	like	ADP
fnp-2627	10	3	most	most	ADJ
fnp-2627	10	4	classifications	classification	NOUN
fnp-2627	10	5	,	,	PUNCT
fnp-2627	10	6	this	this	DET
fnp-2627	10	7	one	one	NOUN
fnp-2627	10	8	is	be	AUX
fnp-2627	10	9	not	not	PART
fnp-2627	10	10	perfect	perfect	ADJ
fnp-2627	10	11	–	–	PUNCT
fnp-2627	10	12	a	a	DET
fnp-2627	10	13	few	few	ADJ
fnp-2627	10	14	discoveries	discovery	NOUN
fnp-2627	10	15	included	include	VERB
fnp-2627	10	16	in	in	ADP
fnp-2627	10	17	the	the	DET
fnp-2627	10	18	“	"	PUNCT
fnp-2627	10	19	etiology	etiology	NOUN
fnp-2627	10	20	/	/	SYM
fnp-2627	10	21	pathogenesis	pathogenesis	NOUN
fnp-2627	10	22	cluster	cluster	NOUN
fnp-2627	10	23	”	"	PUNCT
fnp-2627	10	24	have	have	VERB
fnp-2627	10	25	direct	direct	ADJ
fnp-2627	10	26	implications	implication	NOUN
fnp-2627	10	27	for	for	ADP
fnp-2627	10	28	diagnostics	diagnostic	NOUN
fnp-2627	10	29	and/or	and/or	CCONJ
fnp-2627	10	30	treatment	treatment	NOUN
fnp-2627	10	31	of	of	ADP
fnp-2627	10	32	nmds	nmds	NOUN
fnp-2627	10	33	–	–	PUNCT
fnp-2627	10	34	but	but	CCONJ
fnp-2627	10	35	i	i	PRON
fnp-2627	10	36	hope	hope	VERB
fnp-2627	10	37	it	it	PRON
fnp-2627	10	38	will	will	AUX
fnp-2627	10	39	improve	improve	VERB
fnp-2627	10	40	the	the	DET
fnp-2627	10	41	overall	overall	ADJ
fnp-2627	10	42	readability	readability	NOUN
fnp-2627	10	43	of	of	ADP
fnp-2627	10	44	the	the	DET
fnp-2627	10	45	review	review	NOUN
fnp-2627	10	46	.	.	PUNCT
fnp-2627	10	47	)	)	PUNCT
fnp-2627	11	1	newly	newly	ADV
fnp-2627	11	2	defined	define	VERB
fnp-2627	11	3	/	/	SYM
fnp-2627	11	4	emerging	emerge	VERB
fnp-2627	11	5	neuromuscular	neuromuscular	ADJ
fnp-2627	11	6	diseases	disease	NOUN
fnp-2627	11	7	1	1	NUM
fnp-2627	11	8	.	.	PUNCT
fnp-2627	11	9	newly	newly	ADV
fnp-2627	11	10	defined	define	VERB
fnp-2627	11	11	genetic	genetic	ADJ
fnp-2627	11	12	diseases	disease	NOUN
fnp-2627	11	13	even	even	ADV
fnp-2627	11	14	as	as	ADP
fnp-2627	11	15	our	our	PRON
fnp-2627	11	16	understanding	understanding	NOUN
fnp-2627	11	17	of	of	ADP
fnp-2627	11	18	the	the	DET
fnp-2627	11	19	nmd	nmd	PROPN
fnp-2627	11	20	genetics	genetic	NOUN
fnp-2627	11	21	inches	inch	NOUN
fnp-2627	11	22	closer	close	ADV
fnp-2627	11	23	to	to	ADP
fnp-2627	11	24	completion	completion	NOUN
fnp-2627	11	25	,	,	PUNCT
fnp-2627	11	26	new	new	ADJ
fnp-2627	11	27	genetic	genetic	ADJ
fnp-2627	11	28	nmds	nmds	NOUN
fnp-2627	11	29	continue	continue	VERB
fnp-2627	11	30	to	to	PART
fnp-2627	11	31	be	be	AUX
fnp-2627	11	32	defined	define	VERB
fnp-2627	11	33	;	;	PUNCT
fnp-2627	11	34	in	in	ADP
fnp-2627	11	35	this	this	DET
fnp-2627	11	36	review	review	NOUN
fnp-2627	11	37	,	,	PUNCT
fnp-2627	11	38	i	i	PRON
fnp-2627	11	39	will	will	AUX
fnp-2627	11	40	summarize	summarize	VERB
fnp-2627	11	41	key	key	ADJ
fnp-2627	11	42	features	feature	NOUN
fnp-2627	11	43	of	of	ADP
fnp-2627	11	44	two	two	NUM
fnp-2627	11	45	particularly	particularly	ADV
fnp-2627	11	46	interesting	interesting	ADJ
fnp-2627	11	47	entities	entity	NOUN
fnp-2627	11	48	that	that	PRON
fnp-2627	11	49	were	be	AUX
fnp-2627	11	50	first	first	ADV
fnp-2627	11	51	characterized	characterize	VERB
fnp-2627	11	52	in	in	ADP
fnp-2627	11	53	2019	2019	NUM
fnp-2627	11	54	.	.	PUNCT
fnp-2627	12	1	myoglobinopathy	myoglobinopathy	ADJ
fnp-2627	12	2	is	be	AUX
fnp-2627	12	3	caused	cause	VERB
fnp-2627	12	4	by	by	ADP
fnp-2627	12	5	the	the	DET
fnp-2627	12	6	c.292c	c.292c	PROPN
fnp-2627	12	7	>	>	SYM
fnp-2627	12	8	t	t	PROPN
fnp-2627	12	9	,	,	PUNCT
fnp-2627	12	10	p.his98tyr	p.his98tyr	NOUN
fnp-2627	12	11	mutation	mutation	NOUN
fnp-2627	12	12	in	in	ADP
fnp-2627	12	13	myoglobin	myoglobin	NOUN
fnp-2627	12	14	,	,	PUNCT
fnp-2627	12	15	a	a	DET
fnp-2627	12	16	small	small	ADJ
fnp-2627	12	17	cytoplasmic	cytoplasmic	NOUN
fnp-2627	12	18	hemoprotein	hemoprotein	NOUN
fnp-2627	12	19	that	that	SCONJ
fnp-2627	12	20	buffers	buffer	NOUN
fnp-2627	12	21	intracellular	intracellular	ADJ
fnp-2627	12	22	o2	o2	ADJ
fnp-2627	12	23	concentration	concentration	NOUN
fnp-2627	12	24	and	and	CCONJ
fnp-2627	12	25	regulates	regulate	VERB
fnp-2627	12	26	the	the	DET
fnp-2627	12	27	intracellular	intracellular	ADJ
fnp-2627	12	28	redox	redox	ADJ
fnp-2627	12	29	potential	potential	NOUN
fnp-2627	12	30	in	in	ADP
fnp-2627	12	31	cardiomyocytes	cardiomyocyte	NOUN
fnp-2627	12	32	and	and	CCONJ
fnp-2627	12	33	type	type	NOUN
fnp-2627	12	34	1	1	NUM
fnp-2627	12	35	muscle	muscle	NOUN
fnp-2627	12	36	fibers	fiber	NOUN
fnp-2627	12	37	(	(	PUNCT
fnp-2627	12	38	olive	olive	NOUN
fnp-2627	12	39	et	et	PROPN
fnp-2627	12	40	al	al	PROPN
fnp-2627	12	41	.	.	PROPN
fnp-2627	12	42	,	,	PUNCT
fnp-2627	12	43	2019	2019	NUM
fnp-2627	12	44	)	)	PUNCT
fnp-2627	12	45	.	.	PUNCT
fnp-2627	13	1	through	through	ADP
fnp-2627	13	2	an	an	DET
fnp-2627	13	3	effort	effort	NOUN
fnp-2627	13	4	that	that	PRON
fnp-2627	13	5	involved	involve	VERB
fnp-2627	13	6	two	two	NUM
fnp-2627	13	7	research	research	NOUN
fnp-2627	13	8	teams	team	NOUN
fnp-2627	13	9	on	on	ADP
fnp-2627	13	10	two	two	NUM
fnp-2627	13	11	different	different	ADJ
fnp-2627	13	12	continents	continent	NOUN
fnp-2627	13	13	,	,	PUNCT
fnp-2627	13	14	this	this	DET
fnp-2627	13	15	mutation	mutation	NOUN
fnp-2627	13	16	was	be	AUX
fnp-2627	13	17	detected	detect	VERB
fnp-2627	13	18	in	in	ADP
fnp-2627	13	19	14	14	NUM
fnp-2627	13	20	individuals	individual	NOUN
fnp-2627	13	21	from	from	ADP
fnp-2627	13	22	six	six	NUM
fnp-2627	13	23	different	different	ADJ
fnp-2627	13	24	families	family	NOUN
fnp-2627	13	25	,	,	PUNCT
fnp-2627	13	26	all	all	PRON
fnp-2627	13	27	of	of	ADP
fnp-2627	13	28	whom	whom	PRON
fnp-2627	13	29	were	be	AUX
fnp-2627	13	30	initially	initially	ADV
fnp-2627	13	31	identified	identify	VERB
fnp-2627	13	32	based	base	VERB
fnp-2627	13	33	on	on	ADP
fnp-2627	13	34	the	the	DET
fnp-2627	13	35	unique	unique	ADJ
fnp-2627	13	36	clinicopathologic	clinicopathologic	ADJ
fnp-2627	13	37	features	feature	NOUN
fnp-2627	13	38	of	of	ADP
fnp-2627	13	39	their	their	PRON
fnp-2627	13	40	disease	disease	NOUN
fnp-2627	13	41	.	.	PUNCT
fnp-2627	14	1	clinically	clinically	ADV
fnp-2627	14	2	,	,	PUNCT
fnp-2627	14	3	myoglobinopathy	myoglobinopathy	ADJ
fnp-2627	14	4	presents	present	NOUN
fnp-2627	14	5	with	with	ADP
fnp-2627	14	6	a	a	DET
fnp-2627	14	7	weakness	weakness	NOUN
fnp-2627	14	8	of	of	ADP
fnp-2627	14	9	the	the	DET
fnp-2627	14	10	proximal	proximal	ADJ
fnp-2627	14	11	lower	low	ADJ
fnp-2627	14	12	limb	limb	NOUN
fnp-2627	14	13	and	and	CCONJ
fnp-2627	14	14	axial	axial	ADJ
fnp-2627	14	15	muscles	muscle	NOUN
fnp-2627	14	16	;	;	PUNCT
fnp-2627	14	17	the	the	DET
fnp-2627	14	18	symptoms	symptom	NOUN
fnp-2627	14	19	start	start	VERB
fnp-2627	14	20	in	in	ADP
fnp-2627	14	21	the	the	DET
fnp-2627	14	22	fourth	fourth	ADJ
fnp-2627	14	23	to	to	PART
fnp-2627	14	24	fifth	fifth	ADJ
fnp-2627	14	25	decade	decade	NOUN
fnp-2627	14	26	and	and	CCONJ
fnp-2627	14	27	are	be	AUX
fnp-2627	14	28	slowly	slowly	ADV
fnp-2627	14	29	progressive	progressive	ADJ
fnp-2627	14	30	,	,	PUNCT
fnp-2627	14	31	ultimately	ultimately	ADV
fnp-2627	14	32	involving	involve	VERB
fnp-2627	14	33	distal	distal	ADJ
fnp-2627	14	34	lower	low	ADJ
fnp-2627	14	35	limb	limb	NOUN
fnp-2627	14	36	,	,	PUNCT
fnp-2627	14	37	upper	upper	ADJ
fnp-2627	14	38	limb	limb	NOUN
fnp-2627	14	39	,	,	PUNCT
fnp-2627	14	40	and	and	CCONJ
fnp-2627	14	41	respiratory	respiratory	ADJ
fnp-2627	14	42	muscles	muscle	NOUN
fnp-2627	14	43	.	.	PUNCT
fnp-2627	15	1	creatine	creatine	PROPN
fnp-2627	15	2	kinase	kinase	PROPN
fnp-2627	15	3	levels	level	NOUN
fnp-2627	15	4	are	be	AUX
fnp-2627	15	5	usually	usually	ADV
fnp-2627	15	6	normal	normal	ADJ
fnp-2627	15	7	,	,	PUNCT
fnp-2627	15	8	while	while	SCONJ
fnp-2627	15	9	cardiac	cardiac	ADJ
fnp-2627	15	10	involvement	involvement	NOUN
fnp-2627	15	11	is	be	AUX
fnp-2627	15	12	clinically	clinically	ADV
fnp-2627	15	13	apparent	apparent	ADJ
fnp-2627	15	14	in	in	ADP
fnp-2627	15	15	approximately	approximately	ADV
fnp-2627	15	16	half	half	NOUN
fnp-2627	15	17	of	of	ADP
fnp-2627	15	18	the	the	DET
fnp-2627	15	19	affected	affected	ADJ
fnp-2627	15	20	individuals	individual	NOUN
fnp-2627	15	21	.	.	PUNCT
fnp-2627	16	1	pathologically	pathologically	ADV
fnp-2627	16	2	,	,	PUNCT
fnp-2627	16	3	all	all	DET
fnp-2627	16	4	muscle	muscle	NOUN
fnp-2627	16	5	biopsies	biopsy	NOUN
fnp-2627	16	6	(	(	PUNCT
fnp-2627	16	7	as	as	ADV
fnp-2627	16	8	well	well	ADV
fnp-2627	16	9	as	as	ADP
fnp-2627	16	10	the	the	DET
fnp-2627	16	11	hearts	heart	NOUN
fnp-2627	16	12	from	from	ADP
fnp-2627	16	13	two	two	NUM
fnp-2627	16	14	individuals	individual	NOUN
fnp-2627	16	15	who	who	PRON
fnp-2627	16	16	underwent	undergo	VERB
fnp-2627	16	17	autopsy	autopsy	NOUN
fnp-2627	16	18	)	)	PUNCT
fnp-2627	16	19	showed	show	VERB
fnp-2627	16	20	characteristic	characteristic	ADJ
fnp-2627	16	21	sarcoplasmic	sarcoplasmic	NOUN
fnp-2627	16	22	bodies	body	NOUN
fnp-2627	16	23	that	that	PRON
fnp-2627	16	24	are	be	AUX
fnp-2627	16	25	brown	brown	ADJ
fnp-2627	16	26	on	on	ADP
fnp-2627	16	27	h&e	h&e	PROPN
fnp-2627	16	28	stain	stain	NOUN
fnp-2627	16	29	,	,	PUNCT
fnp-2627	16	30	red	red	ADJ
fnp-2627	16	31	on	on	ADP
fnp-2627	16	32	modified	modify	VERB
fnp-2627	16	33	gomori	gomori	PROPN
fnp-2627	16	34	trichrome	trichrome	NOUN
fnp-2627	16	35	stain	stain	NOUN
fnp-2627	16	36	,	,	PUNCT
fnp-2627	16	37	and	and	CCONJ
fnp-2627	16	38	highly	highly	ADV
fnp-2627	16	39	electron	electron	VERB
fnp-2627	16	40	dense	dense	ADJ
fnp-2627	16	41	on	on	ADP
fnp-2627	16	42	electron	electron	NOUN
fnp-2627	16	43	microscopy	microscopy	NOUN
fnp-2627	16	44	(	(	PUNCT
fnp-2627	16	45	fig	fig	NOUN
fnp-2627	16	46	.	.	NOUN
fnp-2627	16	47	1	1	NUM
fnp-2627	16	48	)	)	PUNCT
fnp-2627	16	49	;	;	PUNCT
fnp-2627	16	50	interestingly	interestingly	ADV
fnp-2627	16	51	,	,	PUNCT
fnp-2627	16	52	these	these	DET
fnp-2627	16	53	sarcoplasmic	sarcoplasmic	ADJ
fnp-2627	16	54	inclusions	inclusion	NOUN
fnp-2627	16	55	rarely	rarely	ADV
fnp-2627	16	56	contain	contain	VERB
fnp-2627	16	57	myoglobin	myoglobin	NOUN
fnp-2627	16	58	and	and	CCONJ
fnp-2627	16	59	seem	seem	VERB
fnp-2627	16	60	to	to	PART
fnp-2627	16	61	be	be	AUX
fnp-2627	16	62	a	a	DET
fnp-2627	16	63	product	product	NOUN
fnp-2627	16	64	of	of	ADP
fnp-2627	16	65	increased	increase	VERB
fnp-2627	16	66	lipid	lipid	NOUN
fnp-2627	16	67	oxidation	oxidation	NOUN
fnp-2627	16	68	.	.	PUNCT
fnp-2627	17	1	(	(	PUNCT
fnp-2627	17	2	late	late	ADJ
fnp-2627	17	3	stage	stage	NOUN
fnp-2627	17	4	biopsies	biopsy	NOUN
fnp-2627	17	5	also	also	ADV
fnp-2627	17	6	show	show	VERB
fnp-2627	17	7	chronic	chronic	ADJ
fnp-2627	17	8	myopathic	myopathic	ADJ
fnp-2627	17	9	changes	change	NOUN
fnp-2627	17	10	and	and	CCONJ
fnp-2627	17	11	autophagic	autophagic	ADJ
fnp-2627	17	12	impairment	impairment	NOUN
fnp-2627	17	13	including	include	VERB
fnp-2627	17	14	rimmed	rimmed	ADJ
fnp-2627	17	15	vacuoles	vacuole	NOUN
fnp-2627	17	16	.	.	PUNCT
fnp-2627	17	17	)	)	PUNCT
fnp-2627	18	1	although	although	SCONJ
fnp-2627	18	2	additional	additional	ADJ
fnp-2627	18	3	work	work	NOUN
fnp-2627	18	4	will	will	AUX
fnp-2627	18	5	be	be	AUX
fnp-2627	18	6	required	require	VERB
fnp-2627	18	7	to	to	PART
fnp-2627	18	8	fully	fully	ADV
fnp-2627	18	9	elucidate	elucidate	VERB
fnp-2627	18	10	the	the	DET
fnp-2627	18	11	molecular	molecular	ADJ
fnp-2627	18	12	mechanisms	mechanism	NOUN
fnp-2627	18	13	underlying	underlie	VERB
fnp-2627	18	14	this	this	DET
fnp-2627	18	15	newly	newly	ADV
fnp-2627	18	16	defined	define	VERB
fnp-2627	18	17	disease	disease	NOUN
fnp-2627	18	18	,	,	PUNCT
fnp-2627	18	19	the	the	DET
fnp-2627	18	20	initial	initial	ADJ
fnp-2627	18	21	biochemical	biochemical	ADJ
fnp-2627	18	22	experiments	experiment	NOUN
fnp-2627	18	23	suggest	suggest	VERB
fnp-2627	18	24	that	that	SCONJ
fnp-2627	18	25	mutant	mutant	ADJ
fnp-2627	18	26	myoglobin	myoglobin	NOUN
fnp-2627	18	27	is	be	AUX
fnp-2627	18	28	more	more	ADV
fnp-2627	18	29	prone	prone	ADJ
fnp-2627	18	30	to	to	ADP
fnp-2627	18	31	the	the	DET
fnp-2627	18	32	loss	loss	NOUN
fnp-2627	18	33	of	of	ADP
fnp-2627	18	34	the	the	DET
fnp-2627	18	35	heme	heme	NOUN
fnp-2627	18	36	moiety	moiety	NOUN
fnp-2627	18	37	and	and	CCONJ
fnp-2627	18	38	is	be	AUX
fnp-2627	18	39	associated	associate	VERB
fnp-2627	18	40	with	with	ADP
fnp-2627	18	41	elevated	elevated	ADJ
fnp-2627	18	42	intracellular	intracellular	ADJ
fnp-2627	18	43	superoxide	superoxide	NOUN
fnp-2627	18	44	levels	level	NOUN
fnp-2627	18	45	,	,	PUNCT
fnp-2627	18	46	suggesting	suggest	VERB
fnp-2627	18	47	that	that	SCONJ
fnp-2627	18	48	impaired	impaired	ADJ
fnp-2627	18	49	redox	redox	NOUN
fnp-2627	18	50	balance	balance	NOUN
fnp-2627	18	51	plays	play	VERB
fnp-2627	18	52	a	a	DET
fnp-2627	18	53	role	role	NOUN
fnp-2627	18	54	in	in	ADP
fnp-2627	18	55	the	the	DET
fnp-2627	18	56	pathogenesis	pathogenesis	NOUN
fnp-2627	18	57	of	of	ADP
fnp-2627	18	58	this	this	DET
fnp-2627	18	59	disease	disease	NOUN
fnp-2627	18	60	.	.	PUNCT
fnp-2627	19	1	figure	figure	NOUN
fnp-2627	19	2	1	1	NUM
fnp-2627	19	3	.	.	PUNCT
fnp-2627	20	1	ultrastructural	ultrastructural	ADJ
fnp-2627	20	2	characterization	characterization	NOUN
fnp-2627	20	3	of	of	ADP
fnp-2627	20	4	sarcoplasmic	sarcoplasmic	ADJ
fnp-2627	20	5	bodies	body	NOUN
fnp-2627	20	6	,	,	PUNCT
fnp-2627	20	7	the	the	DET
fnp-2627	20	8	morphological	morphological	ADJ
fnp-2627	20	9	hallmark	hallmark	NOUN
fnp-2627	20	10	of	of	ADP
fnp-2627	20	11	myoglobinopathy	myoglobinopathy	ADJ
fnp-2627	20	12	:	:	PUNCT
fnp-2627	20	13	electron	electron	NOUN
fnp-2627	20	14	micrographs	micrograph	NOUN
fnp-2627	20	15	(	(	PUNCT
fnp-2627	20	16	a	a	PRON
fnp-2627	20	17	–	–	PUNCT
fnp-2627	20	18	d	d	NOUN
fnp-2627	20	19	)	)	PUNCT
fnp-2627	20	20	show	show	NOUN
fnp-2627	20	21	collections	collection	NOUN
fnp-2627	20	22	of	of	ADP
fnp-2627	20	23	highly	highly	ADV
fnp-2627	20	24	electron	electron	NOUN
fnp-2627	20	25	-	-	PUNCT
fnp-2627	20	26	dense	dense	ADJ
fnp-2627	20	27	bodies	body	NOUN
fnp-2627	20	28	with	with	ADP
fnp-2627	20	29	some	some	DET
fnp-2627	20	30	less	less	ADV
fnp-2627	20	31	dense	dense	ADJ
fnp-2627	20	32	material	material	NOUN
fnp-2627	20	33	at	at	ADP
fnp-2627	20	34	their	their	PRON
fnp-2627	20	35	periphery	periphery	NOUN
fnp-2627	20	36	.	.	PUNCT
fnp-2627	21	1	the	the	DET
fnp-2627	21	2	sarcoplasmic	sarcoplasmic	ADJ
fnp-2627	21	3	bodies	body	NOUN
fnp-2627	21	4	are	be	AUX
fnp-2627	21	5	seen	see	VERB
fnp-2627	21	6	under	under	ADP
fnp-2627	21	7	the	the	DET
fnp-2627	21	8	sarcolemma	sarcolemma	NOUN
fnp-2627	21	9	(	(	PUNCT
fnp-2627	21	10	a	a	NOUN
fnp-2627	21	11	)	)	PUNCT
fnp-2627	21	12	,	,	PUNCT
fnp-2627	21	13	often	often	ADV
fnp-2627	21	14	next	next	ADV
fnp-2627	21	15	to	to	ADP
fnp-2627	21	16	the	the	DET
fnp-2627	21	17	nuclei	nucleus	NOUN
fnp-2627	21	18	.	.	PUNCT
fnp-2627	22	1	some	some	DET
fnp-2627	22	2	sarcoplasmic	sarcoplasmic	ADJ
fnp-2627	22	3	bodies	body	NOUN
fnp-2627	22	4	are	be	AUX
fnp-2627	22	5	surrounded	surround	VERB
fnp-2627	22	6	by	by	ADP
fnp-2627	22	7	a	a	DET
fnp-2627	22	8	membrane	membrane	NOUN
fnp-2627	22	9	(	(	PUNCT
fnp-2627	22	10	b	b	NOUN
fnp-2627	22	11	)	)	PUNCT
fnp-2627	22	12	.	.	PUNCT
fnp-2627	23	1	sarcoplasmic	sarcoplasmic	ADJ
fnp-2627	23	2	bodies	body	NOUN
fnp-2627	23	3	of	of	ADP
fnp-2627	23	4	different	different	ADJ
fnp-2627	23	5	electron	electron	NOUN
fnp-2627	23	6	densities	density	NOUN
fnp-2627	23	7	are	be	AUX
fnp-2627	23	8	seen	see	VERB
fnp-2627	23	9	near	near	ADP
fnp-2627	23	10	several	several	ADJ
fnp-2627	23	11	vesicular	vesicular	ADJ
fnp-2627	23	12	structures	structure	NOUN
fnp-2627	23	13	(	(	PUNCT
fnp-2627	23	14	c	c	NOUN
fnp-2627	23	15	)	)	PUNCT
fnp-2627	23	16	and	and	CCONJ
fnp-2627	23	17	were	be	AUX
fnp-2627	23	18	observed	observe	VERB
fnp-2627	23	19	in	in	ADP
fnp-2627	23	20	the	the	DET
fnp-2627	23	21	cardiac	cardiac	ADJ
fnp-2627	23	22	muscle	muscle	NOUN
fnp-2627	23	23	obtained	obtain	VERB
fnp-2627	23	24	post	post	NOUN
fnp-2627	23	25	mortem	mortem	NOUN
fnp-2627	23	26	from	from	ADP
fnp-2627	23	27	one	one	NUM
fnp-2627	23	28	of	of	ADP
fnp-2627	23	29	the	the	DET
fnp-2627	23	30	affected	affected	ADJ
fnp-2627	23	31	individuals	individual	NOUN
fnp-2627	23	32	(	(	PUNCT
fnp-2627	23	33	d	d	NOUN
fnp-2627	23	34	)	)	PUNCT
fnp-2627	23	35	.	.	PUNCT
fnp-2627	24	1	electron	electron	NOUN
fnp-2627	24	2	micrographs	micrograph	NOUN
fnp-2627	24	3	(	(	PUNCT
fnp-2627	24	4	e	e	NOUN
fnp-2627	24	5	–	–	PUNCT
fnp-2627	24	6	g	g	NOUN
fnp-2627	24	7	)	)	PUNCT
fnp-2627	24	8	and	and	CCONJ
fnp-2627	24	9	the	the	DET
fnp-2627	24	10	corresponding	corresponding	ADJ
fnp-2627	24	11	nanoscale	nanoscale	ADJ
fnp-2627	24	12	secondary	secondary	ADJ
fnp-2627	24	13	ion	ion	NOUN
fnp-2627	24	14	mass	mass	NOUN
fnp-2627	24	15	spectrometry	spectrometry	NOUN
fnp-2627	24	16	images	image	NOUN
fnp-2627	24	17	(	(	PUNCT
fnp-2627	24	18	h	h	NOUN
fnp-2627	24	19	–	–	PUNCT
fnp-2627	24	20	j	j	NOUN
fnp-2627	24	21	)	)	PUNCT
fnp-2627	24	22	.	.	PUNCT
fnp-2627	25	1	blue	blue	ADJ
fnp-2627	25	2	indicates	indicate	VERB
fnp-2627	25	3	sulfur	sulfur	NOUN
fnp-2627	25	4	(	(	PUNCT
fnp-2627	25	5	32s	32s	NUM
fnp-2627	25	6	)	)	PUNCT
fnp-2627	25	7	,	,	PUNCT
fnp-2627	25	8	red	red	ADJ
fnp-2627	25	9	phosphorus	phosphorus	NOUN
fnp-2627	25	10	(	(	PUNCT
fnp-2627	25	11	31p	31p	NUM
fnp-2627	25	12	)	)	PUNCT
fnp-2627	25	13	,	,	PUNCT
fnp-2627	25	14	and	and	CCONJ
fnp-2627	25	15	green	green	ADJ
fnp-2627	25	16	iron	iron	NOUN
fnp-2627	25	17	(	(	PUNCT
fnp-2627	25	18	56fe	56fe	ADJ
fnp-2627	25	19	)	)	PUNCT
fnp-2627	25	20	,	,	PUNCT
fnp-2627	25	21	respectively	respectively	ADV
fnp-2627	25	22	.	.	PUNCT
fnp-2627	26	1	sarcoplasmic	sarcoplasmic	ADJ
fnp-2627	26	2	bodies	body	NOUN
fnp-2627	26	3	are	be	AUX
fnp-2627	26	4	seen	see	VERB
fnp-2627	26	5	interspersed	intersperse	VERB
fnp-2627	26	6	between	between	ADP
fnp-2627	26	7	the	the	DET
fnp-2627	26	8	myofibrils	myofibril	NOUN
fnp-2627	26	9	(	(	PUNCT
fnp-2627	26	10	e	e	NOUN
fnp-2627	26	11	)	)	PUNCT
fnp-2627	26	12	,	,	PUNCT
fnp-2627	26	13	next	next	ADV
fnp-2627	26	14	to	to	ADP
fnp-2627	26	15	nuclei	nucleus	NOUN
fnp-2627	26	16	(	(	PUNCT
fnp-2627	26	17	f	f	NOUN
fnp-2627	26	18	)	)	PUNCT
fnp-2627	26	19	,	,	PUNCT
fnp-2627	26	20	or	or	CCONJ
fnp-2627	26	21	inside	inside	ADP
fnp-2627	26	22	an	an	DET
fnp-2627	26	23	autophagic	autophagic	ADJ
fnp-2627	26	24	vacuole	vacuole	NOUN
fnp-2627	26	25	(	(	PUNCT
fnp-2627	26	26	g	g	NOUN
fnp-2627	26	27	)	)	PUNCT
fnp-2627	26	28	.	.	PUNCT
fnp-2627	27	1	note	note	VERB
fnp-2627	27	2	the	the	DET
fnp-2627	27	3	high	high	ADJ
fnp-2627	27	4	-	-	PUNCT
fnp-2627	27	5	sulfur	sulfur	NOUN
fnp-2627	27	6	signal	signal	NOUN
fnp-2627	27	7	in	in	ADP
fnp-2627	27	8	the	the	DET
fnp-2627	27	9	sarcoplasmic	sarcoplasmic	ADJ
fnp-2627	27	10	bodies	body	NOUN
fnp-2627	27	11	(	(	PUNCT
fnp-2627	27	12	h	h	NOUN
fnp-2627	27	13	–	–	PUNCT
fnp-2627	27	14	j	j	NOUN
fnp-2627	27	15	)	)	PUNCT
fnp-2627	27	16	,	,	PUNCT
fnp-2627	27	17	and	and	CCONJ
fnp-2627	27	18	the	the	DET
fnp-2627	27	19	iron	iron	NOUN
fnp-2627	27	20	signal	signal	NOUN
fnp-2627	27	21	(	(	PUNCT
fnp-2627	27	22	green	green	ADJ
fnp-2627	27	23	dots	dot	NOUN
fnp-2627	27	24	within	within	ADP
fnp-2627	27	25	the	the	DET
fnp-2627	27	26	sarcoplasmic	sarcoplasmic	ADJ
fnp-2627	27	27	bodies	body	NOUN
fnp-2627	27	28	in	in	ADP
fnp-2627	27	29	i	i	PROPN
fnp-2627	27	30	,	,	PUNCT
fnp-2627	27	31	j	j	PROPN
fnp-2627	27	32	)	)	PUNCT
fnp-2627	27	33	.	.	PUNCT
fnp-2627	28	1	scale	scale	NOUN
fnp-2627	28	2	bar	bar	NOUN
fnp-2627	28	3	in	in	ADP
fnp-2627	28	4	a	a	DET
fnp-2627	28	5	=	=	SYM
fnp-2627	28	6	2	2	NUM
fnp-2627	28	7	µm	µm	NOUN
fnp-2627	28	8	,	,	PUNCT
fnp-2627	28	9	b	b	NOUN
fnp-2627	28	10	=	=	SYM
fnp-2627	28	11	5	5	NUM
fnp-2627	28	12	µm	µm	NOUN
fnp-2627	28	13	,	,	PUNCT
fnp-2627	28	14	c	c	NOUN
fnp-2627	28	15	=	=	SYM
fnp-2627	28	16	0.5	0.5	NUM
fnp-2627	28	17	µm	µm	NOUN
fnp-2627	28	18	,	,	PUNCT
fnp-2627	28	19	d	d	NOUN
fnp-2627	28	20	=	=	SYM
fnp-2627	28	21	1	1	NUM
fnp-2627	28	22	µm	µm	NOUN
fnp-2627	28	23	,	,	PUNCT
fnp-2627	28	24	h	h	PROPN
fnp-2627	28	25	–	–	PUNCT
fnp-2627	28	26	j	j	X
fnp-2627	28	27	=	=	SYM
fnp-2627	28	28	4	4	NUM
fnp-2627	28	29	µm	µm	NOUN
fnp-2627	28	30	.	.	PUNCT
fnp-2627	29	1	[	[	X
fnp-2627	29	2	this	this	DET
fnp-2627	29	3	figure	figure	NOUN
fnp-2627	29	4	and	and	CCONJ
fnp-2627	29	5	its	its	PRON
fnp-2627	29	6	legend	legend	NOUN
fnp-2627	29	7	were	be	AUX
fnp-2627	29	8	adopted	adopt	VERB
fnp-2627	29	9	from	from	ADP
fnp-2627	29	10	figure	figure	NOUN
fnp-2627	29	11	5	5	NUM
fnp-2627	29	12	in	in	ADP
fnp-2627	29	13	(	(	PUNCT
fnp-2627	29	14	olive	olive	NOUN
fnp-2627	29	15	et	et	PROPN
fnp-2627	29	16	al	al	PROPN
fnp-2627	29	17	.	.	PROPN
fnp-2627	29	18	,	,	PUNCT
fnp-2627	29	19	2019	2019	NUM
fnp-2627	29	20	)	)	PUNCT
fnp-2627	29	21	;	;	PUNCT
fnp-2627	29	22	this	this	DET
fnp-2627	29	23	use	use	NOUN
fnp-2627	29	24	is	be	AUX
fnp-2627	29	25	permitted	permit	VERB
fnp-2627	29	26	under	under	ADP
fnp-2627	29	27	the	the	DET
fnp-2627	29	28	creative	creative	ADJ
fnp-2627	29	29	commons	common	NOUN
fnp-2627	29	30	attribution	attribution	NOUN
fnp-2627	29	31	4.0	4.0	NUM
fnp-2627	29	32	international	international	ADJ
fnp-2627	29	33	license	license	NOUN
fnp-2627	29	34	.	.	PUNCT
fnp-2627	29	35	]	]	PUNCT
fnp-2627	30	1	a	a	DET
fnp-2627	30	2	different	different	ADJ
fnp-2627	30	3	,	,	PUNCT
fnp-2627	30	4	purely	purely	ADV
fnp-2627	30	5	genetic	genetic	ADJ
fnp-2627	30	6	approach	approach	NOUN
fnp-2627	30	7	was	be	AUX
fnp-2627	30	8	used	use	VERB
fnp-2627	30	9	to	to	PART
fnp-2627	30	10	define	define	VERB
fnp-2627	30	11	a	a	DET
fnp-2627	30	12	new	new	ADJ
fnp-2627	30	13	autosomal	autosomal	ADJ
fnp-2627	30	14	recessive	recessive	ADJ
fnp-2627	30	15	form	form	NOUN
fnp-2627	30	16	of	of	ADP
fnp-2627	30	17	limb	limb	NOUN
fnp-2627	30	18	-	-	PUNCT
fnp-2627	30	19	girdle	girdle	NOUN
fnp-2627	30	20	muscular	muscular	ADJ
fnp-2627	30	21	dystrophy	dystrophy	NOUN
fnp-2627	30	22	that	that	PRON
fnp-2627	30	23	is	be	AUX
fnp-2627	30	24	caused	cause	VERB
fnp-2627	30	25	by	by	ADP
fnp-2627	30	26	biallelic	biallelic	ADJ
fnp-2627	30	27	mutations	mutation	NOUN
fnp-2627	30	28	in	in	ADP
fnp-2627	30	29	popdc3	popdc3	PROPN
fnp-2627	30	30	gene	gene	NOUN
fnp-2627	30	31	:	:	PUNCT
fnp-2627	30	32	5	5	NUM
fnp-2627	30	33	affected	affect	VERB
fnp-2627	30	34	individuals	individual	NOUN
fnp-2627	30	35	from	from	ADP
fnp-2627	30	36	3	3	NUM
fnp-2627	30	37	different	different	ADJ
fnp-2627	30	38	families	family	NOUN
fnp-2627	30	39	were	be	AUX
fnp-2627	30	40	identified	identify	VERB
fnp-2627	30	41	via	via	ADP
fnp-2627	30	42	exome	exome	NOUN
fnp-2627	30	43	sequencing	sequencing	NOUN
fnp-2627	30	44	of	of	ADP
fnp-2627	30	45	a	a	DET
fnp-2627	30	46	cohort	cohort	NOUN
fnp-2627	30	47	of	of	ADP
fnp-2627	30	48	1500	1500	NUM
fnp-2627	30	49	patients	patient	NOUN
fnp-2627	30	50	with	with	ADP
fnp-2627	30	51	presumed	presume	VERB
fnp-2627	30	52	genetic	genetic	ADJ
fnp-2627	30	53	limb	limb	NOUN
fnp-2627	30	54	-	-	PUNCT
fnp-2627	30	55	girdle	girdle	NOUN
fnp-2627	30	56	weakness	weakness	NOUN
fnp-2627	30	57	and	and	CCONJ
fnp-2627	30	58	elevated	elevated	ADJ
fnp-2627	30	59	creatine	creatine	PROPN
fnp-2627	30	60	kinase	kinase	PROPN
fnp-2627	30	61	levels	level	NOUN
fnp-2627	30	62	;	;	PUNCT
fnp-2627	30	63	their	their	PRON
fnp-2627	30	64	muscle	muscle	NOUN
fnp-2627	30	65	biopsies	biopsy	NOUN
fnp-2627	30	66	showed	show	VERB
fnp-2627	30	67	dystrophic	dystrophic	ADJ
fnp-2627	30	68	features	feature	NOUN
fnp-2627	30	69	of	of	ADP
fnp-2627	30	70	variable	variable	ADJ
fnp-2627	30	71	severity	severity	NOUN
fnp-2627	30	72	(	(	PUNCT
fnp-2627	30	73	vissing	visse	VERB
fnp-2627	30	74	et	et	PROPN
fnp-2627	30	75	al	al	PROPN
fnp-2627	30	76	.	.	PROPN
fnp-2627	30	77	,	,	PUNCT
fnp-2627	30	78	2019	2019	NUM
fnp-2627	30	79	)	)	PUNCT
fnp-2627	30	80	.	.	PUNCT
fnp-2627	31	1	popdc3	popdc3	NOUN
fnp-2627	31	2	(	(	PUNCT
fnp-2627	31	3	popeye	popeye	NOUN
fnp-2627	31	4	domain	domain	NOUN
fnp-2627	31	5	containing	contain	VERB
fnp-2627	31	6	3	3	NUM
fnp-2627	31	7	)	)	PUNCT
fnp-2627	31	8	gene	gene	NOUN
fnp-2627	31	9	encodes	encode	VERB
fnp-2627	31	10	a	a	DET
fnp-2627	31	11	membrane	membrane	NOUN
fnp-2627	31	12	protein	protein	NOUN
fnp-2627	31	13	that	that	PRON
fnp-2627	31	14	regulates	regulate	VERB
fnp-2627	31	15	camp	camp	NOUN
fnp-2627	31	16	signaling	signal	VERB
fnp-2627	31	17	,	,	PUNCT
fnp-2627	31	18	is	be	AUX
fnp-2627	31	19	highly	highly	ADV
fnp-2627	31	20	expressed	express	VERB
fnp-2627	31	21	in	in	ADP
fnp-2627	31	22	skeletal	skeletal	ADJ
fnp-2627	31	23	and	and	CCONJ
fnp-2627	31	24	cardiac	cardiac	ADJ
fnp-2627	31	25	muscles	muscle	NOUN
fnp-2627	31	26	,	,	PUNCT
fnp-2627	31	27	and	and	CCONJ
fnp-2627	31	28	has	have	AUX
fnp-2627	31	29	not	not	PART
fnp-2627	31	30	yet	yet	ADV
fnp-2627	31	31	been	be	AUX
fnp-2627	31	32	associated	associate	VERB
fnp-2627	31	33	with	with	ADP
fnp-2627	31	34	any	any	DET
fnp-2627	31	35	human	human	ADJ
fnp-2627	31	36	disease	disease	NOUN
fnp-2627	31	37	.	.	PUNCT
fnp-2627	32	1	interestingly	interestingly	ADV
fnp-2627	32	2	,	,	PUNCT
fnp-2627	32	3	patients	patient	NOUN
fnp-2627	32	4	with	with	ADP
fnp-2627	32	5	popdc3	popdc3	NOUN
fnp-2627	32	6	mutations	mutation	NOUN
fnp-2627	32	7	do	do	AUX
fnp-2627	32	8	not	not	PART
fnp-2627	32	9	show	show	VERB
fnp-2627	32	10	a	a	DET
fnp-2627	32	11	cardiac	cardiac	ADJ
fnp-2627	32	12	phenotype	phenotype	NOUN
fnp-2627	32	13	,	,	PUNCT
fnp-2627	32	14	while	while	SCONJ
fnp-2627	32	15	mutations	mutation	NOUN
fnp-2627	32	16	in	in	ADP
fnp-2627	32	17	two	two	NUM
fnp-2627	32	18	other	other	ADJ
fnp-2627	32	19	members	member	NOUN
fnp-2627	32	20	of	of	ADP
fnp-2627	32	21	the	the	DET
fnp-2627	32	22	same	same	ADJ
fnp-2627	32	23	gene	gene	NOUN
fnp-2627	32	24	family	family	NOUN
fnp-2627	32	25	(	(	PUNCT
fnp-2627	32	26	popdc1	popdc1	NOUN
fnp-2627	32	27	and	and	CCONJ
fnp-2627	32	28	popdc2	popdc2	NOUN
fnp-2627	32	29	)	)	PUNCT
fnp-2627	32	30	cause	cause	VERB
fnp-2627	32	31	a	a	DET
fnp-2627	32	32	cardiac	cardiac	ADJ
fnp-2627	32	33	phenotype	phenotype	NOUN
fnp-2627	32	34	(	(	PUNCT
fnp-2627	32	35	generally	generally	ADV
fnp-2627	32	36	a	a	DET
fnp-2627	32	37	conduction	conduction	NOUN
fnp-2627	32	38	disorder	disorder	NOUN
fnp-2627	32	39	)	)	PUNCT
fnp-2627	32	40	accompanied	accompany	VERB
fnp-2627	32	41	by	by	ADP
fnp-2627	32	42	a	a	DET
fnp-2627	32	43	variable	variable	ADJ
fnp-2627	32	44	skeletal	skeletal	ADJ
fnp-2627	32	45	muscle	muscle	NOUN
fnp-2627	32	46	involvement	involvement	NOUN
fnp-2627	32	47	(	(	PUNCT
fnp-2627	32	48	de	de	X
fnp-2627	32	49	ridder	ridder	PROPN
fnp-2627	32	50	et	et	PROPN
fnp-2627	32	51	al	al	PROPN
fnp-2627	32	52	.	.	PROPN
fnp-2627	32	53	,	,	PUNCT
fnp-2627	32	54	2019	2019	NUM
fnp-2627	32	55	;	;	PUNCT
fnp-2627	32	56	vissing	visse	VERB
fnp-2627	32	57	et	et	PROPN
fnp-2627	32	58	al	al	PROPN
fnp-2627	32	59	.	.	PROPN
fnp-2627	32	60	,	,	PUNCT
fnp-2627	32	61	2019	2019	NUM
fnp-2627	32	62	)	)	PUNCT
fnp-2627	32	63	.	.	PUNCT
fnp-2627	33	1	the	the	DET
fnp-2627	33	2	pathogenesis	pathogenesis	NOUN
fnp-2627	33	3	of	of	ADP
fnp-2627	33	4	this	this	DET
fnp-2627	33	5	new	new	ADJ
fnp-2627	33	6	disorder	disorder	NOUN
fnp-2627	33	7	remains	remain	VERB
fnp-2627	33	8	to	to	PART
fnp-2627	33	9	be	be	AUX
fnp-2627	33	10	elucidated	elucidate	VERB
fnp-2627	33	11	;	;	PUNCT
fnp-2627	33	12	however	however	ADV
fnp-2627	33	13	,	,	PUNCT
fnp-2627	33	14	initial	initial	ADJ
fnp-2627	33	15	studies	study	NOUN
fnp-2627	33	16	suggest	suggest	VERB
fnp-2627	33	17	a	a	DET
fnp-2627	33	18	loss	loss	NOUN
fnp-2627	33	19	-	-	PUNCT
fnp-2627	33	20	of	of	ADP
fnp-2627	33	21	-	-	PUNCT
fnp-2627	33	22	function	function	NOUN
fnp-2627	33	23	mechanism	mechanism	NOUN
fnp-2627	33	24	that	that	PRON
fnp-2627	33	25	leads	lead	VERB
fnp-2627	33	26	to	to	ADP
fnp-2627	33	27	altered	alter	VERB
fnp-2627	33	28	camp	camp	NOUN
fnp-2627	33	29	modulation	modulation	NOUN
fnp-2627	33	30	.	.	PUNCT
fnp-2627	34	1	2	2	X
fnp-2627	34	2	.	.	X
fnp-2627	34	3	emerging	emerge	VERB
fnp-2627	34	4	therapy	therapy	NOUN
fnp-2627	34	5	-	-	PUNCT
fnp-2627	34	6	related	relate	VERB
fnp-2627	34	7	diseases	disease	NOUN
fnp-2627	34	8	introduction	introduction	NOUN
fnp-2627	34	9	of	of	ADP
fnp-2627	34	10	new	new	ADJ
fnp-2627	34	11	therapies	therapy	NOUN
fnp-2627	34	12	has	have	AUX
fnp-2627	34	13	led	lead	VERB
fnp-2627	34	14	to	to	ADP
fnp-2627	34	15	the	the	DET
fnp-2627	34	16	emergence	emergence	NOUN
fnp-2627	34	17	of	of	ADP
fnp-2627	34	18	unusual	unusual	ADJ
fnp-2627	34	19	or	or	CCONJ
fnp-2627	34	20	completely	completely	ADV
fnp-2627	34	21	novel	novel	ADJ
fnp-2627	34	22	nmd	nmd	NOUN
fnp-2627	34	23	phenotypes	phenotype	NOUN
fnp-2627	34	24	;	;	PUNCT
fnp-2627	34	25	in	in	ADP
fnp-2627	34	26	2019	2019	NUM
fnp-2627	34	27	,	,	PUNCT
fnp-2627	34	28	two	two	NUM
fnp-2627	34	29	new	new	ADJ
fnp-2627	34	30	nmd	nmd	PROPN
fnp-2627	34	31	categories	category	NOUN
fnp-2627	34	32	,	,	PUNCT
fnp-2627	34	33	previously	previously	ADV
fnp-2627	34	34	described	describe	VERB
fnp-2627	34	35	only	only	ADV
fnp-2627	34	36	in	in	ADP
fnp-2627	34	37	individual	individual	ADJ
fnp-2627	34	38	case	case	NOUN
fnp-2627	34	39	reports	report	NOUN
fnp-2627	34	40	or	or	CCONJ
fnp-2627	34	41	small	small	ADJ
fnp-2627	34	42	case	case	NOUN
fnp-2627	34	43	series	series	NOUN
fnp-2627	34	44	,	,	PUNCT
fnp-2627	34	45	have	have	AUX
fnp-2627	34	46	been	be	AUX
fnp-2627	34	47	more	more	ADV
fnp-2627	34	48	thoroughly	thoroughly	ADV
fnp-2627	34	49	defined	define	VERB
fnp-2627	34	50	.	.	PUNCT
fnp-2627	35	1	immune	immune	NOUN
fnp-2627	35	2	-	-	PUNCT
fnp-2627	35	3	checkpoint	checkpoint	NOUN
fnp-2627	35	4	inhibitor	inhibitor	NOUN
fnp-2627	35	5	therapy	therapy	NOUN
fnp-2627	35	6	has	have	AUX
fnp-2627	35	7	revolutionized	revolutionize	VERB
fnp-2627	35	8	treatment	treatment	NOUN
fnp-2627	35	9	of	of	ADP
fnp-2627	35	10	patients	patient	NOUN
fnp-2627	35	11	with	with	ADP
fnp-2627	35	12	advanced	advanced	ADJ
fnp-2627	35	13	cancers	cancer	NOUN
fnp-2627	35	14	,	,	PUNCT
fnp-2627	35	15	but	but	CCONJ
fnp-2627	35	16	is	be	AUX
fnp-2627	35	17	often	often	ADV
fnp-2627	35	18	associated	associate	VERB
fnp-2627	35	19	with	with	ADP
fnp-2627	35	20	immune	immune	NOUN
fnp-2627	35	21	-	-	PUNCT
fnp-2627	35	22	related	relate	VERB
fnp-2627	35	23	adverse	adverse	ADJ
fnp-2627	35	24	events	event	NOUN
fnp-2627	35	25	(	(	PUNCT
fnp-2627	35	26	iraes	iraes	NOUN
fnp-2627	35	27	)	)	PUNCT
fnp-2627	35	28	that	that	PRON
fnp-2627	35	29	most	most	ADV
fnp-2627	35	30	commonly	commonly	ADV
fnp-2627	35	31	affect	affect	VERB
fnp-2627	35	32	the	the	DET
fnp-2627	35	33	skin	skin	NOUN
fnp-2627	35	34	,	,	PUNCT
fnp-2627	35	35	gi	gi	NOUN
fnp-2627	35	36	tract	tract	NOUN
fnp-2627	35	37	,	,	PUNCT
fnp-2627	35	38	and	and	CCONJ
fnp-2627	35	39	endocrine	endocrine	ADJ
fnp-2627	35	40	glands	gland	NOUN
fnp-2627	35	41	,	,	PUNCT
fnp-2627	35	42	as	as	ADV
fnp-2627	35	43	well	well	ADV
fnp-2627	35	44	as	as	ADP
fnp-2627	35	45	the	the	DET
fnp-2627	35	46	pns	pns	PROPN
fnp-2627	35	47	.	.	PUNCT
fnp-2627	36	1	neuromuscular	neuromuscular	ADJ
fnp-2627	36	2	iraes	irae	NOUN
fnp-2627	36	3	can	can	AUX
fnp-2627	36	4	be	be	AUX
fnp-2627	36	5	severe	severe	ADJ
fnp-2627	36	6	and	and	CCONJ
fnp-2627	36	7	include	include	VERB
fnp-2627	36	8	myasthenia	myasthenia	NOUN
fnp-2627	36	9	gravis	gravis	PROPN
fnp-2627	36	10	(	(	PUNCT
fnp-2627	36	11	irmg	irmg	NOUN
fnp-2627	36	12	)	)	PUNCT
fnp-2627	36	13	,	,	PUNCT
fnp-2627	36	14	myopathy	myopathy	ADJ
fnp-2627	36	15	(	(	PUNCT
fnp-2627	36	16	irmyositis	irmyositis	NOUN
fnp-2627	36	17	)	)	PUNCT
fnp-2627	36	18	,	,	PUNCT
fnp-2627	36	19	and	and	CCONJ
fnp-2627	36	20	peripheral	peripheral	ADJ
fnp-2627	36	21	neuropathy	neuropathy	ADJ
fnp-2627	36	22	(	(	PUNCT
fnp-2627	36	23	irneuropathy	irneuropathy	ADJ
fnp-2627	36	24	;	;	PUNCT
fnp-2627	36	25	most	most	ADV
fnp-2627	36	26	commonly	commonly	ADV
fnp-2627	36	27	acute	acute	VERB
fnp-2627	36	28	demyelinating	demyelinate	VERB
fnp-2627	36	29	polyradiculoneuropathy	polyradiculoneuropathy	NOUN
fnp-2627	36	30	)	)	PUNCT
fnp-2627	36	31	(	(	PUNCT
fnp-2627	36	32	johansen	johansen	PROPN
fnp-2627	36	33	et	et	PROPN
fnp-2627	36	34	al	al	PROPN
fnp-2627	36	35	.	.	PROPN
fnp-2627	36	36	,	,	PUNCT
fnp-2627	36	37	2019	2019	NUM
fnp-2627	36	38	;	;	PUNCT
fnp-2627	36	39	mohn	mohn	PROPN
fnp-2627	36	40	et	et	PROPN
fnp-2627	36	41	al	al	PROPN
fnp-2627	36	42	.	.	PROPN
fnp-2627	36	43	,	,	PUNCT
fnp-2627	36	44	2019	2019	NUM
fnp-2627	36	45	;	;	PUNCT
fnp-2627	36	46	psimaras	psimara	NOUN
fnp-2627	36	47	et	et	PROPN
fnp-2627	36	48	al	al	PROPN
fnp-2627	36	49	.	.	PROPN
fnp-2627	36	50	,	,	PUNCT
fnp-2627	36	51	2019	2019	NUM
fnp-2627	36	52	)	)	PUNCT
fnp-2627	36	53	.	.	PUNCT
fnp-2627	37	1	while	while	SCONJ
fnp-2627	37	2	these	these	DET
fnp-2627	37	3	neuromuscular	neuromuscular	ADJ
fnp-2627	37	4	iraes	iraes	NOUN
fnp-2627	37	5	share	share	VERB
fnp-2627	37	6	some	some	DET
fnp-2627	37	7	commonalties	commonalty	NOUN
fnp-2627	37	8	with	with	ADP
fnp-2627	37	9	their	their	PRON
fnp-2627	37	10	sporadic	sporadic	ADJ
fnp-2627	37	11	counterparts	counterpart	NOUN
fnp-2627	37	12	,	,	PUNCT
fnp-2627	37	13	several	several	ADJ
fnp-2627	37	14	unique	unique	ADJ
fnp-2627	37	15	features	feature	NOUN
fnp-2627	37	16	have	have	AUX
fnp-2627	37	17	emerged	emerge	VERB
fnp-2627	37	18	.	.	PUNCT
fnp-2627	38	1	for	for	ADP
fnp-2627	38	2	example	example	NOUN
fnp-2627	38	3	,	,	PUNCT
fnp-2627	38	4	up	up	ADP
fnp-2627	38	5	to	to	PART
fnp-2627	38	6	25	25	NUM
fnp-2627	38	7	%	%	NOUN
fnp-2627	38	8	of	of	ADP
fnp-2627	38	9	the	the	DET
fnp-2627	38	10	patients	patient	NOUN
fnp-2627	38	11	show	show	VERB
fnp-2627	38	12	more	more	ADJ
fnp-2627	38	13	than	than	ADP
fnp-2627	38	14	one	one	NUM
fnp-2627	38	15	neuromuscular	neuromuscular	ADJ
fnp-2627	38	16	irae	irae	NOUN
fnp-2627	38	17	,	,	PUNCT
fnp-2627	38	18	with	with	ADP
fnp-2627	38	19	the	the	DET
fnp-2627	38	20	combination	combination	NOUN
fnp-2627	38	21	of	of	ADP
fnp-2627	38	22	irmg	irmg	NOUN
fnp-2627	38	23	and	and	CCONJ
fnp-2627	38	24	irmyositis	irmyositis	NOUN
fnp-2627	38	25	encountered	encounter	VERB
fnp-2627	38	26	most	most	ADV
fnp-2627	38	27	often	often	ADV
fnp-2627	38	28	(	(	PUNCT
fnp-2627	38	29	johansen	johansen	PROPN
fnp-2627	38	30	et	et	PROPN
fnp-2627	38	31	al	al	PROPN
fnp-2627	38	32	.	.	PROPN
fnp-2627	38	33	,	,	PUNCT
fnp-2627	38	34	2019	2019	NUM
fnp-2627	38	35	)	)	PUNCT
fnp-2627	38	36	.	.	PUNCT
fnp-2627	39	1	furthermore	furthermore	ADV
fnp-2627	39	2	,	,	PUNCT
fnp-2627	39	3	irmg	irmg	NOUN
fnp-2627	39	4	is	be	AUX
fnp-2627	39	5	more	more	ADV
fnp-2627	39	6	likely	likely	ADJ
fnp-2627	39	7	to	to	PART
fnp-2627	39	8	be	be	AUX
fnp-2627	39	9	negative	negative	ADJ
fnp-2627	39	10	for	for	ADP
fnp-2627	39	11	achr	achr	PROPN
fnp-2627	39	12	antibodies	antibody	NOUN
fnp-2627	39	13	than	than	ADP
fnp-2627	39	14	idiopathic	idiopathic	ADJ
fnp-2627	39	15	mg	mg	PROPN
fnp-2627	39	16	,	,	PUNCT
fnp-2627	39	17	while	while	SCONJ
fnp-2627	39	18	irmyositis	irmyositis	NOUN
fnp-2627	39	19	is	be	AUX
fnp-2627	39	20	more	more	ADV
fnp-2627	39	21	likely	likely	ADJ
fnp-2627	39	22	to	to	PART
fnp-2627	39	23	involve	involve	VERB
fnp-2627	39	24	oculomotor	oculomotor	NOUN
fnp-2627	39	25	and	and	CCONJ
fnp-2627	39	26	bulbar	bulbar	ADJ
fnp-2627	39	27	muscles	muscle	NOUN
fnp-2627	39	28	than	than	ADP
fnp-2627	39	29	any	any	PRON
fnp-2627	39	30	of	of	ADP
fnp-2627	39	31	idiopathic	idiopathic	ADJ
fnp-2627	39	32	inflammatory	inflammatory	ADJ
fnp-2627	39	33	myopathies	myopathy	NOUN
fnp-2627	39	34	(	(	PUNCT
fnp-2627	39	35	iims	iims	PROPN
fnp-2627	39	36	)	)	PUNCT
fnp-2627	39	37	;	;	PUNCT
fnp-2627	39	38	these	these	PRON
fnp-2627	39	39	features	feature	VERB
fnp-2627	39	40	make	make	VERB
fnp-2627	39	41	clinical	clinical	ADJ
fnp-2627	39	42	distinction	distinction	NOUN
fnp-2627	39	43	between	between	ADP
fnp-2627	39	44	irmg	irmg	NOUN
fnp-2627	39	45	and	and	CCONJ
fnp-2627	39	46	irmyositis	irmyositis	NOUN
fnp-2627	39	47	difficult	difficult	ADJ
fnp-2627	39	48	in	in	ADP
fnp-2627	39	49	many	many	ADJ
fnp-2627	39	50	cases	case	NOUN
fnp-2627	39	51	(	(	PUNCT
fnp-2627	39	52	johansen	johansen	PROPN
fnp-2627	39	53	et	et	PROPN
fnp-2627	39	54	al	al	PROPN
fnp-2627	39	55	.	.	PROPN
fnp-2627	39	56	,	,	PUNCT
fnp-2627	39	57	2019	2019	NUM
fnp-2627	39	58	;	;	PUNCT
fnp-2627	39	59	mohn	mohn	PROPN
fnp-2627	39	60	et	et	PROPN
fnp-2627	39	61	al	al	PROPN
fnp-2627	39	62	.	.	PROPN
fnp-2627	39	63	,	,	PUNCT
fnp-2627	39	64	2019	2019	NUM
fnp-2627	39	65	)	)	PUNCT
fnp-2627	39	66	.	.	PUNCT
fnp-2627	40	1	in	in	ADP
fnp-2627	40	2	addition	addition	NOUN
fnp-2627	40	3	,	,	PUNCT
fnp-2627	40	4	irmyositis	irmyositis	NOUN
fnp-2627	40	5	often	often	ADV
fnp-2627	40	6	involves	involve	VERB
fnp-2627	40	7	axial	axial	ADJ
fnp-2627	40	8	muscles	muscle	NOUN
fnp-2627	40	9	,	,	PUNCT
fnp-2627	40	10	while	while	SCONJ
fnp-2627	40	11	iims	iim	NOUN
fnp-2627	40	12	do	do	VERB
fnp-2627	40	13	not	not	PART
fnp-2627	40	14	(	(	PUNCT
fnp-2627	40	15	touat	touat	PROPN
fnp-2627	40	16	et	et	PROPN
fnp-2627	40	17	al	al	PROPN
fnp-2627	40	18	.	.	PROPN
fnp-2627	40	19	,	,	PUNCT
fnp-2627	40	20	2018	2018	NUM
fnp-2627	40	21	)	)	PUNCT
fnp-2627	40	22	.	.	PUNCT
fnp-2627	41	1	finally	finally	ADV
fnp-2627	41	2	,	,	PUNCT
fnp-2627	41	3	a	a	DET
fnp-2627	41	4	significant	significant	ADJ
fnp-2627	41	5	fraction	fraction	NOUN
fnp-2627	41	6	of	of	ADP
fnp-2627	41	7	patients	patient	NOUN
fnp-2627	41	8	with	with	ADP
fnp-2627	41	9	irmyositis	irmyositis	PROPN
fnp-2627	41	10	shows	show	VERB
fnp-2627	41	11	cardiac	cardiac	ADJ
fnp-2627	41	12	involvement	involvement	NOUN
fnp-2627	41	13	,	,	PUNCT
fnp-2627	41	14	which	which	PRON
fnp-2627	41	15	is	be	AUX
fnp-2627	41	16	not	not	PART
fnp-2627	41	17	typically	typically	ADV
fnp-2627	41	18	seen	see	VERB
fnp-2627	41	19	in	in	ADP
fnp-2627	41	20	iim	iim	NOUN
fnp-2627	41	21	patients	patient	NOUN
fnp-2627	41	22	and	and	CCONJ
fnp-2627	41	23	has	have	VERB
fnp-2627	41	24	a	a	DET
fnp-2627	41	25	poor	poor	ADJ
fnp-2627	41	26	prognosis	prognosis	NOUN
fnp-2627	41	27	(	(	PUNCT
fnp-2627	41	28	anquetil	anquetil	PROPN
fnp-2627	41	29	et	et	PROPN
fnp-2627	41	30	al	al	PROPN
fnp-2627	41	31	.	.	PROPN
fnp-2627	41	32	,	,	PUNCT
fnp-2627	41	33	2018	2018	NUM
fnp-2627	41	34	;	;	PUNCT
fnp-2627	41	35	johansen	johansen	PROPN
fnp-2627	41	36	et	et	PROPN
fnp-2627	41	37	al	al	PROPN
fnp-2627	41	38	.	.	PROPN
fnp-2627	41	39	,	,	PUNCT
fnp-2627	41	40	2019	2019	NUM
fnp-2627	41	41	;	;	PUNCT
fnp-2627	41	42	mohn	mohn	PROPN
fnp-2627	41	43	et	et	PROPN
fnp-2627	41	44	al	al	PROPN
fnp-2627	41	45	.	.	PROPN
fnp-2627	41	46	,	,	PUNCT
fnp-2627	41	47	2019	2019	NUM
fnp-2627	41	48	)	)	PUNCT
fnp-2627	41	49	.	.	PUNCT
fnp-2627	42	1	interestingly	interestingly	ADV
fnp-2627	42	2	,	,	PUNCT
fnp-2627	42	3	while	while	SCONJ
fnp-2627	42	4	the	the	DET
fnp-2627	42	5	rates	rate	NOUN
fnp-2627	42	6	of	of	ADP
fnp-2627	42	7	irneuropathies	irneuropathie	NOUN
fnp-2627	42	8	(	(	PUNCT
fnp-2627	42	9	as	as	ADV
fnp-2627	42	10	well	well	ADV
fnp-2627	42	11	as	as	ADP
fnp-2627	42	12	the	the	DET
fnp-2627	42	13	overall	overall	ADJ
fnp-2627	42	14	irae	irae	NOUN
fnp-2627	42	15	rates	rate	NOUN
fnp-2627	42	16	)	)	PUNCT
fnp-2627	42	17	are	be	AUX
fnp-2627	42	18	higher	high	ADJ
fnp-2627	42	19	in	in	ADP
fnp-2627	42	20	patients	patient	NOUN
fnp-2627	42	21	treated	treat	VERB
fnp-2627	42	22	with	with	ADP
fnp-2627	42	23	ipilimubab	ipilimubab	PROPN
fnp-2627	42	24	(	(	PUNCT
fnp-2627	42	25	the	the	DET
fnp-2627	42	26	anti	anti	ADJ
fnp-2627	42	27	-	-	ADJ
fnp-2627	42	28	ctla-4	ctla-4	NOUN
fnp-2627	42	29	antibody	antibody	NOUN
fnp-2627	42	30	)	)	PUNCT
fnp-2627	42	31	,	,	PUNCT
fnp-2627	42	32	irmg	irmg	NOUN
fnp-2627	42	33	and	and	CCONJ
fnp-2627	42	34	irmyositis	irmyositis	NOUN
fnp-2627	42	35	are	be	AUX
fnp-2627	42	36	particularly	particularly	ADV
fnp-2627	42	37	common	common	ADJ
fnp-2627	42	38	in	in	ADP
fnp-2627	42	39	patients	patient	NOUN
fnp-2627	42	40	treated	treat	VERB
fnp-2627	42	41	with	with	ADP
fnp-2627	42	42	nivolumab	nivolumab	NOUN
fnp-2627	42	43	or	or	CCONJ
fnp-2627	42	44	pembrolizumab	pembrolizumab	NOUN
fnp-2627	42	45	(	(	PUNCT
fnp-2627	42	46	the	the	DET
fnp-2627	42	47	pd-1	pd-1	ADJ
fnp-2627	42	48	blocking	block	VERB
fnp-2627	42	49	antibodies	antibody	NOUN
fnp-2627	42	50	)	)	PUNCT
fnp-2627	42	51	(	(	PUNCT
fnp-2627	42	52	mohn	mohn	PROPN
fnp-2627	42	53	et	et	PROPN
fnp-2627	42	54	al	al	PROPN
fnp-2627	42	55	.	.	PROPN
fnp-2627	42	56	,	,	PUNCT
fnp-2627	42	57	2019	2019	NUM
fnp-2627	42	58	)	)	PUNCT
fnp-2627	42	59	.	.	PUNCT
fnp-2627	43	1	the	the	DET
fnp-2627	43	2	pathogenesis	pathogenesis	NOUN
fnp-2627	43	3	of	of	ADP
fnp-2627	43	4	neuromuscular	neuromuscular	ADJ
fnp-2627	43	5	iraes	iraes	NOUN
fnp-2627	43	6	is	be	AUX
fnp-2627	43	7	incompletely	incompletely	ADV
fnp-2627	43	8	understood	understand	VERB
fnp-2627	43	9	,	,	PUNCT
fnp-2627	43	10	but	but	CCONJ
fnp-2627	43	11	is	be	AUX
fnp-2627	43	12	thought	think	VERB
fnp-2627	43	13	to	to	PART
fnp-2627	43	14	involve	involve	VERB
fnp-2627	43	15	both	both	PRON
fnp-2627	43	16	type	type	NOUN
fnp-2627	43	17	iv	iv	ADP
fnp-2627	43	18	(	(	PUNCT
fnp-2627	43	19	t	t	NOUN
fnp-2627	43	20	cell	cell	NOUN
fnp-2627	43	21	-	-	PUNCT
fnp-2627	43	22	mediated	mediate	VERB
fnp-2627	43	23	)	)	PUNCT
fnp-2627	43	24	and	and	CCONJ
fnp-2627	43	25	type	type	PROPN
fnp-2627	43	26	ii	ii	PROPN
fnp-2627	43	27	(	(	PUNCT
fnp-2627	43	28	antibody	antibody	NOUN
fnp-2627	43	29	-	-	PUNCT
fnp-2627	43	30	mediated	mediate	VERB
fnp-2627	43	31	)	)	PUNCT
fnp-2627	43	32	immune	immune	ADJ
fnp-2627	43	33	mechanisms	mechanism	NOUN
fnp-2627	43	34	(	(	PUNCT
fnp-2627	43	35	psimaras	psimara	NOUN
fnp-2627	43	36	et	et	PROPN
fnp-2627	43	37	al	al	PROPN
fnp-2627	43	38	.	.	PROPN
fnp-2627	43	39	,	,	PUNCT
fnp-2627	43	40	2019	2019	NUM
fnp-2627	43	41	)	)	PUNCT
fnp-2627	43	42	.	.	PUNCT
fnp-2627	44	1	on	on	ADP
fnp-2627	44	2	a	a	DET
fnp-2627	44	3	tissue	tissue	NOUN
fnp-2627	44	4	level	level	NOUN
fnp-2627	44	5	,	,	PUNCT
fnp-2627	44	6	irmyositis	irmyositis	NOUN
fnp-2627	44	7	can	can	AUX
fnp-2627	44	8	take	take	VERB
fnp-2627	44	9	multiple	multiple	ADJ
fnp-2627	44	10	forms	form	NOUN
fnp-2627	44	11	but	but	CCONJ
fnp-2627	44	12	the	the	DET
fnp-2627	44	13	most	most	ADV
fnp-2627	44	14	commonly	commonly	ADV
fnp-2627	44	15	observed	observe	VERB
fnp-2627	44	16	pattern	pattern	NOUN
fnp-2627	44	17	[	[	X
fnp-2627	44	18	perimysial	perimysial	ADJ
fnp-2627	44	19	foci	focus	NOUN
fnp-2627	44	20	of	of	ADP
fnp-2627	44	21	cd8	cd8	PROPN
fnp-2627	44	22	+	+	PROPN
fnp-2627	44	23	t	t	NOUN
fnp-2627	44	24	cells	cell	NOUN
fnp-2627	44	25	and	and	CCONJ
fnp-2627	44	26	cd68	cd68	PROPN
fnp-2627	44	27	+	+	PART
fnp-2627	44	28	macrophages	macrophage	NOUN
fnp-2627	44	29	that	that	PRON
fnp-2627	44	30	are	be	AUX
fnp-2627	44	31	associated	associate	VERB
fnp-2627	44	32	with	with	ADP
fnp-2627	44	33	necrosis	necrosis	NOUN
fnp-2627	44	34	of	of	ADP
fnp-2627	44	35	adjacent	adjacent	ADJ
fnp-2627	44	36	muscle	muscle	NOUN
fnp-2627	44	37	fibers	fiber	NOUN
fnp-2627	44	38	;	;	PUNCT
fnp-2627	44	39	touat	touat	PROPN
fnp-2627	44	40	et	et	PROPN
fnp-2627	44	41	al	al	PROPN
fnp-2627	44	42	.	.	PROPN
fnp-2627	45	1	(	(	PUNCT
fnp-2627	45	2	2018	2018	NUM
fnp-2627	45	3	)	)	PUNCT
fnp-2627	45	4	and	and	CCONJ
fnp-2627	45	5	fig	fig	NOUN
fnp-2627	45	6	.	.	PUNCT
fnp-2627	46	1	2	2	NUM
fnp-2627	46	2	]	]	PUNCT
fnp-2627	46	3	is	be	AUX
fnp-2627	46	4	distinct	distinct	ADJ
fnp-2627	46	5	from	from	ADP
fnp-2627	46	6	the	the	DET
fnp-2627	46	7	patterns	pattern	NOUN
fnp-2627	46	8	seen	see	VERB
fnp-2627	46	9	in	in	ADP
fnp-2627	46	10	iims	iim	NOUN
fnp-2627	46	11	.	.	PUNCT
fnp-2627	47	1	interestingly	interestingly	ADV
fnp-2627	47	2	,	,	PUNCT
fnp-2627	47	3	in	in	ADP
fnp-2627	47	4	some	some	DET
fnp-2627	47	5	cases	case	NOUN
fnp-2627	47	6	identical	identical	ADJ
fnp-2627	47	7	clonal	clonal	ADJ
fnp-2627	47	8	cd8	cd8	PROPN
fnp-2627	47	9	+	+	PROPN
fnp-2627	47	10	cells	cell	NOUN
fnp-2627	47	11	have	have	AUX
fnp-2627	47	12	been	be	AUX
fnp-2627	47	13	detected	detect	VERB
fnp-2627	47	14	within	within	ADP
fnp-2627	47	15	the	the	DET
fnp-2627	47	16	cancer	cancer	NOUN
fnp-2627	47	17	tissue	tissue	NOUN
fnp-2627	47	18	,	,	PUNCT
fnp-2627	47	19	skeletal	skeletal	ADJ
fnp-2627	47	20	muscle	muscle	NOUN
fnp-2627	47	21	,	,	PUNCT
fnp-2627	47	22	and	and	CCONJ
fnp-2627	47	23	myocardium	myocardium	NOUN
fnp-2627	47	24	,	,	PUNCT
fnp-2627	47	25	suggesting	suggest	VERB
fnp-2627	47	26	that	that	SCONJ
fnp-2627	47	27	cross	cross	NOUN
fnp-2627	47	28	-	-	NOUN
fnp-2627	47	29	reactivity	reactivity	NOUN
fnp-2627	47	30	between	between	ADP
fnp-2627	47	31	cancer	cancer	NOUN
fnp-2627	47	32	cells	cell	NOUN
fnp-2627	47	33	and	and	CCONJ
fnp-2627	47	34	myocytes	myocyte	NOUN
fnp-2627	47	35	plays	play	VERB
fnp-2627	47	36	at	at	ADP
fnp-2627	47	37	least	least	ADJ
fnp-2627	47	38	some	some	PRON
fnp-2627	47	39	role	role	NOUN
fnp-2627	47	40	in	in	ADP
fnp-2627	47	41	the	the	DET
fnp-2627	47	42	pathogenesis	pathogenesis	NOUN
fnp-2627	47	43	of	of	ADP
fnp-2627	47	44	irmyositis	irmyositis	PROPN
fnp-2627	47	45	(	(	PUNCT
fnp-2627	47	46	psimaras	psimara	NOUN
fnp-2627	47	47	et	et	PROPN
fnp-2627	47	48	al	al	PROPN
fnp-2627	47	49	.	.	PROPN
fnp-2627	47	50	,	,	PUNCT
fnp-2627	47	51	2019	2019	NUM
fnp-2627	47	52	)	)	PUNCT
fnp-2627	47	53	.	.	PUNCT
fnp-2627	48	1	figure	figure	NOUN
fnp-2627	48	2	2	2	NUM
fnp-2627	48	3	.	.	PUNCT
fnp-2627	49	1	myositis	myositis	PROPN
fnp-2627	49	2	secondary	secondary	ADJ
fnp-2627	49	3	to	to	ADP
fnp-2627	49	4	therapy	therapy	NOUN
fnp-2627	49	5	with	with	ADP
fnp-2627	49	6	immune	immune	ADJ
fnp-2627	49	7	checkpoint	checkpoint	NOUN
fnp-2627	49	8	inhibitors	inhibitor	NOUN
fnp-2627	49	9	(	(	PUNCT
fnp-2627	49	10	irmyositis	irmyositis	NOUN
fnp-2627	49	11	):	):	PUNCT
fnp-2627	49	12	a	a	DET
fnp-2627	49	13	representative	representative	ADJ
fnp-2627	49	14	h&e	h&e	NOUN
fnp-2627	49	15	-	-	PUNCT
fnp-2627	49	16	stained	stain	VERB
fnp-2627	49	17	cryosection	cryosection	NOUN
fnp-2627	49	18	(	(	PUNCT
fnp-2627	49	19	a	a	X
fnp-2627	49	20	)	)	PUNCT
fnp-2627	49	21	shows	show	VERB
fnp-2627	49	22	patches	patch	NOUN
fnp-2627	49	23	of	of	ADP
fnp-2627	49	24	dense	dense	ADJ
fnp-2627	49	25	perimysial	perimysial	ADJ
fnp-2627	49	26	inflammation	inflammation	NOUN
fnp-2627	49	27	that	that	SCONJ
fnp-2627	49	28	focally	focally	ADV
fnp-2627	49	29	extend	extend	VERB
fnp-2627	49	30	into	into	ADP
fnp-2627	49	31	the	the	DET
fnp-2627	49	32	endomysium	endomysium	NOUN
fnp-2627	49	33	and	and	CCONJ
fnp-2627	49	34	abut	abut	VERB
fnp-2627	49	35	clusters	cluster	NOUN
fnp-2627	49	36	of	of	ADP
fnp-2627	49	37	degenerating	degenerate	VERB
fnp-2627	49	38	/	/	SYM
fnp-2627	49	39	regenerating	regenerate	VERB
fnp-2627	49	40	muscle	muscle	NOUN
fnp-2627	49	41	fibers	fiber	NOUN
fnp-2627	49	42	;	;	PUNCT
fnp-2627	49	43	away	away	ADV
fnp-2627	49	44	from	from	ADP
fnp-2627	49	45	the	the	DET
fnp-2627	49	46	inflammatory	inflammatory	ADJ
fnp-2627	49	47	foci	focus	NOUN
fnp-2627	49	48	,	,	PUNCT
fnp-2627	49	49	muscle	muscle	NOUN
fnp-2627	49	50	fibers	fiber	NOUN
fnp-2627	49	51	have	have	VERB
fnp-2627	49	52	a	a	DET
fnp-2627	49	53	relatively	relatively	ADV
fnp-2627	49	54	normal	normal	ADJ
fnp-2627	49	55	appearance	appearance	NOUN
fnp-2627	49	56	.	.	PUNCT
fnp-2627	50	1	immunohistochemistry	immunohistochemistry	NOUN
fnp-2627	50	2	for	for	ADP
fnp-2627	50	3	cd8	cd8	PROPN
fnp-2627	50	4	(	(	PUNCT
fnp-2627	50	5	b	b	NOUN
fnp-2627	50	6	)	)	PUNCT
fnp-2627	50	7	and	and	CCONJ
fnp-2627	50	8	histochemistry	histochemistry	NOUN
fnp-2627	50	9	for	for	ADP
fnp-2627	50	10	acid	acid	ADJ
fnp-2627	50	11	phosphatase	phosphatase	NOUN
fnp-2627	50	12	(	(	PUNCT
fnp-2627	50	13	c	c	NOUN
fnp-2627	50	14	)	)	PUNCT
fnp-2627	50	15	show	show	VERB
fnp-2627	50	16	that	that	SCONJ
fnp-2627	50	17	the	the	DET
fnp-2627	50	18	inflammatory	inflammatory	NOUN
fnp-2627	50	19	infiltrate	infiltrate	VERB
fnp-2627	50	20	largely	largely	ADV
fnp-2627	50	21	consists	consist	VERB
fnp-2627	50	22	of	of	ADP
fnp-2627	50	23	cytotoxic	cytotoxic	ADJ
fnp-2627	50	24	t	t	NOUN
fnp-2627	50	25	cells	cell	NOUN
fnp-2627	50	26	and	and	CCONJ
fnp-2627	50	27	macrophages	macrophage	NOUN
fnp-2627	50	28	,	,	PUNCT
fnp-2627	50	29	respectively	respectively	ADV
fnp-2627	50	30	.	.	PUNCT
fnp-2627	51	1	the	the	DET
fnp-2627	51	2	patient	patient	NOUN
fnp-2627	51	3	was	be	AUX
fnp-2627	51	4	treated	treat	VERB
fnp-2627	51	5	with	with	ADP
fnp-2627	51	6	pembrolizumab	pembrolizumab	NOUN
fnp-2627	51	7	and	and	CCONJ
fnp-2627	51	8	presented	present	VERB
fnp-2627	51	9	with	with	ADP
fnp-2627	51	10	evidence	evidence	NOUN
fnp-2627	51	11	of	of	ADP
fnp-2627	51	12	myocarditis	myocarditis	NOUN
fnp-2627	51	13	as	as	ADV
fnp-2627	51	14	well	well	ADV
fnp-2627	51	15	as	as	ADP
fnp-2627	51	16	limb	limb	NOUN
fnp-2627	51	17	and	and	CCONJ
fnp-2627	51	18	bulbar	bulbar	ADJ
fnp-2627	51	19	weakness	weakness	NOUN
fnp-2627	51	20	approximately	approximately	ADV
fnp-2627	51	21	6	6	NUM
fnp-2627	51	22	weeks	week	NOUN
fnp-2627	51	23	following	follow	VERB
fnp-2627	51	24	the	the	DET
fnp-2627	51	25	last	last	ADJ
fnp-2627	51	26	antibody	antibody	NOUN
fnp-2627	51	27	dose	dose	NOUN
fnp-2627	51	28	.	.	PUNCT
fnp-2627	52	1	scale	scale	NOUN
fnp-2627	52	2	bars	bar	NOUN
fnp-2627	52	3	:	:	PUNCT
fnp-2627	52	4	a	a	DET
fnp-2627	52	5	,	,	PUNCT
fnp-2627	52	6	100	100	NUM
fnp-2627	52	7	µm	µm	NUM
fnp-2627	52	8	;	;	PUNCT
fnp-2627	52	9	b	b	X
fnp-2627	52	10	-	-	SYM
fnp-2627	52	11	c	c	NOUN
fnp-2627	52	12	,	,	PUNCT
fnp-2627	52	13	50	50	NUM
fnp-2627	52	14	µm	µm	NOUN
fnp-2627	52	15	.	.	PUNCT
fnp-2627	53	1	in	in	ADP
fnp-2627	53	2	recent	recent	ADJ
fnp-2627	53	3	years	year	NOUN
fnp-2627	53	4	,	,	PUNCT
fnp-2627	53	5	stem	stem	NOUN
fnp-2627	53	6	cell	cell	NOUN
fnp-2627	53	7	treatments	treatment	NOUN
fnp-2627	53	8	have	have	AUX
fnp-2627	53	9	also	also	ADV
fnp-2627	53	10	risen	rise	VERB
fnp-2627	53	11	in	in	ADP
fnp-2627	53	12	popularity	popularity	NOUN
fnp-2627	53	13	,	,	PUNCT
fnp-2627	53	14	although	although	SCONJ
fnp-2627	53	15	they	they	PRON
fnp-2627	53	16	have	have	VERB
fnp-2627	53	17	no	no	DET
fnp-2627	53	18	documented	document	VERB
fnp-2627	53	19	health	health	NOUN
fnp-2627	53	20	benefits	benefit	NOUN
fnp-2627	53	21	and	and	CCONJ
fnp-2627	53	22	are	be	AUX
fnp-2627	53	23	–	–	PUNCT
fnp-2627	53	24	at	at	ADP
fnp-2627	53	25	least	least	ADJ
fnp-2627	53	26	for	for	ADP
fnp-2627	53	27	now	now	ADV
fnp-2627	53	28	–	–	PUNCT
fnp-2627	53	29	completely	completely	ADV
fnp-2627	53	30	unregulated	unregulated	ADJ
fnp-2627	53	31	.	.	PUNCT
fnp-2627	54	1	in	in	ADP
fnp-2627	54	2	2019	2019	NUM
fnp-2627	54	3	,	,	PUNCT
fnp-2627	54	4	it	it	PRON
fnp-2627	54	5	was	be	AUX
fnp-2627	54	6	recognized	recognize	VERB
fnp-2627	54	7	that	that	SCONJ
fnp-2627	54	8	one	one	NUM
fnp-2627	54	9	relatively	relatively	ADV
fnp-2627	54	10	common	common	ADJ
fnp-2627	54	11	form	form	NOUN
fnp-2627	54	12	of	of	ADP
fnp-2627	54	13	stem	stem	NOUN
fnp-2627	54	14	cell	cell	NOUN
fnp-2627	54	15	treatment	treatment	NOUN
fnp-2627	54	16	,	,	PUNCT
fnp-2627	54	17	intrathecal	intrathecal	ADJ
fnp-2627	54	18	injection	injection	NOUN
fnp-2627	54	19	of	of	ADP
fnp-2627	54	20	allogeneic	allogeneic	ADJ
fnp-2627	54	21	stem	stem	NOUN
fnp-2627	54	22	cells	cell	NOUN
fnp-2627	54	23	,	,	PUNCT
fnp-2627	54	24	can	can	AUX
fnp-2627	54	25	lead	lead	VERB
fnp-2627	54	26	to	to	ADP
fnp-2627	54	27	development	development	NOUN
fnp-2627	54	28	of	of	ADP
fnp-2627	54	29	distinctive	distinctive	ADJ
fnp-2627	54	30	lesions	lesion	NOUN
fnp-2627	54	31	of	of	ADP
fnp-2627	54	32	the	the	DET
fnp-2627	54	33	lumbosacral	lumbosacral	ADJ
fnp-2627	54	34	spinal	spinal	NOUN
fnp-2627	54	35	cord	cord	NOUN
fnp-2627	54	36	and	and	CCONJ
fnp-2627	54	37	spinal	spinal	ADJ
fnp-2627	54	38	cord	cord	NOUN
fnp-2627	54	39	nerve	nerve	NOUN
fnp-2627	54	40	roots	root	NOUN
fnp-2627	54	41	.	.	PUNCT
fnp-2627	55	1	these	these	DET
fnp-2627	55	2	lesions	lesion	NOUN
fnp-2627	55	3	,	,	PUNCT
fnp-2627	55	4	named	name	VERB
fnp-2627	55	5	neuroglial	neuroglial	ADJ
fnp-2627	55	6	stem	stem	NOUN
fnp-2627	55	7	cell	cell	NOUN
fnp-2627	55	8	-	-	PUNCT
fnp-2627	55	9	derived	derive	VERB
fnp-2627	55	10	inflammatory	inflammatory	ADJ
fnp-2627	55	11	pseudotumors	pseudotumor	NOUN
fnp-2627	55	12	[	[	X
fnp-2627	55	13	n	n	CCONJ
fnp-2627	55	14	-	-	PUNCT
fnp-2627	55	15	scipts	scipt	NOUN
fnp-2627	55	16	;	;	PUNCT
fnp-2627	55	17	(	(	PUNCT
fnp-2627	55	18	sloan	sloan	NOUN
fnp-2627	55	19	et	et	PROPN
fnp-2627	55	20	al	al	PROPN
fnp-2627	55	21	.	.	PROPN
fnp-2627	55	22	,	,	PUNCT
fnp-2627	55	23	2019	2019	NUM
fnp-2627	55	24	)	)	PUNCT
fnp-2627	55	25	]	]	PUNCT
fnp-2627	55	26	,	,	PUNCT
fnp-2627	55	27	can	can	AUX
fnp-2627	55	28	clinically	clinically	ADV
fnp-2627	55	29	mimic	mimic	VERB
fnp-2627	55	30	inflammatory	inflammatory	ADJ
fnp-2627	55	31	and	and	CCONJ
fnp-2627	55	32	neoplastic	neoplastic	ADJ
fnp-2627	55	33	disease	disease	NOUN
fnp-2627	55	34	processes	process	NOUN
fnp-2627	55	35	and	and	CCONJ
fnp-2627	55	36	usually	usually	ADV
fnp-2627	55	37	consist	consist	VERB
fnp-2627	55	38	of	of	ADP
fnp-2627	55	39	a	a	DET
fnp-2627	55	40	haphazardly	haphazardly	ADV
fnp-2627	55	41	organized	organize	VERB
fnp-2627	55	42	neuroglial	neuroglial	ADJ
fnp-2627	55	43	tissue	tissue	NOUN
fnp-2627	55	44	that	that	PRON
fnp-2627	55	45	resembles	resemble	VERB
fnp-2627	55	46	a	a	DET
fnp-2627	55	47	low	low	ADJ
fnp-2627	55	48	-	-	PUNCT
fnp-2627	55	49	grade	grade	NOUN
fnp-2627	55	50	neuroglial	neuroglial	ADJ
fnp-2627	55	51	tumor	tumor	NOUN
fnp-2627	55	52	(	(	PUNCT
fnp-2627	55	53	fig	fig	NOUN
fnp-2627	55	54	.	.	PUNCT
fnp-2627	56	1	3	3	NUM
fnp-2627	56	2	)	)	PUNCT
fnp-2627	57	1	;	;	PUNCT
fnp-2627	57	2	typically	typically	ADV
fnp-2627	57	3	,	,	PUNCT
fnp-2627	57	4	there	there	PRON
fnp-2627	57	5	is	be	VERB
fnp-2627	57	6	at	at	ADP
fnp-2627	57	7	least	least	ADJ
fnp-2627	57	8	focal	focal	ADJ
fnp-2627	57	9	inflammatory	inflammatory	ADJ
fnp-2627	57	10	infiltrate	infiltrate	NOUN
fnp-2627	57	11	,	,	PUNCT
fnp-2627	57	12	which	which	PRON
fnp-2627	57	13	likely	likely	ADV
fnp-2627	57	14	represents	represent	VERB
fnp-2627	57	15	a	a	DET
fnp-2627	57	16	host	host	NOUN
fnp-2627	57	17	immune	immune	ADJ
fnp-2627	57	18	response	response	NOUN
fnp-2627	57	19	to	to	ADP
fnp-2627	57	20	foreign	foreign	ADJ
fnp-2627	57	21	antigens	antigen	NOUN
fnp-2627	57	22	.	.	PUNCT
fnp-2627	58	1	while	while	SCONJ
fnp-2627	58	2	it	it	PRON
fnp-2627	58	3	seems	seem	VERB
fnp-2627	58	4	likely	likely	ADJ
fnp-2627	58	5	that	that	SCONJ
fnp-2627	58	6	direct	direct	ADJ
fnp-2627	58	7	injection	injection	NOUN
fnp-2627	58	8	of	of	ADP
fnp-2627	58	9	allogeneic	allogeneic	ADJ
fnp-2627	58	10	stem	stem	NOUN
fnp-2627	58	11	cells	cell	NOUN
fnp-2627	58	12	into	into	ADP
fnp-2627	58	13	other	other	ADJ
fnp-2627	58	14	parts	part	NOUN
fnp-2627	58	15	of	of	ADP
fnp-2627	58	16	the	the	DET
fnp-2627	58	17	body	body	NOUN
fnp-2627	58	18	could	could	AUX
fnp-2627	58	19	lead	lead	VERB
fnp-2627	58	20	to	to	ADP
fnp-2627	58	21	development	development	NOUN
fnp-2627	58	22	of	of	ADP
fnp-2627	58	23	stem	stem	NOUN
fnp-2627	58	24	-	-	PUNCT
fnp-2627	58	25	cell	cell	NOUN
fnp-2627	58	26	derived	derive	VERB
fnp-2627	58	27	pseudotumors	pseudotumor	NOUN
fnp-2627	58	28	with	with	ADP
fnp-2627	58	29	non	non	ADJ
fnp-2627	58	30	-	-	ADJ
fnp-2627	58	31	neuroglial	neuroglial	ADJ
fnp-2627	58	32	differentiation	differentiation	NOUN
fnp-2627	58	33	,	,	PUNCT
fnp-2627	58	34	only	only	ADV
fnp-2627	58	35	neuroglial	neuroglial	ADJ
fnp-2627	58	36	scipts	scipt	NOUN
fnp-2627	58	37	have	have	AUX
fnp-2627	58	38	been	be	AUX
fnp-2627	58	39	reported	report	VERB
fnp-2627	58	40	to	to	ADP
fnp-2627	58	41	date	date	NOUN
fnp-2627	58	42	(	(	PUNCT
fnp-2627	58	43	sloan	sloan	NOUN
fnp-2627	58	44	et	et	PROPN
fnp-2627	58	45	al	al	PROPN
fnp-2627	58	46	.	.	PROPN
fnp-2627	58	47	,	,	PUNCT
fnp-2627	58	48	2019	2019	NUM
fnp-2627	58	49	)	)	PUNCT
fnp-2627	58	50	.	.	PUNCT
fnp-2627	59	1	from	from	ADP
fnp-2627	59	2	a	a	DET
fnp-2627	59	3	diagnostic	diagnostic	ADJ
fnp-2627	59	4	perspective	perspective	NOUN
fnp-2627	59	5	,	,	PUNCT
fnp-2627	59	6	it	it	PRON
fnp-2627	59	7	is	be	AUX
fnp-2627	59	8	critical	critical	ADJ
fnp-2627	59	9	to	to	PART
fnp-2627	59	10	be	be	AUX
fnp-2627	59	11	aware	aware	ADJ
fnp-2627	59	12	of	of	ADP
fnp-2627	59	13	the	the	DET
fnp-2627	59	14	n	n	CCONJ
fnp-2627	59	15	-	-	PUNCT
fnp-2627	59	16	scipt	scipt	NOUN
fnp-2627	59	17	existence	existence	NOUN
fnp-2627	59	18	,	,	PUNCT
fnp-2627	59	19	so	so	SCONJ
fnp-2627	59	20	that	that	SCONJ
fnp-2627	59	21	these	these	DET
fnp-2627	59	22	lesions	lesion	NOUN
fnp-2627	59	23	(	(	PUNCT
fnp-2627	59	24	which	which	PRON
fnp-2627	59	25	at	at	ADP
fnp-2627	59	26	the	the	DET
fnp-2627	59	27	moment	moment	NOUN
fnp-2627	59	28	seem	seem	VERB
fnp-2627	59	29	to	to	PART
fnp-2627	59	30	be	be	AUX
fnp-2627	59	31	best	well	ADV
fnp-2627	59	32	handled	handle	VERB
fnp-2627	59	33	through	through	ADP
fnp-2627	59	34	watchful	watchful	ADJ
fnp-2627	59	35	waiting	waiting	NOUN
fnp-2627	59	36	)	)	PUNCT
fnp-2627	59	37	are	be	AUX
fnp-2627	59	38	distinguished	distinguish	VERB
fnp-2627	59	39	from	from	ADP
fnp-2627	59	40	the	the	DET
fnp-2627	59	41	spinal	spinal	ADJ
fnp-2627	59	42	cord	cord	NOUN
fnp-2627	59	43	tumors	tumor	NOUN
fnp-2627	59	44	that	that	PRON
fnp-2627	59	45	would	would	AUX
fnp-2627	59	46	generally	generally	ADV
fnp-2627	59	47	warrant	warrant	VERB
fnp-2627	59	48	a	a	DET
fnp-2627	59	49	more	more	ADV
fnp-2627	59	50	aggressive	aggressive	ADJ
fnp-2627	59	51	treatment	treatment	NOUN
fnp-2627	59	52	.	.	PUNCT
fnp-2627	60	1	advances	advance	NOUN
fnp-2627	60	2	in	in	ADP
fnp-2627	60	3	understanding	understanding	NOUN
fnp-2627	60	4	of	of	ADP
fnp-2627	60	5	etiology	etiology	NOUN
fnp-2627	60	6	and	and	CCONJ
fnp-2627	60	7	pathogenesis	pathogenesis	NOUN
fnp-2627	60	8	of	of	ADP
fnp-2627	60	9	neuromuscular	neuromuscular	ADJ
fnp-2627	60	10	diseases	disease	NOUN
fnp-2627	60	11	3	3	NUM
fnp-2627	60	12	.	.	X
fnp-2627	60	13	acute	acute	ADJ
fnp-2627	60	14	flaccid	flaccid	ADJ
fnp-2627	60	15	myelitis	myelitis	NOUN
fnp-2627	60	16	:	:	PUNCT
fnp-2627	60	17	mounting	mount	VERB
fnp-2627	60	18	evidence	evidence	NOUN
fnp-2627	60	19	for	for	ADP
fnp-2627	60	20	causation	causation	NOUN
fnp-2627	60	21	by	by	ADP
fnp-2627	60	22	non	non	ADJ
fnp-2627	60	23	-	-	ADJ
fnp-2627	60	24	polio	polio	ADJ
fnp-2627	60	25	enteroviruses	enterovirus	NOUN
fnp-2627	60	26	acute	acute	VERB
fnp-2627	60	27	flaccid	flaccid	ADJ
fnp-2627	60	28	myelitis	myelitis	NOUN
fnp-2627	60	29	(	(	PUNCT
fnp-2627	60	30	afm	afm	PROPN
fnp-2627	60	31	)	)	PUNCT
fnp-2627	60	32	is	be	AUX
fnp-2627	60	33	a	a	DET
fnp-2627	60	34	clinical	clinical	ADJ
fnp-2627	60	35	syndrome	syndrome	NOUN
fnp-2627	60	36	characterized	characterize	VERB
fnp-2627	60	37	by	by	ADP
fnp-2627	60	38	flaccid	flaccid	ADJ
fnp-2627	60	39	limb	limb	NOUN
fnp-2627	60	40	weakness	weakness	NOUN
fnp-2627	60	41	that	that	PRON
fnp-2627	60	42	develops	develop	VERB
fnp-2627	60	43	acutely	acutely	ADV
fnp-2627	60	44	and	and	CCONJ
fnp-2627	60	45	has	have	VERB
fnp-2627	60	46	a	a	DET
fnp-2627	60	47	lower	low	ADJ
fnp-2627	60	48	motor	motor	NOUN
fnp-2627	60	49	neuron	neuron	NOUN
fnp-2627	60	50	pattern	pattern	NOUN
fnp-2627	60	51	;	;	PUNCT
fnp-2627	60	52	the	the	DET
fnp-2627	60	53	current	current	ADJ
fnp-2627	60	54	diagnostic	diagnostic	ADJ
fnp-2627	60	55	criteria	criterion	NOUN
fnp-2627	60	56	also	also	ADV
fnp-2627	60	57	include	include	VERB
fnp-2627	60	58	spinal	spinal	NOUN
fnp-2627	60	59	cord	cord	NOUN
fnp-2627	60	60	imaging	imaging	NOUN
fnp-2627	60	61	findings	finding	VERB
fnp-2627	60	62	suggestive	suggestive	ADJ
fnp-2627	60	63	of	of	ADP
fnp-2627	60	64	anterior	anterior	ADJ
fnp-2627	60	65	myelitis	myelitis	NOUN
fnp-2627	60	66	(	(	PUNCT
fnp-2627	60	67	messacar	messacar	NOUN
fnp-2627	60	68	et	et	PROPN
fnp-2627	60	69	al	al	PROPN
fnp-2627	60	70	.	.	PROPN
fnp-2627	60	71	,	,	PUNCT
fnp-2627	60	72	2018	2018	NUM
fnp-2627	60	73	)	)	PUNCT
fnp-2627	60	74	.	.	PUNCT
fnp-2627	61	1	the	the	DET
fnp-2627	61	2	most	most	ADV
fnp-2627	61	3	common	common	ADJ
fnp-2627	61	4	form	form	NOUN
fnp-2627	61	5	of	of	ADP
fnp-2627	61	6	afm	afm	PROPN
fnp-2627	61	7	used	use	VERB
fnp-2627	61	8	to	to	PART
fnp-2627	61	9	be	be	AUX
fnp-2627	61	10	poliomyelitis	poliomyelitis	NOUN
fnp-2627	61	11	,	,	PUNCT
fnp-2627	61	12	which	which	PRON
fnp-2627	61	13	is	be	AUX
fnp-2627	61	14	caused	cause	VERB
fnp-2627	61	15	by	by	ADP
fnp-2627	61	16	poliovirus	poliovirus	NOUN
fnp-2627	61	17	[	[	X
fnp-2627	61	18	a	a	DET
fnp-2627	61	19	member	member	NOUN
fnp-2627	61	20	of	of	ADP
fnp-2627	61	21	the	the	DET
fnp-2627	61	22	en	en	X
fnp-2627	61	23	terovirus	terovirus	NOUN
fnp-2627	61	24	(	(	PUNCT
fnp-2627	61	25	ev	ev	NOUN
fnp-2627	61	26	)	)	PUNCT
fnp-2627	61	27	genus	genus	NOUN
fnp-2627	61	28	]	]	X
fnp-2627	61	29	;	;	PUNCT
fnp-2627	61	30	as	as	ADP
fnp-2627	61	31	a	a	DET
fnp-2627	61	32	result	result	NOUN
fnp-2627	61	33	,	,	PUNCT
fnp-2627	61	34	afm	afm	PROPN
fnp-2627	61	35	became	become	VERB
fnp-2627	61	36	rare	rare	ADJ
fnp-2627	61	37	worldwide	worldwide	ADV
fnp-2627	61	38	after	after	ADP
fnp-2627	61	39	introduction	introduction	NOUN
fnp-2627	61	40	of	of	ADP
fnp-2627	61	41	the	the	DET
fnp-2627	61	42	anti	anti	ADJ
fnp-2627	61	43	-	-	ADJ
fnp-2627	61	44	polio	polio	ADJ
fnp-2627	61	45	vaccine	vaccine	NOUN
fnp-2627	61	46	in	in	ADP
fnp-2627	61	47	the	the	DET
fnp-2627	61	48	1950s	1950s	NUM
fnp-2627	61	49	.	.	PUNCT
fnp-2627	62	1	a	a	DET
fnp-2627	62	2	small	small	ADJ
fnp-2627	62	3	number	number	NOUN
fnp-2627	62	4	of	of	ADP
fnp-2627	62	5	afm	afm	PROPN
fnp-2627	62	6	cases	case	NOUN
fnp-2627	62	7	in	in	ADP
fnp-2627	62	8	the	the	DET
fnp-2627	62	9	period	period	NOUN
fnp-2627	62	10	from	from	ADP
fnp-2627	62	11	1970	1970	NUM
fnp-2627	62	12	-	-	SYM
fnp-2627	62	13	90	90	NUM
fnp-2627	62	14	was	be	AUX
fnp-2627	62	15	attributed	attribute	VERB
fnp-2627	62	16	to	to	ADP
fnp-2627	62	17	infection	infection	NOUN
fnp-2627	62	18	with	with	ADP
fnp-2627	62	19	ev	ev	PROPN
fnp-2627	62	20	-	-	PUNCT
fnp-2627	62	21	a71	a71	PROPN
fnp-2627	62	22	and	and	CCONJ
fnp-2627	62	23	a	a	DET
fnp-2627	62	24	few	few	ADJ
fnp-2627	62	25	other	other	ADJ
fnp-2627	62	26	viruses	virus	NOUN
fnp-2627	62	27	(	(	PUNCT
fnp-2627	62	28	dyda	dyda	PROPN
fnp-2627	62	29	et	et	PROPN
fnp-2627	62	30	al	al	PROPN
fnp-2627	62	31	.	.	PROPN
fnp-2627	62	32	,	,	PUNCT
fnp-2627	62	33	2018	2018	NUM
fnp-2627	62	34	;	;	PUNCT
fnp-2627	62	35	messacar	messacar	NOUN
fnp-2627	62	36	et	et	PROPN
fnp-2627	62	37	al	al	PROPN
fnp-2627	62	38	.	.	PROPN
fnp-2627	62	39	,	,	PUNCT
fnp-2627	62	40	2018	2018	NUM
fnp-2627	62	41	)	)	PUNCT
fnp-2627	62	42	.	.	PUNCT
fnp-2627	63	1	since	since	SCONJ
fnp-2627	63	2	2012	2012	NUM
fnp-2627	63	3	,	,	PUNCT
fnp-2627	63	4	however	however	ADV
fnp-2627	63	5	,	,	PUNCT
fnp-2627	63	6	afm	afm	PROPN
fnp-2627	63	7	has	have	AUX
fnp-2627	63	8	started	start	VERB
fnp-2627	63	9	to	to	PART
fnp-2627	63	10	increase	increase	VERB
fnp-2627	63	11	in	in	ADP
fnp-2627	63	12	incidence	incidence	NOUN
fnp-2627	63	13	.	.	PUNCT
fnp-2627	64	1	the	the	DET
fnp-2627	64	2	current	current	ADJ
fnp-2627	64	3	form	form	NOUN
fnp-2627	64	4	of	of	ADP
fnp-2627	64	5	this	this	DET
fnp-2627	64	6	disease	disease	NOUN
fnp-2627	64	7	,	,	PUNCT
fnp-2627	64	8	first	first	ADV
fnp-2627	64	9	documented	document	VERB
fnp-2627	64	10	in	in	ADP
fnp-2627	64	11	california	california	PROPN
fnp-2627	64	12	,	,	PUNCT
fnp-2627	64	13	is	be	AUX
fnp-2627	64	14	characterized	characterize	VERB
fnp-2627	64	15	by	by	ADP
fnp-2627	64	16	limb	limb	NOUN
fnp-2627	64	17	paralysis	paralysis	NOUN
fnp-2627	64	18	that	that	PRON
fnp-2627	64	19	occurs	occur	VERB
fnp-2627	64	20	5	5	NUM
fnp-2627	64	21	-	-	SYM
fnp-2627	64	22	7	7	NUM
fnp-2627	64	23	days	day	NOUN
fnp-2627	64	24	after	after	ADP
fnp-2627	64	25	a	a	DET
fnp-2627	64	26	flu	flu	NOUN
fnp-2627	64	27	-	-	PUNCT
fnp-2627	64	28	like	like	ADJ
fnp-2627	64	29	respiratory	respiratory	ADJ
fnp-2627	64	30	illness	illness	NOUN
fnp-2627	64	31	;	;	PUNCT
fnp-2627	64	32	it	it	PRON
fnp-2627	64	33	primarily	primarily	ADV
fnp-2627	64	34	affects	affect	VERB
fnp-2627	64	35	young	young	ADJ
fnp-2627	64	36	children	child	NOUN
fnp-2627	64	37	(	(	PUNCT
fnp-2627	64	38	3	3	NUM
fnp-2627	64	39	-	-	SYM
fnp-2627	64	40	9	9	NUM
fnp-2627	64	41	years	year	NOUN
fnp-2627	64	42	of	of	ADP
fnp-2627	64	43	age	age	NOUN
fnp-2627	64	44	)	)	PUNCT
fnp-2627	64	45	and	and	CCONJ
fnp-2627	64	46	peaks	peak	NOUN
fnp-2627	64	47	in	in	ADP
fnp-2627	64	48	incidence	incidence	NOUN
fnp-2627	64	49	every	every	DET
fnp-2627	64	50	other	other	ADJ
fnp-2627	64	51	year	year	NOUN
fnp-2627	64	52	during	during	ADP
fnp-2627	64	53	the	the	DET
fnp-2627	64	54	summer	summer	NOUN
fnp-2627	64	55	/	/	SYM
fnp-2627	64	56	fall	fall	NOUN
fnp-2627	64	57	season	season	NOUN
fnp-2627	64	58	.	.	PUNCT
fnp-2627	65	1	the	the	DET
fnp-2627	65	2	largest	large	ADJ
fnp-2627	65	3	number	number	NOUN
fnp-2627	65	4	of	of	ADP
fnp-2627	65	5	confirmed	confirm	VERB
fnp-2627	65	6	cases	case	NOUN
fnp-2627	65	7	(	(	PUNCT
fnp-2627	65	8	>	>	SYM
fnp-2627	65	9	500	500	NUM
fnp-2627	65	10	to	to	ADP
fnp-2627	65	11	date	date	NOUN
fnp-2627	65	12	)	)	PUNCT
fnp-2627	65	13	has	have	AUX
fnp-2627	65	14	been	be	AUX
fnp-2627	65	15	reported	report	VERB
fnp-2627	65	16	in	in	ADP
fnp-2627	65	17	the	the	DET
fnp-2627	65	18	us	us	PROPN
fnp-2627	65	19	,	,	PUNCT
fnp-2627	65	20	with	with	ADP
fnp-2627	65	21	sporadic	sporadic	ADJ
fnp-2627	65	22	cases	case	NOUN
fnp-2627	65	23	confirmed	confirm	VERB
fnp-2627	65	24	throughout	throughout	ADP
fnp-2627	65	25	the	the	DET
fnp-2627	65	26	world	world	NOUN
fnp-2627	65	27	(	(	PUNCT
fnp-2627	65	28	schubert	schubert	PROPN
fnp-2627	65	29	et	et	PROPN
fnp-2627	65	30	al	al	PROPN
fnp-2627	65	31	.	.	PROPN
fnp-2627	65	32	,	,	PUNCT
fnp-2627	65	33	2019	2019	NUM
fnp-2627	65	34	)	)	PUNCT
fnp-2627	65	35	.	.	PUNCT
fnp-2627	66	1	in	in	ADP
fnp-2627	66	2	2014	2014	NUM
fnp-2627	66	3	,	,	PUNCT
fnp-2627	66	4	the	the	DET
fnp-2627	66	5	peak	peak	NOUN
fnp-2627	66	6	of	of	ADP
fnp-2627	66	7	afm	afm	PROPN
fnp-2627	66	8	incidence	incidence	NOUN
fnp-2627	66	9	has	have	AUX
fnp-2627	66	10	shown	show	VERB
fnp-2627	66	11	a	a	DET
fnp-2627	66	12	temporal	temporal	ADJ
fnp-2627	66	13	and	and	CCONJ
fnp-2627	66	14	geographic	geographic	ADJ
fnp-2627	66	15	overlap	overlap	NOUN
fnp-2627	66	16	with	with	ADP
fnp-2627	66	17	the	the	DET
fnp-2627	66	18	outbreak	outbreak	NOUN
fnp-2627	66	19	of	of	ADP
fnp-2627	66	20	ev	ev	NOUN
fnp-2627	66	21	-	-	PUNCT
fnp-2627	66	22	d68	d68	NOUN
fnp-2627	66	23	infection	infection	NOUN
fnp-2627	66	24	,	,	PUNCT
fnp-2627	66	25	raising	raise	VERB
fnp-2627	66	26	the	the	DET
fnp-2627	66	27	possibility	possibility	NOUN
fnp-2627	66	28	that	that	SCONJ
fnp-2627	66	29	ev	ev	NOUN
fnp-2627	66	30	-	-	PUNCT
fnp-2627	66	31	d68	d68	PROPN
fnp-2627	66	32	(	(	PUNCT
fnp-2627	66	33	which	which	PRON
fnp-2627	66	34	rarely	rarely	ADV
fnp-2627	66	35	caused	cause	VERB
fnp-2627	66	36	human	human	ADJ
fnp-2627	66	37	disease	disease	NOUN
fnp-2627	66	38	prior	prior	ADV
fnp-2627	66	39	to	to	ADP
fnp-2627	66	40	2008	2008	NUM
fnp-2627	66	41	)	)	PUNCT
fnp-2627	66	42	might	might	AUX
fnp-2627	66	43	be	be	AUX
fnp-2627	66	44	the	the	DET
fnp-2627	66	45	cause	cause	NOUN
fnp-2627	66	46	of	of	ADP
fnp-2627	66	47	recent	recent	ADJ
fnp-2627	66	48	afm	afm	NOUN
fnp-2627	66	49	outbreaks	outbreak	NOUN
fnp-2627	66	50	(	(	PUNCT
fnp-2627	66	51	dyda	dyda	PROPN
fnp-2627	66	52	et	et	PROPN
fnp-2627	66	53	al	al	PROPN
fnp-2627	66	54	.	.	PROPN
fnp-2627	66	55	,	,	PUNCT
fnp-2627	66	56	2018	2018	NUM
fnp-2627	66	57	)	)	PUNCT
fnp-2627	66	58	.	.	PUNCT
fnp-2627	67	1	indeed	indeed	ADV
fnp-2627	67	2	,	,	PUNCT
fnp-2627	67	3	ev	ev	VERB
fnp-2627	67	4	-	-	PUNCT
fnp-2627	67	5	d68	d68	PROPN
fnp-2627	67	6	infection	infection	NOUN
fnp-2627	67	7	meets	meet	VERB
fnp-2627	67	8	many	many	ADJ
fnp-2627	67	9	of	of	ADP
fnp-2627	67	10	the	the	DET
fnp-2627	67	11	bradford	bradford	PROPN
fnp-2627	67	12	-	-	PUNCT
fnp-2627	67	13	hill	hill	NOUN
fnp-2627	67	14	criteria	criterion	NOUN
fnp-2627	67	15	(	(	PUNCT
fnp-2627	67	16	nine	nine	NUM
fnp-2627	67	17	principles	principle	NOUN
fnp-2627	67	18	applied	apply	VERB
fnp-2627	67	19	to	to	PART
fnp-2627	67	20	examine	examine	VERB
fnp-2627	67	21	causality	causality	NOUN
fnp-2627	67	22	)	)	PUNCT
fnp-2627	67	23	that	that	PRON
fnp-2627	67	24	are	be	AUX
fnp-2627	67	25	required	require	VERB
fnp-2627	67	26	to	to	PART
fnp-2627	67	27	establish	establish	VERB
fnp-2627	67	28	it	it	PRON
fnp-2627	67	29	as	as	ADP
fnp-2627	67	30	a	a	DET
fnp-2627	67	31	cause	cause	NOUN
fnp-2627	67	32	of	of	ADP
fnp-2627	67	33	afm	afm	PROPN
fnp-2627	67	34	(	(	PUNCT
fnp-2627	67	35	dyda	dyda	PROPN
fnp-2627	67	36	et	et	PROPN
fnp-2627	67	37	al	al	PROPN
fnp-2627	67	38	.	.	PROPN
fnp-2627	67	39	,	,	PUNCT
fnp-2627	67	40	2018	2018	NUM
fnp-2627	67	41	;	;	PUNCT
fnp-2627	67	42	messacar	messacar	NOUN
fnp-2627	67	43	et	et	PROPN
fnp-2627	67	44	al	al	PROPN
fnp-2627	67	45	.	.	PROPN
fnp-2627	67	46	,	,	PUNCT
fnp-2627	67	47	2018	2018	NUM
fnp-2627	67	48	)	)	PUNCT
fnp-2627	67	49	.	.	PUNCT
fnp-2627	68	1	in	in	ADP
fnp-2627	68	2	particular	particular	ADJ
fnp-2627	68	3	,	,	PUNCT
fnp-2627	68	4	afm	afm	PROPN
fnp-2627	68	5	-	-	PUNCT
fnp-2627	68	6	like	like	ADJ
fnp-2627	68	7	disease	disease	NOUN
fnp-2627	68	8	can	can	AUX
fnp-2627	68	9	be	be	AUX
fnp-2627	68	10	recapitulated	recapitulate	VERB
fnp-2627	68	11	in	in	ADP
fnp-2627	68	12	a	a	DET
fnp-2627	68	13	mouse	mouse	NOUN
fnp-2627	68	14	model	model	NOUN
fnp-2627	68	15	through	through	ADP
fnp-2627	68	16	infection	infection	NOUN
fnp-2627	68	17	with	with	ADP
fnp-2627	68	18	a	a	DET
fnp-2627	68	19	2014	2014	NUM
fnp-2627	68	20	strain	strain	NOUN
fnp-2627	68	21	(	(	PUNCT
fnp-2627	68	22	but	but	CCONJ
fnp-2627	68	23	not	not	PART
fnp-2627	68	24	the	the	DET
fnp-2627	68	25	originally	originally	ADV
fnp-2627	68	26	isolated	isolate	VERB
fnp-2627	68	27	1962	1962	NUM
fnp-2627	68	28	strain	strain	NOUN
fnp-2627	68	29	)	)	PUNCT
fnp-2627	68	30	of	of	ADP
fnp-2627	68	31	ev	ev	NOUN
fnp-2627	68	32	-	-	PUNCT
fnp-2627	68	33	d68	d68	NOUN
fnp-2627	68	34	,	,	PUNCT
fnp-2627	68	35	suggesting	suggest	VERB
fnp-2627	68	36	that	that	SCONJ
fnp-2627	68	37	neurotropism	neurotropism	NOUN
fnp-2627	68	38	might	might	AUX
fnp-2627	68	39	have	have	AUX
fnp-2627	68	40	emerged	emerge	VERB
fnp-2627	68	41	only	only	ADV
fnp-2627	68	42	recently	recently	ADV
fnp-2627	68	43	in	in	ADP
fnp-2627	68	44	ev	ev	ADJ
fnp-2627	68	45	-	-	PUNCT
fnp-2627	68	46	d68	d68	PROPN
fnp-2627	68	47	evolution	evolution	NOUN
fnp-2627	68	48	(	(	PUNCT
fnp-2627	68	49	hixon	hixon	VERB
fnp-2627	68	50	et	et	PROPN
fnp-2627	68	51	al	al	PROPN
fnp-2627	68	52	.	.	PROPN
fnp-2627	68	53	,	,	PUNCT
fnp-2627	68	54	2017	2017	NUM
fnp-2627	68	55	)	)	PUNCT
fnp-2627	68	56	.	.	PUNCT
fnp-2627	69	1	however	however	ADV
fnp-2627	69	2	,	,	PUNCT
fnp-2627	69	3	2016	2016	NUM
fnp-2627	69	4	afm	afm	PROPN
fnp-2627	69	5	cases	case	NOUN
fnp-2627	69	6	have	have	AUX
fnp-2627	69	7	not	not	PART
fnp-2627	69	8	shown	show	VERB
fnp-2627	69	9	a	a	DET
fnp-2627	69	10	clear	clear	ADJ
fnp-2627	69	11	association	association	NOUN
fnp-2627	69	12	with	with	ADP
fnp-2627	69	13	an	an	DET
fnp-2627	69	14	ev	ev	ADJ
fnp-2627	69	15	-	-	PUNCT
fnp-2627	69	16	d68	d68	NOUN
fnp-2627	69	17	outbreak	outbreak	NOUN
fnp-2627	69	18	,	,	PUNCT
fnp-2627	69	19	raising	raise	VERB
fnp-2627	69	20	doubts	doubt	NOUN
fnp-2627	69	21	about	about	ADP
fnp-2627	69	22	the	the	DET
fnp-2627	69	23	causal	causal	PROPN
fnp-2627	69	24	association	association	NOUN
fnp-2627	69	25	between	between	ADP
fnp-2627	69	26	ev	ev	NOUN
fnp-2627	69	27	-	-	PUNCT
fnp-2627	69	28	d68	d68	PROPN
fnp-2627	69	29	and	and	CCONJ
fnp-2627	69	30	afm	afm	PROPN
fnp-2627	69	31	(	(	PUNCT
fnp-2627	69	32	dyda	dyda	PROPN
fnp-2627	69	33	et	et	PROPN
fnp-2627	69	34	al	al	PROPN
fnp-2627	69	35	.	.	PROPN
fnp-2627	69	36	,	,	PUNCT
fnp-2627	69	37	2018	2018	NUM
fnp-2627	69	38	)	)	PUNCT
fnp-2627	69	39	.	.	PUNCT
fnp-2627	70	1	moreover	moreover	ADV
fnp-2627	70	2	,	,	PUNCT
fnp-2627	70	3	ev	ev	PROPN
fnp-2627	70	4	has	have	AUX
fnp-2627	70	5	not	not	PART
fnp-2627	70	6	been	be	AUX
fnp-2627	70	7	detected	detect	VERB
fnp-2627	70	8	in	in	ADP
fnp-2627	70	9	the	the	DET
fnp-2627	70	10	respiratory	respiratory	ADJ
fnp-2627	70	11	or	or	CCONJ
fnp-2627	70	12	gi	gi	VERB
fnp-2627	70	13	specimens	specimen	NOUN
fnp-2627	70	14	from	from	ADP
fnp-2627	70	15	more	more	ADJ
fnp-2627	70	16	than	than	ADP
fnp-2627	70	17	half	half	NOUN
fnp-2627	70	18	of	of	ADP
fnp-2627	70	19	afm	afm	PROPN
fnp-2627	70	20	children	child	NOUN
fnp-2627	70	21	,	,	PUNCT
fnp-2627	70	22	and	and	CCONJ
fnp-2627	70	23	ev	ev	PRON
fnp-2627	70	24	rna	rna	NOUN
fnp-2627	70	25	is	be	AUX
fnp-2627	70	26	very	very	ADV
fnp-2627	70	27	rarely	rarely	ADV
fnp-2627	70	28	detected	detect	VERB
fnp-2627	70	29	in	in	ADP
fnp-2627	70	30	the	the	DET
fnp-2627	70	31	csf	csf	NOUN
fnp-2627	70	32	of	of	ADP
fnp-2627	70	33	afm	afm	PROPN
fnp-2627	70	34	patients	patient	NOUN
fnp-2627	70	35	(	(	PUNCT
fnp-2627	70	36	schubert	schubert	PROPN
fnp-2627	70	37	et	et	PROPN
fnp-2627	70	38	al	al	PROPN
fnp-2627	70	39	.	.	PROPN
fnp-2627	70	40	,	,	PUNCT
fnp-2627	70	41	2019	2019	NUM
fnp-2627	70	42	)	)	PUNCT
fnp-2627	70	43	;	;	PUNCT
fnp-2627	70	44	thus	thus	ADV
fnp-2627	70	45	,	,	PUNCT
fnp-2627	70	46	concerns	concern	NOUN
fnp-2627	70	47	have	have	AUX
fnp-2627	70	48	persisted	persist	VERB
fnp-2627	70	49	that	that	SCONJ
fnp-2627	70	50	recent	recent	ADJ
fnp-2627	70	51	afm	afm	NOUN
fnp-2627	70	52	outbreaks	outbreak	NOUN
fnp-2627	70	53	might	might	AUX
fnp-2627	70	54	be	be	AUX
fnp-2627	70	55	caused	cause	VERB
fnp-2627	70	56	by	by	ADP
fnp-2627	70	57	a	a	DET
fnp-2627	70	58	still	still	ADV
fnp-2627	70	59	unidentified	unidentified	ADJ
fnp-2627	70	60	pathogen	pathogen	NOUN
fnp-2627	70	61	or	or	CCONJ
fnp-2627	70	62	an	an	DET
fnp-2627	70	63	autoimmune	autoimmune	ADJ
fnp-2627	70	64	mechanism	mechanism	NOUN
fnp-2627	70	65	.	.	PUNCT
fnp-2627	71	1	the	the	DET
fnp-2627	71	2	2019	2019	NUM
fnp-2627	71	3	study	study	NOUN
fnp-2627	71	4	by	by	ADP
fnp-2627	71	5	schubert	schubert	PROPN
fnp-2627	71	6	et	et	PROPN
fnp-2627	71	7	al	al	PROPN
fnp-2627	71	8	.	.	PROPN
fnp-2627	71	9	has	have	AUX
fnp-2627	71	10	used	use	VERB
fnp-2627	71	11	a	a	DET
fnp-2627	71	12	multi	multi	ADJ
fnp-2627	71	13	-	-	ADJ
fnp-2627	71	14	pronged	pronged	ADJ
fnp-2627	71	15	approach	approach	NOUN
fnp-2627	71	16	[	[	X
fnp-2627	71	17	metagenomic	metagenomic	ADJ
fnp-2627	71	18	ultra	ultra	ADJ
fnp-2627	71	19	-	-	ADJ
fnp-2627	71	20	deep	deep	ADJ
fnp-2627	71	21	next	next	ADJ
fnp-2627	71	22	generation	generation	NOUN
fnp-2627	71	23	sequencing	sequence	VERB
fnp-2627	71	24	(	(	PUNCT
fnp-2627	71	25	mngs	mng	NOUN
fnp-2627	71	26	)	)	PUNCT
fnp-2627	71	27	of	of	ADP
fnp-2627	71	28	the	the	DET
fnp-2627	71	29	csf	csf	NOUN
fnp-2627	71	30	to	to	PART
fnp-2627	71	31	detect	detect	VERB
fnp-2627	71	32	the	the	DET
fnp-2627	71	33	pathogen	pathogen	NOUN
fnp-2627	71	34	-	-	PUNCT
fnp-2627	71	35	derived	derive	VERB
fnp-2627	71	36	nucleic	nucleic	ADJ
fnp-2627	71	37	acids	acid	NOUN
fnp-2627	71	38	,	,	PUNCT
fnp-2627	71	39	and	and	CCONJ
fnp-2627	71	40	antiviral	antiviral	ADJ
fnp-2627	71	41	antibody	antibody	NOUN
fnp-2627	71	42	detection	detection	NOUN
fnp-2627	71	43	in	in	ADP
fnp-2627	71	44	the	the	DET
fnp-2627	71	45	csf	csf	NOUN
fnp-2627	71	46	using	use	VERB
fnp-2627	71	47	virscan	virscan	PROPN
fnp-2627	71	48	phage	phage	NOUN
fnp-2627	71	49	display	display	NOUN
fnp-2627	71	50	library	library	NOUN
fnp-2627	71	51	and	and	CCONJ
fnp-2627	71	52	ev	ev	ADP
fnp-2627	71	53	elisa	elisa	PROPN
fnp-2627	71	54	)	)	PUNCT
fnp-2627	71	55	to	to	PART
fnp-2627	71	56	analyze	analyze	VERB
fnp-2627	71	57	42	42	NUM
fnp-2627	71	58	afm	afm	PROPN
fnp-2627	71	59	cases	case	NOUN
fnp-2627	71	60	(	(	PUNCT
fnp-2627	71	61	covering	cover	VERB
fnp-2627	71	62	all	all	DET
fnp-2627	71	63	outbreaks	outbreak	NOUN
fnp-2627	71	64	from	from	ADP
fnp-2627	71	65	2012	2012	NUM
fnp-2627	71	66	-	-	SYM
fnp-2627	71	67	2018	2018	NUM
fnp-2627	71	68	)	)	PUNCT
fnp-2627	71	69	and	and	CCONJ
fnp-2627	71	70	58	58	NUM
fnp-2627	71	71	neurologic	neurologic	ADJ
fnp-2627	71	72	disease	disease	NOUN
fnp-2627	71	73	controls	control	NOUN
fnp-2627	71	74	.	.	PUNCT
fnp-2627	72	1	except	except	SCONJ
fnp-2627	72	2	for	for	ADP
fnp-2627	72	3	one	one	NUM
fnp-2627	72	4	already	already	ADV
fnp-2627	72	5	known	know	VERB
fnp-2627	72	6	ev	ev	NOUN
fnp-2627	72	7	-	-	PUNCT
fnp-2627	72	8	d68	d68	NOUN
fnp-2627	72	9	-	-	PUNCT
fnp-2627	72	10	positive	positive	ADJ
fnp-2627	72	11	case	case	NOUN
fnp-2627	72	12	,	,	PUNCT
fnp-2627	72	13	mngs	mng	NOUN
fnp-2627	72	14	failed	fail	VERB
fnp-2627	72	15	to	to	PART
fnp-2627	72	16	discover	discover	VERB
fnp-2627	72	17	any	any	DET
fnp-2627	72	18	csf	csf	ADJ
fnp-2627	72	19	pathogens	pathogen	NOUN
fnp-2627	72	20	in	in	ADP
fnp-2627	72	21	either	either	DET
fnp-2627	72	22	group	group	NOUN
fnp-2627	72	23	.	.	PUNCT
fnp-2627	73	1	however	however	ADV
fnp-2627	73	2	,	,	PUNCT
fnp-2627	73	3	virscan	virscan	PROPN
fnp-2627	73	4	and	and	CCONJ
fnp-2627	73	5	ev	ev	PROPN
fnp-2627	73	6	elisa	elisa	PROPN
fnp-2627	73	7	revealed	reveal	VERB
fnp-2627	73	8	significantly	significantly	ADV
fnp-2627	73	9	higher	high	ADJ
fnp-2627	73	10	levels	level	NOUN
fnp-2627	73	11	of	of	ADP
fnp-2627	73	12	anti	anti	ADJ
fnp-2627	73	13	-	-	ADJ
fnp-2627	73	14	ev	ev	ADJ
fnp-2627	73	15	antibodies	antibody	NOUN
fnp-2627	73	16	in	in	ADP
fnp-2627	73	17	cases	case	NOUN
fnp-2627	73	18	compared	compare	VERB
fnp-2627	73	19	to	to	ADP
fnp-2627	73	20	controls	control	NOUN
fnp-2627	73	21	,	,	PUNCT
fnp-2627	73	22	providing	provide	VERB
fnp-2627	73	23	a	a	DET
fnp-2627	73	24	strong	strong	ADJ
fnp-2627	73	25	support	support	NOUN
fnp-2627	73	26	for	for	ADP
fnp-2627	73	27	evs	evs	NOUN
fnp-2627	73	28	as	as	ADP
fnp-2627	73	29	causative	causative	ADJ
fnp-2627	73	30	agents	agent	NOUN
fnp-2627	73	31	of	of	ADP
fnp-2627	73	32	all	all	DET
fnp-2627	73	33	recent	recent	ADJ
fnp-2627	73	34	afm	afm	PROPN
fnp-2627	73	35	outbreaks	outbreak	NOUN
fnp-2627	73	36	.	.	PUNCT
fnp-2627	74	1	interestingly	interestingly	ADV
fnp-2627	74	2	,	,	PUNCT
fnp-2627	74	3	csf	csf	ADJ
fnp-2627	74	4	from	from	ADP
fnp-2627	74	5	afm	afm	PROPN
fnp-2627	74	6	cases	case	NOUN
fnp-2627	74	7	commonly	commonly	ADV
fnp-2627	74	8	contained	contain	VERB
fnp-2627	74	9	antibodies	antibody	NOUN
fnp-2627	74	10	targeting	target	VERB
fnp-2627	74	11	more	more	ADJ
fnp-2627	74	12	than	than	ADP
fnp-2627	74	13	one	one	NUM
fnp-2627	74	14	ev	ev	ADP
fnp-2627	74	15	;	;	PUNCT
fnp-2627	74	16	thus	thus	ADV
fnp-2627	74	17	,	,	PUNCT
fnp-2627	74	18	viral	viral	ADJ
fnp-2627	74	19	detection	detection	NOUN
fnp-2627	74	20	in	in	ADP
fnp-2627	74	21	the	the	DET
fnp-2627	74	22	spinal	spinal	ADJ
fnp-2627	74	23	cord	cord	NOUN
fnp-2627	74	24	tissue	tissue	NOUN
fnp-2627	74	25	will	will	AUX
fnp-2627	74	26	likely	likely	ADV
fnp-2627	74	27	be	be	AUX
fnp-2627	74	28	required	require	VERB
fnp-2627	74	29	to	to	PART
fnp-2627	74	30	definitively	definitively	ADV
fnp-2627	74	31	establish	establish	VERB
fnp-2627	74	32	which	which	PRON
fnp-2627	74	33	ev	ev	ADP
fnp-2627	74	34	species	specie	NOUN
fnp-2627	74	35	can	can	AUX
fnp-2627	74	36	cause	cause	VERB
fnp-2627	74	37	afm	afm	NOUN
fnp-2627	74	38	.	.	PUNCT
fnp-2627	75	1	in	in	ADP
fnp-2627	75	2	addition	addition	NOUN
fnp-2627	75	3	,	,	PUNCT
fnp-2627	75	4	further	further	ADJ
fnp-2627	75	5	work	work	NOUN
fnp-2627	75	6	will	will	AUX
fnp-2627	75	7	be	be	AUX
fnp-2627	75	8	required	require	VERB
fnp-2627	75	9	to	to	PART
fnp-2627	75	10	determine	determine	VERB
fnp-2627	75	11	the	the	DET
fnp-2627	75	12	sensitivity	sensitivity	NOUN
fnp-2627	75	13	and	and	CCONJ
fnp-2627	75	14	specificity	specificity	NOUN
fnp-2627	75	15	of	of	ADP
fnp-2627	75	16	csf	csf	ADJ
fnp-2627	75	17	ev	ev	INTJ
fnp-2627	75	18	serology	serology	NOUN
fnp-2627	75	19	in	in	ADP
fnp-2627	75	20	afm	afm	PROPN
fnp-2627	75	21	diagnosis	diagnosis	NOUN
fnp-2627	75	22	(	(	PUNCT
fnp-2627	75	23	schubert	schubert	PROPN
fnp-2627	75	24	et	et	PROPN
fnp-2627	75	25	al	al	PROPN
fnp-2627	75	26	.	.	PROPN
fnp-2627	75	27	,	,	PUNCT
fnp-2627	75	28	2019	2019	NUM
fnp-2627	75	29	)	)	PUNCT
fnp-2627	75	30	.	.	PUNCT
fnp-2627	76	1	figure	figure	VERB
fnp-2627	76	2	3	3	NUM
fnp-2627	76	3	.	.	PUNCT
fnp-2627	76	4	neuroglial	neuroglial	ADJ
fnp-2627	76	5	stem	stem	NOUN
fnp-2627	76	6	cell	cell	NOUN
fnp-2627	76	7	-	-	PUNCT
fnp-2627	76	8	derived	derive	VERB
fnp-2627	76	9	inflammatory	inflammatory	ADJ
fnp-2627	76	10	pseudotumor	pseudotumor	NOUN
fnp-2627	76	11	(	(	PUNCT
fnp-2627	76	12	n	n	CCONJ
fnp-2627	76	13	-	-	PUNCT
fnp-2627	76	14	scipt	scipt	NOUN
fnp-2627	76	15	):	):	PUNCT
fnp-2627	76	16	a	a	DET
fnp-2627	76	17	representative	representative	ADJ
fnp-2627	76	18	h&e	h&e	NOUN
fnp-2627	76	19	-	-	PUNCT
fnp-2627	76	20	stained	stain	VERB
fnp-2627	76	21	paraffin	paraffin	NOUN
fnp-2627	76	22	section	section	NOUN
fnp-2627	76	23	(	(	PUNCT
fnp-2627	76	24	a	a	X
fnp-2627	76	25	)	)	PUNCT
fnp-2627	76	26	shows	show	VERB
fnp-2627	76	27	a	a	DET
fnp-2627	76	28	spinal	spinal	ADJ
fnp-2627	76	29	cord	cord	NOUN
fnp-2627	76	30	nerve	nerve	NOUN
fnp-2627	76	31	root	root	NOUN
fnp-2627	76	32	surrounded	surround	VERB
fnp-2627	76	33	by	by	ADP
fnp-2627	76	34	haphazardly	haphazardly	ADV
fnp-2627	76	35	organized	organize	VERB
fnp-2627	76	36	but	but	CCONJ
fnp-2627	76	37	otherwise	otherwise	ADV
fnp-2627	76	38	mature	mature	ADJ
fnp-2627	76	39	-	-	PUNCT
fnp-2627	76	40	appearing	appear	VERB
fnp-2627	76	41	neuroglial	neuroglial	ADJ
fnp-2627	76	42	tissue	tissue	NOUN
fnp-2627	76	43	.	.	PUNCT
fnp-2627	77	1	neurofilament	neurofilament	ADJ
fnp-2627	77	2	immunohistochemistry	immunohistochemistry	NOUN
fnp-2627	77	3	(	(	PUNCT
fnp-2627	77	4	b	b	NOUN
fnp-2627	77	5	)	)	PUNCT
fnp-2627	77	6	highlights	highlight	NOUN
fnp-2627	77	7	intensely	intensely	ADV
fnp-2627	77	8	stained	stain	VERB
fnp-2627	77	9	but	but	CCONJ
fnp-2627	77	10	disorganized	disorganized	ADJ
fnp-2627	77	11	nerve	nerve	NOUN
fnp-2627	77	12	cell	cell	NOUN
fnp-2627	77	13	processes	process	NOUN
fnp-2627	77	14	(	(	PUNCT
fnp-2627	77	15	arrowheads	arrowhead	NOUN
fnp-2627	77	16	)	)	PUNCT
fnp-2627	77	17	that	that	PRON
fnp-2627	77	18	surround	surround	VERB
fnp-2627	77	19	the	the	DET
fnp-2627	77	20	centrally	centrally	ADV
fnp-2627	77	21	located	locate	VERB
fnp-2627	77	22	nerve	nerve	NOUN
fnp-2627	77	23	root	root	NOUN
fnp-2627	77	24	(	(	PUNCT
fnp-2627	77	25	arrow	arrow	NOUN
fnp-2627	77	26	)	)	PUNCT
fnp-2627	77	27	;	;	PUNCT
fnp-2627	77	28	the	the	DET
fnp-2627	77	29	tissue	tissue	NOUN
fnp-2627	77	30	at	at	ADP
fnp-2627	77	31	the	the	DET
fnp-2627	77	32	periphery	periphery	NOUN
fnp-2627	77	33	of	of	ADP
fnp-2627	77	34	the	the	DET
fnp-2627	77	35	specimen	speciman	NOUN
fnp-2627	77	36	shows	show	VERB
fnp-2627	77	37	glial	glial	ADJ
fnp-2627	77	38	differentiation	differentiation	NOUN
fnp-2627	77	39	and	and	CCONJ
fnp-2627	77	40	is	be	AUX
fnp-2627	77	41	neurofilament	neurofilament	ADJ
fnp-2627	77	42	-	-	PUNCT
fnp-2627	77	43	negative	negative	ADJ
fnp-2627	77	44	.	.	PUNCT
fnp-2627	78	1	chronic	chronic	ADJ
fnp-2627	78	2	inflammatory	inflammatory	ADJ
fnp-2627	78	3	infiltrate	infiltrate	NOUN
fnp-2627	78	4	was	be	AUX
fnp-2627	78	5	apparent	apparent	ADJ
fnp-2627	78	6	on	on	ADP
fnp-2627	78	7	other	other	ADJ
fnp-2627	78	8	sections	section	NOUN
fnp-2627	78	9	;	;	PUNCT
fnp-2627	78	10	for	for	ADP
fnp-2627	78	11	additional	additional	ADJ
fnp-2627	78	12	images	image	NOUN
fnp-2627	78	13	and	and	CCONJ
fnp-2627	78	14	clinical	clinical	ADJ
fnp-2627	78	15	history	history	NOUN
fnp-2627	78	16	details	detail	NOUN
fnp-2627	78	17	,	,	PUNCT
fnp-2627	78	18	see	see	VERB
fnp-2627	78	19	the	the	DET
fnp-2627	78	20	original	original	ADJ
fnp-2627	78	21	publication	publication	NOUN
fnp-2627	78	22	(	(	PUNCT
fnp-2627	78	23	sloan	sloan	PROPN
fnp-2627	78	24	et	et	PROPN
fnp-2627	78	25	al	al	PROPN
fnp-2627	78	26	.	.	PROPN
fnp-2627	78	27	,	,	PUNCT
fnp-2627	78	28	2019	2019	NUM
fnp-2627	78	29	)	)	PUNCT
fnp-2627	78	30	.	.	PUNCT
fnp-2627	79	1	scale	scale	NOUN
fnp-2627	79	2	bar	bar	NOUN
fnp-2627	79	3	,	,	PUNCT
fnp-2627	79	4	100	100	NUM
fnp-2627	79	5	µm	µm	NOUN
fnp-2627	79	6	.	.	PROPN
fnp-2627	79	7	4	4	NUM
fnp-2627	79	8	.	.	PUNCT
fnp-2627	79	9	congenital	congenital	ADJ
fnp-2627	79	10	myopathies	myopathy	NOUN
fnp-2627	79	11	:	:	PUNCT
fnp-2627	79	12	new	new	ADJ
fnp-2627	79	13	pathogenetic	pathogenetic	ADJ
fnp-2627	79	14	mechanisms	mechanism	NOUN
fnp-2627	79	15	congenital	congenital	ADJ
fnp-2627	79	16	myopathies	myopathy	NOUN
fnp-2627	79	17	are	be	AUX
fnp-2627	79	18	a	a	DET
fnp-2627	79	19	group	group	NOUN
fnp-2627	79	20	of	of	ADP
fnp-2627	79	21	genetically	genetically	ADV
fnp-2627	79	22	and	and	CCONJ
fnp-2627	79	23	clinically	clinically	ADV
fnp-2627	79	24	heterogeneous	heterogeneous	ADJ
fnp-2627	79	25	disorders	disorder	NOUN
fnp-2627	79	26	that	that	PRON
fnp-2627	79	27	typically	typically	ADV
fnp-2627	79	28	present	present	VERB
fnp-2627	79	29	early	early	ADV
fnp-2627	79	30	in	in	ADP
fnp-2627	79	31	life	life	NOUN
fnp-2627	79	32	with	with	ADP
fnp-2627	79	33	weakness	weakness	NOUN
fnp-2627	79	34	/	/	SYM
fnp-2627	79	35	hypotonia	hypotonia	NOUN
fnp-2627	79	36	and	and	CCONJ
fnp-2627	79	37	delayed	delay	VERB
fnp-2627	79	38	motor	motor	NOUN
fnp-2627	79	39	development	development	NOUN
fnp-2627	79	40	,	,	PUNCT
fnp-2627	79	41	and	and	CCONJ
fnp-2627	79	42	are	be	AUX
fnp-2627	79	43	subsequently	subsequently	ADV
fnp-2627	79	44	characterized	characterize	VERB
fnp-2627	79	45	by	by	ADP
fnp-2627	79	46	a	a	DET
fnp-2627	79	47	stable	stable	ADJ
fnp-2627	79	48	or	or	CCONJ
fnp-2627	79	49	slowly	slowly	ADV
fnp-2627	79	50	progressive	progressive	ADJ
fnp-2627	79	51	disease	disease	NOUN
fnp-2627	79	52	course	course	NOUN
fnp-2627	79	53	.	.	PUNCT
fnp-2627	80	1	histopathologic	histopathologic	PROPN
fnp-2627	80	2	findings	finding	NOUN
fnp-2627	80	3	are	be	AUX
fnp-2627	80	4	variable	variable	ADJ
fnp-2627	80	5	and	and	CCONJ
fnp-2627	80	6	include	include	VERB
fnp-2627	80	7	type	type	NOUN
fnp-2627	80	8	1	1	NUM
fnp-2627	80	9	fiber	fiber	NOUN
fnp-2627	80	10	predominance	predominance	NOUN
fnp-2627	80	11	and	and	CCONJ
fnp-2627	80	12	atrophy	atrophy	NOUN
fnp-2627	80	13	,	,	PUNCT
fnp-2627	80	14	cores	core	NOUN
fnp-2627	80	15	and/or	and/or	CCONJ
fnp-2627	80	16	minicores	minicore	NOUN
fnp-2627	80	17	,	,	PUNCT
fnp-2627	80	18	mislocalization	mislocalization	NOUN
fnp-2627	80	19	of	of	ADP
fnp-2627	80	20	intracellular	intracellular	ADJ
fnp-2627	80	21	organelles	organelle	NOUN
fnp-2627	80	22	(	(	PUNCT
fnp-2627	80	23	including	include	VERB
fnp-2627	80	24	nuclei	nucleus	NOUN
fnp-2627	80	25	)	)	PUNCT
fnp-2627	80	26	,	,	PUNCT
fnp-2627	80	27	and	and	CCONJ
fnp-2627	80	28	various	various	ADJ
fnp-2627	80	29	sarcoplasmic	sarcoplasmic	ADJ
fnp-2627	80	30	inclusions	inclusion	NOUN
fnp-2627	80	31	(	(	PUNCT
fnp-2627	80	32	such	such	ADJ
fnp-2627	80	33	as	as	ADP
fnp-2627	80	34	nemaline	nemaline	ADJ
fnp-2627	80	35	rods	rod	NOUN
fnp-2627	80	36	,	,	PUNCT
fnp-2627	80	37	caps	cap	NOUN
fnp-2627	80	38	,	,	PUNCT
fnp-2627	80	39	and	and	CCONJ
fnp-2627	80	40	cytoplasmic	cytoplasmic	ADJ
fnp-2627	80	41	bodies	body	NOUN
fnp-2627	80	42	)	)	PUNCT
fnp-2627	80	43	.	.	PUNCT
fnp-2627	81	1	the	the	DET
fnp-2627	81	2	well	well	ADV
fnp-2627	81	3	-	-	PUNCT
fnp-2627	81	4	established	establish	VERB
fnp-2627	81	5	pathogenetic	pathogenetic	ADJ
fnp-2627	81	6	mechanisms	mechanism	NOUN
fnp-2627	81	7	include	include	VERB
fnp-2627	81	8	impairments	impairment	NOUN
fnp-2627	81	9	of	of	ADP
fnp-2627	81	10	calcium	calcium	NOUN
fnp-2627	81	11	homeostasis	homeostasis	NOUN
fnp-2627	81	12	,	,	PUNCT
fnp-2627	81	13	excitation	excitation	NOUN
fnp-2627	81	14	-	-	PUNCT
fnp-2627	81	15	contraction	contraction	NOUN
fnp-2627	81	16	coupling	coupling	NOUN
fnp-2627	81	17	,	,	PUNCT
fnp-2627	81	18	sarcomeric	sarcomeric	ADJ
fnp-2627	81	19	filament	filament	NOUN
fnp-2627	81	20	assembly	assembly	NOUN
fnp-2627	81	21	,	,	PUNCT
fnp-2627	81	22	force	force	NOUN
fnp-2627	81	23	generation	generation	NOUN
fnp-2627	81	24	,	,	PUNCT
fnp-2627	81	25	and	and	CCONJ
fnp-2627	81	26	membrane	membrane	NOUN
fnp-2627	81	27	remodeling	remodeling	NOUN
fnp-2627	81	28	.	.	PUNCT
fnp-2627	82	1	excitingly	excitingly	ADV
fnp-2627	82	2	,	,	PUNCT
fnp-2627	82	3	this	this	DET
fnp-2627	82	4	mechanistic	mechanistic	ADJ
fnp-2627	82	5	spectrum	spectrum	NOUN
fnp-2627	82	6	has	have	AUX
fnp-2627	82	7	been	be	AUX
fnp-2627	82	8	significantly	significantly	ADV
fnp-2627	82	9	widened	widen	VERB
fnp-2627	82	10	by	by	ADP
fnp-2627	82	11	the	the	DET
fnp-2627	82	12	work	work	NOUN
fnp-2627	82	13	published	publish	VERB
fnp-2627	82	14	in	in	ADP
fnp-2627	82	15	2019	2019	NUM
fnp-2627	82	16	.	.	PUNCT
fnp-2627	83	1	some	some	PRON
fnp-2627	83	2	of	of	ADP
fnp-2627	83	3	the	the	DET
fnp-2627	83	4	newly	newly	ADV
fnp-2627	83	5	discovered	discover	VERB
fnp-2627	83	6	mechanisms	mechanism	NOUN
fnp-2627	83	7	include	include	VERB
fnp-2627	83	8	(	(	PUNCT
fnp-2627	83	9	i	i	NOUN
fnp-2627	83	10	)	)	PUNCT
fnp-2627	83	11	cell	cell	NOUN
fnp-2627	83	12	cycle	cycle	NOUN
fnp-2627	83	13	acceleration	acceleration	NOUN
fnp-2627	83	14	accompanied	accompany	VERB
fnp-2627	83	15	by	by	ADP
fnp-2627	83	16	reduced	reduced	ADJ
fnp-2627	83	17	cell	cell	NOUN
fnp-2627	83	18	growth	growth	NOUN
fnp-2627	83	19	(	(	PUNCT
fnp-2627	83	20	villar	villar	ADJ
fnp-2627	83	21	-	-	PUNCT
fnp-2627	83	22	quiles	quile	NOUN
fnp-2627	83	23	et	et	NOUN
fnp-2627	83	24	al	al	PROPN
fnp-2627	83	25	.	.	PROPN
fnp-2627	83	26	,	,	PUNCT
fnp-2627	83	27	2019	2019	NUM
fnp-2627	83	28	)	)	PUNCT
fnp-2627	83	29	,	,	PUNCT
fnp-2627	83	30	(	(	PUNCT
fnp-2627	83	31	ii	ii	NOUN
fnp-2627	83	32	)	)	PUNCT
fnp-2627	83	33	impaired	impaired	ADJ
fnp-2627	83	34	redox	redox	NOUN
fnp-2627	83	35	balance	balance	NOUN
fnp-2627	83	36	(	(	PUNCT
fnp-2627	83	37	lornage	lornage	NOUN
fnp-2627	83	38	et	et	PROPN
fnp-2627	83	39	al	al	PROPN
fnp-2627	83	40	.	.	PROPN
fnp-2627	83	41	,	,	PUNCT
fnp-2627	83	42	2019	2019	NUM
fnp-2627	83	43	)	)	PUNCT
fnp-2627	83	44	,	,	PUNCT
fnp-2627	83	45	(	(	PUNCT
fnp-2627	83	46	iii	iii	NOUN
fnp-2627	83	47	)	)	PUNCT
fnp-2627	83	48	altered	alter	VERB
fnp-2627	83	49	muscle	muscle	NOUN
fnp-2627	83	50	kinetics	kinetic	NOUN
fnp-2627	83	51	due	due	ADJ
fnp-2627	83	52	to	to	ADP
fnp-2627	83	53	impaired	impaired	ADJ
fnp-2627	83	54	sarcomere	sarcomere	ADJ
fnp-2627	83	55	relaxation	relaxation	NOUN
fnp-2627	83	56	(	(	PUNCT
fnp-2627	83	57	de	de	X
fnp-2627	83	58	winter	winter	NOUN
fnp-2627	83	59	et	et	NOUN
fnp-2627	83	60	al	al	PROPN
fnp-2627	83	61	.	.	PROPN
fnp-2627	83	62	,	,	PUNCT
fnp-2627	83	63	2020	2020	NUM
fnp-2627	83	64	)	)	PUNCT
fnp-2627	83	65	,	,	PUNCT
fnp-2627	83	66	and	and	CCONJ
fnp-2627	83	67	(	(	PUNCT
fnp-2627	83	68	iv	iv	X
fnp-2627	83	69	)	)	PUNCT
fnp-2627	83	70	nuclear	nuclear	ADJ
fnp-2627	83	71	dysfunction	dysfunction	NOUN
fnp-2627	83	72	secondary	secondary	ADJ
fnp-2627	83	73	to	to	ADP
fnp-2627	83	74	impaired	impaired	ADJ
fnp-2627	83	75	contractility	contractility	NOUN
fnp-2627	83	76	(	(	PUNCT
fnp-2627	83	77	ross	ross	PROPN
fnp-2627	83	78	et	et	PROPN
fnp-2627	83	79	al	al	PROPN
fnp-2627	83	80	.	.	PROPN
fnp-2627	83	81	,	,	PUNCT
fnp-2627	83	82	2019	2019	NUM
fnp-2627	83	83	)	)	PUNCT
fnp-2627	83	84	;	;	PUNCT
fnp-2627	83	85	these	these	DET
fnp-2627	83	86	last	last	ADJ
fnp-2627	83	87	two	two	NUM
fnp-2627	83	88	studies	study	NOUN
fnp-2627	83	89	are	be	AUX
fnp-2627	83	90	particularly	particularly	ADV
fnp-2627	83	91	groundbreaking	groundbreake	VERB
fnp-2627	83	92	and	and	CCONJ
fnp-2627	83	93	will	will	AUX
fnp-2627	83	94	therefore	therefore	ADV
fnp-2627	83	95	be	be	AUX
fnp-2627	83	96	described	describe	VERB
fnp-2627	83	97	in	in	ADP
fnp-2627	83	98	a	a	DET
fnp-2627	83	99	greater	great	ADJ
fnp-2627	83	100	detail	detail	NOUN
fnp-2627	83	101	.	.	PUNCT
fnp-2627	84	1	nemaline	nemaline	ADJ
fnp-2627	84	2	myopathy	myopathy	ADJ
fnp-2627	84	3	(	(	PUNCT
fnp-2627	84	4	nm	nm	NOUN
fnp-2627	84	5	)	)	PUNCT
fnp-2627	84	6	can	can	AUX
fnp-2627	84	7	be	be	AUX
fnp-2627	84	8	caused	cause	VERB
fnp-2627	84	9	by	by	ADP
fnp-2627	84	10	mutations	mutation	NOUN
fnp-2627	84	11	in	in	ADP
fnp-2627	84	12	at	at	ADV
fnp-2627	84	13	least	least	ADJ
fnp-2627	84	14	13	13	NUM
fnp-2627	84	15	genes	gene	NOUN
fnp-2627	84	16	,	,	PUNCT
fnp-2627	84	17	the	the	DET
fnp-2627	84	18	great	great	ADJ
fnp-2627	84	19	majority	majority	NOUN
fnp-2627	84	20	of	of	ADP
fnp-2627	84	21	which	which	PRON
fnp-2627	84	22	encode	encode	ADJ
fnp-2627	84	23	proteins	protein	NOUN
fnp-2627	84	24	that	that	PRON
fnp-2627	84	25	either	either	CCONJ
fnp-2627	84	26	form	form	VERB
fnp-2627	84	27	thin	thin	ADJ
fnp-2627	84	28	filaments	filament	NOUN
fnp-2627	84	29	or	or	CCONJ
fnp-2627	84	30	are	be	AUX
fnp-2627	84	31	associated	associate	VERB
fnp-2627	84	32	with	with	ADP
fnp-2627	84	33	these	these	DET
fnp-2627	84	34	filaments	filament	NOUN
fnp-2627	84	35	.	.	PUNCT
fnp-2627	85	1	a	a	DET
fnp-2627	85	2	recent	recent	ADJ
fnp-2627	85	3	tour	tour	NOUN
fnp-2627	85	4	-	-	PUNCT
fnp-2627	85	5	de	de	ADJ
fnp-2627	85	6	-	-	NOUN
fnp-2627	85	7	force	force	NOUN
fnp-2627	85	8	study	study	NOUN
fnp-2627	85	9	by	by	ADP
fnp-2627	85	10	de	de	PROPN
fnp-2627	85	11	winter	winter	NOUN
fnp-2627	85	12	et	et	PROPN
fnp-2627	85	13	al	al	PROPN
fnp-2627	85	14	.	.	PROPN
fnp-2627	85	15	(	(	PUNCT
fnp-2627	85	16	2020	2020	NUM
fnp-2627	85	17	;	;	PUNCT
fnp-2627	85	18	advanced	advanced	ADJ
fnp-2627	85	19	electronic	electronic	ADJ
fnp-2627	85	20	publication	publication	NOUN
fnp-2627	85	21	in	in	ADP
fnp-2627	85	22	2019	2019	NUM
fnp-2627	85	23	)	)	PUNCT
fnp-2627	85	24	has	have	AUX
fnp-2627	85	25	established	establish	VERB
fnp-2627	85	26	that	that	DET
fnp-2627	85	27	kbtbd13	kbtbd13	NOUN
fnp-2627	85	28	(	(	PUNCT
fnp-2627	85	29	kelch	kelch	PROPN
fnp-2627	85	30	repeat	repeat	VERB
fnp-2627	85	31	and	and	CCONJ
fnp-2627	85	32	btb	btb	NOUN
fnp-2627	85	33	domain	domain	NOUN
fnp-2627	85	34	containing	contain	VERB
fnp-2627	85	35	13	13	NUM
fnp-2627	85	36	)	)	PUNCT
fnp-2627	85	37	,	,	PUNCT
fnp-2627	85	38	the	the	DET
fnp-2627	85	39	mutations	mutation	NOUN
fnp-2627	85	40	in	in	ADP
fnp-2627	85	41	which	which	PRON
fnp-2627	85	42	cause	cause	VERB
fnp-2627	85	43	nem6	nem6	NOUN
fnp-2627	85	44	subtype	subtype	NOUN
fnp-2627	85	45	of	of	ADP
fnp-2627	85	46	nm	nm	NOUN
fnp-2627	85	47	,	,	PUNCT
fnp-2627	85	48	is	be	AUX
fnp-2627	85	49	also	also	ADV
fnp-2627	85	50	an	an	DET
fnp-2627	85	51	actin	actin	NOUN
fnp-2627	85	52	-	-	PUNCT
fnp-2627	85	53	binding	bind	VERB
fnp-2627	85	54	protein	protein	NOUN
fnp-2627	85	55	;	;	PUNCT
fnp-2627	85	56	when	when	SCONJ
fnp-2627	85	57	mutated	mutate	VERB
fnp-2627	85	58	,	,	PUNCT
fnp-2627	85	59	kbtbd13	kbtbd13	PROPN
fnp-2627	85	60	impairs	impair	VERB
fnp-2627	85	61	sarcomere	sarcomere	ADJ
fnp-2627	85	62	relaxation	relaxation	NOUN
fnp-2627	85	63	by	by	ADP
fnp-2627	85	64	altering	alter	VERB
fnp-2627	85	65	the	the	DET
fnp-2627	85	66	structure	structure	NOUN
fnp-2627	85	67	of	of	ADP
fnp-2627	85	68	thin	thin	ADJ
fnp-2627	85	69	filaments	filament	NOUN
fnp-2627	85	70	.	.	PUNCT
fnp-2627	86	1	specifically	specifically	ADV
fnp-2627	86	2	,	,	PUNCT
fnp-2627	86	3	thin	thin	ADJ
fnp-2627	86	4	filaments	filament	NOUN
fnp-2627	86	5	are	be	AUX
fnp-2627	86	6	more	more	ADV
fnp-2627	86	7	tightly	tightly	ADV
fnp-2627	86	8	wound	wound	ADJ
fnp-2627	86	9	and	and	CCONJ
fnp-2627	86	10	stiffer	stiff	ADJ
fnp-2627	86	11	than	than	ADP
fnp-2627	86	12	normal	normal	ADJ
fnp-2627	86	13	when	when	SCONJ
fnp-2627	86	14	they	they	PRON
fnp-2627	86	15	are	be	AUX
fnp-2627	86	16	bound	bind	VERB
fnp-2627	86	17	to	to	PART
fnp-2627	86	18	mutant	mutant	VERB
fnp-2627	86	19	kbtbd13r408c	kbtbd13r408c	NOUN
fnp-2627	86	20	;	;	PUNCT
fnp-2627	86	21	this	this	DET
fnp-2627	86	22	change	change	NOUN
fnp-2627	86	23	in	in	ADP
fnp-2627	86	24	the	the	DET
fnp-2627	86	25	thin	thin	ADJ
fnp-2627	86	26	filament	filament	NOUN
fnp-2627	86	27	compliance	compliance	NOUN
fnp-2627	86	28	disrupts	disrupt	VERB
fnp-2627	86	29	the	the	DET
fnp-2627	86	30	positive	positive	ADJ
fnp-2627	86	31	feedback	feedback	NOUN
fnp-2627	86	32	loop	loop	NOUN
fnp-2627	86	33	that	that	PRON
fnp-2627	86	34	is	be	AUX
fnp-2627	86	35	required	require	VERB
fnp-2627	86	36	for	for	ADP
fnp-2627	86	37	thin	thin	ADJ
fnp-2627	86	38	-	-	PUNCT
fnp-2627	86	39	thick	thick	ADJ
fnp-2627	86	40	filament	filament	NOUN
fnp-2627	86	41	detachment	detachment	NOUN
fnp-2627	86	42	,	,	PUNCT
fnp-2627	86	43	resulting	result	VERB
fnp-2627	86	44	in	in	ADP
fnp-2627	86	45	slowing	slow	VERB
fnp-2627	86	46	of	of	ADP
fnp-2627	86	47	muscle	muscle	NOUN
fnp-2627	86	48	relaxation	relaxation	NOUN
fnp-2627	86	49	that	that	PRON
fnp-2627	86	50	clinically	clinically	ADV
fnp-2627	86	51	characterizes	characterize	VERB
fnp-2627	86	52	nem6	nem6	NOUN
fnp-2627	86	53	.	.	PUNCT
fnp-2627	87	1	given	give	VERB
fnp-2627	87	2	the	the	DET
fnp-2627	87	3	8:1	8:1	NUM
fnp-2627	87	4	stoichiometry	stoichiometry	NOUN
fnp-2627	87	5	of	of	ADP
fnp-2627	87	6	kbtbd13	kbtbd13	NOUN
fnp-2627	87	7	-	-	PUNCT
fnp-2627	87	8	actin	actin	NOUN
fnp-2627	87	9	binding	binding	NOUN
fnp-2627	87	10	,	,	PUNCT
fnp-2627	87	11	which	which	PRON
fnp-2627	87	12	is	be	AUX
fnp-2627	87	13	close	close	ADJ
fnp-2627	87	14	to	to	ADP
fnp-2627	87	15	the	the	DET
fnp-2627	87	16	7:1	7:1	NUM
fnp-2627	87	17	stoichiometry	stoichiometry	NOUN
fnp-2627	87	18	between	between	ADP
fnp-2627	87	19	troponin	troponin	PROPN
fnp-2627	87	20	/	/	SYM
fnp-2627	87	21	tropomyosin	tropomyosin	NOUN
fnp-2627	87	22	and	and	CCONJ
fnp-2627	87	23	actin	actin	NOUN
fnp-2627	87	24	,	,	PUNCT
fnp-2627	87	25	it	it	PRON
fnp-2627	87	26	is	be	AUX
fnp-2627	87	27	possible	possible	ADJ
fnp-2627	87	28	that	that	SCONJ
fnp-2627	87	29	kbtbd13	kbtbd13	NOUN
fnp-2627	87	30	acts	act	VERB
fnp-2627	87	31	in	in	ADP
fnp-2627	87	32	concert	concert	NOUN
fnp-2627	87	33	with	with	ADP
fnp-2627	87	34	those	those	DET
fnp-2627	87	35	well	well	ADV
fnp-2627	87	36	-	-	PUNCT
fnp-2627	87	37	known	know	VERB
fnp-2627	87	38	sarcomeric	sarcomeric	ADJ
fnp-2627	87	39	regulatory	regulatory	ADJ
fnp-2627	87	40	proteins	protein	NOUN
fnp-2627	87	41	to	to	ADP
fnp-2627	87	42	fine	fine	ADJ
fnp-2627	87	43	-	-	PUNCT
fnp-2627	87	44	tune	tune	NOUN
fnp-2627	87	45	muscle	muscle	NOUN
fnp-2627	87	46	contraction	contraction	NOUN
fnp-2627	87	47	kinetics	kinetic	NOUN
fnp-2627	87	48	.	.	PUNCT
fnp-2627	88	1	interestingly	interestingly	ADV
fnp-2627	88	2	,	,	PUNCT
fnp-2627	88	3	deletion	deletion	NOUN
fnp-2627	88	4	of	of	ADP
fnp-2627	88	5	kbtbd13	kbtbd13	NOUN
fnp-2627	88	6	in	in	ADP
fnp-2627	88	7	mice	mouse	NOUN
fnp-2627	88	8	does	do	AUX
fnp-2627	88	9	not	not	PART
fnp-2627	88	10	lead	lead	VERB
fnp-2627	88	11	to	to	ADP
fnp-2627	88	12	slower	slow	ADJ
fnp-2627	88	13	muscle	muscle	NOUN
fnp-2627	88	14	relaxation	relaxation	NOUN
fnp-2627	88	15	,	,	PUNCT
fnp-2627	88	16	suggesting	suggest	VERB
fnp-2627	88	17	that	that	SCONJ
fnp-2627	88	18	kbtbd13r408c	kbtbd13r408c	NOUN
fnp-2627	88	19	is	be	AUX
fnp-2627	88	20	a	a	DET
fnp-2627	88	21	gain	gain	VERB
fnp-2627	88	22	-	-	PUNCT
fnp-2627	88	23	of	of	ADP
fnp-2627	88	24	-	-	PUNCT
fnp-2627	88	25	function	function	NOUN
fnp-2627	88	26	mutation	mutation	NOUN
fnp-2627	88	27	.	.	PUNCT
fnp-2627	89	1	it	it	PRON
fnp-2627	89	2	remains	remain	VERB
fnp-2627	89	3	to	to	PART
fnp-2627	89	4	be	be	AUX
fnp-2627	89	5	shown	show	VERB
fnp-2627	89	6	whether	whether	SCONJ
fnp-2627	89	7	other	other	ADJ
fnp-2627	89	8	mutations	mutation	NOUN
fnp-2627	89	9	in	in	ADP
fnp-2627	89	10	this	this	DET
fnp-2627	89	11	gene	gene	NOUN
fnp-2627	89	12	lead	lead	NOUN
fnp-2627	89	13	to	to	ADP
fnp-2627	89	14	similar	similar	ADJ
fnp-2627	89	15	functional	functional	ADJ
fnp-2627	89	16	deficits	deficit	NOUN
fnp-2627	89	17	and	and	CCONJ
fnp-2627	89	18	to	to	PART
fnp-2627	89	19	elucidate	elucidate	VERB
fnp-2627	89	20	how	how	SCONJ
fnp-2627	89	21	defects	defect	NOUN
fnp-2627	89	22	in	in	ADP
fnp-2627	89	23	muscle	muscle	NOUN
fnp-2627	89	24	relaxation	relaxation	NOUN
fnp-2627	89	25	ultimately	ultimately	ADV
fnp-2627	89	26	lead	lead	VERB
fnp-2627	89	27	to	to	ADP
fnp-2627	89	28	production	production	NOUN
fnp-2627	89	29	of	of	ADP
fnp-2627	89	30	nemaline	nemaline	ADJ
fnp-2627	89	31	rods	rod	NOUN
fnp-2627	89	32	(	(	PUNCT
fnp-2627	89	33	which	which	PRON
fnp-2627	89	34	are	be	AUX
fnp-2627	89	35	recapitulated	recapitulate	VERB
fnp-2627	89	36	in	in	ADP
fnp-2627	89	37	the	the	DET
fnp-2627	89	38	mouse	mouse	NOUN
fnp-2627	89	39	kbtbd13r408c	kbtbd13r408c	NOUN
fnp-2627	89	40	knock	knock	VERB
fnp-2627	89	41	-	-	PUNCT
fnp-2627	89	42	in	in	ADP
fnp-2627	89	43	model	model	NOUN
fnp-2627	89	44	)	)	PUNCT
fnp-2627	89	45	.	.	PUNCT
fnp-2627	90	1	in	in	ADP
fnp-2627	90	2	2019	2019	NUM
fnp-2627	90	3	,	,	PUNCT
fnp-2627	90	4	we	we	PRON
fnp-2627	90	5	have	have	AUX
fnp-2627	90	6	also	also	ADV
fnp-2627	90	7	learned	learn	VERB
fnp-2627	90	8	that	that	SCONJ
fnp-2627	90	9	impaired	impaired	ADJ
fnp-2627	90	10	contractility	contractility	NOUN
fnp-2627	90	11	and	and	CCONJ
fnp-2627	90	12	abnormal	abnormal	ADJ
fnp-2627	90	13	cytoskeletal	cytoskeletal	ADJ
fnp-2627	90	14	organization	organization	NOUN
fnp-2627	90	15	produce	produce	VERB
fnp-2627	90	16	secondary	secondary	ADJ
fnp-2627	90	17	nuclear	nuclear	ADJ
fnp-2627	90	18	deficits	deficit	NOUN
fnp-2627	90	19	,	,	PUNCT
fnp-2627	90	20	which	which	PRON
fnp-2627	90	21	structurally	structurally	ADV
fnp-2627	90	22	–	–	PUNCT
fnp-2627	90	23	and	and	CCONJ
fnp-2627	90	24	possibly	possibly	ADV
fnp-2627	90	25	functionally	functionally	ADV
fnp-2627	90	26	–	–	PUNCT
fnp-2627	90	27	mimic	mimic	ADJ
fnp-2627	90	28	nuclear	nuclear	ADJ
fnp-2627	90	29	abnormalities	abnormality	NOUN
fnp-2627	90	30	seen	see	VERB
fnp-2627	90	31	in	in	ADP
fnp-2627	90	32	patients	patient	NOUN
fnp-2627	90	33	with	with	ADP
fnp-2627	90	34	mutations	mutation	NOUN
fnp-2627	90	35	in	in	ADP
fnp-2627	90	36	the	the	DET
fnp-2627	90	37	nuclear	nuclear	ADJ
fnp-2627	90	38	envelope	envelope	NOUN
fnp-2627	90	39	proteins	protein	NOUN
fnp-2627	90	40	,	,	PUNCT
fnp-2627	90	41	such	such	ADJ
fnp-2627	90	42	as	as	ADP
fnp-2627	90	43	lamins	lamin	NOUN
fnp-2627	90	44	,	,	PUNCT
fnp-2627	90	45	nesprins	nesprin	NOUN
fnp-2627	90	46	,	,	PUNCT
fnp-2627	90	47	and	and	CCONJ
fnp-2627	90	48	emerin	emerin	NOUN
fnp-2627	90	49	(	(	PUNCT
fnp-2627	90	50	ross	ross	PROPN
fnp-2627	90	51	et	et	PROPN
fnp-2627	90	52	al	al	PROPN
fnp-2627	90	53	.	.	PROPN
fnp-2627	90	54	,	,	PUNCT
fnp-2627	90	55	2019	2019	NUM
fnp-2627	90	56	)	)	PUNCT
fnp-2627	90	57	.	.	PUNCT
fnp-2627	91	1	abnormal	abnormal	ADJ
fnp-2627	91	2	spacing	spacing	NOUN
fnp-2627	91	3	of	of	ADP
fnp-2627	91	4	myonuclei	myonuclei	NOUN
fnp-2627	91	5	,	,	PUNCT
fnp-2627	91	6	nuclear	nuclear	ADJ
fnp-2627	91	7	envelope	envelope	NOUN
fnp-2627	91	8	defects	defect	NOUN
fnp-2627	91	9	,	,	PUNCT
fnp-2627	91	10	and	and	CCONJ
fnp-2627	91	11	chromatin	chromatin	NOUN
fnp-2627	91	12	alterations	alteration	NOUN
fnp-2627	91	13	were	be	AUX
fnp-2627	91	14	present	present	ADJ
fnp-2627	91	15	not	not	PART
fnp-2627	91	16	only	only	ADV
fnp-2627	91	17	in	in	ADP
fnp-2627	91	18	the	the	DET
fnp-2627	91	19	skeletal	skeletal	ADJ
fnp-2627	91	20	muscle	muscle	NOUN
fnp-2627	91	21	from	from	ADP
fnp-2627	91	22	patients	patient	NOUN
fnp-2627	91	23	with	with	ADP
fnp-2627	91	24	two	two	NUM
fnp-2627	91	25	different	different	ADJ
fnp-2627	91	26	genetic	genetic	ADJ
fnp-2627	91	27	forms	form	NOUN
fnp-2627	91	28	of	of	ADP
fnp-2627	91	29	nm	nm	NOUN
fnp-2627	91	30	and	and	CCONJ
fnp-2627	91	31	nm	nm	ADJ
fnp-2627	91	32	model	model	NOUN
fnp-2627	91	33	mice	mouse	NOUN
fnp-2627	91	34	,	,	PUNCT
fnp-2627	91	35	but	but	CCONJ
fnp-2627	91	36	also	also	ADV
fnp-2627	91	37	in	in	ADP
fnp-2627	91	38	skeletal	skeletal	ADJ
fnp-2627	91	39	muscle	muscle	NOUN
fnp-2627	91	40	from	from	ADP
fnp-2627	91	41	patients	patient	NOUN
fnp-2627	91	42	with	with	ADP
fnp-2627	91	43	acquired	acquire	VERB
fnp-2627	91	44	(	(	PUNCT
fnp-2627	91	45	immune	immune	NOUN
fnp-2627	91	46	-	-	PUNCT
fnp-2627	91	47	mediated	mediate	VERB
fnp-2627	91	48	)	)	PUNCT
fnp-2627	91	49	forms	form	NOUN
fnp-2627	91	50	of	of	ADP
fnp-2627	91	51	nm	nm	NOUN
fnp-2627	91	52	,	,	PUNCT
fnp-2627	91	53	underscoring	underscore	VERB
fnp-2627	91	54	that	that	SCONJ
fnp-2627	91	55	these	these	DET
fnp-2627	91	56	nuclear	nuclear	ADJ
fnp-2627	91	57	abnormalities	abnormality	NOUN
fnp-2627	91	58	are	be	AUX
fnp-2627	91	59	secondary	secondary	ADJ
fnp-2627	91	60	to	to	ADP
fnp-2627	91	61	impaired	impaired	ADJ
fnp-2627	91	62	contractility	contractility	NOUN
fnp-2627	91	63	rather	rather	ADV
fnp-2627	91	64	than	than	ADP
fnp-2627	91	65	a	a	DET
fnp-2627	91	66	direct	direct	ADJ
fnp-2627	91	67	consequence	consequence	NOUN
fnp-2627	91	68	of	of	ADP
fnp-2627	91	69	nm	nm	DET
fnp-2627	91	70	mutations	mutation	NOUN
fnp-2627	91	71	.	.	PUNCT
fnp-2627	92	1	in	in	ADP
fnp-2627	92	2	addition	addition	NOUN
fnp-2627	92	3	,	,	PUNCT
fnp-2627	92	4	muscle	muscle	NOUN
fnp-2627	92	5	fibers	fiber	NOUN
fnp-2627	92	6	from	from	ADP
fnp-2627	92	7	both	both	DET
fnp-2627	92	8	nm	nm	ADJ
fnp-2627	92	9	patients	patient	NOUN
fnp-2627	92	10	and	and	CCONJ
fnp-2627	92	11	nm	nm	ADJ
fnp-2627	92	12	model	model	NOUN
fnp-2627	92	13	mice	mouse	NOUN
fnp-2627	92	14	showed	show	VERB
fnp-2627	92	15	extensive	extensive	ADJ
fnp-2627	92	16	cytoskeletal	cytoskeletal	ADJ
fnp-2627	92	17	disruption	disruption	NOUN
fnp-2627	92	18	(	(	PUNCT
fnp-2627	92	19	disorganized	disorganized	ADJ
fnp-2627	92	20	microtubules	microtubule	NOUN
fnp-2627	92	21	,	,	PUNCT
fnp-2627	92	22	mislocalized	mislocalize	VERB
fnp-2627	92	23	intermediate	intermediate	ADJ
fnp-2627	92	24	filaments	filament	NOUN
fnp-2627	92	25	composed	compose	VERB
fnp-2627	92	26	of	of	ADP
fnp-2627	92	27	desmin	desmin	ADJ
fnp-2627	92	28	,	,	PUNCT
fnp-2627	92	29	and	and	CCONJ
fnp-2627	92	30	altered	alter	VERB
fnp-2627	92	31	cortical	cortical	ADJ
fnp-2627	92	32	microfilaments	microfilament	NOUN
fnp-2627	92	33	composed	compose	VERB
fnp-2627	92	34	of	of	ADP
fnp-2627	92	35	actin	actin	NOUN
fnp-2627	92	36	)	)	PUNCT
fnp-2627	92	37	;	;	PUNCT
fnp-2627	92	38	given	give	VERB
fnp-2627	92	39	that	that	DET
fnp-2627	92	40	treatment	treatment	NOUN
fnp-2627	92	41	with	with	ADP
fnp-2627	92	42	microtubule	microtubule	NOUN
fnp-2627	92	43	-	-	PUNCT
fnp-2627	92	44	disrupting	disrupt	VERB
fnp-2627	92	45	agents	agent	NOUN
fnp-2627	92	46	was	be	AUX
fnp-2627	92	47	shown	show	VERB
fnp-2627	92	48	to	to	PART
fnp-2627	92	49	alter	alter	VERB
fnp-2627	92	50	nuclear	nuclear	ADJ
fnp-2627	92	51	shape	shape	NOUN
fnp-2627	92	52	in	in	ADP
fnp-2627	92	53	vitro	vitro	NOUN
fnp-2627	92	54	,	,	PUNCT
fnp-2627	92	55	these	these	DET
fnp-2627	92	56	cytoskeletal	cytoskeletal	ADJ
fnp-2627	92	57	alterations	alteration	NOUN
fnp-2627	92	58	likely	likely	ADV
fnp-2627	92	59	also	also	ADV
fnp-2627	92	60	contribute	contribute	VERB
fnp-2627	92	61	to	to	ADP
fnp-2627	92	62	nuclear	nuclear	ADJ
fnp-2627	92	63	deficits	deficit	NOUN
fnp-2627	92	64	seen	see	VERB
fnp-2627	92	65	in	in	ADP
fnp-2627	92	66	the	the	DET
fnp-2627	92	67	nm	nm	ADJ
fnp-2627	92	68	muscle	muscle	NOUN
fnp-2627	92	69	.	.	PUNCT
fnp-2627	93	1	indeed	indeed	ADV
fnp-2627	93	2	,	,	PUNCT
fnp-2627	93	3	we	we	PRON
fnp-2627	93	4	have	have	AUX
fnp-2627	93	5	recently	recently	ADV
fnp-2627	93	6	observed	observe	VERB
fnp-2627	93	7	very	very	ADV
fnp-2627	93	8	similar	similar	ADJ
fnp-2627	93	9	nuclear	nuclear	ADJ
fnp-2627	93	10	defects	defect	NOUN
fnp-2627	93	11	in	in	ADP
fnp-2627	93	12	a	a	DET
fnp-2627	93	13	patient	patient	NOUN
fnp-2627	93	14	with	with	ADP
fnp-2627	93	15	a	a	DET
fnp-2627	93	16	desmin	desmin	ADJ
fnp-2627	93	17	mutation	mutation	NOUN
fnp-2627	93	18	(	(	PUNCT
fnp-2627	93	19	fig	fig	NOUN
fnp-2627	93	20	.	.	PUNCT
fnp-2627	93	21	4	4	NUM
fnp-2627	93	22	)	)	PUNCT
fnp-2627	93	23	;	;	PUNCT
fnp-2627	93	24	thus	thus	ADV
fnp-2627	93	25	,	,	PUNCT
fnp-2627	93	26	secondary	secondary	ADJ
fnp-2627	93	27	nuclear	nuclear	ADJ
fnp-2627	93	28	defects	defect	NOUN
fnp-2627	93	29	(	(	PUNCT
fnp-2627	93	30	and	and	CCONJ
fnp-2627	93	31	consequent	consequent	ADJ
fnp-2627	93	32	gene	gene	NOUN
fnp-2627	93	33	expression	expression	NOUN
fnp-2627	93	34	changes	change	NOUN
fnp-2627	93	35	)	)	PUNCT
fnp-2627	93	36	may	may	AUX
fnp-2627	93	37	be	be	AUX
fnp-2627	93	38	an	an	DET
fnp-2627	93	39	important	important	ADJ
fnp-2627	93	40	but	but	CCONJ
fnp-2627	93	41	overlooked	overlook	VERB
fnp-2627	93	42	cause	cause	NOUN
fnp-2627	93	43	of	of	ADP
fnp-2627	93	44	muscle	muscle	NOUN
fnp-2627	93	45	dysfunction	dysfunction	NOUN
fnp-2627	93	46	that	that	PRON
fnp-2627	93	47	is	be	AUX
fnp-2627	93	48	more	more	ADV
fnp-2627	93	49	widespread	widespread	ADJ
fnp-2627	93	50	than	than	SCONJ
fnp-2627	93	51	currently	currently	ADV
fnp-2627	93	52	recognized	recognize	VERB
fnp-2627	93	53	.	.	PUNCT
fnp-2627	94	1	figure	figure	VERB
fnp-2627	94	2	4	4	NUM
fnp-2627	94	3	.	.	PUNCT
fnp-2627	95	1	nuclear	nuclear	ADJ
fnp-2627	95	2	abnormalities	abnormality	NOUN
fnp-2627	95	3	in	in	ADP
fnp-2627	95	4	a	a	DET
fnp-2627	95	5	case	case	NOUN
fnp-2627	95	6	of	of	ADP
fnp-2627	95	7	myofibrillar	myofibrillar	ADJ
fnp-2627	95	8	myopathy	myopathy	NOUN
fnp-2627	95	9	caused	cause	VERB
fnp-2627	95	10	by	by	ADP
fnp-2627	95	11	a	a	DET
fnp-2627	95	12	desmin	desmin	ADJ
fnp-2627	95	13	mutation	mutation	NOUN
fnp-2627	95	14	:	:	PUNCT
fnp-2627	95	15	representative	representative	ADJ
fnp-2627	95	16	electron	electron	NOUN
fnp-2627	95	17	micrographs	micrograph	NOUN
fnp-2627	95	18	show	show	NOUN
fnp-2627	95	19	marked	mark	VERB
fnp-2627	95	20	nuclear	nuclear	ADJ
fnp-2627	95	21	abnormalities	abnormality	NOUN
fnp-2627	95	22	(	(	PUNCT
fnp-2627	95	23	a	a	DET
fnp-2627	95	24	-	-	PUNCT
fnp-2627	95	25	e	e	NOUN
fnp-2627	95	26	)	)	PUNCT
fnp-2627	95	27	including	include	VERB
fnp-2627	95	28	invaginations	invagination	NOUN
fnp-2627	95	29	of	of	ADP
fnp-2627	95	30	the	the	DET
fnp-2627	95	31	nuclear	nuclear	ADJ
fnp-2627	95	32	membrane	membrane	NOUN
fnp-2627	95	33	(	(	PUNCT
fnp-2627	95	34	a	a	PRON
fnp-2627	95	35	and	and	CCONJ
fnp-2627	95	36	b	b	NOUN
fnp-2627	95	37	,	,	PUNCT
fnp-2627	95	38	arrowheads	arrowhead	NOUN
fnp-2627	95	39	)	)	PUNCT
fnp-2627	95	40	,	,	PUNCT
fnp-2627	95	41	abnormally	abnormally	ADV
fnp-2627	95	42	dense	dense	ADJ
fnp-2627	95	43	chromatin	chromatin	NOUN
fnp-2627	95	44	(	(	PUNCT
fnp-2627	95	45	the	the	DET
fnp-2627	95	46	nucleus	nucleus	NOUN
fnp-2627	95	47	highlighted	highlight	VERB
fnp-2627	95	48	by	by	ADP
fnp-2627	95	49	the	the	DET
fnp-2627	95	50	arrow	arrow	NOUN
fnp-2627	95	51	in	in	ADP
fnp-2627	95	52	b	b	PROPN
fnp-2627	95	53	,	,	PUNCT
fnp-2627	95	54	as	as	ADV
fnp-2627	95	55	well	well	ADV
fnp-2627	95	56	as	as	ADP
fnp-2627	95	57	nuclei	nucleus	NOUN
fnp-2627	95	58	in	in	ADP
fnp-2627	95	59	c	c	PROPN
fnp-2627	95	60	and	and	CCONJ
fnp-2627	95	61	d	d	NOUN
fnp-2627	95	62	)	)	PUNCT
fnp-2627	95	63	,	,	PUNCT
fnp-2627	95	64	and	and	CCONJ
fnp-2627	95	65	nuclear	nuclear	ADJ
fnp-2627	95	66	fragmentation	fragmentation	NOUN
fnp-2627	95	67	(	(	PUNCT
fnp-2627	95	68	c	c	NOUN
fnp-2627	95	69	-	-	PUNCT
fnp-2627	95	70	e	e	NOUN
fnp-2627	95	71	)	)	PUNCT
fnp-2627	95	72	.	.	PUNCT
fnp-2627	96	1	granulofilamentous	granulofilamentous	ADJ
fnp-2627	96	2	material	material	NOUN
fnp-2627	96	3	(	(	PUNCT
fnp-2627	96	4	f	f	X
fnp-2627	96	5	)	)	PUNCT
fnp-2627	96	6	,	,	PUNCT
fnp-2627	96	7	a	a	DET
fnp-2627	96	8	clue	clue	NOUN
fnp-2627	96	9	to	to	ADP
fnp-2627	96	10	the	the	DET
fnp-2627	96	11	correct	correct	ADJ
fnp-2627	96	12	diagnosis	diagnosis	NOUN
fnp-2627	96	13	,	,	PUNCT
fnp-2627	96	14	was	be	AUX
fnp-2627	96	15	seen	see	VERB
fnp-2627	96	16	only	only	ADV
fnp-2627	96	17	focally	focally	ADV
fnp-2627	96	18	.	.	PUNCT
fnp-2627	97	1	subsequent	subsequent	ADJ
fnp-2627	97	2	genetic	genetic	ADJ
fnp-2627	97	3	testing	testing	NOUN
fnp-2627	97	4	revealed	reveal	VERB
fnp-2627	97	5	a	a	DET
fnp-2627	97	6	heterozygous	heterozygous	ADJ
fnp-2627	97	7	des	des	X
fnp-2627	97	8	gene	gene	NOUN
fnp-2627	97	9	mutation	mutation	NOUN
fnp-2627	97	10	[	[	X
fnp-2627	97	11	c.1237_1239delgag	c.1237_1239delgag	CCONJ
fnp-2627	97	12	(	(	PUNCT
fnp-2627	97	13	p.e413del	p.e413del	NOUN
fnp-2627	97	14	)	)	PUNCT
fnp-2627	97	15	]	]	PUNCT
fnp-2627	97	16	.	.	PUNCT
fnp-2627	98	1	scale	scale	NOUN
fnp-2627	98	2	bars	bar	NOUN
fnp-2627	98	3	:	:	PUNCT
fnp-2627	98	4	a	a	PRON
fnp-2627	98	5	and	and	CCONJ
fnp-2627	98	6	e	e	NOUN
fnp-2627	98	7	,	,	PUNCT
fnp-2627	98	8	1	1	NUM
fnp-2627	98	9	µm	µm	NUM
fnp-2627	98	10	;	;	PUNCT
fnp-2627	98	11	b	b	X
fnp-2627	98	12	-	-	SYM
fnp-2627	98	13	d	d	NOUN
fnp-2627	98	14	,	,	PUNCT
fnp-2627	98	15	2	2	NUM
fnp-2627	98	16	µm	µm	NOUN
fnp-2627	98	17	;	;	PUNCT
fnp-2627	98	18	f	f	X
fnp-2627	98	19	,	,	PUNCT
fnp-2627	98	20	4	4	NUM
fnp-2627	98	21	µm	µm	NOUN
fnp-2627	98	22	.	.	PROPN
fnp-2627	98	23	5	5	NUM
fnp-2627	98	24	.	.	PUNCT
fnp-2627	98	25	sporadic	sporadic	ADJ
fnp-2627	98	26	inclusion	inclusion	NOUN
fnp-2627	98	27	body	body	NOUN
fnp-2627	98	28	myositis	myositis	NOUN
fnp-2627	98	29	:	:	PUNCT
fnp-2627	98	30	the	the	DET
fnp-2627	98	31	role	role	NOUN
fnp-2627	98	32	of	of	ADP
fnp-2627	98	33	terminally	terminally	ADV
fnp-2627	98	34	differentiated	differentiate	VERB
fnp-2627	98	35	cytotoxic	cytotoxic	ADJ
fnp-2627	98	36	t	t	NOUN
fnp-2627	98	37	cells	cell	NOUN
fnp-2627	98	38	sporadic	sporadic	ADJ
fnp-2627	98	39	inclusion	inclusion	NOUN
fnp-2627	98	40	body	body	NOUN
fnp-2627	98	41	myositis	myositis	PROPN
fnp-2627	98	42	(	(	PUNCT
fnp-2627	98	43	sibm	sibm	PROPN
fnp-2627	98	44	)	)	PUNCT
fnp-2627	98	45	is	be	AUX
fnp-2627	98	46	the	the	DET
fnp-2627	98	47	most	most	ADV
fnp-2627	98	48	common	common	ADJ
fnp-2627	98	49	skeletal	skeletal	ADJ
fnp-2627	98	50	myopathy	myopathy	ADJ
fnp-2627	98	51	affecting	affect	VERB
fnp-2627	98	52	people	people	NOUN
fnp-2627	98	53	over	over	ADP
fnp-2627	98	54	the	the	DET
fnp-2627	98	55	age	age	NOUN
fnp-2627	98	56	of	of	ADP
fnp-2627	98	57	50	50	NUM
fnp-2627	98	58	;	;	PUNCT
fnp-2627	98	59	it	it	PRON
fnp-2627	98	60	typically	typically	ADV
fnp-2627	98	61	presents	present	VERB
fnp-2627	98	62	with	with	ADP
fnp-2627	98	63	a	a	DET
fnp-2627	98	64	weakness	weakness	NOUN
fnp-2627	98	65	of	of	ADP
fnp-2627	98	66	the	the	DET
fnp-2627	98	67	quadriceps	quadricep	NOUN
fnp-2627	98	68	and	and	CCONJ
fnp-2627	98	69	deep	deep	ADJ
fnp-2627	98	70	finger	finger	NOUN
fnp-2627	98	71	flexor	flexor	ADJ
fnp-2627	98	72	muscles	muscle	NOUN
fnp-2627	98	73	,	,	PUNCT
fnp-2627	98	74	has	have	VERB
fnp-2627	98	75	a	a	DET
fnp-2627	98	76	slowly	slowly	ADV
fnp-2627	98	77	progressive	progressive	ADJ
fnp-2627	98	78	course	course	NOUN
fnp-2627	98	79	resulting	result	VERB
fnp-2627	98	80	in	in	ADP
fnp-2627	98	81	eventual	eventual	ADJ
fnp-2627	98	82	loss	loss	NOUN
fnp-2627	98	83	of	of	ADP
fnp-2627	98	84	mobility	mobility	NOUN
fnp-2627	98	85	,	,	PUNCT
fnp-2627	98	86	and	and	CCONJ
fnp-2627	98	87	is	be	AUX
fnp-2627	98	88	currently	currently	ADV
fnp-2627	98	89	without	without	ADP
fnp-2627	98	90	effective	effective	ADJ
fnp-2627	98	91	therapy	therapy	NOUN
fnp-2627	98	92	.	.	PUNCT
fnp-2627	99	1	pathologically	pathologically	ADV
fnp-2627	99	2	,	,	PUNCT
fnp-2627	99	3	sibm	sibm	PROPN
fnp-2627	99	4	shows	show	VERB
fnp-2627	99	5	both	both	CCONJ
fnp-2627	99	6	inflammatory	inflammatory	ADJ
fnp-2627	99	7	and	and	CCONJ
fnp-2627	99	8	myodegenerative	myodegenerative	ADJ
fnp-2627	99	9	features	feature	NOUN
fnp-2627	99	10	(	(	PUNCT
fnp-2627	99	11	fig	fig	NOUN
fnp-2627	99	12	.	.	PUNCT
fnp-2627	100	1	5a	5a	NUM
fnp-2627	100	2	)	)	PUNCT
fnp-2627	100	3	;	;	PUNCT
fnp-2627	100	4	together	together	ADV
fnp-2627	100	5	with	with	ADP
fnp-2627	100	6	a	a	DET
fnp-2627	100	7	lack	lack	NOUN
fnp-2627	100	8	of	of	ADP
fnp-2627	100	9	response	response	NOUN
fnp-2627	100	10	to	to	ADP
fnp-2627	100	11	immunosuppressive	immunosuppressive	ADJ
fnp-2627	100	12	treatment	treatment	NOUN
fnp-2627	100	13	,	,	PUNCT
fnp-2627	100	14	this	this	DET
fnp-2627	100	15	“	"	PUNCT
fnp-2627	100	16	dual	dual	ADJ
fnp-2627	100	17	”	"	PUNCT
fnp-2627	100	18	nature	nature	NOUN
fnp-2627	100	19	of	of	ADP
fnp-2627	100	20	sibm	sibm	PROPN
fnp-2627	100	21	pathology	pathology	NOUN
fnp-2627	100	22	has	have	AUX
fnp-2627	100	23	led	lead	VERB
fnp-2627	100	24	to	to	ADP
fnp-2627	100	25	a	a	DET
fnp-2627	100	26	long	long	ADV
fnp-2627	100	27	-	-	PUNCT
fnp-2627	100	28	standing	stand	VERB
fnp-2627	100	29	disagreement	disagreement	NOUN
fnp-2627	100	30	about	about	ADP
fnp-2627	100	31	the	the	DET
fnp-2627	100	32	role	role	NOUN
fnp-2627	100	33	of	of	ADP
fnp-2627	100	34	inflammation	inflammation	NOUN
fnp-2627	100	35	in	in	ADP
fnp-2627	100	36	sibm	sibm	PROPN
fnp-2627	100	37	pathogenesis.three	pathogenesis.three	PROPN
fnp-2627	100	38	studies	study	NOUN
fnp-2627	100	39	published	publish	VERB
fnp-2627	100	40	in	in	ADP
fnp-2627	100	41	2019	2019	NUM
fnp-2627	100	42	(	(	PUNCT
fnp-2627	100	43	dzangue	dzangue	NOUN
fnp-2627	100	44	-	-	PUNCT
fnp-2627	100	45	tchoupou	tchoupou	NOUN
fnp-2627	100	46	et	et	PROPN
fnp-2627	100	47	al	al	PROPN
fnp-2627	100	48	.	.	PROPN
fnp-2627	100	49	,	,	PUNCT
fnp-2627	100	50	2019	2019	NUM
fnp-2627	100	51	;	;	PUNCT
fnp-2627	100	52	greenberg	greenberg	PROPN
fnp-2627	100	53	et	et	PROPN
fnp-2627	100	54	al	al	PROPN
fnp-2627	100	55	.	.	PROPN
fnp-2627	100	56	,	,	PUNCT
fnp-2627	100	57	2019	2019	NUM
fnp-2627	100	58	;	;	PUNCT
fnp-2627	100	59	knauss	knauss	PROPN
fnp-2627	100	60	et	et	PROPN
fnp-2627	100	61	al	al	PROPN
fnp-2627	100	62	.	.	PROPN
fnp-2627	100	63	,	,	PUNCT
fnp-2627	100	64	2019	2019	NUM
fnp-2627	100	65	)	)	PUNCT
fnp-2627	100	66	will	will	AUX
fnp-2627	100	67	likely	likely	ADV
fnp-2627	100	68	break	break	VERB
fnp-2627	100	69	this	this	DET
fnp-2627	100	70	impasse	impasse	NOUN
fnp-2627	100	71	by	by	ADP
fnp-2627	100	72	providing	provide	VERB
fnp-2627	100	73	a	a	DET
fnp-2627	100	74	strong	strong	ADJ
fnp-2627	100	75	support	support	NOUN
fnp-2627	100	76	for	for	ADP
fnp-2627	100	77	the	the	DET
fnp-2627	100	78	autoimmune	autoimmune	ADJ
fnp-2627	100	79	nature	nature	NOUN
fnp-2627	100	80	of	of	ADP
fnp-2627	100	81	sibm	sibm	NOUN
fnp-2627	100	82	:	:	PUNCT
fnp-2627	100	83	starting	start	VERB
fnp-2627	100	84	with	with	ADP
fnp-2627	100	85	different	different	ADJ
fnp-2627	100	86	questions	question	NOUN
fnp-2627	100	87	and	and	CCONJ
fnp-2627	100	88	using	use	VERB
fnp-2627	100	89	different	different	ADJ
fnp-2627	100	90	experimental	experimental	ADJ
fnp-2627	100	91	approaches	approach	NOUN
fnp-2627	100	92	,	,	PUNCT
fnp-2627	100	93	these	these	DET
fnp-2627	100	94	studies	study	NOUN
fnp-2627	100	95	have	have	AUX
fnp-2627	100	96	demonstrated	demonstrate	VERB
fnp-2627	100	97	that	that	SCONJ
fnp-2627	100	98	terminally	terminally	ADV
fnp-2627	100	99	differentiated	differentiate	VERB
fnp-2627	100	100	effector	effector	NOUN
fnp-2627	100	101	memory	memory	NOUN
fnp-2627	100	102	t	t	PROPN
fnp-2627	100	103	cells	cell	NOUN
fnp-2627	100	104	(	(	PUNCT
fnp-2627	100	105	so	so	ADV
fnp-2627	100	106	-	-	PUNCT
fnp-2627	100	107	called	call	VERB
fnp-2627	100	108	temra	temra	NOUN
fnp-2627	100	109	cells	cell	NOUN
fnp-2627	100	110	)	)	PUNCT
fnp-2627	100	111	are	be	AUX
fnp-2627	100	112	enriched	enrich	VERB
fnp-2627	100	113	in	in	ADP
fnp-2627	100	114	sibm	sibm	NOUN
fnp-2627	100	115	muscle	muscle	NOUN
fnp-2627	100	116	biopsies	biopsy	NOUN
fnp-2627	100	117	(	(	PUNCT
fnp-2627	100	118	greenberg	greenberg	PROPN
fnp-2627	100	119	et	et	PROPN
fnp-2627	100	120	al	al	PROPN
fnp-2627	100	121	.	.	PROPN
fnp-2627	100	122	,	,	PUNCT
fnp-2627	100	123	2019	2019	NUM
fnp-2627	100	124	;	;	PUNCT
fnp-2627	100	125	knauss	knauss	PROPN
fnp-2627	100	126	et	et	PROPN
fnp-2627	100	127	al	al	PROPN
fnp-2627	100	128	.	.	PROPN
fnp-2627	100	129	,	,	PUNCT
fnp-2627	100	130	2019	2019	NUM
fnp-2627	100	131	)	)	PUNCT
fnp-2627	100	132	as	as	ADV
fnp-2627	100	133	well	well	ADV
fnp-2627	100	134	as	as	ADP
fnp-2627	100	135	peripheral	peripheral	ADJ
fnp-2627	100	136	blood	blood	NOUN
fnp-2627	100	137	of	of	ADP
fnp-2627	100	138	sibm	sibm	NOUN
fnp-2627	100	139	patients	patient	NOUN
fnp-2627	100	140	(	(	PUNCT
fnp-2627	100	141	dzangue	dzangue	NOUN
fnp-2627	100	142	-	-	PUNCT
fnp-2627	100	143	tchoupou	tchoupou	NOUN
fnp-2627	100	144	et	et	PROPN
fnp-2627	100	145	al	al	PROPN
fnp-2627	100	146	.	.	PROPN
fnp-2627	100	147	,	,	PUNCT
fnp-2627	100	148	2019	2019	NUM
fnp-2627	100	149	)	)	PUNCT
fnp-2627	100	150	,	,	PUNCT
fnp-2627	100	151	and	and	CCONJ
fnp-2627	100	152	that	that	SCONJ
fnp-2627	100	153	the	the	DET
fnp-2627	100	154	presence	presence	NOUN
fnp-2627	100	155	of	of	ADP
fnp-2627	100	156	these	these	DET
fnp-2627	100	157	cells	cell	NOUN
fnp-2627	100	158	is	be	AUX
fnp-2627	100	159	fairly	fairly	ADV
fnp-2627	100	160	unique	unique	ADJ
fnp-2627	100	161	for	for	ADP
fnp-2627	100	162	sibm	sibm	NOUN
fnp-2627	100	163	when	when	SCONJ
fnp-2627	100	164	compared	compare	VERB
fnp-2627	100	165	to	to	ADP
fnp-2627	100	166	other	other	ADJ
fnp-2627	100	167	iims	iim	NOUN
fnp-2627	100	168	[	[	X
fnp-2627	100	169	although	although	SCONJ
fnp-2627	100	170	similar	similar	ADJ
fnp-2627	100	171	cells	cell	NOUN
fnp-2627	100	172	were	be	AUX
fnp-2627	100	173	also	also	ADV
fnp-2627	100	174	seen	see	VERB
fnp-2627	100	175	in	in	ADP
fnp-2627	100	176	biopsies	biopsy	NOUN
fnp-2627	100	177	from	from	ADP
fnp-2627	100	178	two	two	NUM
fnp-2627	100	179	patients	patient	NOUN
fnp-2627	100	180	with	with	ADP
fnp-2627	100	181	severe	severe	ADJ
fnp-2627	100	182	,	,	PUNCT
fnp-2627	100	183	treatment	treatment	NOUN
fnp-2627	100	184	-	-	PUNCT
fnp-2627	100	185	resistant	resistant	ADJ
fnp-2627	100	186	irmyositis	irmyositis	NOUN
fnp-2627	100	187	(	(	PUNCT
fnp-2627	100	188	knauss	knauss	PROPN
fnp-2627	100	189	et	et	PROPN
fnp-2627	100	190	al	al	PROPN
fnp-2627	100	191	.	.	PROPN
fnp-2627	100	192	,	,	PUNCT
fnp-2627	100	193	2019	2019	NUM
fnp-2627	100	194	)	)	PUNCT
fnp-2627	100	195	]	]	PUNCT
fnp-2627	100	196	.	.	PUNCT
fnp-2627	101	1	temra	temra	NOUN
fnp-2627	101	2	cells	cell	NOUN
fnp-2627	101	3	are	be	AUX
fnp-2627	101	4	positive	positive	ADJ
fnp-2627	101	5	for	for	ADP
fnp-2627	101	6	cd8	cd8	PROPN
fnp-2627	101	7	,	,	PUNCT
fnp-2627	101	8	t	t	PROPN
fnp-2627	101	9	-	-	PUNCT
fnp-2627	101	10	bet	bet	NOUN
fnp-2627	101	11	(	(	PUNCT
fnp-2627	101	12	a	a	DET
fnp-2627	101	13	transcription	transcription	NOUN
fnp-2627	101	14	factor	factor	NOUN
fnp-2627	101	15	that	that	PRON
fnp-2627	101	16	drives	drive	VERB
fnp-2627	101	17	differentiation	differentiation	NOUN
fnp-2627	101	18	of	of	ADP
fnp-2627	101	19	naïve	naïve	ADJ
fnp-2627	101	20	t	t	NOUN
fnp-2627	101	21	cells	cell	NOUN
fnp-2627	101	22	into	into	ADP
fnp-2627	101	23	cytotoxic	cytotoxic	ADJ
fnp-2627	101	24	t	t	NOUN
fnp-2627	101	25	lymphocytes	lymphocyte	NOUN
fnp-2627	101	26	)	)	PUNCT
fnp-2627	101	27	,	,	PUNCT
fnp-2627	101	28	cd57	cd57	PROPN
fnp-2627	101	29	(	(	PUNCT
fnp-2627	101	30	a	a	DET
fnp-2627	101	31	marker	marker	NOUN
fnp-2627	101	32	of	of	ADP
fnp-2627	101	33	replicative	replicative	ADJ
fnp-2627	101	34	senescence	senescence	NOUN
fnp-2627	101	35	)	)	PUNCT
fnp-2627	101	36	,	,	PUNCT
fnp-2627	101	37	and	and	CCONJ
fnp-2627	101	38	klrg1	klrg1	PROPN
fnp-2627	101	39	(	(	PUNCT
fnp-2627	101	40	killer	killer	NOUN
fnp-2627	101	41	cell	cell	NOUN
fnp-2627	101	42	lectin	lectin	NOUN
fnp-2627	101	43	-	-	PUNCT
fnp-2627	101	44	like	like	ADJ
fnp-2627	101	45	receptor	receptor	NOUN
fnp-2627	101	46	g1	g1	NOUN
fnp-2627	101	47	;	;	PUNCT
fnp-2627	101	48	a	a	DET
fnp-2627	101	49	marker	marker	NOUN
fnp-2627	101	50	of	of	ADP
fnp-2627	101	51	t	t	NOUN
fnp-2627	101	52	cell	cell	NOUN
fnp-2627	101	53	exhaustion	exhaustion	NOUN
fnp-2627	101	54	)	)	PUNCT
fnp-2627	101	55	.	.	PUNCT
fnp-2627	102	1	they	they	PRON
fnp-2627	102	2	contain	contain	VERB
fnp-2627	102	3	high	high	ADJ
fnp-2627	102	4	concentration	concentration	NOUN
fnp-2627	102	5	of	of	ADP
fnp-2627	102	6	cytotoxic	cytotoxic	ADJ
fnp-2627	102	7	enzymes	enzyme	NOUN
fnp-2627	102	8	(	(	PUNCT
fnp-2627	102	9	granzymes	granzyme	NOUN
fnp-2627	102	10	and	and	CCONJ
fnp-2627	102	11	perforin	perforin	NOUN
fnp-2627	102	12	)	)	PUNCT
fnp-2627	102	13	that	that	PRON
fnp-2627	102	14	likely	likely	ADV
fnp-2627	102	15	directly	directly	ADV
fnp-2627	102	16	cause	cause	VERB
fnp-2627	102	17	muscle	muscle	NOUN
fnp-2627	102	18	fiber	fiber	NOUN
fnp-2627	102	19	damage	damage	NOUN
fnp-2627	102	20	,	,	PUNCT
fnp-2627	102	21	are	be	AUX
fnp-2627	102	22	known	know	VERB
fnp-2627	102	23	to	to	PART
fnp-2627	102	24	increase	increase	VERB
fnp-2627	102	25	in	in	ADP
fnp-2627	102	26	peripheral	peripheral	ADJ
fnp-2627	102	27	blood	blood	NOUN
fnp-2627	102	28	with	with	ADP
fnp-2627	102	29	age	age	NOUN
fnp-2627	102	30	,	,	PUNCT
fnp-2627	102	31	and	and	CCONJ
fnp-2627	102	32	are	be	AUX
fnp-2627	102	33	resistant	resistant	ADJ
fnp-2627	102	34	to	to	ADP
fnp-2627	102	35	corticosteroids	corticosteroid	NOUN
fnp-2627	102	36	and	and	CCONJ
fnp-2627	102	37	drugs	drug	NOUN
fnp-2627	102	38	that	that	PRON
fnp-2627	102	39	target	target	VERB
fnp-2627	102	40	actively	actively	ADV
fnp-2627	102	41	dividing	divide	VERB
fnp-2627	102	42	cells	cell	NOUN
fnp-2627	102	43	(	(	PUNCT
fnp-2627	102	44	such	such	ADJ
fnp-2627	102	45	as	as	ADP
fnp-2627	102	46	methotrexate	methotrexate	NOUN
fnp-2627	102	47	)	)	PUNCT
fnp-2627	102	48	;	;	PUNCT
fnp-2627	102	49	the	the	DET
fnp-2627	102	50	latter	latter	ADJ
fnp-2627	102	51	two	two	NUM
fnp-2627	102	52	characteristics	characteristic	NOUN
fnp-2627	102	53	likely	likely	ADV
fnp-2627	102	54	provide	provide	VERB
fnp-2627	102	55	at	at	ADP
fnp-2627	102	56	least	least	ADJ
fnp-2627	102	57	partial	partial	ADJ
fnp-2627	102	58	explanation	explanation	NOUN
fnp-2627	102	59	for	for	ADP
fnp-2627	102	60	the	the	DET
fnp-2627	102	61	age	age	NOUN
fnp-2627	102	62	dependence	dependence	NOUN
fnp-2627	102	63	and	and	CCONJ
fnp-2627	102	64	resistance	resistance	NOUN
fnp-2627	102	65	to	to	ADP
fnp-2627	102	66	immunosuppression	immunosuppression	NOUN
fnp-2627	102	67	that	that	PRON
fnp-2627	102	68	are	be	AUX
fnp-2627	102	69	characteristic	characteristic	ADJ
fnp-2627	102	70	of	of	ADP
fnp-2627	102	71	sibm	sibm	PROPN
fnp-2627	102	72	.	.	PUNCT
fnp-2627	103	1	figure	figure	NOUN
fnp-2627	103	2	5	5	NUM
fnp-2627	103	3	.	.	PUNCT
fnp-2627	103	4	distinct	distinct	ADJ
fnp-2627	103	5	patterns	pattern	NOUN
fnp-2627	103	6	of	of	ADP
fnp-2627	103	7	lc3	lc3	NOUN
fnp-2627	103	8	and	and	CCONJ
fnp-2627	103	9	p62	p62	NOUN
fnp-2627	103	10	immunostaining	immunostaine	VERB
fnp-2627	103	11	in	in	ADP
fnp-2627	103	12	sporadic	sporadic	ADJ
fnp-2627	103	13	inclusion	inclusion	NOUN
fnp-2627	103	14	body	body	NOUN
fnp-2627	103	15	myositis	myositis	PROPN
fnp-2627	103	16	(	(	PUNCT
fnp-2627	103	17	sibm	sibm	PROPN
fnp-2627	103	18	)	)	PUNCT
fnp-2627	103	19	and	and	CCONJ
fnp-2627	103	20	immune	immune	NOUN
fnp-2627	103	21	-	-	PUNCT
fnp-2627	103	22	mediated	mediate	VERB
fnp-2627	103	23	necrotizing	necrotizing	NOUN
fnp-2627	103	24	myopathy	myopathy	NOUN
fnp-2627	103	25	(	(	PUNCT
fnp-2627	103	26	imnm	imnm	PROPN
fnp-2627	103	27	):	):	PUNCT
fnp-2627	103	28	a	a	DET
fnp-2627	103	29	typical	typical	ADJ
fnp-2627	103	30	sibm	sibm	NOUN
fnp-2627	103	31	case	case	NOUN
fnp-2627	103	32	(	(	PUNCT
fnp-2627	103	33	a	a	DET
fnp-2627	103	34	-	-	PUNCT
fnp-2627	103	35	c	c	NOUN
fnp-2627	103	36	)	)	PUNCT
fnp-2627	103	37	shows	show	VERB
fnp-2627	103	38	inflammatory	inflammatory	ADJ
fnp-2627	103	39	and	and	CCONJ
fnp-2627	103	40	myodegenerative	myodegenerative	ADJ
fnp-2627	103	41	changes	change	NOUN
fnp-2627	103	42	on	on	ADP
fnp-2627	103	43	h&e	h&e	PROPN
fnp-2627	103	44	staining	stain	VERB
fnp-2627	103	45	(	(	PUNCT
fnp-2627	103	46	a	a	NOUN
fnp-2627	103	47	)	)	PUNCT
fnp-2627	103	48	and	and	CCONJ
fnp-2627	103	49	dense	dense	ADJ
fnp-2627	103	50	,	,	PUNCT
fnp-2627	103	51	largely	largely	ADV
fnp-2627	103	52	subsarcolemmal	subsarcolemmal	ADJ
fnp-2627	103	53	protein	protein	NOUN
fnp-2627	103	54	aggregates	aggregate	NOUN
fnp-2627	103	55	and	and	CCONJ
fnp-2627	103	56	vacuoles	vacuole	NOUN
fnp-2627	103	57	on	on	ADP
fnp-2627	103	58	lc3	lc3	X
fnp-2627	103	59	(	(	PUNCT
fnp-2627	103	60	b	b	NOUN
fnp-2627	103	61	)	)	PUNCT
fnp-2627	103	62	and	and	CCONJ
fnp-2627	103	63	p62	p62	NOUN
fnp-2627	103	64	(	(	PUNCT
fnp-2627	103	65	c	c	NOUN
fnp-2627	103	66	)	)	PUNCT
fnp-2627	103	67	immunostaining	immunostaine	VERB
fnp-2627	103	68	.	.	PUNCT
fnp-2627	104	1	in	in	ADP
fnp-2627	104	2	contrast	contrast	NOUN
fnp-2627	104	3	,	,	PUNCT
fnp-2627	104	4	an	an	DET
fnp-2627	104	5	imnm	imnm	PROPN
fnp-2627	104	6	case	case	NOUN
fnp-2627	104	7	(	(	PUNCT
fnp-2627	104	8	d	d	X
fnp-2627	104	9	-	-	PUNCT
fnp-2627	104	10	f	f	NOUN
fnp-2627	104	11	)	)	PUNCT
fnp-2627	104	12	shows	show	VERB
fnp-2627	104	13	randomly	randomly	ADV
fnp-2627	104	14	distributed	distribute	VERB
fnp-2627	104	15	degenerating	degenerating	NOUN
fnp-2627	104	16	/	/	SYM
fnp-2627	104	17	regenerating	regenerate	VERB
fnp-2627	104	18	fibers	fiber	NOUN
fnp-2627	104	19	and	and	CCONJ
fnp-2627	104	20	the	the	DET
fnp-2627	104	21	absence	absence	NOUN
fnp-2627	104	22	of	of	ADP
fnp-2627	104	23	significant	significant	ADJ
fnp-2627	104	24	inflammation	inflammation	NOUN
fnp-2627	104	25	on	on	ADP
fnp-2627	104	26	h&e	h&e	PROPN
fnp-2627	104	27	(	(	PUNCT
fnp-2627	104	28	d	d	NOUN
fnp-2627	104	29	)	)	PUNCT
fnp-2627	104	30	and	and	CCONJ
fnp-2627	104	31	multiple	multiple	ADJ
fnp-2627	104	32	fibers	fiber	NOUN
fnp-2627	104	33	with	with	ADP
fnp-2627	104	34	diffuse	diffuse	NOUN
fnp-2627	104	35	,	,	PUNCT
fnp-2627	104	36	finely	finely	ADV
fnp-2627	104	37	punctate	punctate	VERB
fnp-2627	104	38	staining	stain	VERB
fnp-2627	104	39	on	on	ADP
fnp-2627	104	40	lc3	lc3	X
fnp-2627	104	41	(	(	PUNCT
fnp-2627	104	42	e	e	NOUN
fnp-2627	104	43	)	)	PUNCT
fnp-2627	104	44	and	and	CCONJ
fnp-2627	104	45	p62	p62	NOUN
fnp-2627	104	46	(	(	PUNCT
fnp-2627	104	47	f	f	X
fnp-2627	104	48	)	)	PUNCT
fnp-2627	104	49	immunostaining	immunostaine	VERB
fnp-2627	104	50	.	.	PUNCT
fnp-2627	105	1	for	for	ADP
fnp-2627	105	2	both	both	DET
fnp-2627	105	3	cases	case	NOUN
fnp-2627	105	4	,	,	PUNCT
fnp-2627	105	5	h&e	h&e	PROPN
fnp-2627	105	6	stain	stain	NOUN
fnp-2627	105	7	was	be	AUX
fnp-2627	105	8	performed	perform	VERB
fnp-2627	105	9	on	on	ADP
fnp-2627	105	10	cryosections	cryosection	NOUN
fnp-2627	105	11	,	,	PUNCT
fnp-2627	105	12	while	while	SCONJ
fnp-2627	105	13	lc3	lc3	NOUN
fnp-2627	105	14	and	and	CCONJ
fnp-2627	105	15	p62	p62	NOUN
fnp-2627	105	16	immunohistochemistries	immunohistochemistry	NOUN
fnp-2627	105	17	were	be	AUX
fnp-2627	105	18	performed	perform	VERB
fnp-2627	105	19	on	on	ADP
fnp-2627	105	20	formalin	formalin	NOUN
fnp-2627	105	21	-	-	PUNCT
fnp-2627	105	22	fixed	fix	VERB
fnp-2627	105	23	,	,	PUNCT
fnp-2627	105	24	paraffin	paraffin	NOUN
fnp-2627	105	25	-	-	PUNCT
fnp-2627	105	26	embedded	embed	VERB
fnp-2627	105	27	tissue	tissue	NOUN
fnp-2627	105	28	sections	section	NOUN
fnp-2627	105	29	.	.	PUNCT
fnp-2627	106	1	scale	scale	NOUN
fnp-2627	106	2	bars	bar	NOUN
fnp-2627	106	3	,	,	PUNCT
fnp-2627	106	4	50	50	NUM
fnp-2627	106	5	µm	µm	NOUN
fnp-2627	106	6	.	.	PUNCT
fnp-2627	107	1	in	in	ADP
fnp-2627	107	2	addition	addition	NOUN
fnp-2627	107	3	to	to	ADP
fnp-2627	107	4	providing	provide	VERB
fnp-2627	107	5	insight	insight	NOUN
fnp-2627	107	6	into	into	ADP
fnp-2627	107	7	sibm	sibm	NOUN
fnp-2627	107	8	pathogenesis	pathogenesis	NOUN
fnp-2627	107	9	,	,	PUNCT
fnp-2627	107	10	these	these	DET
fnp-2627	107	11	studies	study	NOUN
fnp-2627	107	12	have	have	VERB
fnp-2627	107	13	important	important	ADJ
fnp-2627	107	14	implications	implication	NOUN
fnp-2627	107	15	for	for	ADP
fnp-2627	107	16	the	the	DET
fnp-2627	107	17	sibm	sibm	NOUN
fnp-2627	107	18	diagnosis	diagnosis	NOUN
fnp-2627	107	19	and	and	CCONJ
fnp-2627	107	20	treatment	treatment	NOUN
fnp-2627	107	21	.	.	PUNCT
fnp-2627	108	1	of	of	ADP
fnp-2627	108	2	particular	particular	ADJ
fnp-2627	108	3	interest	interest	NOUN
fnp-2627	108	4	,	,	PUNCT
fnp-2627	108	5	the	the	DET
fnp-2627	108	6	study	study	NOUN
fnp-2627	108	7	by	by	ADP
fnp-2627	108	8	greenberg	greenberg	PROPN
fnp-2627	108	9	at	at	ADP
fnp-2627	108	10	al	al	PROPN
fnp-2627	108	11	.	.	PROPN
fnp-2627	109	1	(	(	PUNCT
fnp-2627	109	2	2019	2019	NUM
fnp-2627	109	3	)	)	PUNCT
fnp-2627	109	4	included	include	VERB
fnp-2627	109	5	10	10	NUM
fnp-2627	109	6	samples	sample	NOUN
fnp-2627	109	7	from	from	ADP
fnp-2627	109	8	patients	patient	NOUN
fnp-2627	109	9	diagnosed	diagnose	VERB
fnp-2627	109	10	with	with	ADP
fnp-2627	109	11	polymyositis	polymyositis	PROPN
fnp-2627	109	12	(	(	PUNCT
fnp-2627	109	13	pm	pm	NOUN
fnp-2627	109	14	)	)	PUNCT
fnp-2627	109	15	,	,	PUNCT
fnp-2627	109	16	an	an	DET
fnp-2627	109	17	iim	iim	NOUN
fnp-2627	109	18	that	that	PRON
fnp-2627	109	19	was	be	AUX
fnp-2627	109	20	historically	historically	ADV
fnp-2627	109	21	thought	think	VERB
fnp-2627	109	22	to	to	PART
fnp-2627	109	23	share	share	VERB
fnp-2627	109	24	the	the	DET
fnp-2627	109	25	sibm	sibm	NOUN
fnp-2627	109	26	inflammatory	inflammatory	ADJ
fnp-2627	109	27	profile	profile	NOUN
fnp-2627	109	28	but	but	CCONJ
fnp-2627	109	29	lack	lack	VERB
fnp-2627	109	30	its	its	PRON
fnp-2627	109	31	myodegenerative	myodegenerative	ADJ
fnp-2627	109	32	phenotype	phenotype	NOUN
fnp-2627	109	33	and	and	CCONJ
fnp-2627	109	34	its	its	PRON
fnp-2627	109	35	refractoriness	refractoriness	NOUN
fnp-2627	109	36	to	to	ADP
fnp-2627	109	37	therapy	therapy	NOUN
fnp-2627	109	38	.	.	PUNCT
fnp-2627	110	1	the	the	DET
fnp-2627	110	2	existence	existence	NOUN
fnp-2627	110	3	of	of	ADP
fnp-2627	110	4	pm	pm	NOUN
fnp-2627	110	5	as	as	ADP
fnp-2627	110	6	a	a	DET
fnp-2627	110	7	distinct	distinct	ADJ
fnp-2627	110	8	iim	iim	NOUN
fnp-2627	110	9	subtype	subtype	NOUN
fnp-2627	110	10	has	have	AUX
fnp-2627	110	11	recently	recently	ADV
fnp-2627	110	12	been	be	AUX
fnp-2627	110	13	called	call	VERB
fnp-2627	110	14	into	into	ADP
fnp-2627	110	15	question	question	NOUN
fnp-2627	110	16	,	,	PUNCT
fnp-2627	110	17	given	give	VERB
fnp-2627	110	18	that	that	SCONJ
fnp-2627	110	19	most	most	ADJ
fnp-2627	110	20	patients	patient	NOUN
fnp-2627	110	21	diagnosed	diagnose	VERB
fnp-2627	110	22	with	with	ADP
fnp-2627	110	23	pm	pm	NOUN
fnp-2627	110	24	based	base	VERB
fnp-2627	110	25	on	on	ADP
fnp-2627	110	26	the	the	DET
fnp-2627	110	27	1975	1975	NUM
fnp-2627	110	28	bohan	bohan	PROPN
fnp-2627	110	29	&	&	CCONJ
fnp-2627	110	30	peter	peter	PROPN
fnp-2627	110	31	criteria	criterion	NOUN
fnp-2627	110	32	can	can	AUX
fnp-2627	110	33	be	be	AUX
fnp-2627	110	34	reclassified	reclassify	VERB
fnp-2627	110	35	as	as	ADP
fnp-2627	110	36	one	one	NUM
fnp-2627	110	37	of	of	ADP
fnp-2627	110	38	the	the	DET
fnp-2627	110	39	other	other	ADJ
fnp-2627	110	40	iims	iims	NOUN
fnp-2627	110	41	[	[	X
fnp-2627	110	42	early	early	ADJ
fnp-2627	110	43	stage	stage	NOUN
fnp-2627	110	44	sibm	sibm	NOUN
fnp-2627	110	45	,	,	PUNCT
fnp-2627	110	46	immune	immune	NOUN
fnp-2627	110	47	-	-	PUNCT
fnp-2627	110	48	mediated	mediate	VERB
fnp-2627	110	49	necrotizing	necrotizing	NOUN
fnp-2627	110	50	myopathy	myopathy	NOUN
fnp-2627	110	51	(	(	PUNCT
fnp-2627	110	52	imnm	imnm	PROPN
fnp-2627	110	53	)	)	PUNCT
fnp-2627	110	54	,	,	PUNCT
fnp-2627	110	55	antisynthetase	antisynthetase	NOUN
fnp-2627	110	56	syndrome	syndrome	NOUN
fnp-2627	110	57	-	-	PUNCT
fnp-2627	110	58	associated	associate	VERB
fnp-2627	110	59	myositis	myositis	NOUN
fnp-2627	110	60	(	(	PUNCT
fnp-2627	110	61	asm	asm	NOUN
fnp-2627	110	62	)	)	PUNCT
fnp-2627	110	63	,	,	PUNCT
fnp-2627	110	64	or	or	CCONJ
fnp-2627	110	65	dermatomyositis	dermatomyositis	PROPN
fnp-2627	110	66	(	(	PUNCT
fnp-2627	110	67	dm	dm	PROPN
fnp-2627	110	68	)	)	PUNCT
fnp-2627	110	69	]	]	PUNCT
fnp-2627	110	70	using	use	VERB
fnp-2627	110	71	the	the	DET
fnp-2627	110	72	current	current	ADJ
fnp-2627	110	73	clinicoseropathologic	clinicoseropathologic	ADJ
fnp-2627	110	74	criteria	criterion	NOUN
fnp-2627	110	75	(	(	PUNCT
fnp-2627	110	76	allenbach	allenbach	NOUN
fnp-2627	110	77	et	et	PROPN
fnp-2627	110	78	al	al	PROPN
fnp-2627	110	79	.	.	PROPN
fnp-2627	110	80	,	,	PUNCT
fnp-2627	110	81	2017	2017	NUM
fnp-2627	110	82	;	;	PUNCT
fnp-2627	110	83	tanboon	tanboon	NOUN
fnp-2627	110	84	and	and	CCONJ
fnp-2627	110	85	nishino	nishino	PROPN
fnp-2627	110	86	,	,	PUNCT
fnp-2627	110	87	2019	2019	NUM
fnp-2627	110	88	)	)	PUNCT
fnp-2627	110	89	.	.	PUNCT
fnp-2627	111	1	however	however	ADV
fnp-2627	111	2	,	,	PUNCT
fnp-2627	111	3	greenberg	greenberg	PROPN
fnp-2627	111	4	and	and	CCONJ
fnp-2627	111	5	co	co	NOUN
fnp-2627	111	6	-	-	NOUN
fnp-2627	111	7	authors	author	NOUN
fnp-2627	111	8	have	have	AUX
fnp-2627	111	9	demonstrated	demonstrate	VERB
fnp-2627	111	10	an	an	DET
fnp-2627	111	11	important	important	ADJ
fnp-2627	111	12	difference	difference	NOUN
fnp-2627	111	13	between	between	ADP
fnp-2627	111	14	their	their	PRON
fnp-2627	111	15	“	"	PUNCT
fnp-2627	111	16	pm	pm	NOUN
fnp-2627	111	17	”	"	PUNCT
fnp-2627	111	18	and	and	CCONJ
fnp-2627	111	19	sibm	sibm	NOUN
fnp-2627	111	20	samples	sample	NOUN
fnp-2627	111	21	:	:	PUNCT
fnp-2627	111	22	while	while	SCONJ
fnp-2627	111	23	cd8	cd8	PROPN
fnp-2627	111	24	+	+	PROPN
fnp-2627	111	25	lymphocytes	lymphocyte	NOUN
fnp-2627	111	26	invading	invade	VERB
fnp-2627	111	27	muscle	muscle	NOUN
fnp-2627	111	28	fibers	fiber	NOUN
fnp-2627	111	29	in	in	ADP
fnp-2627	111	30	sibm	sibm	NOUN
fnp-2627	111	31	biopsies	biopsy	NOUN
fnp-2627	111	32	were	be	AUX
fnp-2627	111	33	abundant	abundant	ADJ
fnp-2627	111	34	and	and	CCONJ
fnp-2627	111	35	cd57	cd57	PROPN
fnp-2627	111	36	-	-	PUNCT
fnp-2627	111	37	positive	positive	ADJ
fnp-2627	111	38	,	,	PUNCT
fnp-2627	111	39	the	the	DET
fnp-2627	111	40	cd8	cd8	PROPN
fnp-2627	111	41	+	+	PROPN
fnp-2627	111	42	t	t	PROPN
fnp-2627	111	43	lymphocytes	lymphocyte	VERB
fnp-2627	111	44	invading	invade	VERB
fnp-2627	111	45	muscle	muscle	NOUN
fnp-2627	111	46	fibers	fiber	NOUN
fnp-2627	111	47	in	in	ADP
fnp-2627	111	48	“	"	PUNCT
fnp-2627	111	49	pm	pm	NOUN
fnp-2627	111	50	”	"	PUNCT
fnp-2627	111	51	biopsies	biopsy	NOUN
fnp-2627	111	52	were	be	AUX
fnp-2627	111	53	sparse	sparse	ADJ
fnp-2627	111	54	and	and	CCONJ
fnp-2627	111	55	cd57	cd57	PROPN
fnp-2627	111	56	-	-	PUNCT
fnp-2627	111	57	negative	negative	ADJ
fnp-2627	111	58	.	.	PUNCT
fnp-2627	112	1	additional	additional	ADJ
fnp-2627	112	2	work	work	NOUN
fnp-2627	112	3	will	will	AUX
fnp-2627	112	4	be	be	AUX
fnp-2627	112	5	required	require	VERB
fnp-2627	112	6	to	to	PART
fnp-2627	112	7	establish	establish	VERB
fnp-2627	112	8	whether	whether	SCONJ
fnp-2627	112	9	pathologically	pathologically	ADV
fnp-2627	112	10	diagnosed	diagnose	VERB
fnp-2627	112	11	pm	pm	NOUN
fnp-2627	112	12	is	be	AUX
fnp-2627	112	13	a	a	DET
fnp-2627	112	14	distinct	distinct	ADJ
fnp-2627	112	15	(	(	PUNCT
fnp-2627	112	16	albeit	albeit	SCONJ
fnp-2627	112	17	rare	rare	ADJ
fnp-2627	112	18	)	)	PUNCT
fnp-2627	112	19	disease	disease	NOUN
fnp-2627	112	20	entity	entity	NOUN
fnp-2627	112	21	or	or	CCONJ
fnp-2627	112	22	whether	whether	SCONJ
fnp-2627	112	23	it	it	PRON
fnp-2627	112	24	corresponds	correspond	VERB
fnp-2627	112	25	to	to	ADP
fnp-2627	112	26	an	an	DET
fnp-2627	112	27	early	early	ADJ
fnp-2627	112	28	stage	stage	NOUN
fnp-2627	112	29	of	of	ADP
fnp-2627	112	30	sibm	sibm	NOUN
fnp-2627	112	31	that	that	PRON
fnp-2627	112	32	lacks	lack	VERB
fnp-2627	112	33	senescent	senescent	ADJ
fnp-2627	112	34	,	,	PUNCT
fnp-2627	112	35	cd57+klrg1	cd57+klrg1	NOUN
fnp-2627	112	36	+	+	CCONJ
fnp-2627	112	37	temra	temra	NOUN
fnp-2627	112	38	cells	cell	NOUN
fnp-2627	112	39	and	and	CCONJ
fnp-2627	112	40	thus	thus	ADV
fnp-2627	112	41	remains	remain	VERB
fnp-2627	112	42	responsive	responsive	ADJ
fnp-2627	112	43	to	to	ADP
fnp-2627	112	44	immunosuppressive	immunosuppressive	ADJ
fnp-2627	112	45	therapy	therapy	NOUN
fnp-2627	112	46	.	.	PUNCT
fnp-2627	113	1	either	either	DET
fnp-2627	113	2	way	way	NOUN
fnp-2627	113	3	,	,	PUNCT
fnp-2627	113	4	these	these	DET
fnp-2627	113	5	findings	finding	NOUN
fnp-2627	113	6	raise	raise	VERB
fnp-2627	113	7	a	a	DET
fnp-2627	113	8	possibility	possibility	NOUN
fnp-2627	113	9	that	that	SCONJ
fnp-2627	113	10	the	the	DET
fnp-2627	113	11	presence	presence	NOUN
fnp-2627	113	12	of	of	ADP
fnp-2627	113	13	cd8+cd57+klrg1	cd8+cd57+klrg1	PROPN
fnp-2627	113	14	+	+	SYM
fnp-2627	113	15	t	t	NOUN
fnp-2627	113	16	cells	cell	NOUN
fnp-2627	113	17	in	in	ADP
fnp-2627	113	18	an	an	DET
fnp-2627	113	19	iim	iim	NOUN
fnp-2627	113	20	biopsy	biopsy	NOUN
fnp-2627	113	21	could	could	AUX
fnp-2627	113	22	serve	serve	VERB
fnp-2627	113	23	as	as	ADP
fnp-2627	113	24	a	a	DET
fnp-2627	113	25	prognostic	prognostic	ADJ
fnp-2627	113	26	marker	marker	NOUN
fnp-2627	113	27	of	of	ADP
fnp-2627	113	28	resistance	resistance	NOUN
fnp-2627	113	29	to	to	ADP
fnp-2627	113	30	the	the	DET
fnp-2627	113	31	currently	currently	ADV
fnp-2627	113	32	available	available	ADJ
fnp-2627	113	33	immunosuppressive	immunosuppressive	ADJ
fnp-2627	113	34	therapies	therapy	NOUN
fnp-2627	113	35	,	,	PUNCT
fnp-2627	113	36	a	a	DET
fnp-2627	113	37	clinically	clinically	ADV
fnp-2627	113	38	important	important	ADJ
fnp-2627	113	39	application	application	NOUN
fnp-2627	113	40	that	that	PRON
fnp-2627	113	41	warrants	warrant	VERB
fnp-2627	113	42	future	future	ADJ
fnp-2627	113	43	study	study	NOUN
fnp-2627	113	44	.	.	PUNCT
fnp-2627	114	1	in	in	ADP
fnp-2627	114	2	addition	addition	NOUN
fnp-2627	114	3	,	,	PUNCT
fnp-2627	114	4	expression	expression	NOUN
fnp-2627	114	5	of	of	ADP
fnp-2627	114	6	klrg1	klrg1	NOUN
fnp-2627	114	7	by	by	ADP
fnp-2627	114	8	sibm	sibm	NOUN
fnp-2627	114	9	temra	temra	NOUN
fnp-2627	114	10	cells	cell	NOUN
fnp-2627	114	11	may	may	AUX
fnp-2627	114	12	have	have	VERB
fnp-2627	114	13	therapeutic	therapeutic	ADJ
fnp-2627	114	14	implications	implication	NOUN
fnp-2627	114	15	:	:	PUNCT
fnp-2627	114	16	given	give	VERB
fnp-2627	114	17	that	that	SCONJ
fnp-2627	114	18	this	this	DET
fnp-2627	114	19	protein	protein	NOUN
fnp-2627	114	20	is	be	AUX
fnp-2627	114	21	not	not	PART
fnp-2627	114	22	expressed	express	VERB
fnp-2627	114	23	by	by	ADP
fnp-2627	114	24	central	central	ADJ
fnp-2627	114	25	memory	memory	NOUN
fnp-2627	114	26	t	t	NOUN
fnp-2627	114	27	cells	cell	NOUN
fnp-2627	114	28	and	and	CCONJ
fnp-2627	114	29	regulatory	regulatory	ADJ
fnp-2627	114	30	t	t	NOUN
fnp-2627	114	31	cells	cell	NOUN
fnp-2627	114	32	,	,	PUNCT
fnp-2627	114	33	it	it	PRON
fnp-2627	114	34	could	could	AUX
fnp-2627	114	35	be	be	AUX
fnp-2627	114	36	used	use	VERB
fnp-2627	114	37	as	as	ADP
fnp-2627	114	38	a	a	DET
fnp-2627	114	39	basis	basis	NOUN
fnp-2627	114	40	for	for	ADP
fnp-2627	114	41	development	development	NOUN
fnp-2627	114	42	of	of	ADP
fnp-2627	114	43	a	a	DET
fnp-2627	114	44	future	future	ADJ
fnp-2627	114	45	sibm	sibm	NOUN
fnp-2627	114	46	therapeutic	therapeutic	ADJ
fnp-2627	114	47	(	(	PUNCT
fnp-2627	114	48	greenberg	greenberg	PROPN
fnp-2627	114	49	et	et	PROPN
fnp-2627	114	50	al	al	PROPN
fnp-2627	114	51	.	.	PROPN
fnp-2627	114	52	,	,	PUNCT
fnp-2627	114	53	2019	2019	NUM
fnp-2627	114	54	)	)	PUNCT
fnp-2627	114	55	.	.	PUNCT
fnp-2627	115	1	6	6	X
fnp-2627	115	2	.	.	X
fnp-2627	115	3	immune	immune	NOUN
fnp-2627	115	4	-	-	PUNCT
fnp-2627	115	5	mediated	mediate	VERB
fnp-2627	115	6	necrotizing	necrotizing	NOUN
fnp-2627	115	7	myopathies	myopathy	NOUN
fnp-2627	115	8	:	:	PUNCT
fnp-2627	115	9	mechanisms	mechanism	NOUN
fnp-2627	115	10	of	of	ADP
fnp-2627	115	11	cell	cell	NOUN
fnp-2627	115	12	injury	injury	NOUN
fnp-2627	115	13	mmune	mmune	NOUN
fnp-2627	115	14	-	-	PUNCT
fnp-2627	115	15	mediated	mediate	VERB
fnp-2627	115	16	necrotizing	necrotizing	NOUN
fnp-2627	115	17	myopathies	myopathy	NOUN
fnp-2627	115	18	(	(	PUNCT
fnp-2627	115	19	imnms	imnms	NOUN
fnp-2627	115	20	)	)	PUNCT
fnp-2627	115	21	are	be	AUX
fnp-2627	115	22	a	a	DET
fnp-2627	115	23	unique	unique	ADJ
fnp-2627	115	24	class	class	NOUN
fnp-2627	115	25	of	of	ADP
fnp-2627	115	26	iims	iim	NOUN
fnp-2627	115	27	for	for	ADP
fnp-2627	115	28	which	which	PRON
fnp-2627	115	29	the	the	DET
fnp-2627	115	30	consensus	consensus	NOUN
fnp-2627	115	31	clinicoseropathologic	clinicoseropathologic	ADJ
fnp-2627	115	32	criteria	criterion	NOUN
fnp-2627	115	33	were	be	AUX
fnp-2627	115	34	defined	define	VERB
fnp-2627	115	35	at	at	ADP
fnp-2627	115	36	a	a	DET
fnp-2627	115	37	workshop	workshop	NOUN
fnp-2627	115	38	held	hold	VERB
fnp-2627	115	39	in	in	ADP
fnp-2627	115	40	2016	2016	NUM
fnp-2627	115	41	(	(	PUNCT
fnp-2627	115	42	allenbach	allenbach	NOUN
fnp-2627	115	43	et	et	PROPN
fnp-2627	115	44	al	al	PROPN
fnp-2627	115	45	.	.	PROPN
fnp-2627	115	46	,	,	PUNCT
fnp-2627	115	47	2018	2018	NUM
fnp-2627	115	48	)	)	PUNCT
fnp-2627	115	49	.	.	PUNCT
fnp-2627	116	1	imnms	imnms	NOUN
fnp-2627	116	2	have	have	AUX
fnp-2627	116	3	been	be	AUX
fnp-2627	116	4	linked	link	VERB
fnp-2627	116	5	to	to	ADP
fnp-2627	116	6	autoantibodies	autoantibody	NOUN
fnp-2627	116	7	against	against	ADP
fnp-2627	116	8	signal	signal	NOUN
fnp-2627	116	9	recognition	recognition	NOUN
fnp-2627	116	10	particle	particle	NOUN
fnp-2627	116	11	(	(	PUNCT
fnp-2627	116	12	srp	srp	PROPN
fnp-2627	116	13	)	)	PUNCT
fnp-2627	116	14	and	and	CCONJ
fnp-2627	116	15	3	3	NUM
fnp-2627	116	16	-	-	PUNCT
fnp-2627	116	17	hydroxy-3	hydroxy-3	NUM
fnp-2627	116	18	-	-	PUNCT
fnp-2627	116	19	methylglutaryl	methylglutaryl	ADJ
fnp-2627	116	20	-	-	PUNCT
fnp-2627	116	21	coa	coa	NOUN
fnp-2627	116	22	reductase	reductase	NOUN
fnp-2627	116	23	(	(	PUNCT
fnp-2627	116	24	hmgcr	hmgcr	NOUN
fnp-2627	116	25	)	)	PUNCT
fnp-2627	116	26	,	,	PUNCT
fnp-2627	116	27	but	but	CCONJ
fnp-2627	116	28	approximately	approximately	ADV
fnp-2627	116	29	one	one	NUM
fnp-2627	116	30	third	third	NOUN
fnp-2627	116	31	of	of	ADP
fnp-2627	116	32	cases	case	NOUN
fnp-2627	116	33	is	be	AUX
fnp-2627	116	34	seronegative	seronegative	ADJ
fnp-2627	116	35	and	and	CCONJ
fnp-2627	116	36	requires	require	VERB
fnp-2627	116	37	histopathologic	histopathologic	ADJ
fnp-2627	116	38	diagnosis	diagnosis	NOUN
fnp-2627	116	39	(	(	PUNCT
fnp-2627	116	40	bergua	bergua	NOUN
fnp-2627	116	41	et	et	PROPN
fnp-2627	116	42	al	al	PROPN
fnp-2627	116	43	.	.	PROPN
fnp-2627	116	44	,	,	PUNCT
fnp-2627	116	45	2019	2019	NUM
fnp-2627	116	46	)	)	PUNCT
fnp-2627	116	47	.	.	PUNCT
fnp-2627	117	1	regardless	regardless	ADV
fnp-2627	117	2	of	of	ADP
fnp-2627	117	3	the	the	DET
fnp-2627	117	4	serologic	serologic	ADJ
fnp-2627	117	5	subtype	subtype	NOUN
fnp-2627	117	6	,	,	PUNCT
fnp-2627	117	7	pathologic	pathologic	ADJ
fnp-2627	117	8	features	feature	NOUN
fnp-2627	117	9	of	of	ADP
fnp-2627	117	10	imnm	imnm	PROPN
fnp-2627	117	11	include	include	VERB
fnp-2627	117	12	randomly	randomly	ADV
fnp-2627	117	13	distributed	distribute	VERB
fnp-2627	117	14	necrotic	necrotic	ADJ
fnp-2627	117	15	and	and	CCONJ
fnp-2627	117	16	regenerating	regenerate	VERB
fnp-2627	117	17	muscle	muscle	NOUN
fnp-2627	117	18	fibers	fiber	NOUN
fnp-2627	117	19	(	(	PUNCT
fnp-2627	117	20	fig	fig	NOUN
fnp-2627	117	21	.	.	PUNCT
fnp-2627	118	1	5d	5d	NUM
fnp-2627	118	2	)	)	PUNCT
fnp-2627	118	3	,	,	PUNCT
fnp-2627	118	4	variable	variable	ADJ
fnp-2627	118	5	mhc-1	mhc-1	NUM
fnp-2627	118	6	upregulation	upregulation	NOUN
fnp-2627	118	7	,	,	PUNCT
fnp-2627	118	8	sarcolemmal	sarcolemmal	ADJ
fnp-2627	118	9	complement	complement	NOUN
fnp-2627	118	10	deposition	deposition	NOUN
fnp-2627	118	11	,	,	PUNCT
fnp-2627	118	12	and	and	CCONJ
fnp-2627	118	13	a	a	DET
fnp-2627	118	14	scant	scant	ADJ
fnp-2627	118	15	to	to	PART
fnp-2627	118	16	absent	absent	VERB
fnp-2627	118	17	lymphocytic	lymphocytic	ADJ
fnp-2627	118	18	infiltrate	infiltrate	NOUN
fnp-2627	118	19	.	.	PUNCT
fnp-2627	119	1	previous	previous	ADJ
fnp-2627	119	2	work	work	NOUN
fnp-2627	119	3	has	have	AUX
fnp-2627	119	4	shown	show	VERB
fnp-2627	119	5	that	that	SCONJ
fnp-2627	119	6	in	in	ADP
fnp-2627	119	7	vitro	vitro	X
fnp-2627	119	8	treatment	treatment	NOUN
fnp-2627	119	9	with	with	ADP
fnp-2627	119	10	either	either	CCONJ
fnp-2627	119	11	anti	anti	NOUN
fnp-2627	119	12	-	-	ADJ
fnp-2627	119	13	srp	srp	ADJ
fnp-2627	119	14	or	or	CCONJ
fnp-2627	119	15	anti	anti	ADJ
fnp-2627	119	16	-	-	ADJ
fnp-2627	119	17	hmgcr	hmgcr	ADJ
fnp-2627	119	18	antibodies	antibody	NOUN
fnp-2627	119	19	leads	lead	VERB
fnp-2627	119	20	to	to	ADP
fnp-2627	119	21	impaired	impaired	ADJ
fnp-2627	119	22	myoblast	myoblast	ADJ
fnp-2627	119	23	fusion	fusion	NOUN
fnp-2627	119	24	and	and	CCONJ
fnp-2627	119	25	muscle	muscle	NOUN
fnp-2627	119	26	fiber	fiber	NOUN
fnp-2627	119	27	atrophy	atrophy	NOUN
fnp-2627	119	28	(	(	PUNCT
fnp-2627	119	29	arouche	arouche	NOUN
fnp-2627	119	30	-	-	PUNCT
fnp-2627	119	31	delaperche	delaperche	PROPN
fnp-2627	119	32	et	et	PROPN
fnp-2627	119	33	al	al	PROPN
fnp-2627	119	34	.	.	PROPN
fnp-2627	119	35	,	,	PUNCT
fnp-2627	119	36	2017	2017	NUM
fnp-2627	119	37	)	)	PUNCT
fnp-2627	119	38	,	,	PUNCT
fnp-2627	119	39	suggesting	suggest	VERB
fnp-2627	119	40	that	that	SCONJ
fnp-2627	119	41	these	these	DET
fnp-2627	119	42	autoantibodies	autoantibody	NOUN
fnp-2627	119	43	play	play	VERB
fnp-2627	119	44	a	a	DET
fnp-2627	119	45	causative	causative	ADJ
fnp-2627	119	46	role	role	NOUN
fnp-2627	119	47	in	in	ADP
fnp-2627	119	48	imnm	imnm	PROPN
fnp-2627	119	49	pathogenesis	pathogenesis	NOUN
fnp-2627	119	50	.	.	PUNCT
fnp-2627	120	1	a	a	DET
fnp-2627	120	2	study	study	NOUN
fnp-2627	120	3	from	from	ADP
fnp-2627	120	4	the	the	DET
fnp-2627	120	5	same	same	ADJ
fnp-2627	120	6	group	group	NOUN
fnp-2627	120	7	published	publish	VERB
fnp-2627	120	8	in	in	ADP
fnp-2627	120	9	2019	2019	NUM
fnp-2627	120	10	has	have	AUX
fnp-2627	120	11	taken	take	VERB
fnp-2627	120	12	the	the	DET
fnp-2627	120	13	field	field	NOUN
fnp-2627	120	14	a	a	DET
fnp-2627	120	15	step	step	NOUN
fnp-2627	120	16	further	far	ADV
fnp-2627	120	17	by	by	ADP
fnp-2627	120	18	demonstrating	demonstrate	VERB
fnp-2627	120	19	the	the	DET
fnp-2627	120	20	causative	causative	ADJ
fnp-2627	120	21	effect	effect	NOUN
fnp-2627	120	22	of	of	ADP
fnp-2627	120	23	these	these	DET
fnp-2627	120	24	two	two	NUM
fnp-2627	120	25	antibodies	antibody	NOUN
fnp-2627	120	26	in	in	ADP
fnp-2627	120	27	vivo	vivo	NOUN
fnp-2627	120	28	:	:	PUNCT
fnp-2627	120	29	mice	mouse	NOUN
fnp-2627	120	30	treated	treat	VERB
fnp-2627	120	31	with	with	ADP
fnp-2627	120	32	either	either	CCONJ
fnp-2627	120	33	anti	anti	ADJ
fnp-2627	120	34	-	-	ADJ
fnp-2627	120	35	srp+	srp+	ADJ
fnp-2627	120	36	or	or	CCONJ
fnp-2627	120	37	anti	anti	ADJ
fnp-2627	120	38	-	-	ADJ
fnp-2627	120	39	hmgcr+	hmgcr+	ADJ
fnp-2627	120	40	patient	patient	NOUN
fnp-2627	120	41	-	-	PUNCT
fnp-2627	120	42	derived	derive	VERB
fnp-2627	120	43	plasma	plasma	NOUN
fnp-2627	120	44	develop	develop	VERB
fnp-2627	120	45	weakness	weakness	NOUN
fnp-2627	120	46	and	and	CCONJ
fnp-2627	120	47	necrotizing	necrotizing	NOUN
fnp-2627	120	48	myopathy	myopathy	NOUN
fnp-2627	120	49	that	that	SCONJ
fnp-2627	120	50	closely	closely	ADV
fnp-2627	120	51	resembles	resemble	VERB
fnp-2627	120	52	human	human	ADJ
fnp-2627	120	53	imnm	imnm	NOUN
fnp-2627	120	54	(	(	PUNCT
fnp-2627	120	55	bergua	bergua	NOUN
fnp-2627	120	56	et	et	PROPN
fnp-2627	120	57	al	al	PROPN
fnp-2627	120	58	.	.	PROPN
fnp-2627	120	59	,	,	PUNCT
fnp-2627	120	60	2019	2019	NUM
fnp-2627	120	61	)	)	PUNCT
fnp-2627	120	62	.	.	PUNCT
fnp-2627	121	1	in	in	ADP
fnp-2627	121	2	a	a	DET
fnp-2627	121	3	further	further	ADJ
fnp-2627	121	4	agreement	agreement	NOUN
fnp-2627	121	5	with	with	ADP
fnp-2627	121	6	human	human	ADJ
fnp-2627	121	7	disease	disease	NOUN
fnp-2627	121	8	,	,	PUNCT
fnp-2627	121	9	muscle	muscle	NOUN
fnp-2627	121	10	deficiency	deficiency	NOUN
fnp-2627	121	11	is	be	AUX
fnp-2627	121	12	worse	bad	ADJ
fnp-2627	121	13	following	follow	VERB
fnp-2627	121	14	treatment	treatment	NOUN
fnp-2627	121	15	with	with	ADP
fnp-2627	121	16	anti	anti	ADJ
fnp-2627	121	17	-	-	NOUN
fnp-2627	121	18	srp	srp	ADJ
fnp-2627	121	19	than	than	ADP
fnp-2627	121	20	with	with	ADP
fnp-2627	121	21	anti	anti	ADJ
fnp-2627	121	22	-	-	ADJ
fnp-2627	121	23	hmgcr	hmgcr	ADJ
fnp-2627	121	24	antibodies	antibodie	VERB
fnp-2627	121	25	,	,	PUNCT
fnp-2627	121	26	but	but	CCONJ
fnp-2627	121	27	both	both	DET
fnp-2627	121	28	antisera	antisera	NOUN
fnp-2627	121	29	require	require	VERB
fnp-2627	121	30	functional	functional	ADJ
fnp-2627	121	31	complement	complement	NOUN
fnp-2627	121	32	pathway	pathway	NOUN
fnp-2627	121	33	to	to	PART
fnp-2627	121	34	produce	produce	VERB
fnp-2627	121	35	the	the	DET
fnp-2627	121	36	disease	disease	NOUN
fnp-2627	121	37	phenotype	phenotype	NOUN
fnp-2627	121	38	.	.	PUNCT
fnp-2627	122	1	taken	take	VERB
fnp-2627	122	2	together	together	ADV
fnp-2627	122	3	,	,	PUNCT
fnp-2627	122	4	these	these	DET
fnp-2627	122	5	studies	study	NOUN
fnp-2627	122	6	provide	provide	VERB
fnp-2627	122	7	a	a	DET
fnp-2627	122	8	conclusive	conclusive	ADJ
fnp-2627	122	9	evidence	evidence	NOUN
fnp-2627	122	10	for	for	ADP
fnp-2627	122	11	the	the	DET
fnp-2627	122	12	key	key	ADJ
fnp-2627	122	13	role	role	NOUN
fnp-2627	122	14	of	of	ADP
fnp-2627	122	15	type	type	NOUN
fnp-2627	122	16	ii	ii	PROPN
fnp-2627	122	17	(	(	PUNCT
fnp-2627	122	18	antibodyand	antibodyand	PROPN
fnp-2627	122	19	complement	complement	NOUN
fnp-2627	122	20	-	-	PUNCT
fnp-2627	122	21	mediated	mediate	VERB
fnp-2627	122	22	)	)	PUNCT
fnp-2627	122	23	immune	immune	ADJ
fnp-2627	122	24	mechanisms	mechanism	NOUN
fnp-2627	122	25	in	in	ADP
fnp-2627	122	26	imnm	imnm	PROPN
fnp-2627	122	27	pathogenesis	pathogenesis	NOUN
fnp-2627	122	28	.	.	PUNCT
fnp-2627	123	1	interestingly	interestingly	ADV
fnp-2627	123	2	,	,	PUNCT
fnp-2627	123	3	target	target	VERB
fnp-2627	123	4	antigens	antigen	NOUN
fnp-2627	123	5	of	of	ADP
fnp-2627	123	6	the	the	DET
fnp-2627	123	7	two	two	NUM
fnp-2627	123	8	known	know	VERB
fnp-2627	123	9	imnm	imnm	NOUN
fnp-2627	123	10	autoantibodies	autoantibody	NOUN
fnp-2627	123	11	(	(	PUNCT
fnp-2627	123	12	the	the	DET
fnp-2627	123	13	signal	signal	ADJ
fnp-2627	123	14	peptide	peptide	NOUN
fnp-2627	123	15	-	-	PUNCT
fnp-2627	123	16	binding	bind	VERB
fnp-2627	123	17	54	54	NUM
fnp-2627	123	18	kda	kda	NOUN
fnp-2627	123	19	subunit	subunit	NOUN
fnp-2627	123	20	of	of	ADP
fnp-2627	123	21	the	the	DET
fnp-2627	123	22	srp	srp	PROPN
fnp-2627	123	23	ribonucleoprotein	ribonucleoprotein	PROPN
fnp-2627	123	24	complex	complex	ADJ
fnp-2627	123	25	and	and	CCONJ
fnp-2627	123	26	hgmcr	hgmcr	ADJ
fnp-2627	123	27	,	,	PUNCT
fnp-2627	123	28	the	the	DET
fnp-2627	123	29	rate	rate	NOUN
fnp-2627	123	30	-	-	PUNCT
fnp-2627	123	31	limiting	limit	VERB
fnp-2627	123	32	enzyme	enzyme	NOUN
fnp-2627	123	33	in	in	ADP
fnp-2627	123	34	the	the	DET
fnp-2627	123	35	cholesterol	cholesterol	NOUN
fnp-2627	123	36	biosynthetic	biosynthetic	ADJ
fnp-2627	123	37	pathway	pathway	NOUN
fnp-2627	123	38	)	)	PUNCT
fnp-2627	123	39	are	be	AUX
fnp-2627	123	40	both	both	PRON
fnp-2627	123	41	expressed	express	VERB
fnp-2627	123	42	in	in	ADP
fnp-2627	123	43	the	the	DET
fnp-2627	123	44	er	er	INTJ
fnp-2627	123	45	of	of	ADP
fnp-2627	123	46	all	all	DET
fnp-2627	123	47	cell	cell	NOUN
fnp-2627	123	48	types	type	NOUN
fnp-2627	123	49	(	(	PUNCT
fnp-2627	123	50	bergua	bergua	NOUN
fnp-2627	123	51	et	et	PROPN
fnp-2627	123	52	al	al	PROPN
fnp-2627	123	53	.	.	PROPN
fnp-2627	123	54	,	,	PUNCT
fnp-2627	123	55	2019	2019	NUM
fnp-2627	123	56	)	)	PUNCT
fnp-2627	123	57	.	.	PUNCT
fnp-2627	124	1	given	give	VERB
fnp-2627	124	2	the	the	DET
fnp-2627	124	3	ubiquitous	ubiquitous	ADJ
fnp-2627	124	4	expression	expression	NOUN
fnp-2627	124	5	of	of	ADP
fnp-2627	124	6	these	these	DET
fnp-2627	124	7	antigens	antigen	NOUN
fnp-2627	124	8	,	,	PUNCT
fnp-2627	124	9	it	it	PRON
fnp-2627	124	10	remains	remain	VERB
fnp-2627	124	11	unclear	unclear	ADJ
fnp-2627	124	12	why	why	SCONJ
fnp-2627	124	13	anti	anti	ADJ
fnp-2627	124	14	-	-	ADJ
fnp-2627	124	15	srp	srp	ADJ
fnp-2627	124	16	and	and	CCONJ
fnp-2627	124	17	anti	anti	ADJ
fnp-2627	124	18	-	-	ADJ
fnp-2627	124	19	hmgcr	hmgcr	ADJ
fnp-2627	124	20	antibodies	antibody	NOUN
fnp-2627	124	21	selectively	selectively	ADV
fnp-2627	124	22	target	target	VERB
fnp-2627	124	23	skeletal	skeletal	ADJ
fnp-2627	124	24	muscle	muscle	NOUN
fnp-2627	124	25	in	in	ADP
fnp-2627	124	26	both	both	DET
fnp-2627	124	27	humans	human	NOUN
fnp-2627	124	28	and	and	CCONJ
fnp-2627	124	29	mice	mouse	NOUN
fnp-2627	124	30	.	.	PUNCT
fnp-2627	125	1	however	however	ADV
fnp-2627	125	2	,	,	PUNCT
fnp-2627	125	3	the	the	DET
fnp-2627	125	4	er	er	INTJ
fnp-2627	125	5	localization	localization	NOUN
fnp-2627	125	6	of	of	ADP
fnp-2627	125	7	both	both	DET
fnp-2627	125	8	autoantibody	autoantibody	ADJ
fnp-2627	125	9	targets	target	NOUN
fnp-2627	125	10	may	may	AUX
fnp-2627	125	11	be	be	AUX
fnp-2627	125	12	significant	significant	ADJ
fnp-2627	125	13	for	for	ADP
fnp-2627	125	14	imnm	imnm	PROPN
fnp-2627	125	15	pathogenesis	pathogenesis	NOUN
fnp-2627	125	16	:	:	PUNCT
fnp-2627	125	17	a	a	DET
fnp-2627	125	18	2019	2019	NUM
fnp-2627	125	19	study	study	NOUN
fnp-2627	125	20	has	have	AUX
fnp-2627	125	21	shown	show	VERB
fnp-2627	125	22	that	that	SCONJ
fnp-2627	125	23	human	human	ADJ
fnp-2627	125	24	imnm	imnm	PROPN
fnp-2627	125	25	muscle	muscle	NOUN
fnp-2627	125	26	biopsies	biopsy	NOUN
fnp-2627	125	27	of	of	ADP
fnp-2627	125	28	any	any	DET
fnp-2627	125	29	serotype	serotype	NOUN
fnp-2627	125	30	show	show	NOUN
fnp-2627	125	31	increased	increase	VERB
fnp-2627	125	32	er	er	INTJ
fnp-2627	125	33	stress	stress	NOUN
fnp-2627	125	34	,	,	PUNCT
fnp-2627	125	35	activation	activation	NOUN
fnp-2627	125	36	of	of	ADP
fnp-2627	125	37	the	the	DET
fnp-2627	125	38	unfolded	unfolded	ADJ
fnp-2627	125	39	protein	protein	NOUN
fnp-2627	125	40	response	response	NOUN
fnp-2627	125	41	,	,	PUNCT
fnp-2627	125	42	and	and	CCONJ
fnp-2627	125	43	upregulation	upregulation	NOUN
fnp-2627	125	44	of	of	ADP
fnp-2627	125	45	the	the	DET
fnp-2627	125	46	chaperone	chaperone	NOUN
fnp-2627	125	47	-	-	PUNCT
fnp-2627	125	48	assisted	assist	VERB
fnp-2627	125	49	selective	selective	ADJ
fnp-2627	125	50	autophagy	autophagy	NOUN
fnp-2627	125	51	(	(	PUNCT
fnp-2627	125	52	casa	casa	PROPN
fnp-2627	125	53	)	)	PUNCT
fnp-2627	125	54	pathway	pathway	NOUN
fnp-2627	125	55	(	(	PUNCT
fnp-2627	125	56	fischer	fischer	PROPN
fnp-2627	125	57	et	et	PROPN
fnp-2627	125	58	al	al	PROPN
fnp-2627	125	59	.	.	PROPN
fnp-2627	125	60	,	,	PUNCT
fnp-2627	125	61	2019	2019	NUM
fnp-2627	125	62	)	)	PUNCT
fnp-2627	125	63	.	.	PUNCT
fnp-2627	126	1	notably	notably	ADV
fnp-2627	126	2	,	,	PUNCT
fnp-2627	126	3	activation	activation	NOUN
fnp-2627	126	4	of	of	ADP
fnp-2627	126	5	the	the	DET
fnp-2627	126	6	casa	casa	PROPN
fnp-2627	126	7	pathway	pathway	NOUN
fnp-2627	126	8	in	in	ADP
fnp-2627	126	9	imnms	imnms	NOUN
fnp-2627	126	10	is	be	AUX
fnp-2627	126	11	associated	associate	VERB
fnp-2627	126	12	with	with	ADP
fnp-2627	126	13	a	a	DET
fnp-2627	126	14	unique	unique	ADJ
fnp-2627	126	15	pattern	pattern	NOUN
fnp-2627	126	16	of	of	ADP
fnp-2627	126	17	immunostaining	immunostaine	VERB
fnp-2627	126	18	for	for	ADP
fnp-2627	126	19	autophagy	autophagy	ADV
fnp-2627	126	20	-	-	PUNCT
fnp-2627	126	21	associated	associate	VERB
fnp-2627	126	22	proteins	protein	NOUN
fnp-2627	126	23	lc3	lc3	NOUN
fnp-2627	126	24	and	and	CCONJ
fnp-2627	126	25	p62	p62	NOUN
fnp-2627	126	26	/	/	SYM
fnp-2627	126	27	sqstm1	sqstm1	NOUN
fnp-2627	126	28	:	:	PUNCT
fnp-2627	126	29	instead	instead	ADV
fnp-2627	126	30	of	of	ADP
fnp-2627	126	31	the	the	DET
fnp-2627	126	32	coarse	coarse	ADJ
fnp-2627	126	33	lc3and	lc3and	PROPN
fnp-2627	126	34	p62	p62	NOUN
fnp-2627	126	35	-	-	PUNCT
fnp-2627	126	36	positive	positive	ADJ
fnp-2627	126	37	vacuoles	vacuole	NOUN
fnp-2627	126	38	and	and	CCONJ
fnp-2627	126	39	protein	protein	NOUN
fnp-2627	126	40	aggregates	aggregate	NOUN
fnp-2627	126	41	seen	see	VERB
fnp-2627	126	42	in	in	ADP
fnp-2627	126	43	autophagic	autophagic	ADJ
fnp-2627	126	44	vacuolar	vacuolar	ADJ
fnp-2627	126	45	myopathies	myopathy	NOUN
fnp-2627	126	46	and	and	CCONJ
fnp-2627	126	47	sibm	sibm	NOUN
fnp-2627	126	48	[	[	X
fnp-2627	126	49	figs	fig	NOUN
fnp-2627	126	50	.	.	PUNCT
fnp-2627	127	1	5b	5b	NUM
fnp-2627	127	2	and	and	CCONJ
fnp-2627	127	3	5c	5c	NUM
fnp-2627	127	4	;	;	PUNCT
fnp-2627	127	5	also	also	ADV
fnp-2627	127	6	reviewed	review	VERB
fnp-2627	127	7	in	in	ADP
fnp-2627	127	8	(	(	PUNCT
fnp-2627	127	9	margeta	margeta	NOUN
fnp-2627	127	10	,	,	PUNCT
fnp-2627	127	11	2019	2019	NUM
fnp-2627	127	12	)	)	PUNCT
fnp-2627	127	13	]	]	PUNCT
fnp-2627	127	14	,	,	PUNCT
fnp-2627	127	15	imnm	imnm	PROPN
fnp-2627	127	16	biopsies	biopsy	NOUN
fnp-2627	127	17	show	show	VERB
fnp-2627	127	18	diffusely	diffusely	ADV
fnp-2627	127	19	punctate	punctate	NOUN
fnp-2627	127	20	and	and	CCONJ
fnp-2627	127	21	often	often	ADV
fnp-2627	127	22	quite	quite	ADV
fnp-2627	127	23	strong	strong	ADJ
fnp-2627	127	24	staining	staining	NOUN
fnp-2627	127	25	of	of	ADP
fnp-2627	127	26	a	a	DET
fnp-2627	127	27	variable	variable	ADJ
fnp-2627	127	28	subset	subset	NOUN
fnp-2627	127	29	of	of	ADP
fnp-2627	127	30	non	non	ADJ
fnp-2627	127	31	-	-	ADJ
fnp-2627	127	32	necrotic	necrotic	ADJ
fnp-2627	127	33	muscle	muscle	NOUN
fnp-2627	127	34	fibers	fiber	NOUN
fnp-2627	127	35	(	(	PUNCT
fnp-2627	127	36	figs	fig	NOUN
fnp-2627	127	37	.	.	PUNCT
fnp-2627	128	1	5e	5e	NOUN
fnp-2627	128	2	and	and	CCONJ
fnp-2627	128	3	5f	5f	NUM
fnp-2627	128	4	)	)	PUNCT
fnp-2627	128	5	.	.	PUNCT
fnp-2627	129	1	while	while	SCONJ
fnp-2627	129	2	it	it	PRON
fnp-2627	129	3	remains	remain	VERB
fnp-2627	129	4	to	to	PART
fnp-2627	129	5	be	be	AUX
fnp-2627	129	6	shown	show	VERB
fnp-2627	129	7	how	how	SCONJ
fnp-2627	129	8	antibody	antibody	NOUN
fnp-2627	129	9	-	-	PUNCT
fnp-2627	129	10	mediated	mediate	VERB
fnp-2627	129	11	cell	cell	NOUN
fnp-2627	129	12	injury	injury	NOUN
fnp-2627	129	13	leads	lead	VERB
fnp-2627	129	14	to	to	ADP
fnp-2627	129	15	activation	activation	NOUN
fnp-2627	129	16	of	of	ADP
fnp-2627	129	17	the	the	DET
fnp-2627	129	18	casa	casa	PROPN
fnp-2627	129	19	pathway	pathway	NOUN
fnp-2627	130	1	[	[	X
fnp-2627	130	2	the	the	DET
fnp-2627	130	3	impairment	impairment	NOUN
fnp-2627	130	4	of	of	ADP
fnp-2627	130	5	which	which	PRON
fnp-2627	130	6	plays	play	VERB
fnp-2627	130	7	a	a	DET
fnp-2627	130	8	role	role	NOUN
fnp-2627	130	9	in	in	ADP
fnp-2627	130	10	the	the	DET
fnp-2627	130	11	pathogenesis	pathogenesis	NOUN
fnp-2627	130	12	of	of	ADP
fnp-2627	130	13	myofibrillar	myofibrillar	ADJ
fnp-2627	130	14	myopathies	myopathy	NOUN
fnp-2627	130	15	;	;	PUNCT
fnp-2627	130	16	reviewed	review	VERB
fnp-2627	130	17	in	in	ADP
fnp-2627	130	18	(	(	PUNCT
fnp-2627	130	19	margeta	margeta	NOUN
fnp-2627	130	20	,	,	PUNCT
fnp-2627	130	21	2019	2019	NUM
fnp-2627	130	22	)	)	PUNCT
fnp-2627	130	23	]	]	PUNCT
fnp-2627	130	24	,	,	PUNCT
fnp-2627	130	25	this	this	DET
fnp-2627	130	26	unique	unique	ADJ
fnp-2627	130	27	lc3and	lc3and	NOUN
fnp-2627	130	28	p62	p62	NOUN
fnp-2627	130	29	-	-	PUNCT
fnp-2627	130	30	staining	stain	VERB
fnp-2627	130	31	pattern	pattern	NOUN
fnp-2627	130	32	is	be	AUX
fnp-2627	130	33	likely	likely	ADJ
fnp-2627	130	34	to	to	PART
fnp-2627	130	35	prove	prove	VERB
fnp-2627	130	36	useful	useful	ADJ
fnp-2627	130	37	in	in	ADP
fnp-2627	130	38	diagnostically	diagnostically	ADV
fnp-2627	130	39	challenging	challenge	VERB
fnp-2627	130	40	imnm	imnm	NOUN
fnp-2627	130	41	cases	case	NOUN
fnp-2627	130	42	;	;	PUNCT
fnp-2627	130	43	however	however	ADV
fnp-2627	130	44	,	,	PUNCT
fnp-2627	130	45	additional	additional	ADJ
fnp-2627	130	46	work	work	NOUN
fnp-2627	130	47	will	will	AUX
fnp-2627	130	48	be	be	AUX
fnp-2627	130	49	required	require	VERB
fnp-2627	130	50	to	to	PART
fnp-2627	130	51	establish	establish	VERB
fnp-2627	130	52	its	its	PRON
fnp-2627	130	53	sensitivity	sensitivity	NOUN
fnp-2627	130	54	and	and	CCONJ
fnp-2627	130	55	specificity	specificity	NOUN
fnp-2627	130	56	for	for	ADP
fnp-2627	130	57	imnms	imnms	PRON
fnp-2627	130	58	relative	relative	ADJ
fnp-2627	130	59	to	to	ADP
fnp-2627	130	60	other	other	ADJ
fnp-2627	130	61	conditions	condition	NOUN
fnp-2627	130	62	in	in	ADP
fnp-2627	130	63	the	the	DET
fnp-2627	130	64	histopathologic	histopathologic	ADJ
fnp-2627	130	65	differential	differential	ADJ
fnp-2627	130	66	diagnosis	diagnosis	NOUN
fnp-2627	130	67	(	(	PUNCT
fnp-2627	130	68	toxic	toxic	ADJ
fnp-2627	130	69	necrotizing	necrotizing	NOUN
fnp-2627	130	70	myopathies	myopathy	NOUN
fnp-2627	130	71	and	and	CCONJ
fnp-2627	130	72	other	other	ADJ
fnp-2627	130	73	iims	iim	NOUN
fnp-2627	130	74	)	)	PUNCT
fnp-2627	130	75	.	.	PUNCT
fnp-2627	131	1	advances	advance	NOUN
fnp-2627	131	2	in	in	ADP
fnp-2627	131	3	neuromuscular	neuromuscular	ADJ
fnp-2627	131	4	disease	disease	NOUN
fnp-2627	131	5	diagnostics	diagnostic	NOUN
fnp-2627	131	6	7	7	NUM
fnp-2627	131	7	.	.	PUNCT
fnp-2627	131	8	idiopathic	idiopathic	ADJ
fnp-2627	131	9	inflammatory	inflammatory	ADJ
fnp-2627	131	10	myopathies	myopathy	NOUN
fnp-2627	131	11	:	:	PUNCT
fnp-2627	131	12	myositis	myositis	NOUN
fnp-2627	131	13	-	-	PUNCT
fnp-2627	131	14	specific	specific	ADJ
fnp-2627	131	15	antibodies	antibody	NOUN
fnp-2627	131	16	and	and	CCONJ
fnp-2627	131	17	interferon	interferon	ADJ
fnp-2627	131	18	activation	activation	NOUN
fnp-2627	131	19	signatures	signature	NOUN
fnp-2627	131	20	as	as	SCONJ
fnp-2627	131	21	already	already	ADV
fnp-2627	131	22	mentioned	mention	VERB
fnp-2627	131	23	,	,	PUNCT
fnp-2627	131	24	iims	iim	NOUN
fnp-2627	131	25	are	be	AUX
fnp-2627	131	26	currently	currently	ADV
fnp-2627	131	27	divided	divide	VERB
fnp-2627	131	28	into	into	ADP
fnp-2627	131	29	four	four	NUM
fnp-2627	131	30	distinct	distinct	ADJ
fnp-2627	131	31	classes	class	NOUN
fnp-2627	131	32	dm	dm	NOUN
fnp-2627	131	33	,	,	PUNCT
fnp-2627	131	34	asm	asm	NOUN
fnp-2627	131	35	,	,	PUNCT
fnp-2627	131	36	imnm	imnm	PROPN
fnp-2627	131	37	,	,	PUNCT
fnp-2627	131	38	and	and	CCONJ
fnp-2627	131	39	sibm	sibm	NOUN
fnp-2627	131	40	based	base	VERB
fnp-2627	131	41	on	on	ADP
fnp-2627	131	42	the	the	DET
fnp-2627	131	43	most	most	ADJ
fnp-2627	131	44	up	up	ADP
fnp-2627	131	45	-	-	PUNCT
fnp-2627	131	46	to	to	ADP
fnp-2627	131	47	-	-	PUNCT
fnp-2627	131	48	date	date	NOUN
fnp-2627	131	49	clinicoseropathologic	clinicoseropathologic	ADJ
fnp-2627	131	50	criteria	criterion	NOUN
fnp-2627	131	51	[	[	X
fnp-2627	131	52	first	first	ADV
fnp-2627	131	53	comprehensively	comprehensively	ADV
fnp-2627	131	54	outlined	outline	VERB
fnp-2627	131	55	in	in	ADP
fnp-2627	131	56	a	a	DET
fnp-2627	131	57	review	review	NOUN
fnp-2627	131	58	by	by	ADP
fnp-2627	131	59	allenbach	allenbach	NOUN
fnp-2627	131	60	at	at	ADP
fnp-2627	131	61	al	al	PROPN
fnp-2627	131	62	.	.	PUNCT
fnp-2627	132	1	(	(	PUNCT
fnp-2627	132	2	2017	2017	NUM
fnp-2627	132	3	)	)	PUNCT
fnp-2627	132	4	and	and	CCONJ
fnp-2627	132	5	further	far	ADV
fnp-2627	132	6	updated	update	VERB
fnp-2627	132	7	in	in	ADP
fnp-2627	132	8	a	a	DET
fnp-2627	132	9	recent	recent	ADJ
fnp-2627	132	10	review	review	NOUN
fnp-2627	132	11	by	by	ADP
fnp-2627	132	12	tanboon	tanboon	NOUN
fnp-2627	132	13	and	and	CCONJ
fnp-2627	132	14	nishino	nishino	PROPN
fnp-2627	132	15	(	(	PUNCT
fnp-2627	132	16	2019	2019	NUM
fnp-2627	132	17	)	)	PUNCT
fnp-2627	132	18	]	]	PUNCT
fnp-2627	132	19	.	.	PUNCT
fnp-2627	133	1	this	this	DET
fnp-2627	133	2	classification	classification	NOUN
fnp-2627	133	3	has	have	AUX
fnp-2627	133	4	been	be	AUX
fnp-2627	133	5	developed	develop	VERB
fnp-2627	133	6	based	base	VERB
fnp-2627	133	7	on	on	ADP
fnp-2627	133	8	advances	advance	NOUN
fnp-2627	133	9	made	make	VERB
fnp-2627	133	10	over	over	ADP
fnp-2627	133	11	the	the	DET
fnp-2627	133	12	last	last	ADJ
fnp-2627	133	13	5	5	NUM
fnp-2627	133	14	-	-	SYM
fnp-2627	133	15	10	10	NUM
fnp-2627	133	16	years	year	NOUN
fnp-2627	133	17	and	and	CCONJ
fnp-2627	133	18	is	be	AUX
fnp-2627	133	19	largely	largely	ADV
fnp-2627	133	20	(	(	PUNCT
fnp-2627	133	21	although	although	SCONJ
fnp-2627	133	22	not	not	PART
fnp-2627	133	23	entirely	entirely	ADV
fnp-2627	133	24	)	)	PUNCT
fnp-2627	133	25	based	base	VERB
fnp-2627	133	26	on	on	ADP
fnp-2627	133	27	the	the	DET
fnp-2627	133	28	association	association	NOUN
fnp-2627	133	29	of	of	ADP
fnp-2627	133	30	individual	individual	ADJ
fnp-2627	133	31	iim	iim	PROPN
fnp-2627	133	32	classes	class	NOUN
fnp-2627	133	33	with	with	ADP
fnp-2627	133	34	different	different	ADJ
fnp-2627	133	35	myositis	myositis	NOUN
fnp-2627	133	36	-	-	PUNCT
fnp-2627	133	37	specific	specific	ADJ
fnp-2627	133	38	antibodies	antibody	NOUN
fnp-2627	133	39	(	(	PUNCT
fnp-2627	133	40	msa	msa	PROPN
fnp-2627	133	41	)	)	PUNCT
fnp-2627	133	42	;	;	PUNCT
fnp-2627	133	43	while	while	SCONJ
fnp-2627	133	44	these	these	DET
fnp-2627	133	45	autoantibodies	autoantibody	NOUN
fnp-2627	133	46	sometimes	sometimes	ADV
fnp-2627	133	47	directly	directly	ADV
fnp-2627	133	48	mediate	mediate	VERB
fnp-2627	133	49	muscle	muscle	NOUN
fnp-2627	133	50	injury	injury	NOUN
fnp-2627	133	51	(	(	PUNCT
fnp-2627	133	52	as	as	SCONJ
fnp-2627	133	53	already	already	ADV
fnp-2627	133	54	discussed	discuss	VERB
fnp-2627	133	55	for	for	ADP
fnp-2627	133	56	imnms	imnms	NOUN
fnp-2627	133	57	in	in	ADP
fnp-2627	133	58	discovery	discovery	NOUN
fnp-2627	133	59	#	#	SYM
fnp-2627	133	60	6	6	NUM
fnp-2627	133	61	)	)	PUNCT
fnp-2627	133	62	,	,	PUNCT
fnp-2627	133	63	more	more	ADV
fnp-2627	133	64	often	often	ADV
fnp-2627	133	65	they	they	PRON
fnp-2627	133	66	represent	represent	VERB
fnp-2627	133	67	a	a	DET
fnp-2627	133	68	diagnostically	diagnostically	ADV
fnp-2627	133	69	useful	useful	ADJ
fnp-2627	133	70	epiphenomenon	epiphenomenon	NOUN
fnp-2627	133	71	/	/	SYM
fnp-2627	133	72	disease	disease	NOUN
fnp-2627	133	73	marker	marker	NOUN
fnp-2627	133	74	.	.	PUNCT
fnp-2627	134	1	the	the	DET
fnp-2627	134	2	discovery	discovery	PROPN
fnp-2627	134	3	of	of	ADP
fnp-2627	134	4	msa	msa	PROPN
fnp-2627	134	5	has	have	AUX
fnp-2627	134	6	revolutionized	revolutionize	VERB
fnp-2627	134	7	iim	iim	NOUN
fnp-2627	134	8	diagnostics	diagnostic	NOUN
fnp-2627	134	9	because	because	SCONJ
fnp-2627	134	10	of	of	ADP
fnp-2627	134	11	their	their	PRON
fnp-2627	134	12	high	high	ADJ
fnp-2627	134	13	specificity	specificity	NOUN
fnp-2627	134	14	,	,	PUNCT
fnp-2627	134	15	but	but	CCONJ
fnp-2627	134	16	the	the	DET
fnp-2627	134	17	sensitivity	sensitivity	NOUN
fnp-2627	134	18	remains	remain	VERB
fnp-2627	134	19	relatively	relatively	ADV
fnp-2627	134	20	low	low	ADJ
fnp-2627	134	21	.	.	PUNCT
fnp-2627	135	1	for	for	ADP
fnp-2627	135	2	example	example	NOUN
fnp-2627	135	3	,	,	PUNCT
fnp-2627	135	4	two	two	NUM
fnp-2627	135	5	retrospective	retrospective	ADJ
fnp-2627	135	6	studies	study	NOUN
fnp-2627	135	7	of	of	ADP
fnp-2627	135	8	large	large	ADJ
fnp-2627	135	9	european	european	ADJ
fnp-2627	135	10	iim	iim	PROPN
fnp-2627	135	11	cohorts	cohort	NOUN
fnp-2627	135	12	published	publish	VERB
fnp-2627	135	13	in	in	ADP
fnp-2627	135	14	2019	2019	NUM
fnp-2627	135	15	found	find	VERB
fnp-2627	135	16	that	that	SCONJ
fnp-2627	135	17	msa	msa	PROPN
fnp-2627	135	18	are	be	AUX
fnp-2627	135	19	negative	negative	ADJ
fnp-2627	135	20	in	in	ADP
fnp-2627	135	21	40	40	NUM
fnp-2627	135	22	-	-	SYM
fnp-2627	135	23	60	60	NUM
fnp-2627	135	24	%	%	NOUN
fnp-2627	135	25	of	of	ADP
fnp-2627	135	26	iim	iim	NOUN
fnp-2627	135	27	patients	patient	NOUN
fnp-2627	135	28	(	(	PUNCT
fnp-2627	135	29	betteridge	betteridge	NOUN
fnp-2627	135	30	et	et	PROPN
fnp-2627	135	31	al	al	PROPN
fnp-2627	135	32	.	.	PROPN
fnp-2627	135	33	,	,	PUNCT
fnp-2627	135	34	2019	2019	NUM
fnp-2627	135	35	;	;	PUNCT
fnp-2627	135	36	montagnese	montagnese	NOUN
fnp-2627	135	37	et	et	PROPN
fnp-2627	135	38	al	al	PROPN
fnp-2627	135	39	.	.	PROPN
fnp-2627	135	40	,	,	PUNCT
fnp-2627	135	41	2019	2019	NUM
fnp-2627	135	42	)	)	PUNCT
fnp-2627	135	43	;	;	PUNCT
fnp-2627	135	44	in	in	ADP
fnp-2627	135	45	these	these	DET
fnp-2627	135	46	msa	msa	PROPN
fnp-2627	135	47	-	-	ADJ
fnp-2627	135	48	negative	negative	ADJ
fnp-2627	135	49	cases	case	NOUN
fnp-2627	135	50	(	(	PUNCT
fnp-2627	135	51	as	as	ADV
fnp-2627	135	52	well	well	ADV
fnp-2627	135	53	as	as	ADP
fnp-2627	135	54	in	in	ADP
fnp-2627	135	55	rare	rare	ADJ
fnp-2627	135	56	cases	case	NOUN
fnp-2627	135	57	with	with	ADP
fnp-2627	135	58	more	more	ADJ
fnp-2627	135	59	than	than	ADP
fnp-2627	135	60	one	one	NUM
fnp-2627	135	61	msa	msa	PROPN
fnp-2627	135	62	present	present	ADJ
fnp-2627	135	63	or	or	CCONJ
fnp-2627	135	64	in	in	ADP
fnp-2627	135	65	cases	case	NOUN
fnp-2627	135	66	for	for	ADP
fnp-2627	135	67	which	which	PRON
fnp-2627	135	68	msa	msa	PROPN
fnp-2627	135	69	information	information	NOUN
fnp-2627	135	70	is	be	AUX
fnp-2627	135	71	lacking	lack	VERB
fnp-2627	135	72	)	)	PUNCT
fnp-2627	135	73	,	,	PUNCT
fnp-2627	135	74	muscle	muscle	NOUN
fnp-2627	135	75	biopsy	biopsy	NOUN
fnp-2627	135	76	remains	remain	VERB
fnp-2627	135	77	the	the	DET
fnp-2627	135	78	cornerstone	cornerstone	NOUN
fnp-2627	135	79	of	of	ADP
fnp-2627	135	80	iim	iim	ADJ
fnp-2627	135	81	diagnosis	diagnosis	NOUN
fnp-2627	135	82	.	.	PUNCT
fnp-2627	136	1	figure	figure	NOUN
fnp-2627	136	2	6	6	NUM
fnp-2627	136	3	.	.	PUNCT
fnp-2627	137	1	dermatomyositis	dermatomyositis	PROPN
fnp-2627	137	2	(	(	PUNCT
fnp-2627	137	3	dm	dm	NOUN
fnp-2627	137	4	)	)	PUNCT
fnp-2627	137	5	variants	variant	NOUN
fnp-2627	137	6	:	:	PUNCT
fnp-2627	137	7	(	(	PUNCT
fnp-2627	137	8	a	a	X
fnp-2627	137	9	)	)	PUNCT
fnp-2627	137	10	a	a	DET
fnp-2627	137	11	“	"	PUNCT
fnp-2627	137	12	classic	classic	ADJ
fnp-2627	137	13	”	"	PUNCT
fnp-2627	137	14	dm	dm	NOUN
fnp-2627	137	15	case	case	NOUN
fnp-2627	137	16	shows	show	NOUN
fnp-2627	137	17	marked	mark	VERB
fnp-2627	137	18	perifascicular	perifascicular	ADJ
fnp-2627	137	19	fiber	fiber	NOUN
fnp-2627	137	20	atrophy	atrophy	NOUN
fnp-2627	137	21	but	but	CCONJ
fnp-2627	137	22	no	no	DET
fnp-2627	137	23	significant	significant	ADJ
fnp-2627	137	24	inflammation	inflammation	NOUN
fnp-2627	137	25	in	in	ADP
fnp-2627	137	26	the	the	DET
fnp-2627	137	27	perimysium	perimysium	NOUN
fnp-2627	137	28	or	or	CCONJ
fnp-2627	137	29	endomysium	endomysium	NOUN
fnp-2627	137	30	;	;	PUNCT
fnp-2627	137	31	the	the	DET
fnp-2627	137	32	patient	patient	NOUN
fnp-2627	137	33	’s	’s	PART
fnp-2627	137	34	antibody	antibody	NOUN
fnp-2627	137	35	status	status	NOUN
fnp-2627	137	36	is	be	AUX
fnp-2627	137	37	not	not	PART
fnp-2627	137	38	known	know	VERB
fnp-2627	137	39	,	,	PUNCT
fnp-2627	137	40	but	but	CCONJ
fnp-2627	137	41	the	the	DET
fnp-2627	137	42	overall	overall	ADJ
fnp-2627	137	43	clinicopathologic	clinicopathologic	ADJ
fnp-2627	137	44	findings	finding	NOUN
fnp-2627	137	45	fit	fit	ADJ
fnp-2627	137	46	best	well	ADV
fnp-2627	137	47	with	with	ADP
fnp-2627	137	48	the	the	DET
fnp-2627	137	49	anti	anti	ADJ
fnp-2627	137	50	-	-	ADJ
fnp-2627	137	51	tif1γ	tif1γ	ADJ
fnp-2627	137	52	-	-	PUNCT
fnp-2627	137	53	associated	associate	VERB
fnp-2627	137	54	dm	dm	NOUN
fnp-2627	137	55	.	.	PUNCT
fnp-2627	138	1	(	(	PUNCT
fnp-2627	138	2	b	b	X
fnp-2627	138	3	)	)	PUNCT
fnp-2627	138	4	a	a	DET
fnp-2627	138	5	typical	typical	ADJ
fnp-2627	138	6	case	case	NOUN
fnp-2627	138	7	of	of	ADP
fnp-2627	138	8	anti	anti	ADJ
fnp-2627	138	9	-	-	ADJ
fnp-2627	138	10	mi-2	mi-2	ADV
fnp-2627	138	11	-	-	PUNCT
fnp-2627	138	12	associated	associate	VERB
fnp-2627	138	13	dm	dm	PROPN
fnp-2627	138	14	also	also	ADV
fnp-2627	138	15	shows	show	VERB
fnp-2627	138	16	perifascicular	perifascicular	ADJ
fnp-2627	138	17	atrophy	atrophy	NOUN
fnp-2627	138	18	,	,	PUNCT
fnp-2627	138	19	but	but	CCONJ
fnp-2627	138	20	could	could	AUX
fnp-2627	138	21	be	be	AUX
fnp-2627	138	22	confused	confuse	VERB
fnp-2627	138	23	with	with	ADP
fnp-2627	138	24	anti	anti	ADJ
fnp-2627	138	25	-	-	ADJ
fnp-2627	138	26	synthetase	synthetase	ADJ
fnp-2627	138	27	syndrome	syndrome	NOUN
fnp-2627	138	28	-	-	PUNCT
fnp-2627	138	29	associated	associate	VERB
fnp-2627	138	30	myositis	myositis	NOUN
fnp-2627	138	31	given	give	VERB
fnp-2627	138	32	the	the	DET
fnp-2627	138	33	presence	presence	NOUN
fnp-2627	138	34	of	of	ADP
fnp-2627	138	35	perimysial	perimysial	ADJ
fnp-2627	138	36	and	and	CCONJ
fnp-2627	138	37	focally	focally	ADV
fnp-2627	138	38	endomysial	endomysial	ADJ
fnp-2627	138	39	inflammation	inflammation	NOUN
fnp-2627	138	40	,	,	PUNCT
fnp-2627	138	41	perimysial	perimysial	ADJ
fnp-2627	138	42	fragmentation	fragmentation	NOUN
fnp-2627	138	43	,	,	PUNCT
fnp-2627	138	44	and	and	CCONJ
fnp-2627	138	45	patchy	patchy	ADJ
fnp-2627	138	46	necrosis	necrosis	NOUN
fnp-2627	138	47	of	of	ADP
fnp-2627	138	48	perifascicular	perifascicular	ADJ
fnp-2627	138	49	muscle	muscle	NOUN
fnp-2627	138	50	fibers	fiber	NOUN
fnp-2627	138	51	.	.	PUNCT
fnp-2627	139	1	(	(	PUNCT
fnp-2627	139	2	c	c	X
fnp-2627	139	3	)	)	PUNCT
fnp-2627	139	4	a	a	DET
fnp-2627	139	5	case	case	NOUN
fnp-2627	139	6	of	of	ADP
fnp-2627	139	7	anti	anti	ADJ
fnp-2627	139	8	-	-	ADJ
fnp-2627	139	9	mda5	mda5	NOUN
fnp-2627	139	10	-	-	PUNCT
fnp-2627	139	11	associated	associate	VERB
fnp-2627	139	12	dm	dm	PROPN
fnp-2627	139	13	shows	show	VERB
fnp-2627	139	14	moderate	moderate	ADJ
fnp-2627	139	15	processing	processing	NOUN
fnp-2627	139	16	artifacts	artifact	NOUN
fnp-2627	139	17	but	but	CCONJ
fnp-2627	139	18	no	no	DET
fnp-2627	139	19	significant	significant	ADJ
fnp-2627	139	20	pathologic	pathologic	ADJ
fnp-2627	139	21	changes	change	NOUN
fnp-2627	139	22	;	;	PUNCT
fnp-2627	139	23	the	the	DET
fnp-2627	139	24	only	only	ADJ
fnp-2627	139	25	significant	significant	ADJ
fnp-2627	139	26	abnormality	abnormality	NOUN
fnp-2627	139	27	was	be	AUX
fnp-2627	139	28	mild	mild	ADJ
fnp-2627	139	29	upregulation	upregulation	NOUN
fnp-2627	139	30	of	of	ADP
fnp-2627	139	31	mhc	mhc	PROPN
fnp-2627	139	32	-	-	PUNCT
fnp-2627	139	33	i	i	PROPN
fnp-2627	139	34	complex	complex	NOUN
fnp-2627	139	35	in	in	ADP
fnp-2627	139	36	all	all	DET
fnp-2627	139	37	muscle	muscle	NOUN
fnp-2627	139	38	fibers	fiber	NOUN
fnp-2627	139	39	(	(	PUNCT
fnp-2627	139	40	not	not	PART
fnp-2627	139	41	shown	show	VERB
fnp-2627	139	42	)	)	PUNCT
fnp-2627	139	43	.	.	PUNCT
fnp-2627	140	1	for	for	ADP
fnp-2627	140	2	all	all	DET
fnp-2627	140	3	three	three	NUM
fnp-2627	140	4	cases	case	NOUN
fnp-2627	140	5	,	,	PUNCT
fnp-2627	140	6	images	image	NOUN
fnp-2627	140	7	show	show	VERB
fnp-2627	140	8	representative	representative	ADJ
fnp-2627	140	9	h&e	h&e	PROPN
fnp-2627	140	10	-	-	PUNCT
fnp-2627	140	11	stained	stain	VERB
fnp-2627	140	12	cryosections	cryosection	NOUN
fnp-2627	140	13	.	.	PUNCT
fnp-2627	141	1	scale	scale	NOUN
fnp-2627	141	2	bar	bar	NOUN
fnp-2627	141	3	,	,	PUNCT
fnp-2627	141	4	100	100	NUM
fnp-2627	141	5	µm	µm	NOUN
fnp-2627	141	6	.	.	PUNCT
fnp-2627	142	1	histopathologically	histopathologically	ADV
fnp-2627	142	2	,	,	PUNCT
fnp-2627	142	3	most	most	ADJ
fnp-2627	142	4	cases	case	NOUN
fnp-2627	142	5	of	of	ADP
fnp-2627	142	6	dm	dm	PROPN
fnp-2627	142	7	,	,	PUNCT
fnp-2627	142	8	imnm	imnm	PROPN
fnp-2627	142	9	,	,	PUNCT
fnp-2627	142	10	asm	asm	NOUN
fnp-2627	142	11	,	,	PUNCT
fnp-2627	142	12	and	and	CCONJ
fnp-2627	142	13	sibm	sibm	NOUN
fnp-2627	142	14	are	be	AUX
fnp-2627	142	15	easily	easily	ADV
fnp-2627	142	16	distinguishable	distinguishable	ADJ
fnp-2627	142	17	[	[	PUNCT
fnp-2627	142	18	for	for	ADP
fnp-2627	142	19	a	a	DET
fnp-2627	142	20	review	review	NOUN
fnp-2627	142	21	of	of	ADP
fnp-2627	142	22	up	up	ADP
fnp-2627	142	23	-	-	PUNCT
fnp-2627	142	24	to	to	ADP
fnp-2627	142	25	-	-	PUNCT
fnp-2627	142	26	date	date	NOUN
fnp-2627	142	27	pathologic	pathologic	ADJ
fnp-2627	142	28	criteria	criterion	NOUN
fnp-2627	142	29	,	,	PUNCT
fnp-2627	142	30	see	see	VERB
fnp-2627	142	31	tanboon	tanboon	NOUN
fnp-2627	142	32	and	and	CCONJ
fnp-2627	142	33	nishino	nishino	PROPN
fnp-2627	142	34	(	(	PUNCT
fnp-2627	142	35	2019	2019	NUM
fnp-2627	142	36	)	)	PUNCT
fnp-2627	142	37	]	]	PUNCT
fnp-2627	142	38	;	;	PUNCT
fnp-2627	142	39	however	however	ADV
fnp-2627	142	40	,	,	PUNCT
fnp-2627	142	41	a	a	DET
fnp-2627	142	42	few	few	ADJ
fnp-2627	142	43	entities	entity	NOUN
fnp-2627	142	44	can	can	AUX
fnp-2627	142	45	create	create	VERB
fnp-2627	142	46	diagnostic	diagnostic	ADJ
fnp-2627	142	47	difficulties	difficulty	NOUN
fnp-2627	142	48	.	.	PUNCT
fnp-2627	143	1	for	for	ADP
fnp-2627	143	2	example	example	NOUN
fnp-2627	143	3	,	,	PUNCT
fnp-2627	143	4	anti	anti	ADJ
fnp-2627	143	5	-	-	ADJ
fnp-2627	143	6	mda5	mda5	NOUN
fnp-2627	143	7	-	-	PUNCT
fnp-2627	143	8	associated	associate	VERB
fnp-2627	143	9	subtype	subtype	NOUN
fnp-2627	143	10	of	of	ADP
fnp-2627	143	11	dm	dm	PRON
fnp-2627	143	12	generally	generally	ADV
fnp-2627	143	13	lacks	lack	VERB
fnp-2627	143	14	perifascicular	perifascicular	ADJ
fnp-2627	143	15	atrophy	atrophy	NOUN
fnp-2627	143	16	(	(	PUNCT
fnp-2627	143	17	a	a	DET
fnp-2627	143	18	key	key	ADJ
fnp-2627	143	19	diagnostic	diagnostic	ADJ
fnp-2627	143	20	feature	feature	NOUN
fnp-2627	143	21	of	of	ADP
fnp-2627	143	22	dm	dm	NOUN
fnp-2627	143	23	;	;	PUNCT
fnp-2627	143	24	fig	fig	NOUN
fnp-2627	143	25	.	.	PUNCT
fnp-2627	143	26	6a	6a	NOUN
fnp-2627	143	27	)	)	PUNCT
fnp-2627	143	28	and	and	CCONJ
fnp-2627	143	29	can	can	AUX
fnp-2627	143	30	therefore	therefore	ADV
fnp-2627	143	31	mimic	mimic	VERB
fnp-2627	143	32	imnm	imnm	NOUN
fnp-2627	143	33	or	or	CCONJ
fnp-2627	143	34	even	even	ADV
fnp-2627	143	35	normal	normal	ADJ
fnp-2627	143	36	muscle	muscle	NOUN
fnp-2627	143	37	(	(	PUNCT
fnp-2627	143	38	fig	fig	NOUN
fnp-2627	143	39	.	.	PUNCT
fnp-2627	144	1	6c	6c	NOUN
fnp-2627	144	2	)	)	PUNCT
fnp-2627	144	3	,	,	PUNCT
fnp-2627	144	4	while	while	SCONJ
fnp-2627	144	5	anti	anti	ADJ
fnp-2627	144	6	-	-	ADJ
fnp-2627	144	7	mi-2	mi-2	ADV
fnp-2627	144	8	-	-	PUNCT
fnp-2627	144	9	associated	associate	VERB
fnp-2627	144	10	dm	dm	PROPN
fnp-2627	144	11	shows	show	VERB
fnp-2627	144	12	prominent	prominent	ADJ
fnp-2627	144	13	perimysial	perimysial	ADJ
fnp-2627	144	14	inflammation	inflammation	NOUN
fnp-2627	144	15	and	and	CCONJ
fnp-2627	144	16	perifascicular	perifascicular	ADJ
fnp-2627	144	17	fiber	fiber	NOUN
fnp-2627	144	18	necrosis	necrosis	NOUN
fnp-2627	144	19	that	that	PRON
fnp-2627	144	20	can	can	AUX
fnp-2627	144	21	mimic	mimic	VERB
fnp-2627	144	22	asm	asm	NOUN
fnp-2627	144	23	(	(	PUNCT
fnp-2627	144	24	fig	fig	NOUN
fnp-2627	144	25	.	.	PUNCT
fnp-2627	144	26	6b	6b	NUM
fnp-2627	144	27	)	)	PUNCT
fnp-2627	144	28	.	.	PUNCT
fnp-2627	145	1	the	the	DET
fnp-2627	145	2	interferon	interferon	ADJ
fnp-2627	145	3	-	-	PUNCT
fnp-2627	145	4	induced	induce	VERB
fnp-2627	145	5	gene	gene	NOUN
fnp-2627	145	6	expression	expression	NOUN
fnp-2627	145	7	signatures	signature	NOUN
fnp-2627	145	8	associated	associate	VERB
fnp-2627	145	9	with	with	ADP
fnp-2627	145	10	different	different	ADJ
fnp-2627	145	11	iim	iim	NOUN
fnp-2627	145	12	classes	class	NOUN
fnp-2627	145	13	,	,	PUNCT
fnp-2627	145	14	which	which	PRON
fnp-2627	145	15	were	be	AUX
fnp-2627	145	16	defined	define	VERB
fnp-2627	145	17	in	in	ADP
fnp-2627	145	18	two	two	NUM
fnp-2627	145	19	separate	separate	ADJ
fnp-2627	145	20	studies	study	NOUN
fnp-2627	145	21	published	publish	VERB
fnp-2627	145	22	in	in	ADP
fnp-2627	145	23	2019	2019	NUM
fnp-2627	145	24	(	(	PUNCT
fnp-2627	145	25	pinal	pinal	PROPN
fnp-2627	145	26	-	-	PUNCT
fnp-2627	145	27	fernandez	fernandez	PROPN
fnp-2627	145	28	et	et	PROPN
fnp-2627	145	29	al	al	PROPN
fnp-2627	145	30	.	.	PROPN
fnp-2627	145	31	,	,	PUNCT
fnp-2627	145	32	2019	2019	NUM
fnp-2627	145	33	;	;	PUNCT
fnp-2627	145	34	rigolet	rigolet	VERB
fnp-2627	145	35	et	et	PROPN
fnp-2627	145	36	al	al	PROPN
fnp-2627	145	37	.	.	PROPN
fnp-2627	145	38	,	,	PUNCT
fnp-2627	145	39	2019	2019	NUM
fnp-2627	145	40	)	)	PUNCT
fnp-2627	145	41	,	,	PUNCT
fnp-2627	145	42	confirm	confirm	VERB
fnp-2627	145	43	the	the	DET
fnp-2627	145	44	validity	validity	NOUN
fnp-2627	145	45	of	of	ADP
fnp-2627	145	46	the	the	DET
fnp-2627	145	47	current	current	ADJ
fnp-2627	145	48	iim	iim	NOUN
fnp-2627	145	49	classification	classification	NOUN
fnp-2627	145	50	and	and	CCONJ
fnp-2627	145	51	identify	identify	VERB
fnp-2627	145	52	immunohistochemical	immunohistochemical	ADJ
fnp-2627	145	53	markers	marker	NOUN
fnp-2627	145	54	of	of	ADP
fnp-2627	145	55	these	these	DET
fnp-2627	145	56	interferon	interferon	ADJ
fnp-2627	145	57	responses	response	NOUN
fnp-2627	145	58	,	,	PUNCT
fnp-2627	145	59	which	which	PRON
fnp-2627	145	60	will	will	AUX
fnp-2627	145	61	likely	likely	ADV
fnp-2627	145	62	prove	prove	VERB
fnp-2627	145	63	diagnostically	diagnostically	ADV
fnp-2627	145	64	useful	useful	ADJ
fnp-2627	145	65	.	.	PUNCT
fnp-2627	146	1	in	in	ADP
fnp-2627	146	2	particular	particular	ADJ
fnp-2627	146	3	,	,	PUNCT
fnp-2627	146	4	both	both	DET
fnp-2627	146	5	studies	study	NOUN
fnp-2627	146	6	have	have	AUX
fnp-2627	146	7	shown	show	VERB
fnp-2627	146	8	that	that	SCONJ
fnp-2627	146	9	all	all	DET
fnp-2627	146	10	subtypes	subtype	NOUN
fnp-2627	146	11	of	of	ADP
fnp-2627	146	12	dm	dm	PROPN
fnp-2627	146	13	(	(	PUNCT
fnp-2627	146	14	including	include	VERB
fnp-2627	146	15	the	the	DET
fnp-2627	146	16	histologically	histologically	ADV
fnp-2627	146	17	atypical	atypical	ADJ
fnp-2627	146	18	cases	case	NOUN
fnp-2627	146	19	associated	associate	VERB
fnp-2627	146	20	with	with	ADP
fnp-2627	146	21	anti	anti	ADJ
fnp-2627	146	22	-	-	ADJ
fnp-2627	146	23	mda5	mda5	ADJ
fnp-2627	146	24	and	and	CCONJ
fnp-2627	146	25	anti	anti	ADJ
fnp-2627	146	26	-	-	ADJ
fnp-2627	146	27	mi-2	mi-2	NOUN
fnp-2627	146	28	antibodies	antibodie	VERB
fnp-2627	146	29	)	)	PUNCT
fnp-2627	146	30	show	show	NOUN
fnp-2627	146	31	activation	activation	NOUN
fnp-2627	146	32	of	of	ADP
fnp-2627	146	33	the	the	DET
fnp-2627	146	34	type	type	NOUN
fnp-2627	146	35	i	i	PRON
fnp-2627	146	36	interferon	interferon	ADJ
fnp-2627	146	37	(	(	PUNCT
fnp-2627	146	38	infα	infα	PROPN
fnp-2627	146	39	/	/	SYM
fnp-2627	146	40	β	β	NOUN
fnp-2627	146	41	)	)	PUNCT
fnp-2627	146	42	pathway	pathway	NOUN
fnp-2627	146	43	and	and	CCONJ
fnp-2627	146	44	prominent	prominent	ADJ
fnp-2627	146	45	upregulation	upregulation	NOUN
fnp-2627	146	46	of	of	ADP
fnp-2627	146	47	ifn1	ifn1	NOUN
fnp-2627	146	48	-	-	PUNCT
fnp-2627	146	49	inducible	inducible	ADJ
fnp-2627	146	50	genes	gene	NOUN
fnp-2627	146	51	such	such	ADJ
fnp-2627	146	52	as	as	ADP
fnp-2627	146	53	mxa	mxa	NOUN
fnp-2627	146	54	(	(	PUNCT
fnp-2627	146	55	myxovirus	myxovirus	NOUN
fnp-2627	146	56	resistance	resistance	NOUN
fnp-2627	146	57	protein	protein	NOUN
fnp-2627	146	58	a	a	PRON
fnp-2627	146	59	)	)	PUNCT
fnp-2627	146	60	,	,	PUNCT
fnp-2627	146	61	which	which	PRON
fnp-2627	146	62	can	can	AUX
fnp-2627	146	63	be	be	AUX
fnp-2627	146	64	used	use	VERB
fnp-2627	146	65	as	as	ADP
fnp-2627	146	66	an	an	DET
fnp-2627	146	67	immunohistochemical	immunohistochemical	ADJ
fnp-2627	146	68	marker	marker	NOUN
fnp-2627	146	69	of	of	ADP
fnp-2627	146	70	the	the	DET
fnp-2627	146	71	inf1	inf1	ADJ
fnp-2627	146	72	response	response	NOUN
fnp-2627	146	73	.	.	PUNCT
fnp-2627	147	1	in	in	ADP
fnp-2627	147	2	dm	dm	PROPN
fnp-2627	147	3	,	,	PUNCT
fnp-2627	147	4	mxa	mxa	PROPN
fnp-2627	147	5	generally	generally	ADV
fnp-2627	147	6	shows	show	VERB
fnp-2627	147	7	sarcolemmal	sarcolemmal	ADJ
fnp-2627	147	8	staining	stain	VERB
fnp-2627	147	9	in	in	ADP
fnp-2627	147	10	perifascicular	perifascicular	ADJ
fnp-2627	147	11	fibers	fiber	NOUN
fnp-2627	147	12	;	;	PUNCT
fnp-2627	147	13	the	the	DET
fnp-2627	147	14	exception	exception	NOUN
fnp-2627	147	15	is	be	AUX
fnp-2627	147	16	anti	anti	ADJ
fnp-2627	147	17	-	-	ADJ
fnp-2627	147	18	mda5	mda5	NOUN
fnp-2627	147	19	-	-	PUNCT
fnp-2627	147	20	associated	associate	VERB
fnp-2627	147	21	dm	dm	NOUN
fnp-2627	147	22	,	,	PUNCT
fnp-2627	147	23	where	where	SCONJ
fnp-2627	147	24	mxa	mxa	NOUN
fnp-2627	147	25	staining	stain	VERB
fnp-2627	147	26	is	be	AUX
fnp-2627	147	27	scattered	scatter	VERB
fnp-2627	147	28	or	or	CCONJ
fnp-2627	147	29	diffuse	diffuse	NOUN
fnp-2627	147	30	but	but	CCONJ
fnp-2627	147	31	not	not	PART
fnp-2627	147	32	perifascicular	perifascicular	ADJ
fnp-2627	147	33	(	(	PUNCT
fnp-2627	147	34	tanboon	tanboon	NOUN
fnp-2627	147	35	and	and	CCONJ
fnp-2627	147	36	nishino	nishino	PROPN
fnp-2627	147	37	,	,	PUNCT
fnp-2627	147	38	2019	2019	NUM
fnp-2627	147	39	)	)	PUNCT
fnp-2627	147	40	.	.	PUNCT
fnp-2627	148	1	in	in	ADP
fnp-2627	148	2	contrast	contrast	NOUN
fnp-2627	148	3	,	,	PUNCT
fnp-2627	148	4	both	both	DET
fnp-2627	148	5	asm	asm	NOUN
fnp-2627	148	6	cases	case	NOUN
fnp-2627	148	7	(	(	PUNCT
fnp-2627	148	8	regardless	regardless	ADV
fnp-2627	148	9	of	of	ADP
fnp-2627	148	10	the	the	DET
fnp-2627	148	11	nature	nature	NOUN
fnp-2627	148	12	of	of	ADP
fnp-2627	148	13	the	the	DET
fnp-2627	148	14	associated	associated	ADJ
fnp-2627	148	15	anti	anti	ADJ
fnp-2627	148	16	-	-	ADJ
fnp-2627	148	17	synthetase	synthetase	ADJ
fnp-2627	148	18	antibody	antibody	NOUN
fnp-2627	148	19	)	)	PUNCT
fnp-2627	148	20	and	and	CCONJ
fnp-2627	148	21	sibm	sibm	NOUN
fnp-2627	148	22	cases	case	NOUN
fnp-2627	148	23	show	show	VERB
fnp-2627	148	24	activation	activation	NOUN
fnp-2627	148	25	of	of	ADP
fnp-2627	148	26	the	the	DET
fnp-2627	148	27	interferon	interferon	ADJ
fnp-2627	148	28	type	type	NOUN
fnp-2627	148	29	ii	ii	PROPN
fnp-2627	148	30	pathway	pathway	NOUN
fnp-2627	148	31	(	(	PUNCT
fnp-2627	148	32	i.e.	i.e.	X
fnp-2627	148	33	upregulation	upregulation	NOUN
fnp-2627	148	34	of	of	ADP
fnp-2627	148	35	infγ	infγ	NOUN
fnp-2627	148	36	-	-	PUNCT
fnp-2627	148	37	inducible	inducible	ADJ
fnp-2627	148	38	genes	gene	NOUN
fnp-2627	148	39	)	)	PUNCT
fnp-2627	148	40	;	;	PUNCT
fnp-2627	148	41	mhc	mhc	PROPN
fnp-2627	148	42	-	-	PUNCT
fnp-2627	148	43	ii	ii	PROPN
fnp-2627	148	44	,	,	PUNCT
fnp-2627	148	45	an	an	DET
fnp-2627	148	46	immunohistochemical	immunohistochemical	ADJ
fnp-2627	148	47	marker	marker	NOUN
fnp-2627	148	48	of	of	ADP
fnp-2627	148	49	infγ	infγ	NOUN
fnp-2627	148	50	activation	activation	NOUN
fnp-2627	148	51	,	,	PUNCT
fnp-2627	148	52	can	can	AUX
fnp-2627	148	53	be	be	AUX
fnp-2627	148	54	used	use	VERB
fnp-2627	148	55	to	to	PART
fnp-2627	148	56	monitor	monitor	VERB
fnp-2627	148	57	this	this	DET
fnp-2627	148	58	pathway	pathway	NOUN
fnp-2627	148	59	in	in	ADP
fnp-2627	148	60	muscle	muscle	NOUN
fnp-2627	148	61	biopsies	biopsy	NOUN
fnp-2627	148	62	(	(	PUNCT
fnp-2627	148	63	rigolet	rigolet	VERB
fnp-2627	148	64	et	et	PROPN
fnp-2627	148	65	al	al	PROPN
fnp-2627	148	66	.	.	PROPN
fnp-2627	148	67	,	,	PUNCT
fnp-2627	148	68	2019	2019	NUM
fnp-2627	148	69	)	)	PUNCT
fnp-2627	148	70	and	and	CCONJ
fnp-2627	148	71	could	could	AUX
fnp-2627	148	72	therefore	therefore	ADV
fnp-2627	148	73	be	be	AUX
fnp-2627	148	74	useful	useful	ADJ
fnp-2627	148	75	for	for	ADP
fnp-2627	148	76	distinguishing	distinguish	VERB
fnp-2627	148	77	asm	asm	NOUN
fnp-2627	148	78	from	from	ADP
fnp-2627	148	79	anti	anti	ADJ
fnp-2627	148	80	-	-	ADJ
fnp-2627	148	81	mi-2	mi-2	NOUN
fnp-2627	148	82	-	-	PUNCT
fnp-2627	148	83	dm	dm	NOUN
fnp-2627	148	84	in	in	ADP
fnp-2627	148	85	challenging	challenging	ADJ
fnp-2627	148	86	cases	case	NOUN
fnp-2627	148	87	.	.	PUNCT
fnp-2627	149	1	[	[	X
fnp-2627	149	2	of	of	ADP
fnp-2627	149	3	note	note	NOUN
fnp-2627	149	4	,	,	PUNCT
fnp-2627	149	5	dm	dm	PROPN
fnp-2627	149	6	muscle	muscle	NOUN
fnp-2627	149	7	biopsies	biopsy	NOUN
fnp-2627	149	8	do	do	AUX
fnp-2627	149	9	show	show	VERB
fnp-2627	149	10	a	a	DET
fnp-2627	149	11	weak	weak	ADJ
fnp-2627	149	12	activation	activation	NOUN
fnp-2627	149	13	of	of	ADP
fnp-2627	149	14	infγ	infγ	NOUN
fnp-2627	149	15	pathway	pathway	NOUN
fnp-2627	149	16	(	(	PUNCT
fnp-2627	149	17	pinal	pinal	PROPN
fnp-2627	149	18	-	-	PUNCT
fnp-2627	149	19	fernandez	fernandez	PROPN
fnp-2627	149	20	et	et	PROPN
fnp-2627	149	21	al	al	PROPN
fnp-2627	149	22	.	.	PROPN
fnp-2627	149	23	,	,	PUNCT
fnp-2627	149	24	2019	2019	NUM
fnp-2627	149	25	;	;	PUNCT
fnp-2627	149	26	rigolet	rigolet	VERB
fnp-2627	149	27	et	et	PROPN
fnp-2627	149	28	al	al	PROPN
fnp-2627	149	29	.	.	PROPN
fnp-2627	149	30	,	,	PUNCT
fnp-2627	149	31	2019	2019	NUM
fnp-2627	149	32	)	)	PUNCT
fnp-2627	149	33	;	;	PUNCT
fnp-2627	149	34	however	however	ADV
fnp-2627	149	35	,	,	PUNCT
fnp-2627	149	36	at	at	ADP
fnp-2627	149	37	least	least	ADJ
fnp-2627	149	38	for	for	ADP
fnp-2627	149	39	mhc	mhc	PROPN
fnp-2627	149	40	-	-	PUNCT
fnp-2627	149	41	ii	ii	PROPN
fnp-2627	149	42	proteins	protein	NOUN
fnp-2627	149	43	that	that	PRON
fnp-2627	149	44	activation	activation	NOUN
fnp-2627	149	45	is	be	AUX
fnp-2627	149	46	several	several	ADJ
fnp-2627	149	47	orders	order	NOUN
fnp-2627	149	48	of	of	ADP
fnp-2627	149	49	magnitude	magnitude	NOUN
fnp-2627	149	50	lower	low	ADJ
fnp-2627	149	51	than	than	ADP
fnp-2627	149	52	in	in	ADP
fnp-2627	149	53	asm	asm	NOUN
fnp-2627	149	54	and	and	CCONJ
fnp-2627	149	55	sibm	sibm	NOUN
fnp-2627	149	56	biopsies	biopsy	NOUN
fnp-2627	149	57	.	.	PUNCT
fnp-2627	150	1	thus	thus	ADV
fnp-2627	150	2	,	,	PUNCT
fnp-2627	150	3	it	it	PRON
fnp-2627	150	4	should	should	AUX
fnp-2627	150	5	be	be	AUX
fnp-2627	150	6	possible	possible	ADJ
fnp-2627	150	7	to	to	PART
fnp-2627	150	8	optimize	optimize	VERB
fnp-2627	150	9	mhc	mhc	PROPN
fnp-2627	150	10	-	-	PUNCT
fnp-2627	150	11	ii	ii	PROPN
fnp-2627	150	12	staining	stain	VERB
fnp-2627	150	13	to	to	PART
fnp-2627	150	14	effectively	effectively	ADV
fnp-2627	150	15	differentiate	differentiate	VERB
fnp-2627	150	16	between	between	ADP
fnp-2627	150	17	dm	dm	PROPN
fnp-2627	150	18	and	and	CCONJ
fnp-2627	150	19	asm	asm	NOUN
fnp-2627	150	20	cases	case	NOUN
fnp-2627	150	21	.	.	PUNCT
fnp-2627	150	22	]	]	PUNCT
fnp-2627	151	1	finally	finally	ADV
fnp-2627	151	2	,	,	PUNCT
fnp-2627	151	3	both	both	DET
fnp-2627	151	4	studies	study	NOUN
fnp-2627	151	5	found	find	VERB
fnp-2627	151	6	that	that	SCONJ
fnp-2627	151	7	imnm	imnm	PROPN
fnp-2627	151	8	biopsies	biopsy	NOUN
fnp-2627	151	9	do	do	AUX
fnp-2627	151	10	not	not	PART
fnp-2627	151	11	exhibit	exhibit	VERB
fnp-2627	151	12	either	either	DET
fnp-2627	151	13	type	type	NOUN
fnp-2627	151	14	i	i	PRON
fnp-2627	151	15	or	or	CCONJ
fnp-2627	151	16	type	type	PROPN
fnp-2627	151	17	ii	ii	PROPN
fnp-2627	151	18	interferon	interferon	PROPN
fnp-2627	151	19	signature	signature	NOUN
fnp-2627	151	20	,	,	PUNCT
fnp-2627	151	21	further	far	ADV
fnp-2627	151	22	validating	validate	VERB
fnp-2627	151	23	their	their	PRON
fnp-2627	151	24	separation	separation	NOUN
fnp-2627	151	25	into	into	ADP
fnp-2627	151	26	a	a	DET
fnp-2627	151	27	separate	separate	ADJ
fnp-2627	151	28	iim	iim	NOUN
fnp-2627	151	29	category	category	NOUN
fnp-2627	151	30	(	(	PUNCT
fnp-2627	151	31	pinal	pinal	PROPN
fnp-2627	151	32	-	-	PUNCT
fnp-2627	151	33	fernandez	fernandez	PROPN
fnp-2627	151	34	et	et	PROPN
fnp-2627	151	35	al	al	PROPN
fnp-2627	151	36	.	.	PROPN
fnp-2627	151	37	,	,	PUNCT
fnp-2627	151	38	2019	2019	NUM
fnp-2627	151	39	;	;	PUNCT
fnp-2627	151	40	rigolet	rigolet	VERB
fnp-2627	151	41	et	et	PROPN
fnp-2627	151	42	al	al	PROPN
fnp-2627	151	43	.	.	PROPN
fnp-2627	151	44	,	,	PUNCT
fnp-2627	151	45	2019	2019	NUM
fnp-2627	151	46	)	)	PUNCT
fnp-2627	151	47	.	.	PUNCT
fnp-2627	152	1	thus	thus	ADV
fnp-2627	152	2	,	,	PUNCT
fnp-2627	152	3	neuromuscular	neuromuscular	ADJ
fnp-2627	152	4	pathology	pathology	NOUN
fnp-2627	152	5	laboratories	laboratory	NOUN
fnp-2627	152	6	that	that	PRON
fnp-2627	152	7	see	see	VERB
fnp-2627	152	8	a	a	DET
fnp-2627	152	9	lot	lot	NOUN
fnp-2627	152	10	of	of	ADP
fnp-2627	152	11	iim	iim	NOUN
fnp-2627	152	12	cases	case	NOUN
fnp-2627	152	13	should	should	AUX
fnp-2627	152	14	consider	consider	VERB
fnp-2627	152	15	adding	add	VERB
fnp-2627	152	16	mxa	mxa	NOUN
fnp-2627	152	17	and	and	CCONJ
fnp-2627	152	18	mhc	mhc	PROPN
fnp-2627	152	19	-	-	PUNCT
fnp-2627	152	20	ii	ii	PROPN
fnp-2627	152	21	immunostains	immunostain	NOUN
fnp-2627	152	22	to	to	ADP
fnp-2627	152	23	their	their	PRON
fnp-2627	152	24	stain	stain	NOUN
fnp-2627	152	25	repertoire	repertoire	NOUN
fnp-2627	152	26	,	,	PUNCT
fnp-2627	152	27	so	so	SCONJ
fnp-2627	152	28	that	that	SCONJ
fnp-2627	152	29	these	these	DET
fnp-2627	152	30	markers	marker	NOUN
fnp-2627	152	31	can	can	AUX
fnp-2627	152	32	be	be	AUX
fnp-2627	152	33	evaluated	evaluate	VERB
fnp-2627	152	34	in	in	ADP
fnp-2627	152	35	diagnostically	diagnostically	ADV
fnp-2627	152	36	challenging	challenge	VERB
fnp-2627	152	37	iim	iim	ADJ
fnp-2627	152	38	cases	case	NOUN
fnp-2627	152	39	.	.	PUNCT
fnp-2627	153	1	what	what	PRON
fnp-2627	153	2	are	be	AUX
fnp-2627	153	3	the	the	DET
fnp-2627	153	4	sources	source	NOUN
fnp-2627	153	5	of	of	ADP
fnp-2627	153	6	infα	infα	PROPN
fnp-2627	153	7	/	/	SYM
fnp-2627	153	8	β	β	X
fnp-2627	153	9	and	and	CCONJ
fnp-2627	153	10	infγ	infγ	PROPN
fnp-2627	153	11	that	that	PRON
fnp-2627	153	12	drive	drive	VERB
fnp-2627	153	13	these	these	DET
fnp-2627	153	14	differential	differential	ADJ
fnp-2627	153	15	responses	response	NOUN
fnp-2627	153	16	?	?	PUNCT
fnp-2627	154	1	that	that	PRON
fnp-2627	154	2	remains	remain	VERB
fnp-2627	154	3	to	to	PART
fnp-2627	154	4	be	be	AUX
fnp-2627	154	5	definitively	definitively	ADV
fnp-2627	154	6	established	establish	VERB
fnp-2627	154	7	;	;	PUNCT
fnp-2627	154	8	however	however	ADV
fnp-2627	154	9	,	,	PUNCT
fnp-2627	154	10	the	the	DET
fnp-2627	154	11	most	most	ADV
fnp-2627	154	12	likely	likely	ADJ
fnp-2627	154	13	candidate	candidate	NOUN
fnp-2627	154	14	for	for	ADP
fnp-2627	154	15	the	the	DET
fnp-2627	154	16	infα	infα	PROPN
fnp-2627	154	17	/	/	SYM
fnp-2627	154	18	β	β	NOUN
fnp-2627	154	19	source	source	NOUN
fnp-2627	154	20	are	be	AUX
fnp-2627	154	21	plasmacytoid	plasmacytoid	ADJ
fnp-2627	154	22	dendritic	dendritic	ADJ
fnp-2627	154	23	cells	cell	NOUN
fnp-2627	154	24	,	,	PUNCT
fnp-2627	154	25	which	which	PRON
fnp-2627	154	26	are	be	AUX
fnp-2627	154	27	increased	increase	VERB
fnp-2627	154	28	in	in	ADP
fnp-2627	154	29	dm	dm	PROPN
fnp-2627	154	30	muscle	muscle	NOUN
fnp-2627	154	31	,	,	PUNCT
fnp-2627	154	32	while	while	SCONJ
fnp-2627	154	33	the	the	DET
fnp-2627	154	34	most	most	ADV
fnp-2627	154	35	likely	likely	ADJ
fnp-2627	154	36	candidate	candidate	NOUN
fnp-2627	154	37	for	for	ADP
fnp-2627	154	38	the	the	DET
fnp-2627	154	39	infγ	infγ	PROPN
fnp-2627	154	40	source	source	NOUN
fnp-2627	154	41	are	be	AUX
fnp-2627	154	42	cd8	cd8	PROPN
fnp-2627	154	43	+	+	PROPN
fnp-2627	154	44	t	t	NOUN
fnp-2627	154	45	cells	cell	NOUN
fnp-2627	154	46	,	,	PUNCT
fnp-2627	154	47	which	which	PRON
fnp-2627	154	48	were	be	AUX
fnp-2627	154	49	observed	observe	VERB
fnp-2627	154	50	in	in	ADP
fnp-2627	154	51	a	a	DET
fnp-2627	154	52	close	close	ADJ
fnp-2627	154	53	vicinity	vicinity	NOUN
fnp-2627	154	54	of	of	ADP
fnp-2627	154	55	mhc	mhc	PROPN
fnp-2627	154	56	-	-	PUNCT
fnp-2627	154	57	ii	ii	NOUN
fnp-2627	154	58	-	-	PUNCT
fnp-2627	154	59	expressing	express	VERB
fnp-2627	154	60	fibers	fiber	NOUN
fnp-2627	154	61	in	in	ADP
fnp-2627	154	62	both	both	PRON
fnp-2627	154	63	asm	asm	NOUN
fnp-2627	154	64	and	and	CCONJ
fnp-2627	154	65	sibm	sibm	NOUN
fnp-2627	154	66	(	(	PUNCT
fnp-2627	154	67	rigolet	rigolet	PROPN
fnp-2627	154	68	et	et	PROPN
fnp-2627	154	69	al	al	PROPN
fnp-2627	154	70	.	.	PROPN
fnp-2627	154	71	,	,	PUNCT
fnp-2627	154	72	2019	2019	NUM
fnp-2627	154	73	)	)	PUNCT
fnp-2627	154	74	.	.	PUNCT
fnp-2627	155	1	8	8	X
fnp-2627	155	2	.	.	X
fnp-2627	155	3	emerging	emerge	VERB
fnp-2627	155	4	diagnostic	diagnostic	ADJ
fnp-2627	155	5	techniques	technique	NOUN
fnp-2627	155	6	the	the	DET
fnp-2627	155	7	reduced	reduced	ADJ
fnp-2627	155	8	cost	cost	NOUN
fnp-2627	155	9	and	and	CCONJ
fnp-2627	155	10	widespread	widespread	ADJ
fnp-2627	155	11	availability	availability	NOUN
fnp-2627	155	12	of	of	ADP
fnp-2627	155	13	advanced	advanced	ADJ
fnp-2627	155	14	genetic	genetic	ADJ
fnp-2627	155	15	testing	testing	NOUN
fnp-2627	155	16	techniques	technique	NOUN
fnp-2627	155	17	[	[	X
fnp-2627	155	18	such	such	ADJ
fnp-2627	155	19	as	as	ADP
fnp-2627	155	20	disease	disease	NOUN
fnp-2627	155	21	gene	gene	NOUN
fnp-2627	155	22	panels	panel	NOUN
fnp-2627	155	23	and	and	CCONJ
fnp-2627	155	24	whole	whole	ADJ
fnp-2627	155	25	exome	exome	NOUN
fnp-2627	155	26	sequencing	sequence	VERB
fnp-2627	155	27	(	(	PUNCT
fnp-2627	155	28	wes	wes	PROPN
fnp-2627	155	29	)	)	PUNCT
fnp-2627	155	30	]	]	PUNCT
fnp-2627	155	31	have	have	AUX
fnp-2627	155	32	led	lead	VERB
fnp-2627	155	33	to	to	ADP
fnp-2627	155	34	a	a	DET
fnp-2627	155	35	dramatic	dramatic	ADJ
fnp-2627	155	36	diagnostic	diagnostic	ADJ
fnp-2627	155	37	improvement	improvement	NOUN
fnp-2627	155	38	for	for	ADP
fnp-2627	155	39	many	many	ADJ
fnp-2627	155	40	inherited	inherit	VERB
fnp-2627	155	41	nmds	nmds	NOUN
fnp-2627	155	42	.	.	PUNCT
fnp-2627	156	1	however	however	ADV
fnp-2627	156	2	,	,	PUNCT
fnp-2627	156	3	even	even	ADV
fnp-2627	156	4	with	with	ADP
fnp-2627	156	5	the	the	DET
fnp-2627	156	6	aid	aid	NOUN
fnp-2627	156	7	of	of	ADP
fnp-2627	156	8	these	these	DET
fnp-2627	156	9	advanced	advance	VERB
fnp-2627	156	10	molecular	molecular	ADJ
fnp-2627	156	11	techniques	technique	NOUN
fnp-2627	156	12	,	,	PUNCT
fnp-2627	156	13	50	50	NUM
fnp-2627	156	14	-	-	SYM
fnp-2627	156	15	75	75	NUM
fnp-2627	156	16	%	%	NOUN
fnp-2627	156	17	of	of	ADP
fnp-2627	156	18	presumed	presume	VERB
fnp-2627	156	19	genetic	genetic	ADJ
fnp-2627	156	20	nmd	nmd	PROPN
fnp-2627	156	21	cases	case	NOUN
fnp-2627	156	22	currently	currently	ADV
fnp-2627	156	23	remains	remain	VERB
fnp-2627	156	24	undiagnosed	undiagnosed	ADJ
fnp-2627	156	25	(	(	PUNCT
fnp-2627	156	26	cummings	cummings	PROPN
fnp-2627	156	27	et	et	PROPN
fnp-2627	156	28	al	al	PROPN
fnp-2627	156	29	.	.	PROPN
fnp-2627	156	30	,	,	PUNCT
fnp-2627	156	31	2017	2017	NUM
fnp-2627	156	32	)	)	PUNCT
fnp-2627	156	33	;	;	PUNCT
fnp-2627	156	34	the	the	DET
fnp-2627	156	35	underlying	underlying	ADJ
fnp-2627	156	36	reasons	reason	NOUN
fnp-2627	156	37	include	include	VERB
fnp-2627	156	38	challenges	challenge	NOUN
fnp-2627	156	39	involved	involve	VERB
fnp-2627	156	40	in	in	ADP
fnp-2627	156	41	interpretation	interpretation	NOUN
fnp-2627	156	42	of	of	ADP
fnp-2627	156	43	the	the	DET
fnp-2627	156	44	variants	variant	NOUN
fnp-2627	156	45	of	of	ADP
fnp-2627	156	46	unknown	unknown	ADJ
fnp-2627	156	47	significance	significance	NOUN
fnp-2627	156	48	and	and	CCONJ
fnp-2627	156	49	of	of	ADP
fnp-2627	156	50	variants	variant	NOUN
fnp-2627	156	51	in	in	ADP
fnp-2627	156	52	the	the	DET
fnp-2627	156	53	genes	gene	NOUN
fnp-2627	156	54	previously	previously	ADV
fnp-2627	156	55	not	not	PART
fnp-2627	156	56	linked	link	VERB
fnp-2627	156	57	to	to	ADP
fnp-2627	156	58	human	human	ADJ
fnp-2627	156	59	disease	disease	NOUN
fnp-2627	156	60	,	,	PUNCT
fnp-2627	156	61	the	the	DET
fnp-2627	156	62	inability	inability	NOUN
fnp-2627	156	63	of	of	ADP
fnp-2627	156	64	these	these	DET
fnp-2627	156	65	techniques	technique	NOUN
fnp-2627	156	66	to	to	PART
fnp-2627	156	67	detect	detect	VERB
fnp-2627	156	68	certain	certain	ADJ
fnp-2627	156	69	types	type	NOUN
fnp-2627	156	70	of	of	ADP
fnp-2627	156	71	genetic	genetic	ADJ
fnp-2627	156	72	alterations	alteration	NOUN
fnp-2627	156	73	(	(	PUNCT
fnp-2627	156	74	such	such	ADJ
fnp-2627	156	75	as	as	ADP
fnp-2627	156	76	structural	structural	ADJ
fnp-2627	156	77	re	re	NOUN
fnp-2627	156	78	-	-	NOUN
fnp-2627	156	79	arrangements	arrangement	NOUN
fnp-2627	156	80	and	and	CCONJ
fnp-2627	156	81	copy	copy	VERB
fnp-2627	156	82	number	number	NOUN
fnp-2627	156	83	variants	variant	NOUN
fnp-2627	156	84	)	)	PUNCT
fnp-2627	156	85	,	,	PUNCT
fnp-2627	156	86	and	and	CCONJ
fnp-2627	156	87	the	the	DET
fnp-2627	156	88	lack	lack	NOUN
fnp-2627	156	89	of	of	ADP
fnp-2627	156	90	coverage	coverage	NOUN
fnp-2627	156	91	of	of	ADP
fnp-2627	156	92	intronic	intronic	ADJ
fnp-2627	156	93	and	and	CCONJ
fnp-2627	156	94	regulatory	regulatory	ADJ
fnp-2627	156	95	regions	region	NOUN
fnp-2627	156	96	(	(	PUNCT
fnp-2627	156	97	gonorazky	gonorazky	PROPN
fnp-2627	156	98	et	et	PROPN
fnp-2627	156	99	al	al	PROPN
fnp-2627	156	100	.	.	PROPN
fnp-2627	156	101	,	,	PUNCT
fnp-2627	156	102	2019	2019	NUM
fnp-2627	156	103	)	)	PUNCT
fnp-2627	156	104	.	.	PUNCT
fnp-2627	157	1	in	in	ADP
fnp-2627	157	2	such	such	ADJ
fnp-2627	157	3	diagnostically	diagnostically	ADV
fnp-2627	157	4	challenging	challenging	ADJ
fnp-2627	157	5	cases	case	NOUN
fnp-2627	157	6	,	,	PUNCT
fnp-2627	157	7	transcriptome	transcriptome	ADJ
fnp-2627	157	8	analysis	analysis	NOUN
fnp-2627	157	9	(	(	PUNCT
fnp-2627	157	10	rna	rna	NOUN
fnp-2627	157	11	-	-	PUNCT
fnp-2627	157	12	seq	seq	NOUN
fnp-2627	157	13	)	)	PUNCT
fnp-2627	157	14	will	will	AUX
fnp-2627	157	15	likely	likely	ADV
fnp-2627	157	16	prove	prove	VERB
fnp-2627	157	17	beneficial	beneficial	ADJ
fnp-2627	157	18	.	.	PUNCT
fnp-2627	158	1	indeed	indeed	ADV
fnp-2627	158	2	,	,	PUNCT
fnp-2627	158	3	a	a	DET
fnp-2627	158	4	recent	recent	ADJ
fnp-2627	158	5	study	study	NOUN
fnp-2627	158	6	has	have	AUX
fnp-2627	158	7	shown	show	VERB
fnp-2627	158	8	that	that	SCONJ
fnp-2627	158	9	rna	rna	NOUN
fnp-2627	158	10	-	-	PUNCT
fnp-2627	158	11	seq	seq	NOUN
fnp-2627	158	12	resolved	resolve	VERB
fnp-2627	158	13	36	36	NUM
fnp-2627	158	14	%	%	NOUN
fnp-2627	158	15	of	of	ADP
fnp-2627	158	16	their	their	PRON
fnp-2627	158	17	paneland	paneland	NOUN
fnp-2627	158	18	/	/	SYM
fnp-2627	158	19	or	or	CCONJ
fnp-2627	158	20	wes	wes	PROPN
fnp-2627	158	21	-	-	PUNCT
fnp-2627	158	22	negative	negative	ADJ
fnp-2627	158	23	nmd	nmd	PROPN
fnp-2627	158	24	cases	case	NOUN
fnp-2627	158	25	(	(	PUNCT
fnp-2627	158	26	gonorazky	gonorazky	PROPN
fnp-2627	158	27	et	et	PROPN
fnp-2627	158	28	al	al	PROPN
fnp-2627	158	29	.	.	PROPN
fnp-2627	158	30	,	,	PUNCT
fnp-2627	158	31	2019	2019	NUM
fnp-2627	158	32	)	)	PUNCT
fnp-2627	158	33	;	;	PUNCT
fnp-2627	158	34	an	an	DET
fnp-2627	158	35	essentially	essentially	ADV
fnp-2627	158	36	identical	identical	ADJ
fnp-2627	158	37	diagnostic	diagnostic	ADJ
fnp-2627	158	38	yield	yield	NOUN
fnp-2627	158	39	(	(	PUNCT
fnp-2627	158	40	35	35	NUM
fnp-2627	158	41	%	%	NOUN
fnp-2627	158	42	)	)	PUNCT
fnp-2627	158	43	was	be	AUX
fnp-2627	158	44	reported	report	VERB
fnp-2627	158	45	in	in	ADP
fnp-2627	158	46	a	a	DET
fnp-2627	158	47	2017	2017	NUM
fnp-2627	158	48	study	study	NOUN
fnp-2627	158	49	that	that	PRON
fnp-2627	158	50	used	use	VERB
fnp-2627	158	51	a	a	DET
fnp-2627	158	52	different	different	ADJ
fnp-2627	158	53	nmd	nmd	NOUN
fnp-2627	158	54	patient	patient	NOUN
fnp-2627	158	55	cohort	cohort	NOUN
fnp-2627	158	56	(	(	PUNCT
fnp-2627	158	57	cummings	cumming	NOUN
fnp-2627	158	58	et	et	PROPN
fnp-2627	158	59	al	al	PROPN
fnp-2627	158	60	.	.	PROPN
fnp-2627	158	61	,	,	PUNCT
fnp-2627	158	62	2017	2017	NUM
fnp-2627	158	63	)	)	PUNCT
fnp-2627	158	64	.	.	PUNCT
fnp-2627	159	1	importantly	importantly	ADV
fnp-2627	159	2	,	,	PUNCT
fnp-2627	159	3	gene	gene	NOUN
fnp-2627	159	4	expression	expression	NOUN
fnp-2627	159	5	is	be	AUX
fnp-2627	159	6	tissue	tissue	NOUN
fnp-2627	159	7	-	-	PUNCT
fnp-2627	159	8	dependent	dependent	ADJ
fnp-2627	159	9	;	;	PUNCT
fnp-2627	159	10	thus	thus	ADV
fnp-2627	159	11	,	,	PUNCT
fnp-2627	159	12	the	the	DET
fnp-2627	159	13	effectiveness	effectiveness	NOUN
fnp-2627	159	14	of	of	ADP
fnp-2627	159	15	rna	rna	NOUN
fnp-2627	159	16	-	-	PUNCT
fnp-2627	159	17	seq	seq	NOUN
fnp-2627	159	18	for	for	ADP
fnp-2627	159	19	diagnostic	diagnostic	ADJ
fnp-2627	159	20	testing	testing	NOUN
fnp-2627	159	21	hinges	hinge	NOUN
fnp-2627	159	22	on	on	ADP
fnp-2627	159	23	the	the	DET
fnp-2627	159	24	use	use	NOUN
fnp-2627	159	25	of	of	ADP
fnp-2627	159	26	disease	disease	NOUN
fnp-2627	159	27	-	-	PUNCT
fnp-2627	159	28	relevant	relevant	ADJ
fnp-2627	159	29	source	source	NOUN
fnp-2627	159	30	material	material	NOUN
fnp-2627	159	31	.	.	PUNCT
fnp-2627	160	1	in	in	ADP
fnp-2627	160	2	the	the	DET
fnp-2627	160	3	context	context	NOUN
fnp-2627	160	4	of	of	ADP
fnp-2627	160	5	genetic	genetic	ADJ
fnp-2627	160	6	muscle	muscle	NOUN
fnp-2627	160	7	disease	disease	NOUN
fnp-2627	160	8	,	,	PUNCT
fnp-2627	160	9	biopsied	biopsied	ADJ
fnp-2627	160	10	muscle	muscle	NOUN
fnp-2627	160	11	represents	represent	VERB
fnp-2627	160	12	the	the	DET
fnp-2627	160	13	ideal	ideal	ADJ
fnp-2627	160	14	specimen	speciman	NOUN
fnp-2627	160	15	,	,	PUNCT
fnp-2627	160	16	while	while	SCONJ
fnp-2627	160	17	peripheral	peripheral	ADJ
fnp-2627	160	18	blood	blood	NOUN
fnp-2627	160	19	is	be	AUX
fnp-2627	160	20	inadequate	inadequate	ADJ
fnp-2627	160	21	;	;	PUNCT
fnp-2627	160	22	unmodified	unmodified	ADJ
fnp-2627	160	23	skin	skin	NOUN
fnp-2627	160	24	-	-	PUNCT
fnp-2627	160	25	derived	derive	VERB
fnp-2627	160	26	fibroblasts	fibroblast	NOUN
fnp-2627	160	27	can	can	AUX
fnp-2627	160	28	be	be	AUX
fnp-2627	160	29	useful	useful	ADJ
fnp-2627	160	30	for	for	ADP
fnp-2627	160	31	some	some	DET
fnp-2627	160	32	diseases	disease	NOUN
fnp-2627	160	33	(	(	PUNCT
fnp-2627	160	34	such	such	ADJ
fnp-2627	160	35	as	as	ADP
fnp-2627	160	36	congenital	congenital	ADJ
fnp-2627	160	37	muscular	muscular	ADJ
fnp-2627	160	38	dystrophies	dystrophy	NOUN
fnp-2627	160	39	)	)	PUNCT
fnp-2627	160	40	,	,	PUNCT
fnp-2627	160	41	but	but	CCONJ
fnp-2627	160	42	the	the	DET
fnp-2627	160	43	diagnostic	diagnostic	ADJ
fnp-2627	160	44	yield	yield	NOUN
fnp-2627	160	45	is	be	AUX
fnp-2627	160	46	substantially	substantially	ADV
fnp-2627	160	47	enhanced	enhance	VERB
fnp-2627	160	48	if	if	SCONJ
fnp-2627	160	49	fibroblasts	fibroblast	NOUN
fnp-2627	160	50	are	be	AUX
fnp-2627	160	51	transdifferentiated	transdifferentiate	VERB
fnp-2627	160	52	into	into	ADP
fnp-2627	160	53	myotubes	myotube	NOUN
fnp-2627	160	54	in	in	ADP
fnp-2627	160	55	vitro	vitro	X
fnp-2627	160	56	(	(	PUNCT
fnp-2627	160	57	gonorazky	gonorazky	PROPN
fnp-2627	160	58	et	et	PROPN
fnp-2627	160	59	al	al	PROPN
fnp-2627	160	60	.	.	PROPN
fnp-2627	160	61	,	,	PUNCT
fnp-2627	160	62	2019	2019	NUM
fnp-2627	160	63	)	)	PUNCT
fnp-2627	160	64	.	.	PUNCT
fnp-2627	161	1	importantly	importantly	ADV
fnp-2627	161	2	,	,	PUNCT
fnp-2627	161	3	expression	expression	NOUN
fnp-2627	161	4	of	of	ADP
fnp-2627	161	5	the	the	DET
fnp-2627	161	6	muscle	muscle	NOUN
fnp-2627	161	7	-	-	PUNCT
fnp-2627	161	8	specific	specific	ADJ
fnp-2627	161	9	transcripts	transcript	NOUN
fnp-2627	161	10	was	be	AUX
fnp-2627	161	11	significantly	significantly	ADV
fnp-2627	161	12	lower	low	ADJ
fnp-2627	161	13	in	in	ADP
fnp-2627	161	14	transdifferentiated	transdifferentiate	VERB
fnp-2627	161	15	myotubes	myotube	NOUN
fnp-2627	161	16	than	than	ADP
fnp-2627	161	17	in	in	ADP
fnp-2627	161	18	the	the	DET
fnp-2627	161	19	matched	match	VERB
fnp-2627	161	20	muscle	muscle	NOUN
fnp-2627	161	21	biopsy	biopsy	NOUN
fnp-2627	161	22	samples	sample	NOUN
fnp-2627	161	23	for	for	ADP
fnp-2627	161	24	most	most	ADJ
fnp-2627	161	25	genes	gene	NOUN
fnp-2627	161	26	;	;	PUNCT
fnp-2627	161	27	therefore	therefore	ADV
fnp-2627	161	28	,	,	PUNCT
fnp-2627	161	29	muscle	muscle	NOUN
fnp-2627	161	30	biopsies	biopsy	NOUN
fnp-2627	161	31	will	will	AUX
fnp-2627	161	32	likely	likely	ADV
fnp-2627	161	33	remain	remain	VERB
fnp-2627	161	34	the	the	DET
fnp-2627	161	35	gold	gold	ADJ
fnp-2627	161	36	standard	standard	NOUN
fnp-2627	161	37	for	for	ADP
fnp-2627	161	38	diagnostic	diagnostic	ADJ
fnp-2627	161	39	transcriptomics	transcriptomic	NOUN
fnp-2627	161	40	.	.	PUNCT
fnp-2627	162	1	however	however	ADV
fnp-2627	162	2	,	,	PUNCT
fnp-2627	162	3	the	the	DET
fnp-2627	162	4	transdifferentiation	transdifferentiation	NOUN
fnp-2627	162	5	approach	approach	NOUN
fnp-2627	162	6	may	may	AUX
fnp-2627	162	7	prove	prove	VERB
fnp-2627	162	8	useful	useful	ADJ
fnp-2627	162	9	when	when	SCONJ
fnp-2627	162	10	muscle	muscle	NOUN
fnp-2627	162	11	biopsy	biopsy	NOUN
fnp-2627	162	12	can	can	AUX
fnp-2627	162	13	not	not	PART
fnp-2627	162	14	be	be	AUX
fnp-2627	162	15	performed	perform	VERB
fnp-2627	162	16	or	or	CCONJ
fnp-2627	162	17	when	when	SCONJ
fnp-2627	162	18	accurate	accurate	ADJ
fnp-2627	162	19	diagnosis	diagnosis	NOUN
fnp-2627	162	20	requires	require	VERB
fnp-2627	162	21	correlation	correlation	NOUN
fnp-2627	162	22	of	of	ADP
fnp-2627	162	23	gene	gene	NOUN
fnp-2627	162	24	expression	expression	NOUN
fnp-2627	162	25	patterns	pattern	NOUN
fnp-2627	162	26	between	between	ADP
fnp-2627	162	27	the	the	DET
fnp-2627	162	28	proband	proband	NOUN
fnp-2627	162	29	and	and	CCONJ
fnp-2627	162	30	other	other	ADJ
fnp-2627	162	31	family	family	NOUN
fnp-2627	162	32	members	member	NOUN
fnp-2627	162	33	(	(	PUNCT
fnp-2627	162	34	gonorazky	gonorazky	PROPN
fnp-2627	162	35	et	et	PROPN
fnp-2627	162	36	al	al	PROPN
fnp-2627	162	37	.	.	PROPN
fnp-2627	162	38	,	,	PUNCT
fnp-2627	162	39	2019	2019	NUM
fnp-2627	162	40	)	)	PUNCT
fnp-2627	162	41	.	.	PUNCT
fnp-2627	163	1	another	another	DET
fnp-2627	163	2	approach	approach	NOUN
fnp-2627	163	3	for	for	ADP
fnp-2627	163	4	improving	improve	VERB
fnp-2627	163	5	muscle	muscle	NOUN
fnp-2627	163	6	disease	disease	NOUN
fnp-2627	163	7	diagnostics	diagnostic	NOUN
fnp-2627	163	8	is	be	AUX
fnp-2627	163	9	based	base	VERB
fnp-2627	163	10	on	on	ADP
fnp-2627	163	11	the	the	DET
fnp-2627	163	12	use	use	NOUN
fnp-2627	163	13	of	of	ADP
fnp-2627	163	14	automated	automate	VERB
fnp-2627	163	15	image	image	NOUN
fnp-2627	163	16	-	-	PUNCT
fnp-2627	163	17	analysis	analysis	NOUN
fnp-2627	163	18	methods	method	NOUN
fnp-2627	163	19	and	and	CCONJ
fnp-2627	163	20	artificial	artificial	ADJ
fnp-2627	163	21	intelligence	intelligence	NOUN
fnp-2627	163	22	(	(	PUNCT
fnp-2627	163	23	ai	ai	NOUN
fnp-2627	163	24	)	)	PUNCT
fnp-2627	163	25	tools	tool	NOUN
fnp-2627	163	26	during	during	ADP
fnp-2627	163	27	muscle	muscle	NOUN
fnp-2627	163	28	biopsy	biopsy	NOUN
fnp-2627	163	29	evaluations	evaluation	NOUN
fnp-2627	163	30	.	.	PUNCT
fnp-2627	164	1	to	to	ADP
fnp-2627	164	2	this	this	DET
fnp-2627	164	3	end	end	NOUN
fnp-2627	164	4	,	,	PUNCT
fnp-2627	164	5	a	a	DET
fnp-2627	164	6	french	french	ADJ
fnp-2627	164	7	group	group	NOUN
fnp-2627	164	8	has	have	AUX
fnp-2627	164	9	recently	recently	ADV
fnp-2627	164	10	developed	develop	VERB
fnp-2627	164	11	a	a	DET
fnp-2627	164	12	fully	fully	ADV
fnp-2627	164	13	automated	automate	VERB
fnp-2627	164	14	macro	macro	ADJ
fnp-2627	164	15	script	script	NOUN
fnp-2627	164	16	for	for	ADP
fnp-2627	164	17	image	image	NOUN
fnp-2627	164	18	j	j	PROPN
fnp-2627	164	19	that	that	PRON
fnp-2627	164	20	performs	perform	VERB
fnp-2627	164	21	muscle	muscle	NOUN
fnp-2627	164	22	fiber	fiber	NOUN
fnp-2627	164	23	measurements	measurement	NOUN
fnp-2627	164	24	(	(	PUNCT
fnp-2627	164	25	such	such	ADJ
fnp-2627	164	26	as	as	ADP
fnp-2627	164	27	total	total	ADJ
fnp-2627	164	28	fiber	fiber	NOUN
fnp-2627	164	29	number	number	NOUN
fnp-2627	164	30	,	,	PUNCT
fnp-2627	164	31	type	type	NOUN
fnp-2627	164	32	1	1	NUM
fnp-2627	164	33	and	and	CCONJ
fnp-2627	164	34	type	type	NOUN
fnp-2627	164	35	2	2	NUM
fnp-2627	164	36	fiber	fiber	NOUN
fnp-2627	164	37	proportion	proportion	NOUN
fnp-2627	164	38	,	,	PUNCT
fnp-2627	164	39	and	and	CCONJ
fnp-2627	164	40	muscle	muscle	NOUN
fnp-2627	164	41	fiber	fiber	NOUN
fnp-2627	164	42	diameter	diameter	NOUN
fnp-2627	164	43	)	)	PUNCT
fnp-2627	164	44	that	that	PRON
fnp-2627	164	45	are	be	AUX
fnp-2627	164	46	routinely	routinely	ADV
fnp-2627	164	47	assessed	assess	VERB
fnp-2627	164	48	during	during	ADP
fnp-2627	164	49	muscle	muscle	NOUN
fnp-2627	164	50	biopsy	biopsy	NOUN
fnp-2627	164	51	evaluation	evaluation	NOUN
fnp-2627	164	52	,	,	PUNCT
fnp-2627	164	53	but	but	CCONJ
fnp-2627	164	54	are	be	AUX
fnp-2627	164	55	typically	typically	ADV
fnp-2627	164	56	estimated	estimate	VERB
fnp-2627	164	57	and	and	CCONJ
fnp-2627	164	58	reported	report	VERB
fnp-2627	164	59	in	in	ADP
fnp-2627	164	60	a	a	DET
fnp-2627	164	61	semi	semi	ADJ
fnp-2627	164	62	-	-	ADJ
fnp-2627	164	63	quantitative	quantitative	ADJ
fnp-2627	164	64	fashion	fashion	NOUN
fnp-2627	164	65	(	(	PUNCT
fnp-2627	164	66	reyes	reyes	NOUN
fnp-2627	164	67	-	-	PUNCT
fnp-2627	164	68	fernandez	fernandez	PROPN
fnp-2627	164	69	et	et	PROPN
fnp-2627	164	70	al	al	PROPN
fnp-2627	164	71	.	.	PROPN
fnp-2627	164	72	,	,	PUNCT
fnp-2627	164	73	2019	2019	NUM
fnp-2627	164	74	)	)	PUNCT
fnp-2627	164	75	.	.	PUNCT
fnp-2627	165	1	in	in	ADP
fnp-2627	165	2	addition	addition	NOUN
fnp-2627	165	3	to	to	ADP
fnp-2627	165	4	validating	validate	VERB
fnp-2627	165	5	the	the	DET
fnp-2627	165	6	macro	macro	ADJ
fnp-2627	165	7	script	script	NOUN
fnp-2627	165	8	(	(	PUNCT
fnp-2627	165	9	which	which	PRON
fnp-2627	165	10	analyzes	analyze	VERB
fnp-2627	165	11	images	image	NOUN
fnp-2627	165	12	from	from	ADP
fnp-2627	165	13	immunofluorescence	immunofluorescence	NOUN
fnp-2627	165	14	-	-	PUNCT
fnp-2627	165	15	stained	stain	VERB
fnp-2627	165	16	sections	section	NOUN
fnp-2627	165	17	and	and	CCONJ
fnp-2627	165	18	is	be	AUX
fnp-2627	165	19	available	available	ADJ
fnp-2627	165	20	for	for	ADP
fnp-2627	165	21	download	download	NOUN
fnp-2627	165	22	as	as	ADP
fnp-2627	165	23	the	the	DET
fnp-2627	165	24	manuscript	manuscript	NOUN
fnp-2627	165	25	supplementary	supplementary	ADJ
fnp-2627	165	26	material	material	NOUN
fnp-2627	165	27	)	)	PUNCT
fnp-2627	165	28	,	,	PUNCT
fnp-2627	165	29	this	this	DET
fnp-2627	165	30	study	study	NOUN
fnp-2627	165	31	has	have	AUX
fnp-2627	165	32	used	use	VERB
fnp-2627	165	33	quantitative	quantitative	ADJ
fnp-2627	165	34	morphometry	morphometry	NOUN
fnp-2627	165	35	to	to	PART
fnp-2627	165	36	definitively	definitively	ADV
fnp-2627	165	37	demonstrate	demonstrate	VERB
fnp-2627	165	38	that	that	SCONJ
fnp-2627	165	39	the	the	DET
fnp-2627	165	40	size	size	NOUN
fnp-2627	165	41	of	of	ADP
fnp-2627	165	42	type	type	NOUN
fnp-2627	165	43	2	2	NUM
fnp-2627	165	44	fibers	fiber	NOUN
fnp-2627	165	45	decreases	decrease	NOUN
fnp-2627	165	46	with	with	ADP
fnp-2627	165	47	age	age	NOUN
fnp-2627	165	48	but	but	CCONJ
fnp-2627	165	49	increases	increase	NOUN
fnp-2627	165	50	with	with	ADP
fnp-2627	165	51	obesity	obesity	NOUN
fnp-2627	165	52	,	,	PUNCT
fnp-2627	165	53	an	an	DET
fnp-2627	165	54	observation	observation	NOUN
fnp-2627	165	55	that	that	PRON
fnp-2627	165	56	has	have	VERB
fnp-2627	165	57	relevance	relevance	NOUN
fnp-2627	165	58	for	for	ADP
fnp-2627	165	59	routine	routine	ADJ
fnp-2627	165	60	muscle	muscle	NOUN
fnp-2627	165	61	biopsy	biopsy	NOUN
fnp-2627	165	62	interpretation	interpretation	NOUN
fnp-2627	165	63	(	(	PUNCT
fnp-2627	165	64	reyes	reyes	NOUN
fnp-2627	165	65	-	-	PUNCT
fnp-2627	165	66	fernandez	fernandez	PROPN
fnp-2627	165	67	et	et	PROPN
fnp-2627	165	68	al	al	PROPN
fnp-2627	165	69	.	.	PROPN
fnp-2627	165	70	,	,	PUNCT
fnp-2627	165	71	2019	2019	NUM
fnp-2627	165	72	)	)	PUNCT
fnp-2627	165	73	.	.	PUNCT
fnp-2627	166	1	notably	notably	ADV
fnp-2627	166	2	,	,	PUNCT
fnp-2627	166	3	the	the	DET
fnp-2627	166	4	authors	author	NOUN
fnp-2627	166	5	are	be	AUX
fnp-2627	166	6	in	in	ADP
fnp-2627	166	7	the	the	DET
fnp-2627	166	8	process	process	NOUN
fnp-2627	166	9	of	of	ADP
fnp-2627	166	10	adopting	adopt	VERB
fnp-2627	166	11	their	their	PRON
fnp-2627	166	12	macro	macro	ADJ
fnp-2627	166	13	script	script	NOUN
fnp-2627	166	14	for	for	ADP
fnp-2627	166	15	use	use	NOUN
fnp-2627	166	16	on	on	ADP
fnp-2627	166	17	immunoperoxidase	immunoperoxidase	NOUN
fnp-2627	166	18	-	-	PUNCT
fnp-2627	166	19	stained	stain	VERB
fnp-2627	166	20	sections	section	NOUN
fnp-2627	166	21	,	,	PUNCT
fnp-2627	166	22	which	which	PRON
fnp-2627	166	23	will	will	AUX
fnp-2627	166	24	make	make	VERB
fnp-2627	166	25	it	it	PRON
fnp-2627	166	26	more	more	ADV
fnp-2627	166	27	routinely	routinely	ADV
fnp-2627	166	28	applicable	applicable	ADJ
fnp-2627	166	29	to	to	ADP
fnp-2627	166	30	most	most	ADJ
fnp-2627	166	31	pathology	pathology	NOUN
fnp-2627	166	32	practices	practice	NOUN
fnp-2627	166	33	.	.	PUNCT
fnp-2627	167	1	more	more	ADV
fnp-2627	167	2	provocatively	provocatively	ADV
fnp-2627	167	3	,	,	PUNCT
fnp-2627	167	4	a	a	DET
fnp-2627	167	5	study	study	NOUN
fnp-2627	167	6	presented	present	VERB
fnp-2627	167	7	at	at	ADP
fnp-2627	167	8	the	the	DET
fnp-2627	167	9	2019	2019	NUM
fnp-2627	167	10	world	world	NOUN
fnp-2627	167	11	muscle	muscle	NOUN
fnp-2627	167	12	society	society	PROPN
fnp-2627	167	13	congress	congress	PROPN
fnp-2627	167	14	(	(	PUNCT
fnp-2627	167	15	kabeya	kabeya	PROPN
fnp-2627	167	16	et	et	PROPN
fnp-2627	167	17	al	al	PROPN
fnp-2627	167	18	.	.	PROPN
fnp-2627	167	19	,	,	PUNCT
fnp-2627	167	20	2019	2019	NUM
fnp-2627	167	21	)	)	PUNCT
fnp-2627	167	22	has	have	AUX
fnp-2627	167	23	shown	show	VERB
fnp-2627	167	24	that	that	SCONJ
fnp-2627	167	25	a	a	DET
fnp-2627	167	26	deep	deep	ADJ
fnp-2627	167	27	neural	neural	ADJ
fnp-2627	167	28	network	network	NOUN
fnp-2627	167	29	model	model	NOUN
fnp-2627	167	30	(	(	PUNCT
fnp-2627	167	31	“	"	PUNCT
fnp-2627	167	32	ai	ai	ADJ
fnp-2627	167	33	-	-	PUNCT
fnp-2627	167	34	based	base	VERB
fnp-2627	167	35	muscle	muscle	NOUN
fnp-2627	167	36	histopathologist	histopathologist	NOUN
fnp-2627	167	37	”	"	PUNCT
fnp-2627	167	38	)	)	PUNCT
fnp-2627	167	39	can	can	AUX
fnp-2627	167	40	use	use	VERB
fnp-2627	167	41	images	image	NOUN
fnp-2627	167	42	from	from	ADP
fnp-2627	167	43	h&e	h&e	NOUN
fnp-2627	167	44	-	-	PUNCT
fnp-2627	167	45	stained	stain	VERB
fnp-2627	167	46	slides	slide	NOUN
fnp-2627	167	47	to	to	PART
fnp-2627	167	48	differentiate	differentiate	VERB
fnp-2627	167	49	several	several	ADJ
fnp-2627	167	50	major	major	ADJ
fnp-2627	167	51	muscular	muscular	ADJ
fnp-2627	167	52	dystrophies	dystrophy	NOUN
fnp-2627	167	53	subtypes	subtype	NOUN
fnp-2627	167	54	better	well	ADV
fnp-2627	167	55	than	than	ADP
fnp-2627	167	56	physicians	physician	NOUN
fnp-2627	167	57	(	(	PUNCT
fnp-2627	167	58	although	although	SCONJ
fnp-2627	167	59	the	the	DET
fnp-2627	167	60	study	study	NOUN
fnp-2627	167	61	abstract	abstract	NOUN
fnp-2627	167	62	does	do	AUX
fnp-2627	167	63	not	not	PART
fnp-2627	167	64	indicate	indicate	VERB
fnp-2627	167	65	whether	whether	SCONJ
fnp-2627	167	66	those	those	DET
fnp-2627	167	67	physicians	physician	NOUN
fnp-2627	167	68	were	be	AUX
fnp-2627	167	69	expert	expert	ADJ
fnp-2627	167	70	muscle	muscle	NOUN
fnp-2627	167	71	pathologists	pathologist	NOUN
fnp-2627	167	72	)	)	PUNCT
fnp-2627	167	73	.	.	PUNCT
fnp-2627	168	1	while	while	SCONJ
fnp-2627	168	2	intriguing	intriguing	ADJ
fnp-2627	168	3	,	,	PUNCT
fnp-2627	168	4	the	the	DET
fnp-2627	168	5	validity	validity	NOUN
fnp-2627	168	6	of	of	ADP
fnp-2627	168	7	these	these	DET
fnp-2627	168	8	results	result	NOUN
fnp-2627	168	9	needs	need	VERB
fnp-2627	168	10	to	to	PART
fnp-2627	168	11	be	be	AUX
fnp-2627	168	12	replicated	replicate	VERB
fnp-2627	168	13	by	by	ADP
fnp-2627	168	14	future	future	ADJ
fnp-2627	168	15	studies	study	NOUN
fnp-2627	168	16	.	.	PUNCT
fnp-2627	169	1	in	in	ADP
fnp-2627	169	2	particular	particular	ADJ
fnp-2627	169	3	,	,	PUNCT
fnp-2627	169	4	nmd	nmd	PROPN
fnp-2627	169	5	diagnosis	diagnosis	NOUN
fnp-2627	169	6	generally	generally	ADV
fnp-2627	169	7	requires	require	VERB
fnp-2627	169	8	interpretation	interpretation	NOUN
fnp-2627	169	9	of	of	ADP
fnp-2627	169	10	many	many	ADJ
fnp-2627	169	11	different	different	ADJ
fnp-2627	169	12	stains	stain	NOUN
fnp-2627	169	13	and	and	CCONJ
fnp-2627	169	14	integration	integration	NOUN
fnp-2627	169	15	of	of	ADP
fnp-2627	169	16	clinical	clinical	ADJ
fnp-2627	169	17	,	,	PUNCT
fnp-2627	169	18	laboratory	laboratory	NOUN
fnp-2627	169	19	,	,	PUNCT
fnp-2627	169	20	and	and	CCONJ
fnp-2627	169	21	histopathologic	histopathologic	NOUN
fnp-2627	169	22	findings	finding	NOUN
fnp-2627	169	23	;	;	PUNCT
fnp-2627	169	24	thus	thus	ADV
fnp-2627	169	25	,	,	PUNCT
fnp-2627	169	26	it	it	PRON
fnp-2627	169	27	is	be	AUX
fnp-2627	169	28	fairly	fairly	ADV
fnp-2627	169	29	unlikely	unlikely	ADJ
fnp-2627	169	30	that	that	SCONJ
fnp-2627	169	31	the	the	DET
fnp-2627	169	32	diagnostic	diagnostic	ADJ
fnp-2627	169	33	proficiency	proficiency	NOUN
fnp-2627	169	34	of	of	ADP
fnp-2627	169	35	an	an	DET
fnp-2627	169	36	“	"	PUNCT
fnp-2627	169	37	ai	ai	NOUN
fnp-2627	169	38	-	-	PUNCT
fnp-2627	169	39	based	base	VERB
fnp-2627	169	40	muscle	muscle	NOUN
fnp-2627	169	41	histopathologist	histopathologist	NOUN
fnp-2627	169	42	”	"	PUNCT
fnp-2627	169	43	will	will	AUX
fnp-2627	169	44	generalize	generalize	VERB
fnp-2627	169	45	to	to	ADP
fnp-2627	169	46	a	a	DET
fnp-2627	169	47	broader	broad	ADJ
fnp-2627	169	48	set	set	NOUN
fnp-2627	169	49	of	of	ADP
fnp-2627	169	50	nmds	nmds	NOUN
fnp-2627	169	51	.	.	PUNCT
fnp-2627	170	1	at	at	ADP
fnp-2627	170	2	the	the	DET
fnp-2627	170	3	same	same	ADJ
fnp-2627	170	4	time	time	NOUN
fnp-2627	170	5	,	,	PUNCT
fnp-2627	170	6	it	it	PRON
fnp-2627	170	7	is	be	AUX
fnp-2627	170	8	likely	likely	ADJ
fnp-2627	170	9	that	that	SCONJ
fnp-2627	170	10	the	the	DET
fnp-2627	170	11	best	good	ADJ
fnp-2627	170	12	diagnostic	diagnostic	ADJ
fnp-2627	170	13	yield	yield	NOUN
fnp-2627	170	14	will	will	AUX
fnp-2627	170	15	ultimately	ultimately	ADV
fnp-2627	170	16	be	be	AUX
fnp-2627	170	17	achieved	achieve	VERB
fnp-2627	170	18	through	through	ADP
fnp-2627	170	19	the	the	DET
fnp-2627	170	20	combined	combine	VERB
fnp-2627	170	21	efforts	effort	NOUN
fnp-2627	170	22	of	of	ADP
fnp-2627	170	23	ai	ai	NOUN
fnp-2627	170	24	and	and	CCONJ
fnp-2627	170	25	human	human	ADJ
fnp-2627	170	26	pathologists	pathologist	NOUN
fnp-2627	170	27	,	,	PUNCT
fnp-2627	170	28	as	as	SCONJ
fnp-2627	170	29	was	be	AUX
fnp-2627	170	30	previously	previously	ADV
fnp-2627	170	31	demonstrated	demonstrate	VERB
fnp-2627	170	32	for	for	ADP
fnp-2627	170	33	the	the	DET
fnp-2627	170	34	other	other	ADJ
fnp-2627	170	35	fields	field	NOUN
fnp-2627	170	36	of	of	ADP
fnp-2627	170	37	medicine	medicine	NOUN
fnp-2627	170	38	that	that	PRON
fnp-2627	170	39	are	be	AUX
fnp-2627	170	40	based	base	VERB
fnp-2627	170	41	on	on	ADP
fnp-2627	170	42	image	image	NOUN
fnp-2627	170	43	interpretation	interpretation	NOUN
fnp-2627	170	44	(	(	PUNCT
fnp-2627	170	45	such	such	ADJ
fnp-2627	170	46	as	as	ADP
fnp-2627	170	47	radiology	radiology	NOUN
fnp-2627	170	48	)	)	PUNCT
fnp-2627	170	49	.	.	PUNCT
fnp-2627	171	1	advances	advance	NOUN
fnp-2627	171	2	in	in	ADP
fnp-2627	171	3	neuromuscular	neuromuscular	ADJ
fnp-2627	171	4	disease	disease	NOUN
fnp-2627	171	5	treatment	treatment	NOUN
fnp-2627	171	6	development	development	NOUN
fnp-2627	171	7	of	of	ADP
fnp-2627	171	8	new	new	ADJ
fnp-2627	171	9	disease	disease	NOUN
fnp-2627	171	10	therapies	therapy	NOUN
fnp-2627	171	11	takes	take	VERB
fnp-2627	171	12	decades	decade	NOUN
fnp-2627	171	13	of	of	ADP
fnp-2627	171	14	work	work	NOUN
fnp-2627	171	15	,	,	PUNCT
fnp-2627	171	16	with	with	ADP
fnp-2627	171	17	clinical	clinical	ADJ
fnp-2627	171	18	trials	trial	NOUN
fnp-2627	171	19	that	that	PRON
fnp-2627	171	20	span	span	VERB
fnp-2627	171	21	years	year	NOUN
fnp-2627	171	22	and	and	CCONJ
fnp-2627	171	23	report	report	VERB
fnp-2627	171	24	their	their	PRON
fnp-2627	171	25	results	result	NOUN
fnp-2627	171	26	thorough	thorough	ADJ
fnp-2627	171	27	multiple	multiple	ADJ
fnp-2627	171	28	papers	paper	NOUN
fnp-2627	171	29	published	publish	VERB
fnp-2627	171	30	over	over	ADP
fnp-2627	171	31	time	time	NOUN
fnp-2627	171	32	;	;	PUNCT
fnp-2627	171	33	as	as	ADP
fnp-2627	171	34	such	such	ADJ
fnp-2627	171	35	,	,	PUNCT
fnp-2627	171	36	it	it	PRON
fnp-2627	171	37	is	be	AUX
fnp-2627	171	38	not	not	PART
fnp-2627	171	39	entirely	entirely	ADV
fnp-2627	171	40	appropriate	appropriate	ADJ
fnp-2627	171	41	to	to	PART
fnp-2627	171	42	designate	designate	VERB
fnp-2627	171	43	any	any	PRON
fnp-2627	171	44	of	of	ADP
fnp-2627	171	45	the	the	DET
fnp-2627	171	46	recently	recently	ADV
fnp-2627	171	47	approved	approve	VERB
fnp-2627	171	48	genetic	genetic	ADJ
fnp-2627	171	49	treatments	treatment	NOUN
fnp-2627	171	50	as	as	ADP
fnp-2627	171	51	a	a	DET
fnp-2627	171	52	2019	2019	NUM
fnp-2627	171	53	discovery	discovery	NOUN
fnp-2627	171	54	.	.	PUNCT
fnp-2627	172	1	at	at	ADP
fnp-2627	172	2	the	the	DET
fnp-2627	172	3	same	same	ADJ
fnp-2627	172	4	time	time	NOUN
fnp-2627	172	5	,	,	PUNCT
fnp-2627	172	6	these	these	DET
fnp-2627	172	7	new	new	ADJ
fnp-2627	172	8	treatments	treatment	NOUN
fnp-2627	172	9	were	be	AUX
fnp-2627	172	10	among	among	ADP
fnp-2627	172	11	of	of	ADP
fnp-2627	172	12	the	the	DET
fnp-2627	172	13	“	"	PUNCT
fnp-2627	172	14	hottest	hot	ADJ
fnp-2627	172	15	”	"	PUNCT
fnp-2627	172	16	nmd	nmd	PROPN
fnp-2627	172	17	advances	advance	NOUN
fnp-2627	172	18	in	in	ADP
fnp-2627	172	19	2019	2019	NUM
fnp-2627	172	20	,	,	PUNCT
fnp-2627	172	21	and	and	CCONJ
fnp-2627	172	22	therefore	therefore	ADV
fnp-2627	172	23	had	have	VERB
fnp-2627	172	24	to	to	PART
fnp-2627	172	25	be	be	AUX
fnp-2627	172	26	included	include	VERB
fnp-2627	172	27	in	in	ADP
fnp-2627	172	28	this	this	DET
fnp-2627	172	29	review	review	NOUN
fnp-2627	172	30	.	.	PUNCT
fnp-2627	173	1	9	9	X
fnp-2627	173	2	.	.	X
fnp-2627	173	3	a	a	DET
fnp-2627	173	4	success	success	NOUN
fnp-2627	173	5	story	story	NOUN
fnp-2627	173	6	:	:	PUNCT
fnp-2627	173	7	genetic	genetic	ADJ
fnp-2627	173	8	therapies	therapy	NOUN
fnp-2627	173	9	for	for	ADP
fnp-2627	173	10	spinal	spinal	ADJ
fnp-2627	173	11	muscular	muscular	ADJ
fnp-2627	173	12	atrophy	atrophy	NOUN
fnp-2627	173	13	spinal	spinal	VERB
fnp-2627	173	14	muscular	muscular	ADJ
fnp-2627	173	15	atrophy	atrophy	NOUN
fnp-2627	173	16	(	(	PUNCT
fnp-2627	173	17	sma	sma	PROPN
fnp-2627	173	18	)	)	PUNCT
fnp-2627	173	19	is	be	AUX
fnp-2627	173	20	an	an	DET
fnp-2627	173	21	autosomal	autosomal	ADJ
fnp-2627	173	22	recessive	recessive	ADJ
fnp-2627	173	23	neurodegenerative	neurodegenerative	ADJ
fnp-2627	173	24	disease	disease	NOUN
fnp-2627	173	25	that	that	PRON
fnp-2627	173	26	affects	affect	VERB
fnp-2627	173	27	the	the	DET
fnp-2627	173	28	alpha	alpha	NOUN
fnp-2627	173	29	motor	motor	NOUN
fnp-2627	173	30	neurons	neuron	NOUN
fnp-2627	173	31	in	in	ADP
fnp-2627	173	32	the	the	DET
fnp-2627	173	33	anterior	anterior	ADJ
fnp-2627	173	34	horn	horn	NOUN
fnp-2627	173	35	of	of	ADP
fnp-2627	173	36	the	the	DET
fnp-2627	173	37	spinal	spinal	NOUN
fnp-2627	173	38	cord	cord	NOUN
fnp-2627	173	39	,	,	PUNCT
fnp-2627	173	40	resulting	result	VERB
fnp-2627	173	41	in	in	ADP
fnp-2627	173	42	neurogenic	neurogenic	ADJ
fnp-2627	173	43	muscle	muscle	NOUN
fnp-2627	173	44	atrophy	atrophy	NOUN
fnp-2627	173	45	and	and	CCONJ
fnp-2627	173	46	weakness	weakness	NOUN
fnp-2627	173	47	;	;	PUNCT
fnp-2627	173	48	the	the	DET
fnp-2627	173	49	onset	onset	NOUN
fnp-2627	173	50	of	of	ADP
fnp-2627	173	51	disease	disease	NOUN
fnp-2627	173	52	varies	vary	VERB
fnp-2627	173	53	from	from	ADP
fnp-2627	173	54	the	the	DET
fnp-2627	173	55	first	first	ADJ
fnp-2627	173	56	6	6	NUM
fnp-2627	173	57	months	month	NOUN
fnp-2627	173	58	of	of	ADP
fnp-2627	173	59	age	age	NOUN
fnp-2627	173	60	for	for	ADP
fnp-2627	173	61	the	the	DET
fnp-2627	173	62	most	most	ADV
fnp-2627	173	63	severe	severe	ADJ
fnp-2627	173	64	infantile	infantile	ADJ
fnp-2627	173	65	form	form	NOUN
fnp-2627	173	66	(	(	PUNCT
fnp-2627	173	67	sma1	sma1	PROPN
fnp-2627	173	68	)	)	PUNCT
fnp-2627	173	69	to	to	ADP
fnp-2627	173	70	the	the	DET
fnp-2627	173	71	second	second	ADJ
fnp-2627	173	72	or	or	CCONJ
fnp-2627	173	73	third	third	ADJ
fnp-2627	173	74	decade	decade	NOUN
fnp-2627	173	75	for	for	ADP
fnp-2627	173	76	the	the	DET
fnp-2627	173	77	mildest	mild	ADJ
fnp-2627	173	78	form	form	NOUN
fnp-2627	173	79	(	(	PUNCT
fnp-2627	173	80	sma4	sma4	PROPN
fnp-2627	173	81	)	)	PUNCT
fnp-2627	173	82	.	.	PUNCT
fnp-2627	174	1	sma	sma	PROPN
fnp-2627	174	2	is	be	AUX
fnp-2627	174	3	caused	cause	VERB
fnp-2627	174	4	by	by	ADP
fnp-2627	174	5	loss	loss	NOUN
fnp-2627	174	6	-	-	PUNCT
fnp-2627	174	7	of	of	ADP
fnp-2627	174	8	-	-	PUNCT
fnp-2627	174	9	function	function	NOUN
fnp-2627	174	10	mutations	mutation	NOUN
fnp-2627	174	11	in	in	ADP
fnp-2627	174	12	both	both	DET
fnp-2627	174	13	copies	copy	NOUN
fnp-2627	174	14	of	of	ADP
fnp-2627	174	15	smn1	smn1	PROPN
fnp-2627	174	16	(	(	PUNCT
fnp-2627	174	17	survival	survival	PROPN
fnp-2627	174	18	motor	motor	PROPN
fnp-2627	174	19	neuron	neuron	PROPN
fnp-2627	174	20	1	1	NUM
fnp-2627	174	21	)	)	PUNCT
fnp-2627	174	22	gene	gene	NOUN
fnp-2627	174	23	,	,	PUNCT
fnp-2627	174	24	but	but	CCONJ
fnp-2627	174	25	clinical	clinical	ADJ
fnp-2627	174	26	phenotype	phenotype	NOUN
fnp-2627	174	27	is	be	AUX
fnp-2627	174	28	modified	modify	VERB
fnp-2627	174	29	by	by	ADP
fnp-2627	174	30	the	the	DET
fnp-2627	174	31	presence	presence	NOUN
fnp-2627	174	32	of	of	ADP
fnp-2627	174	33	the	the	DET
fnp-2627	174	34	paralog	paralog	NOUN
fnp-2627	174	35	gene	gene	NOUN
fnp-2627	174	36	,	,	PUNCT
fnp-2627	174	37	smn2	smn2	PROPN
fnp-2627	174	38	,	,	PUNCT
fnp-2627	174	39	which	which	PRON
fnp-2627	174	40	yields	yield	VERB
fnp-2627	174	41	only	only	ADV
fnp-2627	174	42	a	a	DET
fnp-2627	174	43	small	small	ADJ
fnp-2627	174	44	number	number	NOUN
fnp-2627	174	45	of	of	ADP
fnp-2627	174	46	full	full	ADJ
fnp-2627	174	47	length	length	NOUN
fnp-2627	174	48	transcripts	transcript	NOUN
fnp-2627	174	49	(	(	PUNCT
fnp-2627	174	50	due	due	ADP
fnp-2627	174	51	to	to	ADP
fnp-2627	174	52	a	a	DET
fnp-2627	174	53	mutation	mutation	NOUN
fnp-2627	174	54	in	in	ADP
fnp-2627	174	55	the	the	DET
fnp-2627	174	56	exon	exon	NOUN
fnp-2627	174	57	7	7	NUM
fnp-2627	174	58	that	that	PRON
fnp-2627	174	59	alters	alter	VERB
fnp-2627	174	60	gene	gene	NOUN
fnp-2627	174	61	splicing	splicing	NOUN
fnp-2627	174	62	)	)	PUNCT
fnp-2627	174	63	and	and	CCONJ
fnp-2627	174	64	is	be	AUX
fnp-2627	174	65	present	present	ADJ
fnp-2627	174	66	in	in	ADP
fnp-2627	174	67	a	a	DET
fnp-2627	174	68	variable	variable	ADJ
fnp-2627	174	69	number	number	NOUN
fnp-2627	174	70	of	of	ADP
fnp-2627	174	71	copies	copy	NOUN
fnp-2627	174	72	in	in	ADP
fnp-2627	174	73	different	different	ADJ
fnp-2627	174	74	individuals	individual	NOUN
fnp-2627	174	75	.	.	PUNCT
fnp-2627	175	1	the	the	DET
fnp-2627	175	2	first	first	ADJ
fnp-2627	175	3	genetic	genetic	ADJ
fnp-2627	175	4	therapy	therapy	NOUN
fnp-2627	175	5	for	for	ADP
fnp-2627	175	6	sma	sma	PROPN
fnp-2627	175	7	,	,	PUNCT
fnp-2627	175	8	an	an	DET
fnp-2627	175	9	intrathecally	intrathecally	ADV
fnp-2627	175	10	delivered	deliver	VERB
fnp-2627	175	11	antisense	antisense	NOUN
fnp-2627	175	12	oligonucleotide	oligonucleotide	NOUN
fnp-2627	175	13	(	(	PUNCT
fnp-2627	175	14	aso	aso	PROPN
fnp-2627	175	15	)	)	PUNCT
fnp-2627	175	16	called	call	VERB
fnp-2627	175	17	nusinersen	nusinersen	NOUN
fnp-2627	175	18	,	,	PUNCT
fnp-2627	175	19	was	be	AUX
fnp-2627	175	20	approved	approve	VERB
fnp-2627	175	21	in	in	ADP
fnp-2627	175	22	the	the	DET
fnp-2627	175	23	us	us	PROPN
fnp-2627	175	24	in	in	ADP
fnp-2627	175	25	2016	2016	NUM
fnp-2627	175	26	and	and	CCONJ
fnp-2627	175	27	in	in	ADP
fnp-2627	175	28	europe	europe	PROPN
fnp-2627	175	29	in	in	ADP
fnp-2627	175	30	2017	2017	NUM
fnp-2627	175	31	based	base	VERB
fnp-2627	175	32	on	on	ADP
fnp-2627	175	33	the	the	DET
fnp-2627	175	34	results	result	NOUN
fnp-2627	175	35	of	of	ADP
fnp-2627	175	36	clinical	clinical	ADJ
fnp-2627	175	37	trials	trial	NOUN
fnp-2627	175	38	done	do	VERB
fnp-2627	175	39	with	with	ADP
fnp-2627	175	40	sma1	sma1	NOUN
fnp-2627	175	41	and	and	CCONJ
fnp-2627	175	42	sma2	sma2	NOUN
fnp-2627	175	43	infants	infant	NOUN
fnp-2627	175	44	;	;	PUNCT
fnp-2627	175	45	additional	additional	ADJ
fnp-2627	175	46	clinical	clinical	ADJ
fnp-2627	175	47	trials	trial	NOUN
fnp-2627	175	48	for	for	ADP
fnp-2627	175	49	other	other	ADJ
fnp-2627	175	50	sma	sma	NOUN
fnp-2627	175	51	subgroups	subgroup	NOUN
fnp-2627	175	52	are	be	AUX
fnp-2627	175	53	still	still	ADV
fnp-2627	175	54	ongoing	ongoing	ADJ
fnp-2627	175	55	.	.	PUNCT
fnp-2627	176	1	[	[	X
fnp-2627	176	2	for	for	ADP
fnp-2627	176	3	a	a	DET
fnp-2627	176	4	succinct	succinct	ADJ
fnp-2627	176	5	but	but	CCONJ
fnp-2627	176	6	comprehensive	comprehensive	ADJ
fnp-2627	176	7	review	review	NOUN
fnp-2627	176	8	of	of	ADP
fnp-2627	176	9	all	all	DET
fnp-2627	176	10	treatment	treatment	NOUN
fnp-2627	176	11	approaches	approach	NOUN
fnp-2627	176	12	summarized	summarize	VERB
fnp-2627	176	13	in	in	ADP
fnp-2627	176	14	this	this	DET
fnp-2627	176	15	section	section	NOUN
fnp-2627	176	16	,	,	PUNCT
fnp-2627	176	17	see	see	VERB
fnp-2627	176	18	(	(	PUNCT
fnp-2627	176	19	vita	vita	X
fnp-2627	176	20	et	et	PROPN
fnp-2627	176	21	al	al	PROPN
fnp-2627	176	22	.	.	PROPN
fnp-2627	176	23	,	,	PUNCT
fnp-2627	176	24	2019	2019	NUM
fnp-2627	176	25	)	)	PUNCT
fnp-2627	176	26	.	.	PUNCT
fnp-2627	176	27	]	]	PUNCT
fnp-2627	177	1	nusinersen	nusinersen	PROPN
fnp-2627	177	2	binds	bind	VERB
fnp-2627	177	3	to	to	ADP
fnp-2627	177	4	the	the	DET
fnp-2627	177	5	smn2	smn2	ADJ
fnp-2627	177	6	pre	pre	ADJ
fnp-2627	177	7	-	-	ADJ
fnp-2627	177	8	mrna	mrna	ADJ
fnp-2627	177	9	downstream	downstream	NOUN
fnp-2627	177	10	of	of	ADP
fnp-2627	177	11	exon	exon	PROPN
fnp-2627	177	12	7	7	NUM
fnp-2627	177	13	,	,	PUNCT
fnp-2627	177	14	resulting	result	VERB
fnp-2627	177	15	in	in	ADP
fnp-2627	177	16	an	an	DET
fnp-2627	177	17	increase	increase	NOUN
fnp-2627	177	18	in	in	ADP
fnp-2627	177	19	the	the	DET
fnp-2627	177	20	expression	expression	NOUN
fnp-2627	177	21	of	of	ADP
fnp-2627	177	22	smn	smn	NOUN
fnp-2627	177	23	protein	protein	NOUN
fnp-2627	177	24	and	and	CCONJ
fnp-2627	177	25	a	a	DET
fnp-2627	177	26	significant	significant	ADJ
fnp-2627	177	27	improvement	improvement	NOUN
fnp-2627	177	28	in	in	ADP
fnp-2627	177	29	motor	motor	NOUN
fnp-2627	177	30	function	function	NOUN
fnp-2627	177	31	and	and	CCONJ
fnp-2627	177	32	patient	patient	ADJ
fnp-2627	177	33	survival	survival	NOUN
fnp-2627	177	34	.	.	PUNCT
fnp-2627	178	1	risdiplam	risdiplam	PROPN
fnp-2627	178	2	,	,	PUNCT
fnp-2627	178	3	an	an	DET
fnp-2627	178	4	orally	orally	ADV
fnp-2627	178	5	available	available	ADJ
fnp-2627	178	6	small	small	ADJ
fnp-2627	178	7	molecule	molecule	NOUN
fnp-2627	178	8	therapeutic	therapeutic	ADJ
fnp-2627	178	9	that	that	PRON
fnp-2627	178	10	also	also	ADV
fnp-2627	178	11	acts	act	VERB
fnp-2627	178	12	as	as	ADP
fnp-2627	178	13	a	a	DET
fnp-2627	178	14	splicing	splicing	NOUN
fnp-2627	178	15	modifier	modifier	NOUN
fnp-2627	178	16	of	of	ADP
fnp-2627	178	17	smn2	smn2	PROPN
fnp-2627	178	18	mrna	mrna	PROPN
fnp-2627	178	19	,	,	PUNCT
fnp-2627	178	20	is	be	AUX
fnp-2627	178	21	still	still	ADV
fnp-2627	178	22	in	in	ADP
fnp-2627	178	23	clinical	clinical	ADJ
fnp-2627	178	24	trials	trial	NOUN
fnp-2627	178	25	;	;	PUNCT
fnp-2627	178	26	however	however	ADV
fnp-2627	178	27	,	,	PUNCT
fnp-2627	178	28	based	base	VERB
fnp-2627	178	29	on	on	ADP
fnp-2627	178	30	the	the	DET
fnp-2627	178	31	promising	promising	ADJ
fnp-2627	178	32	early	early	ADJ
fnp-2627	178	33	results	result	NOUN
fnp-2627	178	34	,	,	PUNCT
fnp-2627	178	35	it	it	PRON
fnp-2627	178	36	has	have	AUX
fnp-2627	178	37	been	be	AUX
fnp-2627	178	38	placed	place	VERB
fnp-2627	178	39	on	on	ADP
fnp-2627	178	40	an	an	DET
fnp-2627	178	41	accelerated	accelerated	ADJ
fnp-2627	178	42	pathway	pathway	NOUN
fnp-2627	178	43	for	for	ADP
fnp-2627	178	44	the	the	DET
fnp-2627	178	45	approval	approval	NOUN
fnp-2627	178	46	by	by	ADP
fnp-2627	178	47	ema	ema	PROPN
fnp-2627	178	48	(	(	PUNCT
fnp-2627	178	49	european	european	PROPN
fnp-2627	178	50	medicines	medicine	NOUN
fnp-2627	178	51	agency	agency	NOUN
fnp-2627	178	52	)	)	PUNCT
fnp-2627	178	53	.	.	PUNCT
fnp-2627	179	1	an	an	DET
fnp-2627	179	2	alternate	alternate	ADJ
fnp-2627	179	3	approach	approach	NOUN
fnp-2627	179	4	for	for	ADP
fnp-2627	179	5	sma	sma	NOUN
fnp-2627	179	6	treatment	treatment	NOUN
fnp-2627	179	7	is	be	AUX
fnp-2627	179	8	to	to	PART
fnp-2627	179	9	directly	directly	ADV
fnp-2627	179	10	replace	replace	VERB
fnp-2627	179	11	the	the	DET
fnp-2627	179	12	defective	defective	ADJ
fnp-2627	179	13	smn1	smn1	NOUN
fnp-2627	179	14	gene	gene	NOUN
fnp-2627	179	15	;	;	PUNCT
fnp-2627	179	16	this	this	DET
fnp-2627	179	17	approach	approach	NOUN
fnp-2627	179	18	has	have	AUX
fnp-2627	179	19	led	lead	VERB
fnp-2627	179	20	to	to	ADP
fnp-2627	179	21	development	development	NOUN
fnp-2627	179	22	of	of	ADP
fnp-2627	179	23	aav9	aav9	PROPN
fnp-2627	179	24	-	-	PUNCT
fnp-2627	179	25	smn	smn	PROPN
fnp-2627	179	26	(	(	PUNCT
fnp-2627	179	27	also	also	ADV
fnp-2627	179	28	called	call	VERB
fnp-2627	179	29	avxs-101	avxs-101	NOUN
fnp-2627	179	30	or	or	CCONJ
fnp-2627	179	31	zolgensma	zolgensma	NOUN
fnp-2627	179	32	)	)	PUNCT
fnp-2627	179	33	,	,	PUNCT
fnp-2627	179	34	an	an	DET
fnp-2627	179	35	aav9	aav9	PROPN
fnp-2627	179	36	(	(	PUNCT
fnp-2627	179	37	adeno	adeno	NOUN
fnp-2627	179	38	-	-	PUNCT
fnp-2627	179	39	associated	associate	VERB
fnp-2627	179	40	virus	virus	NOUN
fnp-2627	179	41	9	9	NUM
fnp-2627	179	42	)	)	PUNCT
fnp-2627	179	43	vector	vector	NOUN
fnp-2627	179	44	carrying	carry	VERB
fnp-2627	179	45	human	human	ADJ
fnp-2627	179	46	smn	smn	PROPN
fnp-2627	179	47	transgene	transgene	NOUN
fnp-2627	179	48	that	that	PRON
fnp-2627	179	49	was	be	AUX
fnp-2627	179	50	approved	approve	VERB
fnp-2627	179	51	for	for	ADP
fnp-2627	179	52	sma	sma	NOUN
fnp-2627	179	53	treatment	treatment	NOUN
fnp-2627	179	54	by	by	ADP
fnp-2627	179	55	fda	fda	PROPN
fnp-2627	179	56	(	(	PUNCT
fnp-2627	179	57	federal	federal	ADJ
fnp-2627	179	58	drug	drug	NOUN
fnp-2627	179	59	administration	administration	NOUN
fnp-2627	179	60	)	)	PUNCT
fnp-2627	179	61	in	in	ADP
fnp-2627	179	62	may	may	PROPN
fnp-2627	179	63	2019	2019	NUM
fnp-2627	179	64	(	(	PUNCT
fnp-2627	179	65	al	al	PROPN
fnp-2627	179	66	-	-	PUNCT
fnp-2627	179	67	zaidy	zaidy	PROPN
fnp-2627	179	68	and	and	CCONJ
fnp-2627	179	69	mendell	mendell	NOUN
fnp-2627	179	70	,	,	PUNCT
fnp-2627	179	71	2019	2019	NUM
fnp-2627	179	72	)	)	PUNCT
fnp-2627	179	73	.	.	PUNCT
fnp-2627	180	1	the	the	DET
fnp-2627	180	2	availability	availability	NOUN
fnp-2627	180	3	of	of	ADP
fnp-2627	180	4	multiple	multiple	ADJ
fnp-2627	180	5	treatment	treatment	NOUN
fnp-2627	180	6	options	option	NOUN
fnp-2627	180	7	raises	raise	VERB
fnp-2627	180	8	many	many	ADJ
fnp-2627	180	9	interesting	interesting	ADJ
fnp-2627	180	10	questions	question	NOUN
fnp-2627	180	11	that	that	PRON
fnp-2627	180	12	will	will	AUX
fnp-2627	180	13	need	need	VERB
fnp-2627	180	14	to	to	PART
fnp-2627	180	15	be	be	AUX
fnp-2627	180	16	addressed	address	VERB
fnp-2627	180	17	going	go	VERB
fnp-2627	180	18	forward	forward	ADV
fnp-2627	180	19	.	.	PUNCT
fnp-2627	181	1	are	be	AUX
fnp-2627	181	2	some	some	PRON
fnp-2627	181	3	of	of	ADP
fnp-2627	181	4	these	these	DET
fnp-2627	181	5	treatments	treatment	NOUN
fnp-2627	181	6	superior	superior	ADJ
fnp-2627	181	7	to	to	ADP
fnp-2627	181	8	others	other	NOUN
fnp-2627	181	9	?	?	PUNCT
fnp-2627	182	1	(	(	PUNCT
fnp-2627	182	2	an	an	DET
fnp-2627	182	3	indirect	indirect	ADJ
fnp-2627	182	4	comparison	comparison	NOUN
fnp-2627	182	5	between	between	ADP
fnp-2627	182	6	nusinersen	nusinersen	NOUN
fnp-2627	182	7	and	and	CCONJ
fnp-2627	182	8	avxs-101	avxs-101	NOUN
fnp-2627	182	9	has	have	AUX
fnp-2627	182	10	been	be	AUX
fnp-2627	182	11	done	do	VERB
fnp-2627	182	12	and	and	CCONJ
fnp-2627	182	13	suggests	suggest	VERB
fnp-2627	182	14	that	that	SCONJ
fnp-2627	182	15	avxs-101	avxs-101	NOUN
fnp-2627	182	16	is	be	AUX
fnp-2627	182	17	more	more	ADV
fnp-2627	182	18	effective	effective	ADJ
fnp-2627	182	19	(	(	PUNCT
fnp-2627	182	20	dabbous	dabbous	VERB
fnp-2627	182	21	et	et	PROPN
fnp-2627	182	22	al	al	PROPN
fnp-2627	182	23	.	.	PROPN
fnp-2627	182	24	,	,	PUNCT
fnp-2627	182	25	2019	2019	NUM
fnp-2627	182	26	)	)	PUNCT
fnp-2627	182	27	;	;	PUNCT
fnp-2627	182	28	however	however	ADV
fnp-2627	182	29	,	,	PUNCT
fnp-2627	182	30	that	that	DET
fnp-2627	182	31	study	study	NOUN
fnp-2627	182	32	had	have	VERB
fnp-2627	182	33	significant	significant	ADJ
fnp-2627	182	34	limitations	limitation	NOUN
fnp-2627	182	35	.	.	PUNCT
fnp-2627	183	1	thus	thus	ADV
fnp-2627	183	2	,	,	PUNCT
fnp-2627	183	3	a	a	DET
fnp-2627	183	4	direct	direct	ADJ
fnp-2627	183	5	comparison	comparison	NOUN
fnp-2627	183	6	of	of	ADP
fnp-2627	183	7	these	these	DET
fnp-2627	183	8	two	two	NUM
fnp-2627	183	9	drugs	drug	NOUN
fnp-2627	183	10	is	be	AUX
fnp-2627	183	11	needed	need	VERB
fnp-2627	183	12	,	,	PUNCT
fnp-2627	183	13	but	but	CCONJ
fnp-2627	183	14	will	will	AUX
fnp-2627	183	15	be	be	AUX
fnp-2627	183	16	challenging	challenge	VERB
fnp-2627	183	17	to	to	PART
fnp-2627	183	18	perform	perform	VERB
fnp-2627	183	19	given	give	VERB
fnp-2627	183	20	the	the	DET
fnp-2627	183	21	associated	associated	ADJ
fnp-2627	183	22	cost	cost	NOUN
fnp-2627	183	23	and	and	CCONJ
fnp-2627	183	24	ethical	ethical	ADJ
fnp-2627	183	25	considerations	consideration	NOUN
fnp-2627	183	26	.	.	PUNCT
fnp-2627	183	27	)	)	PUNCT
fnp-2627	184	1	if	if	SCONJ
fnp-2627	184	2	two	two	NUM
fnp-2627	184	3	treatments	treatment	NOUN
fnp-2627	184	4	are	be	AUX
fnp-2627	184	5	based	base	VERB
fnp-2627	184	6	on	on	ADP
fnp-2627	184	7	different	different	ADJ
fnp-2627	184	8	genetic	genetic	ADJ
fnp-2627	184	9	strategies	strategy	NOUN
fnp-2627	184	10	,	,	PUNCT
fnp-2627	184	11	would	would	AUX
fnp-2627	184	12	a	a	DET
fnp-2627	184	13	combination	combination	NOUN
fnp-2627	184	14	therapy	therapy	NOUN
fnp-2627	184	15	be	be	AUX
fnp-2627	184	16	more	more	ADV
fnp-2627	184	17	effective	effective	ADJ
fnp-2627	184	18	than	than	ADP
fnp-2627	184	19	either	either	DET
fnp-2627	184	20	treatment	treatment	NOUN
fnp-2627	184	21	alone	alone	ADV
fnp-2627	184	22	?	?	PUNCT
fnp-2627	185	1	how	how	SCONJ
fnp-2627	185	2	will	will	AUX
fnp-2627	185	3	treatment	treatment	NOUN
fnp-2627	185	4	efficacy	efficacy	NOUN
fnp-2627	185	5	differ	differ	VERB
fnp-2627	185	6	depending	depend	VERB
fnp-2627	185	7	on	on	ADP
fnp-2627	185	8	the	the	DET
fnp-2627	185	9	sma	sma	NOUN
fnp-2627	185	10	subtype	subtype	NOUN
fnp-2627	185	11	and	and	CCONJ
fnp-2627	185	12	the	the	DET
fnp-2627	185	13	age	age	NOUN
fnp-2627	185	14	at	at	ADP
fnp-2627	185	15	which	which	PRON
fnp-2627	185	16	the	the	DET
fnp-2627	185	17	treatment	treatment	NOUN
fnp-2627	185	18	is	be	AUX
fnp-2627	185	19	started	start	VERB
fnp-2627	185	20	?	?	PUNCT
fnp-2627	186	1	as	as	SCONJ
fnp-2627	186	2	expected	expect	VERB
fnp-2627	186	3	for	for	ADP
fnp-2627	186	4	a	a	DET
fnp-2627	186	5	neurodegenerative	neurodegenerative	ADJ
fnp-2627	186	6	disease	disease	NOUN
fnp-2627	186	7	,	,	PUNCT
fnp-2627	186	8	the	the	DET
fnp-2627	186	9	treatment	treatment	NOUN
fnp-2627	186	10	is	be	AUX
fnp-2627	186	11	more	more	ADV
fnp-2627	186	12	effective	effective	ADJ
fnp-2627	186	13	if	if	SCONJ
fnp-2627	186	14	it	it	PRON
fnp-2627	186	15	is	be	AUX
fnp-2627	186	16	initiated	initiate	VERB
fnp-2627	186	17	before	before	SCONJ
fnp-2627	186	18	significant	significant	ADJ
fnp-2627	186	19	neuron	neuron	NOUN
fnp-2627	186	20	loss	loss	NOUN
fnp-2627	186	21	has	have	AUX
fnp-2627	186	22	occurred	occur	VERB
fnp-2627	186	23	(	(	PUNCT
fnp-2627	186	24	de	de	X
fnp-2627	186	25	vivo	vivo	NOUN
fnp-2627	186	26	et	et	PROPN
fnp-2627	186	27	al	al	PROPN
fnp-2627	186	28	.	.	PROPN
fnp-2627	186	29	,	,	PUNCT
fnp-2627	186	30	2019	2019	NUM
fnp-2627	186	31	)	)	PUNCT
fnp-2627	186	32	;	;	PUNCT
fnp-2627	186	33	depending	depend	VERB
fnp-2627	186	34	on	on	ADP
fnp-2627	186	35	the	the	DET
fnp-2627	186	36	sma	sma	NOUN
fnp-2627	186	37	subtype	subtype	NOUN
fnp-2627	186	38	,	,	PUNCT
fnp-2627	186	39	this	this	PRON
fnp-2627	186	40	may	may	AUX
fnp-2627	186	41	require	require	VERB
fnp-2627	186	42	perinatal	perinatal	ADJ
fnp-2627	186	43	or	or	CCONJ
fnp-2627	186	44	even	even	ADV
fnp-2627	186	45	prenatal	prenatal	ADJ
fnp-2627	186	46	diagnosis	diagnosis	NOUN
fnp-2627	186	47	.	.	PUNCT
fnp-2627	187	1	indeed	indeed	ADV
fnp-2627	187	2	,	,	PUNCT
fnp-2627	187	3	a	a	DET
fnp-2627	187	4	large	large	ADJ
fnp-2627	187	5	autopsy	autopsy	ADJ
fnp-2627	187	6	study	study	NOUN
fnp-2627	187	7	published	publish	VERB
fnp-2627	187	8	in	in	ADP
fnp-2627	187	9	2019	2019	NUM
fnp-2627	187	10	has	have	AUX
fnp-2627	187	11	shown	show	VERB
fnp-2627	187	12	that	that	SCONJ
fnp-2627	187	13	smn	smn	NOUN
fnp-2627	187	14	protein	protein	NOUN
fnp-2627	187	15	levels	level	NOUN
fnp-2627	187	16	in	in	ADP
fnp-2627	187	17	the	the	DET
fnp-2627	187	18	human	human	ADJ
fnp-2627	187	19	spinal	spinal	NOUN
fnp-2627	187	20	cord	cord	NOUN
fnp-2627	187	21	decline	decline	VERB
fnp-2627	187	22	rapidly	rapidly	ADV
fnp-2627	187	23	during	during	ADP
fnp-2627	187	24	development	development	NOUN
fnp-2627	187	25	,	,	PUNCT
fnp-2627	187	26	with	with	ADP
fnp-2627	187	27	a	a	DET
fnp-2627	187	28	critical	critical	ADJ
fnp-2627	187	29	window	window	NOUN
fnp-2627	187	30	that	that	PRON
fnp-2627	187	31	spans	span	VERB
fnp-2627	187	32	from	from	ADP
fnp-2627	187	33	3	3	NUM
fnp-2627	187	34	months	month	NOUN
fnp-2627	187	35	before	before	ADP
fnp-2627	187	36	to	to	ADP
fnp-2627	187	37	3	3	NUM
fnp-2627	187	38	months	month	NOUN
fnp-2627	187	39	after	after	ADP
fnp-2627	187	40	birth	birth	NOUN
fnp-2627	187	41	(	(	PUNCT
fnp-2627	187	42	ramos	ramos	PROPN
fnp-2627	187	43	et	et	PROPN
fnp-2627	187	44	al	al	PROPN
fnp-2627	187	45	.	.	PROPN
fnp-2627	187	46	,	,	PUNCT
fnp-2627	187	47	2019	2019	NUM
fnp-2627	187	48	)	)	PUNCT
fnp-2627	187	49	;	;	PUNCT
fnp-2627	187	50	this	this	DET
fnp-2627	187	51	finding	finding	NOUN
fnp-2627	187	52	highlights	highlight	VERB
fnp-2627	187	53	the	the	DET
fnp-2627	187	54	need	need	NOUN
fnp-2627	187	55	for	for	ADP
fnp-2627	187	56	development	development	NOUN
fnp-2627	187	57	of	of	ADP
fnp-2627	187	58	newborn	newborn	ADJ
fnp-2627	187	59	sma	sma	NOUN
fnp-2627	187	60	screening	screening	NOUN
fnp-2627	187	61	programs	program	NOUN
fnp-2627	187	62	,	,	PUNCT
fnp-2627	187	63	which	which	PRON
fnp-2627	187	64	are	be	AUX
fnp-2627	187	65	already	already	ADV
fnp-2627	187	66	being	be	AUX
fnp-2627	187	67	piloted	pilot	VERB
fnp-2627	187	68	in	in	ADP
fnp-2627	187	69	several	several	ADJ
fnp-2627	187	70	different	different	ADJ
fnp-2627	187	71	countries	country	NOUN
fnp-2627	187	72	(	(	PUNCT
fnp-2627	187	73	dangouloff	dangouloff	NOUN
fnp-2627	187	74	et	et	PROPN
fnp-2627	187	75	al	al	PROPN
fnp-2627	187	76	.	.	PROPN
fnp-2627	187	77	,	,	PUNCT
fnp-2627	187	78	2019	2019	NUM
fnp-2627	187	79	;	;	PUNCT
fnp-2627	188	1	vill	vill	NOUN
fnp-2627	188	2	et	et	PROPN
fnp-2627	188	3	al	al	PROPN
fnp-2627	188	4	.	.	PROPN
fnp-2627	188	5	,	,	PUNCT
fnp-2627	188	6	2019	2019	NUM
fnp-2627	188	7	)	)	PUNCT
fnp-2627	188	8	.	.	PUNCT
fnp-2627	189	1	10	10	NUM
fnp-2627	189	2	.	.	PUNCT
fnp-2627	190	1	on	on	ADP
fnp-2627	190	2	the	the	DET
fnp-2627	190	3	horizon	horizon	NOUN
fnp-2627	190	4	:	:	PUNCT
fnp-2627	190	5	genetic	genetic	ADJ
fnp-2627	190	6	therapies	therapy	NOUN
fnp-2627	190	7	for	for	ADP
fnp-2627	190	8	inherited	inherit	VERB
fnp-2627	190	9	myopathies	myopathy	NOUN
fnp-2627	190	10	aside	aside	ADV
fnp-2627	190	11	from	from	ADP
fnp-2627	190	12	sma	sma	PROPN
fnp-2627	190	13	,	,	PUNCT
fnp-2627	190	14	the	the	DET
fnp-2627	190	15	only	only	ADJ
fnp-2627	190	16	currently	currently	ADV
fnp-2627	190	17	approved	approve	VERB
fnp-2627	190	18	genetic	genetic	ADJ
fnp-2627	190	19	therapies	therapy	NOUN
fnp-2627	190	20	for	for	ADP
fnp-2627	190	21	neuromuscular	neuromuscular	ADJ
fnp-2627	190	22	disease	disease	NOUN
fnp-2627	190	23	are	be	AUX
fnp-2627	190	24	three	three	NUM
fnp-2627	190	25	new	new	ADJ
fnp-2627	190	26	drugs	drug	NOUN
fnp-2627	190	27	for	for	ADP
fnp-2627	190	28	duchenne	duchenne	ADJ
fnp-2627	190	29	muscular	muscular	ADJ
fnp-2627	190	30	dystrophy	dystrophy	NOUN
fnp-2627	190	31	(	(	PUNCT
fnp-2627	190	32	dmd	dmd	NOUN
fnp-2627	190	33	)	)	PUNCT
fnp-2627	190	34	,	,	PUNCT
fnp-2627	190	35	which	which	PRON
fnp-2627	190	36	is	be	AUX
fnp-2627	190	37	a	a	DET
fnp-2627	190	38	severe	severe	ADJ
fnp-2627	190	39	progressive	progressive	ADJ
fnp-2627	190	40	x	x	ADJ
fnp-2627	190	41	-	-	ADJ
fnp-2627	190	42	linked	link	VERB
fnp-2627	190	43	muscle	muscle	NOUN
fnp-2627	190	44	disorder	disorder	NOUN
fnp-2627	190	45	caused	cause	VERB
fnp-2627	190	46	by	by	ADP
fnp-2627	190	47	the	the	DET
fnp-2627	190	48	lack	lack	NOUN
fnp-2627	190	49	of	of	ADP
fnp-2627	190	50	membrane	membrane	NOUN
fnp-2627	190	51	-	-	PUNCT
fnp-2627	190	52	associated	associate	VERB
fnp-2627	190	53	dystrophin	dystrophin	ADJ
fnp-2627	190	54	protein	protein	NOUN
fnp-2627	190	55	;	;	PUNCT
fnp-2627	190	56	however	however	ADV
fnp-2627	190	57	,	,	PUNCT
fnp-2627	190	58	based	base	VERB
fnp-2627	190	59	on	on	ADP
fnp-2627	190	60	their	their	PRON
fnp-2627	190	61	rather	rather	ADV
fnp-2627	190	62	modest	modest	ADJ
fnp-2627	190	63	effects	effect	NOUN
fnp-2627	190	64	to	to	ADP
fnp-2627	190	65	date	date	NOUN
fnp-2627	190	66	and	and	CCONJ
fnp-2627	190	67	on	on	ADP
fnp-2627	190	68	the	the	DET
fnp-2627	190	69	conditional	conditional	ADJ
fnp-2627	190	70	and	and	CCONJ
fnp-2627	190	71	inconsistent	inconsistent	ADJ
fnp-2627	190	72	nature	nature	NOUN
fnp-2627	190	73	of	of	ADP
fnp-2627	190	74	the	the	DET
fnp-2627	190	75	approvals	approval	NOUN
fnp-2627	190	76	that	that	PRON
fnp-2627	190	77	were	be	AUX
fnp-2627	190	78	rendered	render	VERB
fnp-2627	190	79	by	by	ADP
fnp-2627	190	80	fda	fda	PROPN
fnp-2627	190	81	and	and	CCONJ
fnp-2627	190	82	ema	ema	PROPN
fnp-2627	190	83	,	,	PUNCT
fnp-2627	190	84	these	these	DET
fnp-2627	190	85	treatments	treatment	NOUN
fnp-2627	190	86	have	have	VERB
fnp-2627	190	87	yet	yet	ADV
fnp-2627	190	88	to	to	PART
fnp-2627	190	89	prove	prove	VERB
fnp-2627	190	90	their	their	PRON
fnp-2627	190	91	therapeutic	therapeutic	ADJ
fnp-2627	190	92	utility	utility	NOUN
fnp-2627	190	93	and	and	CCONJ
fnp-2627	190	94	are	be	AUX
fnp-2627	190	95	best	well	ADV
fnp-2627	190	96	still	still	ADV
fnp-2627	190	97	considered	consider	VERB
fnp-2627	190	98	as	as	ADP
fnp-2627	190	99	being	be	AUX
fnp-2627	190	100	“	"	PUNCT
fnp-2627	190	101	under	under	ADP
fnp-2627	190	102	development	development	NOUN
fnp-2627	190	103	”	"	PUNCT
fnp-2627	190	104	(	(	PUNCT
fnp-2627	190	105	vita	vita	NOUN
fnp-2627	190	106	et	et	PROPN
fnp-2627	190	107	al	al	PROPN
fnp-2627	190	108	.	.	PROPN
fnp-2627	190	109	,	,	PUNCT
fnp-2627	190	110	2019	2019	NUM
fnp-2627	190	111	)	)	PUNCT
fnp-2627	190	112	.	.	PUNCT
fnp-2627	191	1	ataluren	ataluren	PROPN
fnp-2627	191	2	is	be	AUX
fnp-2627	191	3	an	an	DET
fnp-2627	191	4	orally	orally	ADV
fnp-2627	191	5	bioavailable	bioavailable	ADJ
fnp-2627	191	6	drug	drug	NOUN
fnp-2627	191	7	that	that	PRON
fnp-2627	191	8	binds	bind	VERB
fnp-2627	191	9	ribosomal	ribosomal	NOUN
fnp-2627	191	10	rna	rna	NOUN
fnp-2627	191	11	and	and	CCONJ
fnp-2627	191	12	interferes	interfere	VERB
fnp-2627	191	13	with	with	ADP
fnp-2627	191	14	recognition	recognition	NOUN
fnp-2627	191	15	of	of	ADP
fnp-2627	191	16	premature	premature	ADJ
fnp-2627	191	17	stop	stop	VERB
fnp-2627	191	18	codons	codon	NOUN
fnp-2627	191	19	present	present	ADJ
fnp-2627	191	20	in	in	ADP
fnp-2627	191	21	10	10	NUM
fnp-2627	191	22	-	-	SYM
fnp-2627	191	23	15	15	NUM
fnp-2627	191	24	%	%	NOUN
fnp-2627	191	25	of	of	ADP
fnp-2627	191	26	dmd	dmd	NOUN
fnp-2627	191	27	patients	patient	NOUN
fnp-2627	191	28	;	;	PUNCT
fnp-2627	191	29	it	it	PRON
fnp-2627	191	30	received	receive	VERB
fnp-2627	191	31	a	a	DET
fnp-2627	191	32	conditional	conditional	ADJ
fnp-2627	191	33	approval	approval	NOUN
fnp-2627	191	34	from	from	ADP
fnp-2627	191	35	ema	ema	PROPN
fnp-2627	191	36	in	in	ADP
fnp-2627	191	37	2014	2014	NUM
fnp-2627	191	38	,	,	PUNCT
fnp-2627	191	39	but	but	CCONJ
fnp-2627	191	40	the	the	DET
fnp-2627	191	41	evaluation	evaluation	NOUN
fnp-2627	191	42	of	of	ADP
fnp-2627	191	43	long	long	ADJ
fnp-2627	191	44	-	-	PUNCT
fnp-2627	191	45	term	term	NOUN
fnp-2627	191	46	outcomes	outcome	NOUN
fnp-2627	191	47	is	be	AUX
fnp-2627	191	48	still	still	ADV
fnp-2627	191	49	ongoing	ongoing	ADJ
fnp-2627	191	50	.	.	PUNCT
fnp-2627	192	1	the	the	DET
fnp-2627	192	2	other	other	ADJ
fnp-2627	192	3	two	two	NUM
fnp-2627	192	4	conditionally	conditionally	ADV
fnp-2627	192	5	approved	approve	VERB
fnp-2627	192	6	treatments	treatment	NOUN
fnp-2627	192	7	for	for	ADP
fnp-2627	192	8	dmd	dmd	NOUN
fnp-2627	192	9	are	be	AUX
fnp-2627	192	10	based	base	VERB
fnp-2627	192	11	on	on	ADP
fnp-2627	192	12	the	the	DET
fnp-2627	192	13	exon	exon	NOUN
fnp-2627	192	14	-	-	PUNCT
fnp-2627	192	15	skipping	skip	VERB
fnp-2627	192	16	aso	aso	NOUN
fnp-2627	192	17	technology	technology	NOUN
fnp-2627	192	18	;	;	PUNCT
fnp-2627	192	19	the	the	DET
fnp-2627	192	20	goal	goal	NOUN
fnp-2627	192	21	of	of	ADP
fnp-2627	192	22	this	this	DET
fnp-2627	192	23	therapy	therapy	NOUN
fnp-2627	192	24	is	be	AUX
fnp-2627	192	25	to	to	PART
fnp-2627	192	26	“	"	PUNCT
fnp-2627	192	27	trick	trick	VERB
fnp-2627	192	28	”	"	PUNCT
fnp-2627	192	29	the	the	DET
fnp-2627	192	30	cellular	cellular	ADJ
fnp-2627	192	31	machinery	machinery	NOUN
fnp-2627	192	32	to	to	PART
fnp-2627	192	33	restore	restore	VERB
fnp-2627	192	34	the	the	DET
fnp-2627	192	35	reading	reading	NOUN
fnp-2627	192	36	frame	frame	NOUN
fnp-2627	192	37	by	by	ADP
fnp-2627	192	38	skipping	skip	VERB
fnp-2627	192	39	over	over	ADP
fnp-2627	192	40	the	the	DET
fnp-2627	192	41	mutant	mutant	ADJ
fnp-2627	192	42	exon	exon	NOUN
fnp-2627	192	43	,	,	PUNCT
fnp-2627	192	44	resulting	result	VERB
fnp-2627	192	45	in	in	ADP
fnp-2627	192	46	an	an	DET
fnp-2627	192	47	internally	internally	ADV
fnp-2627	192	48	truncated	truncated	ADJ
fnp-2627	192	49	but	but	CCONJ
fnp-2627	192	50	functional	functional	ADJ
fnp-2627	192	51	protein	protein	NOUN
fnp-2627	192	52	.	.	PUNCT
fnp-2627	193	1	eteplirsen	eteplirsen	PROPN
fnp-2627	193	2	,	,	PUNCT
fnp-2627	193	3	which	which	PRON
fnp-2627	193	4	targets	target	VERB
fnp-2627	193	5	the	the	DET
fnp-2627	193	6	splice	splice	NOUN
fnp-2627	193	7	-	-	PUNCT
fnp-2627	193	8	donor	donor	NOUN
fnp-2627	193	9	region	region	NOUN
fnp-2627	193	10	of	of	ADP
fnp-2627	193	11	exon	exon	PROPN
fnp-2627	193	12	51	51	NUM
fnp-2627	193	13	(	(	PUNCT
fnp-2627	193	14	mutated	mutate	VERB
fnp-2627	193	15	in	in	ADP
fnp-2627	193	16	13	13	NUM
fnp-2627	193	17	%	%	NOUN
fnp-2627	193	18	of	of	ADP
fnp-2627	193	19	dmd	dmd	NOUN
fnp-2627	193	20	patients	patient	NOUN
fnp-2627	193	21	)	)	PUNCT
fnp-2627	193	22	,	,	PUNCT
fnp-2627	193	23	was	be	AUX
fnp-2627	193	24	conditionally	conditionally	ADV
fnp-2627	193	25	approved	approve	VERB
fnp-2627	193	26	by	by	ADP
fnp-2627	193	27	fda	fda	PROPN
fnp-2627	193	28	in	in	ADP
fnp-2627	193	29	2016	2016	NUM
fnp-2627	193	30	but	but	CCONJ
fnp-2627	193	31	failed	fail	VERB
fnp-2627	193	32	to	to	PART
fnp-2627	193	33	receive	receive	VERB
fnp-2627	193	34	an	an	DET
fnp-2627	193	35	approval	approval	NOUN
fnp-2627	193	36	from	from	ADP
fnp-2627	193	37	ema	ema	PROPN
fnp-2627	193	38	(	(	PUNCT
fnp-2627	193	39	aartsma	aartsma	PROPN
fnp-2627	193	40	-	-	PUNCT
fnp-2627	193	41	rus	rus	NOUN
fnp-2627	193	42	and	and	CCONJ
fnp-2627	193	43	goemans	goeman	NOUN
fnp-2627	193	44	,	,	PUNCT
fnp-2627	193	45	2019	2019	NUM
fnp-2627	193	46	)	)	PUNCT
fnp-2627	193	47	;	;	PUNCT
fnp-2627	193	48	a	a	DET
fnp-2627	193	49	phase	phase	NOUN
fnp-2627	193	50	3	3	NUM
fnp-2627	193	51	clinical	clinical	ADJ
fnp-2627	193	52	trial	trial	NOUN
fnp-2627	193	53	to	to	PART
fnp-2627	193	54	evaluate	evaluate	VERB
fnp-2627	193	55	its	its	PRON
fnp-2627	193	56	efficacy	efficacy	NOUN
fnp-2627	193	57	is	be	AUX
fnp-2627	193	58	still	still	ADV
fnp-2627	193	59	ongoing	ongoing	ADJ
fnp-2627	193	60	.	.	PUNCT
fnp-2627	194	1	golodirsen	golodirsen	PROPN
fnp-2627	194	2	(	(	PUNCT
fnp-2627	194	3	exon	exon	PROPN
fnp-2627	194	4	53	53	NUM
fnp-2627	194	5	;	;	PUNCT
fnp-2627	194	6	8	8	NUM
fnp-2627	194	7	%	%	NOUN
fnp-2627	194	8	of	of	ADP
fnp-2627	194	9	dmd	dmd	NOUN
fnp-2627	194	10	patients	patient	NOUN
fnp-2627	194	11	)	)	PUNCT
fnp-2627	194	12	has	have	AUX
fnp-2627	194	13	been	be	AUX
fnp-2627	194	14	approved	approve	VERB
fnp-2627	194	15	by	by	ADP
fnp-2627	194	16	fda	fda	PROPN
fnp-2627	194	17	in	in	ADP
fnp-2627	194	18	december	december	PROPN
fnp-2627	194	19	2019	2019	NUM
fnp-2627	194	20	(	(	PUNCT
fnp-2627	194	21	https://www.drugs.com/newdrugs/fda-approves-vyondys-53-golodirsen-duchenne-muscular-dystrophy-dmd-patients-amenable-skipping-exon-5119.html	https://www.drugs.com/newdrugs/fda-approves-vyondys-53-golodirsen-duchenne-muscular-dystrophy-dmd-patients-amenable-skipping-exon-5119.html	PROPN
fnp-2627	194	22	;	;	PUNCT
fnp-2627	194	23	accessed	access	VERB
fnp-2627	194	24	on	on	ADP
fnp-2627	194	25	12/26/2019	12/26/2019	NUM
fnp-2627	194	26	)	)	PUNCT
fnp-2627	194	27	,	,	PUNCT
fnp-2627	194	28	while	while	SCONJ
fnp-2627	194	29	clinical	clinical	ADJ
fnp-2627	194	30	trials	trial	NOUN
fnp-2627	194	31	for	for	ADP
fnp-2627	194	32	casimirsen	casimirsen	PROPN
fnp-2627	194	33	(	(	PUNCT
fnp-2627	194	34	exon	exon	PROPN
fnp-2627	194	35	45	45	NUM
fnp-2627	194	36	;	;	PUNCT
fnp-2627	194	37	8	8	NUM
fnp-2627	194	38	%	%	NOUN
fnp-2627	194	39	of	of	ADP
fnp-2627	194	40	dmd	dmd	NOUN
fnp-2627	194	41	patients	patient	NOUN
fnp-2627	194	42	)	)	PUNCT
fnp-2627	194	43	and	and	CCONJ
fnp-2627	194	44	suvodirsen	suvodirsen	VERB
fnp-2627	194	45	(	(	PUNCT
fnp-2627	194	46	exon	exon	NOUN
fnp-2627	194	47	51	51	NUM
fnp-2627	194	48	)	)	PUNCT
fnp-2627	194	49	are	be	AUX
fnp-2627	194	50	still	still	ADV
fnp-2627	194	51	ongoing	ongoing	ADJ
fnp-2627	194	52	(	(	PUNCT
fnp-2627	194	53	vita	vita	X
fnp-2627	194	54	et	et	PROPN
fnp-2627	194	55	al	al	PROPN
fnp-2627	194	56	.	.	PROPN
fnp-2627	194	57	,	,	PUNCT
fnp-2627	194	58	2019	2019	NUM
fnp-2627	194	59	)	)	PUNCT
fnp-2627	194	60	.	.	PUNCT
fnp-2627	195	1	based	base	VERB
fnp-2627	195	2	on	on	ADP
fnp-2627	195	3	the	the	DET
fnp-2627	195	4	animal	animal	NOUN
fnp-2627	195	5	model	model	NOUN
fnp-2627	195	6	studies	study	NOUN
fnp-2627	195	7	,	,	PUNCT
fnp-2627	195	8	similar	similar	ADJ
fnp-2627	195	9	exon	exon	NOUN
fnp-2627	195	10	skipping	skip	VERB
fnp-2627	195	11	treatments	treatment	NOUN
fnp-2627	195	12	may	may	AUX
fnp-2627	195	13	also	also	ADV
fnp-2627	195	14	prove	prove	VERB
fnp-2627	195	15	valuable	valuable	ADJ
fnp-2627	195	16	for	for	ADP
fnp-2627	195	17	limb	limb	NOUN
fnp-2627	195	18	-	-	PUNCT
fnp-2627	195	19	girdle	girdle	NOUN
fnp-2627	195	20	and	and	CCONJ
fnp-2627	195	21	congenital	congenital	ADJ
fnp-2627	195	22	muscular	muscular	ADJ
fnp-2627	195	23	dystrophies	dystrophy	NOUN
fnp-2627	195	24	(	(	PUNCT
fnp-2627	195	25	hwang	hwang	PROPN
fnp-2627	195	26	and	and	CCONJ
fnp-2627	195	27	yokota	yokota	PROPN
fnp-2627	195	28	,	,	PUNCT
fnp-2627	195	29	2019	2019	NUM
fnp-2627	195	30	)	)	PUNCT
fnp-2627	195	31	.	.	PUNCT
fnp-2627	196	1	excitingly	excitingly	ADV
fnp-2627	196	2	,	,	PUNCT
fnp-2627	196	3	new	new	ADJ
fnp-2627	196	4	treatments	treatment	NOUN
fnp-2627	196	5	for	for	ADP
fnp-2627	196	6	other	other	ADJ
fnp-2627	196	7	genetic	genetic	ADJ
fnp-2627	196	8	myopathies	myopathy	NOUN
fnp-2627	196	9	are	be	AUX
fnp-2627	196	10	also	also	ADV
fnp-2627	196	11	under	under	ADP
fnp-2627	196	12	active	active	ADJ
fnp-2627	196	13	development	development	NOUN
fnp-2627	196	14	;	;	PUNCT
fnp-2627	196	15	several	several	ADJ
fnp-2627	196	16	different	different	ADJ
fnp-2627	196	17	therapeutic	therapeutic	ADJ
fnp-2627	196	18	strategies	strategy	NOUN
fnp-2627	196	19	are	be	AUX
fnp-2627	196	20	being	be	AUX
fnp-2627	196	21	evaluated	evaluate	VERB
fnp-2627	196	22	through	through	ADP
fnp-2627	196	23	ongoing	ongoing	ADJ
fnp-2627	196	24	or	or	CCONJ
fnp-2627	196	25	planned	plan	VERB
fnp-2627	196	26	clinical	clinical	ADJ
fnp-2627	196	27	trials	trial	NOUN
fnp-2627	196	28	and	and	CCONJ
fnp-2627	196	29	include	include	VERB
fnp-2627	196	30	aav	aav	PROPN
fnp-2627	196	31	vector	vector	NOUN
fnp-2627	196	32	-	-	PUNCT
fnp-2627	196	33	based	base	VERB
fnp-2627	196	34	gene	gene	NOUN
fnp-2627	196	35	replacement	replacement	NOUN
fnp-2627	196	36	therapies	therapy	NOUN
fnp-2627	196	37	(	(	PUNCT
fnp-2627	196	38	for	for	ADP
fnp-2627	196	39	x	x	VERB
fnp-2627	196	40	-	-	VERB
fnp-2627	196	41	linked	link	VERB
fnp-2627	196	42	myotubular	myotubular	ADJ
fnp-2627	196	43	myopathy	myopathy	ADJ
fnp-2627	196	44	and	and	CCONJ
fnp-2627	196	45	pompe	pompe	PROPN
fnp-2627	196	46	disease	disease	PROPN
fnp-2627	196	47	)	)	PUNCT
fnp-2627	196	48	,	,	PUNCT
fnp-2627	196	49	aso	aso	NOUN
fnp-2627	196	50	-	-	PUNCT
fnp-2627	196	51	based	base	VERB
fnp-2627	196	52	therapy	therapy	NOUN
fnp-2627	196	53	aimed	aim	VERB
fnp-2627	196	54	at	at	ADP
fnp-2627	196	55	reduction	reduction	NOUN
fnp-2627	196	56	of	of	ADP
fnp-2627	196	57	toxic	toxic	ADJ
fnp-2627	196	58	rna	rna	NOUN
fnp-2627	196	59	production	production	NOUN
fnp-2627	196	60	(	(	PUNCT
fnp-2627	196	61	for	for	ADP
fnp-2627	196	62	myotonic	myotonic	ADJ
fnp-2627	196	63	dystrophy	dystrophy	NOUN
fnp-2627	196	64	type	type	NOUN
fnp-2627	196	65	1	1	NUM
fnp-2627	196	66	)	)	PUNCT
fnp-2627	196	67	,	,	PUNCT
fnp-2627	196	68	chaperone	chaperone	NOUN
fnp-2627	196	69	therapy	therapy	NOUN
fnp-2627	196	70	(	(	PUNCT
fnp-2627	196	71	for	for	ADP
fnp-2627	196	72	pompe	pompe	PROPN
fnp-2627	196	73	disease	disease	PROPN
fnp-2627	196	74	)	)	PUNCT
fnp-2627	196	75	,	,	PUNCT
fnp-2627	196	76	and	and	CCONJ
fnp-2627	196	77	the	the	DET
fnp-2627	196	78	second	second	ADJ
fnp-2627	196	79	generation	generation	NOUN
fnp-2627	196	80	enzyme	enzyme	NOUN
fnp-2627	196	81	-	-	PUNCT
fnp-2627	196	82	replacement	replacement	NOUN
fnp-2627	196	83	therapy	therapy	NOUN
fnp-2627	196	84	(	(	PUNCT
fnp-2627	196	85	also	also	ADV
fnp-2627	196	86	for	for	ADP
fnp-2627	196	87	pompe	pompe	PROPN
fnp-2627	196	88	disease	disease	PROPN
fnp-2627	196	89	)	)	PUNCT
fnp-2627	196	90	(	(	PUNCT
fnp-2627	196	91	vita	vita	NOUN
fnp-2627	196	92	et	et	PROPN
fnp-2627	196	93	al	al	PROPN
fnp-2627	196	94	.	.	PROPN
fnp-2627	196	95	,	,	PUNCT
fnp-2627	196	96	2019	2019	NUM
fnp-2627	196	97	)	)	PUNCT
fnp-2627	196	98	.	.	PUNCT
fnp-2627	197	1	initial	initial	ADJ
fnp-2627	197	2	results	result	NOUN
fnp-2627	197	3	that	that	PRON
fnp-2627	197	4	are	be	AUX
fnp-2627	197	5	available	available	ADJ
fnp-2627	197	6	to	to	ADP
fnp-2627	197	7	date	date	NOUN
fnp-2627	197	8	are	be	AUX
fnp-2627	197	9	promising	promise	VERB
fnp-2627	197	10	;	;	PUNCT
fnp-2627	197	11	thus	thus	ADV
fnp-2627	197	12	,	,	PUNCT
fnp-2627	197	13	with	with	ADP
fnp-2627	197	14	some	some	DET
fnp-2627	197	15	luck	luck	NOUN
fnp-2627	197	16	,	,	PUNCT
fnp-2627	197	17	at	at	ADP
fnp-2627	197	18	least	least	ADJ
fnp-2627	197	19	some	some	PRON
fnp-2627	197	20	of	of	ADP
fnp-2627	197	21	these	these	DET
fnp-2627	197	22	new	new	ADJ
fnp-2627	197	23	treatments	treatment	NOUN
fnp-2627	197	24	will	will	AUX
fnp-2627	197	25	prove	prove	VERB
fnp-2627	197	26	beneficial	beneficial	ADJ
fnp-2627	197	27	enough	enough	ADV
fnp-2627	197	28	to	to	PART
fnp-2627	197	29	be	be	AUX
fnp-2627	197	30	covered	cover	VERB
fnp-2627	197	31	in	in	ADP
fnp-2627	197	32	a	a	DET
fnp-2627	197	33	future	future	ADJ
fnp-2627	197	34	update	update	NOUN
fnp-2627	197	35	.	.	PUNCT
fnp-2627	198	1	at	at	ADP
fnp-2627	198	2	the	the	DET
fnp-2627	198	3	same	same	ADJ
fnp-2627	198	4	time	time	NOUN
fnp-2627	198	5	,	,	PUNCT
fnp-2627	198	6	all	all	DET
fnp-2627	198	7	these	these	DET
fnp-2627	198	8	new	new	ADJ
fnp-2627	198	9	gene	gene	NOUN
fnp-2627	198	10	therapies	therapy	NOUN
fnp-2627	198	11	are	be	AUX
fnp-2627	198	12	likely	likely	ADJ
fnp-2627	198	13	to	to	PART
fnp-2627	198	14	be	be	AUX
fnp-2627	198	15	highly	highly	ADV
fnp-2627	198	16	expensive	expensive	ADJ
fnp-2627	198	17	;	;	PUNCT
fnp-2627	198	18	for	for	ADP
fnp-2627	198	19	example	example	NOUN
fnp-2627	198	20	,	,	PUNCT
fnp-2627	198	21	the	the	DET
fnp-2627	198	22	list	list	NOUN
fnp-2627	198	23	price	price	NOUN
fnp-2627	198	24	of	of	ADP
fnp-2627	198	25	nusinersen	nusinersen	ADJ
fnp-2627	198	26	treatment	treatment	NOUN
fnp-2627	198	27	in	in	ADP
fnp-2627	198	28	the	the	DET
fnp-2627	198	29	us	us	PROPN
fnp-2627	198	30	is	be	AUX
fnp-2627	198	31	$	$	SYM
fnp-2627	198	32	750,000	750,000	NUM
fnp-2627	198	33	in	in	ADP
fnp-2627	198	34	the	the	DET
fnp-2627	198	35	first	first	ADJ
fnp-2627	198	36	year	year	NOUN
fnp-2627	198	37	and	and	CCONJ
fnp-2627	198	38	$	$	SYM
fnp-2627	198	39	375,000	375,000	NUM
fnp-2627	198	40	/	/	SYM
fnp-2627	198	41	year	year	NOUN
fnp-2627	198	42	after	after	ADP
fnp-2627	198	43	that	that	PRON
fnp-2627	198	44	.	.	PUNCT
fnp-2627	199	1	thus	thus	ADV
fnp-2627	199	2	,	,	PUNCT
fnp-2627	199	3	an	an	DET
fnp-2627	199	4	increase	increase	NOUN
fnp-2627	199	5	in	in	ADP
fnp-2627	199	6	the	the	DET
fnp-2627	199	7	availability	availability	NOUN
fnp-2627	199	8	of	of	ADP
fnp-2627	199	9	genetic	genetic	ADJ
fnp-2627	199	10	therapies	therapy	NOUN
fnp-2627	199	11	raises	raise	VERB
fnp-2627	199	12	important	important	ADJ
fnp-2627	199	13	socio	socio	NOUN
fnp-2627	199	14	-	-	PUNCT
fnp-2627	199	15	economic	economic	ADJ
fnp-2627	199	16	and	and	CCONJ
fnp-2627	199	17	ethical	ethical	ADJ
fnp-2627	199	18	questions	question	NOUN
fnp-2627	199	19	that	that	PRON
fnp-2627	199	20	will	will	AUX
fnp-2627	199	21	have	have	VERB
fnp-2627	199	22	to	to	PART
fnp-2627	199	23	be	be	AUX
fnp-2627	199	24	addressed	address	VERB
fnp-2627	199	25	before	before	SCONJ
fnp-2627	199	26	their	their	PRON
fnp-2627	199	27	full	full	ADJ
fnp-2627	199	28	benefits	benefit	NOUN
fnp-2627	199	29	can	can	AUX
fnp-2627	199	30	be	be	AUX
fnp-2627	199	31	realized	realize	VERB
fnp-2627	199	32	.	.	PUNCT
fnp-2627	200	1	disclosure	disclosure	NOUN
fnp-2627	200	2	statement	statement	NOUN
fnp-2627	200	3	the	the	DET
fnp-2627	200	4	author	author	NOUN
fnp-2627	200	5	is	be	AUX
fnp-2627	200	6	a	a	DET
fnp-2627	200	7	consultant	consultant	NOUN
fnp-2627	200	8	for	for	ADP
fnp-2627	200	9	audentes	audente	NOUN
fnp-2627	200	10	therapeutics	therapeutic	NOUN
fnp-2627	200	11	;	;	PUNCT
fnp-2627	200	12	she	she	PRON
fnp-2627	200	13	serves	serve	VERB
fnp-2627	200	14	as	as	ADP
fnp-2627	200	15	a	a	DET
fnp-2627	200	16	member	member	NOUN
fnp-2627	200	17	of	of	ADP
fnp-2627	200	18	the	the	DET
fnp-2627	200	19	muscle	muscle	NOUN
fnp-2627	200	20	biopsy	biopsy	PROPN
fnp-2627	200	21	review	review	PROPN
fnp-2627	200	22	committee	committee	PROPN
fnp-2627	200	23	for	for	ADP
fnp-2627	200	24	the	the	DET
fnp-2627	200	25	aspiro	aspiro	ADJ
fnp-2627	200	26	clinical	clinical	ADJ
fnp-2627	200	27	trial	trial	NOUN
fnp-2627	200	28	(	(	PUNCT
fnp-2627	200	29	nct03199469	nct03199469	ADJ
fnp-2627	200	30	)	)	PUNCT
fnp-2627	200	31	,	,	PUNCT
fnp-2627	200	32	which	which	PRON
fnp-2627	200	33	is	be	AUX
fnp-2627	200	34	evaluating	evaluate	VERB
fnp-2627	200	35	the	the	DET
fnp-2627	200	36	safety	safety	NOUN
fnp-2627	200	37	and	and	CCONJ
fnp-2627	200	38	efficacy	efficacy	NOUN
fnp-2627	200	39	of	of	ADP
fnp-2627	200	40	gene	gene	NOUN
fnp-2627	200	41	transfer	transfer	NOUN
fnp-2627	200	42	in	in	ADP
fnp-2627	200	43	x	x	ADJ
fnp-2627	200	44	-	-	ADJ
fnp-2627	200	45	linked	link	VERB
fnp-2627	200	46	myotubular	myotubular	ADJ
fnp-2627	200	47	myopathy	myopathy	NOUN
fnp-2627	200	48	.	.	PUNCT
fnp-2627	201	1	acknowledgements	acknowledgement	NOUN
fnp-2627	201	2	i	i	PRON
fnp-2627	201	3	am	be	AUX
fnp-2627	201	4	grateful	grateful	ADJ
fnp-2627	201	5	to	to	PART
fnp-2627	201	6	drs	drs	VERB
fnp-2627	201	7	.	.	PUNCT
fnp-2627	202	1	michael	michael	PROPN
fnp-2627	202	2	lawlor	lawlor	PROPN
fnp-2627	202	3	,	,	PUNCT
fnp-2627	202	4	nigel	nigel	PROPN
fnp-2627	202	5	g.	g.	PROPN
fnp-2627	202	6	laing	laing	PROPN
fnp-2627	202	7	,	,	PUNCT
fnp-2627	202	8	and	and	CCONJ
fnp-2627	202	9	benedikt	benedikt	NOUN
fnp-2627	202	10	schoser	schoser	NOUN
fnp-2627	202	11	for	for	ADP
fnp-2627	202	12	helpful	helpful	ADJ
fnp-2627	202	13	input	input	NOUN
fnp-2627	202	14	during	during	ADP
fnp-2627	202	15	the	the	DET
fnp-2627	202	16	conceptualization	conceptualization	NOUN
fnp-2627	202	17	stage	stage	NOUN
fnp-2627	202	18	of	of	ADP
fnp-2627	202	19	this	this	DET
fnp-2627	202	20	review	review	NOUN
fnp-2627	202	21	,	,	PUNCT
fnp-2627	202	22	to	to	ADP
fnp-2627	202	23	dr	dr	PROPN
fnp-2627	202	24	.	.	PROPN
fnp-2627	202	25	emily	emily	PROPN
fnp-2627	202	26	sloan	sloan	PROPN
fnp-2627	202	27	for	for	ADP
fnp-2627	202	28	n	n	CCONJ
fnp-2627	202	29	-	-	PUNCT
fnp-2627	202	30	scipt	scipt	NOUN
fnp-2627	202	31	images	image	NOUN
fnp-2627	202	32	,	,	PUNCT
fnp-2627	202	33	and	and	CCONJ
fnp-2627	202	34	to	to	ADP
fnp-2627	202	35	ms	ms	PROPN
fnp-2627	202	36	.	.	PROPN
fnp-2627	202	37	christine	christine	PROPN
fnp-2627	202	38	lin	lin	PROPN
fnp-2627	202	39	for	for	ADP
fnp-2627	202	40	assistance	assistance	NOUN
fnp-2627	202	41	with	with	ADP
fnp-2627	202	42	figure	figure	NOUN
fnp-2627	202	43	preparation	preparation	NOUN
fnp-2627	202	44	.	.	PUNCT
fnp-2627	203	1	this	this	DET
fnp-2627	203	2	work	work	NOUN
fnp-2627	203	3	was	be	AUX
fnp-2627	203	4	supported	support	VERB
fnp-2627	203	5	by	by	ADP
fnp-2627	203	6	the	the	DET
fnp-2627	203	7	muscular	muscular	ADJ
fnp-2627	203	8	dystrophy	dystrophy	NOUN
fnp-2627	203	9	association	association	NOUN
fnp-2627	203	10	grant	grant	NOUN
fnp-2627	203	11	mda514303	mda514303	X
fnp-2627	203	12	.	.	PUNCT
fnp-2627	204	1	references	reference	NOUN
fnp-2627	204	2	aartsma	aartsma	PROPN
fnp-2627	204	3	-	-	PUNCT
fnp-2627	204	4	rus	rus	PROPN
fnp-2627	204	5	,	,	PUNCT
fnp-2627	204	6	a.	a.	NOUN
fnp-2627	204	7	,	,	PUNCT
fnp-2627	204	8	and	and	CCONJ
fnp-2627	204	9	goemans	goeman	NOUN
fnp-2627	204	10	,	,	PUNCT
fnp-2627	204	11	n.	n.	NOUN
fnp-2627	204	12	(	(	PUNCT
fnp-2627	204	13	2019	2019	NUM
fnp-2627	204	14	)	)	PUNCT
fnp-2627	204	15	.	.	PUNCT
fnp-2627	205	1	a	a	DET
fnp-2627	205	2	sequel	sequel	NOUN
fnp-2627	205	3	to	to	ADP
fnp-2627	205	4	the	the	DET
fnp-2627	205	5	eteplirsen	eteplirsen	ADJ
fnp-2627	205	6	saga	saga	NOUN
fnp-2627	205	7	:	:	PUNCT
fnp-2627	205	8	eteplirsen	eteplirsen	NOUN
fnp-2627	205	9	is	be	AUX
fnp-2627	205	10	approved	approve	VERB
fnp-2627	205	11	in	in	ADP
fnp-2627	205	12	the	the	DET
fnp-2627	205	13	united	united	PROPN
fnp-2627	205	14	states	states	PROPN
fnp-2627	205	15	but	but	CCONJ
fnp-2627	205	16	was	be	AUX
fnp-2627	205	17	not	not	PART
fnp-2627	205	18	approved	approve	VERB
fnp-2627	205	19	in	in	ADP
fnp-2627	205	20	europe	europe	PROPN
fnp-2627	205	21	.	.	PUNCT
fnp-2627	206	1	nucleic	nucleic	ADJ
fnp-2627	206	2	acid	acid	PROPN
fnp-2627	206	3	ther	ther	PROPN
fnp-2627	206	4	29	29	NUM
fnp-2627	206	5	,	,	PUNCT
fnp-2627	206	6	13	13	NUM
fnp-2627	206	7	-	-	SYM
fnp-2627	206	8	15	15	NUM
fnp-2627	206	9	.	.	PUNCT
fnp-2627	207	1	allenbach	allenbach	PROPN
fnp-2627	207	2	,	,	PUNCT
fnp-2627	207	3	y.	y.	NOUN
fnp-2627	207	4	,	,	PUNCT
fnp-2627	207	5	benveniste	benveniste	VERB
fnp-2627	207	6	,	,	PUNCT
fnp-2627	207	7	o.	o.	NOUN
fnp-2627	207	8	,	,	PUNCT
fnp-2627	207	9	goebel	goebel	NOUN
fnp-2627	207	10	,	,	PUNCT
fnp-2627	207	11	h.h	h.h	PROPN
fnp-2627	207	12	.	.	PROPN
fnp-2627	207	13	,	,	PUNCT
fnp-2627	207	14	and	and	CCONJ
fnp-2627	207	15	stenzel	stenzel	PROPN
fnp-2627	207	16	,	,	PUNCT
fnp-2627	207	17	w.	w.	PROPN
fnp-2627	207	18	(	(	PUNCT
fnp-2627	207	19	2017	2017	NUM
fnp-2627	207	20	)	)	PUNCT
fnp-2627	207	21	.	.	PUNCT
fnp-2627	208	1	integrated	integrate	VERB
fnp-2627	208	2	classification	classification	NOUN
fnp-2627	208	3	of	of	ADP
fnp-2627	208	4	inflammatory	inflammatory	ADJ
fnp-2627	208	5	myopathies	myopathy	NOUN
fnp-2627	208	6	.	.	PUNCT
fnp-2627	209	1	neuropathol	neuropathol	PROPN
fnp-2627	209	2	appl	appl	PROPN
fnp-2627	209	3	neurobiol	neurobiol	PROPN
fnp-2627	209	4	43	43	NUM
fnp-2627	209	5	,	,	PUNCT
fnp-2627	209	6	62	62	NUM
fnp-2627	209	7	-	-	SYM
fnp-2627	209	8	81	81	NUM
fnp-2627	209	9	.	.	PUNCT
fnp-2627	210	1	allenbach	allenbach	PROPN
fnp-2627	210	2	,	,	PUNCT
fnp-2627	210	3	y.	y.	PROPN
fnp-2627	210	4	,	,	PUNCT
fnp-2627	210	5	mammen	mammen	PROPN
fnp-2627	210	6	,	,	PUNCT
fnp-2627	210	7	a.l	a.l	PROPN
fnp-2627	210	8	.	.	PROPN
fnp-2627	210	9	,	,	PUNCT
fnp-2627	210	10	benveniste	benveniste	VERB
fnp-2627	210	11	,	,	PUNCT
fnp-2627	210	12	o.	o.	PROPN
fnp-2627	210	13	,	,	PUNCT
fnp-2627	210	14	stenzel	stenzel	PROPN
fnp-2627	210	15	,	,	PUNCT
fnp-2627	210	16	w.	w.	PROPN
fnp-2627	210	17	,	,	PUNCT
fnp-2627	210	18	on	on	ADP
fnp-2627	210	19	behalf	behalf	NOUN
fnp-2627	210	20	of	of	ADP
fnp-2627	210	21	the	the	DET
fnp-2627	210	22	immune	immune	NOUN
fnp-2627	210	23	-	-	PUNCT
fnp-2627	210	24	mediated	mediate	VERB
fnp-2627	210	25	necrotizing	necrotizing	NOUN
fnp-2627	210	26	myopathies	myopathy	NOUN
fnp-2627	210	27	working	working	NOUN
fnp-2627	210	28	group	group	NOUN
fnp-2627	210	29	(	(	PUNCT
fnp-2627	210	30	2018	2018	NUM
fnp-2627	210	31	)	)	PUNCT
fnp-2627	210	32	.	.	PUNCT
fnp-2627	211	1	224th	224th	PROPN
fnp-2627	211	2	enmc	enmc	VERB
fnp-2627	211	3	international	international	ADJ
fnp-2627	211	4	workshop	workshop	NOUN
fnp-2627	211	5	:	:	PUNCT
fnp-2627	211	6	clinico	clinico	NOUN
fnp-2627	211	7	-	-	PUNCT
fnp-2627	211	8	sero	sero	ADJ
fnp-2627	211	9	-	-	PUNCT
fnp-2627	211	10	pathological	pathological	ADJ
fnp-2627	211	11	classification	classification	NOUN
fnp-2627	211	12	of	of	ADP
fnp-2627	211	13	immune	immune	NOUN
fnp-2627	211	14	-	-	PUNCT
fnp-2627	211	15	mediated	mediate	VERB
fnp-2627	211	16	necrotizing	necrotizing	NOUN
fnp-2627	211	17	myopathies	myopathy	NOUN
fnp-2627	211	18	zandvoort	zandvoort	NOUN
fnp-2627	211	19	,	,	PUNCT
fnp-2627	211	20	the	the	DET
fnp-2627	211	21	netherlands	netherlands	PROPN
fnp-2627	211	22	,	,	PUNCT
fnp-2627	211	23	14	14	NUM
fnp-2627	211	24	-	-	SYM
fnp-2627	211	25	16	16	NUM
fnp-2627	211	26	october	october	PROPN
fnp-2627	211	27	2016	2016	NUM
fnp-2627	211	28	.	.	PUNCT
fnp-2627	212	1	neuromuscul	neuromuscul	PROPN
fnp-2627	212	2	disord	disord	PROPN
fnp-2627	212	3	28	28	NUM
fnp-2627	212	4	,	,	PUNCT
fnp-2627	212	5	87	87	NUM
fnp-2627	212	6	-	-	SYM
fnp-2627	212	7	99	99	NUM
fnp-2627	212	8	.	.	PUNCT
fnp-2627	213	1	anquetil	anquetil	PROPN
fnp-2627	213	2	,	,	PUNCT
fnp-2627	213	3	c.	c.	PROPN
fnp-2627	213	4	,	,	PUNCT
fnp-2627	213	5	salem	salem	PROPN
fnp-2627	213	6	,	,	PUNCT
fnp-2627	213	7	j.e	j.e	PROPN
fnp-2627	213	8	.	.	PROPN
fnp-2627	213	9	,	,	PUNCT
fnp-2627	213	10	lebrun	lebrun	NOUN
fnp-2627	213	11	-	-	PUNCT
fnp-2627	213	12	vignes	vigne	NOUN
fnp-2627	213	13	,	,	PUNCT
fnp-2627	213	14	b.	b.	PROPN
fnp-2627	213	15	,	,	PUNCT
fnp-2627	213	16	johnson	johnson	PROPN
fnp-2627	213	17	,	,	PUNCT
fnp-2627	213	18	d.b	d.b	PROPN
fnp-2627	213	19	.	.	PROPN
fnp-2627	213	20	,	,	PUNCT
fnp-2627	213	21	mammen	mammen	PROPN
fnp-2627	213	22	,	,	PUNCT
fnp-2627	213	23	a.l	a.l	PROPN
fnp-2627	213	24	.	.	PROPN
fnp-2627	213	25	,	,	PUNCT
fnp-2627	213	26	stenzel	stenzel	PROPN
fnp-2627	213	27	,	,	PUNCT
fnp-2627	213	28	w.	w.	PROPN
fnp-2627	213	29	,	,	PUNCT
fnp-2627	213	30	leonard	leonard	PROPN
fnp-2627	213	31	-	-	PUNCT
fnp-2627	213	32	louis	louis	PROPN
fnp-2627	213	33	,	,	PUNCT
fnp-2627	213	34	s.	s.	PROPN
fnp-2627	213	35	,	,	PUNCT
fnp-2627	213	36	benveniste	benveniste	VERB
fnp-2627	213	37	,	,	PUNCT
fnp-2627	213	38	o.	o.	NOUN
fnp-2627	213	39	,	,	PUNCT
fnp-2627	213	40	moslehi	moslehi	PROPN
fnp-2627	213	41	,	,	PUNCT
fnp-2627	213	42	j.j	j.j	PROPN
fnp-2627	213	43	.	.	PROPN
fnp-2627	213	44	,	,	PUNCT
fnp-2627	213	45	and	and	CCONJ
fnp-2627	213	46	allenbach	allenbach	ADV
fnp-2627	213	47	,	,	PUNCT
fnp-2627	213	48	y.	y.	PROPN
fnp-2627	213	49	(	(	PUNCT
fnp-2627	213	50	2018	2018	NUM
fnp-2627	213	51	)	)	PUNCT
fnp-2627	213	52	.	.	PUNCT
fnp-2627	214	1	immune	immune	ADJ
fnp-2627	214	2	checkpoint	checkpoint	NOUN
fnp-2627	214	3	inhibitor	inhibitor	NOUN
fnp-2627	214	4	-	-	PUNCT
fnp-2627	214	5	associated	associate	VERB
fnp-2627	214	6	myositis	myositis	NOUN
fnp-2627	214	7	.	.	PUNCT
fnp-2627	215	1	circulation	circulation	NOUN
fnp-2627	215	2	138	138	NUM
fnp-2627	215	3	,	,	PUNCT
fnp-2627	215	4	743	743	NUM
fnp-2627	215	5	-	-	SYM
fnp-2627	215	6	745	745	NUM
fnp-2627	215	7	.	.	PUNCT
fnp-2627	216	1	al	al	PROPN
fnp-2627	216	2	-	-	PUNCT
fnp-2627	216	3	zaidy	zaidy	PROPN
fnp-2627	216	4	,	,	PUNCT
fnp-2627	216	5	s.a	s.a	PROPN
fnp-2627	216	6	.	.	PROPN
fnp-2627	216	7	,	,	PUNCT
fnp-2627	216	8	and	and	CCONJ
fnp-2627	216	9	mendell	mendell	PROPN
fnp-2627	216	10	,	,	PUNCT
fnp-2627	216	11	j.r	j.r	PROPN
fnp-2627	216	12	.	.	PROPN
fnp-2627	216	13	(	(	PUNCT
fnp-2627	216	14	2019	2019	NUM
fnp-2627	216	15	)	)	PUNCT
fnp-2627	216	16	.	.	PUNCT
fnp-2627	217	1	from	from	ADP
fnp-2627	217	2	clinical	clinical	ADJ
fnp-2627	217	3	trials	trial	NOUN
fnp-2627	217	4	to	to	ADP
fnp-2627	217	5	clinical	clinical	ADJ
fnp-2627	217	6	practice	practice	NOUN
fnp-2627	217	7	:	:	PUNCT
fnp-2627	217	8	practical	practical	ADJ
fnp-2627	217	9	considerations	consideration	NOUN
fnp-2627	217	10	for	for	ADP
fnp-2627	217	11	gene	gene	NOUN
fnp-2627	217	12	replacement	replacement	NOUN
fnp-2627	217	13	therapy	therapy	NOUN
fnp-2627	217	14	in	in	ADP
fnp-2627	217	15	sma	sma	PROPN
fnp-2627	217	16	type	type	NOUN
fnp-2627	217	17	1	1	NUM
fnp-2627	217	18	.	.	PUNCT
fnp-2627	217	19	pediatr	pediatr	ADJ
fnp-2627	217	20	neurol	neurol	NOUN
fnp-2627	217	21	100	100	NUM
fnp-2627	217	22	,	,	PUNCT
fnp-2627	217	23	3	3	NUM
fnp-2627	217	24	-	-	SYM
fnp-2627	217	25	11	11	NUM
fnp-2627	217	26	.	.	PUNCT
fnp-2627	217	27	arouche	arouche	PROPN
fnp-2627	217	28	-	-	PUNCT
fnp-2627	217	29	delaperche	delaperche	PROPN
fnp-2627	217	30	,	,	PUNCT
fnp-2627	217	31	l.	l.	PROPN
fnp-2627	217	32	,	,	PUNCT
fnp-2627	217	33	allenbach	allenbach	ADV
fnp-2627	217	34	,	,	PUNCT
fnp-2627	217	35	y.	y.	PROPN
fnp-2627	217	36	,	,	PUNCT
fnp-2627	217	37	amelin	amelin	PROPN
fnp-2627	217	38	,	,	PUNCT
fnp-2627	217	39	d.	d.	PROPN
fnp-2627	217	40	,	,	PUNCT
fnp-2627	217	41	preusse	preusse	PROPN
fnp-2627	217	42	,	,	PUNCT
fnp-2627	217	43	c.	c.	NOUN
fnp-2627	217	44	,	,	PUNCT
fnp-2627	217	45	mouly	mouly	ADV
fnp-2627	217	46	,	,	PUNCT
fnp-2627	217	47	v.	v.	ADV
fnp-2627	217	48	,	,	PUNCT
fnp-2627	217	49	mauhin	mauhin	NOUN
fnp-2627	217	50	,	,	PUNCT
fnp-2627	217	51	w.	w.	PROPN
fnp-2627	217	52	,	,	PUNCT
fnp-2627	217	53	tchoupou	tchoupou	NOUN
fnp-2627	217	54	,	,	PUNCT
fnp-2627	217	55	g.d	g.d	NOUN
fnp-2627	217	56	.	.	PROPN
fnp-2627	217	57	,	,	PUNCT
fnp-2627	217	58	drouot	drouot	PROPN
fnp-2627	217	59	,	,	PUNCT
fnp-2627	217	60	l.	l.	PROPN
fnp-2627	217	61	,	,	PUNCT
fnp-2627	217	62	boyer	boyer	PROPN
fnp-2627	217	63	,	,	PUNCT
fnp-2627	217	64	o.	o.	PROPN
fnp-2627	217	65	,	,	PUNCT
fnp-2627	217	66	stenzel	stenzel	PROPN
fnp-2627	217	67	,	,	PUNCT
fnp-2627	217	68	w.	w.	PROPN
fnp-2627	217	69	,	,	PUNCT
fnp-2627	217	70	et	et	PROPN
fnp-2627	217	71	al	al	PROPN
fnp-2627	217	72	.	.	PUNCT
fnp-2627	218	1	(	(	PUNCT
fnp-2627	218	2	2017	2017	NUM
fnp-2627	218	3	)	)	PUNCT
fnp-2627	218	4	.	.	PUNCT
fnp-2627	219	1	pathogenic	pathogenic	ADJ
fnp-2627	219	2	role	role	NOUN
fnp-2627	219	3	of	of	ADP
fnp-2627	219	4	anti	anti	ADJ
fnp-2627	219	5	-	-	ADJ
fnp-2627	219	6	signal	signal	ADJ
fnp-2627	219	7	recognition	recognition	NOUN
fnp-2627	219	8	protein	protein	NOUN
fnp-2627	219	9	and	and	CCONJ
fnp-2627	219	10	anti-3	anti-3	PROPN
fnp-2627	219	11	-	-	PUNCT
fnp-2627	219	12	hydroxy-3	hydroxy-3	PROPN
fnp-2627	219	13	-	-	PUNCT
fnp-2627	219	14	methylglutaryl	methylglutaryl	ADJ
fnp-2627	219	15	-	-	PUNCT
fnp-2627	219	16	coa	coa	NOUN
fnp-2627	219	17	reductase	reductase	NOUN
fnp-2627	219	18	antibodies	antibodie	VERB
fnp-2627	219	19	in	in	ADP
fnp-2627	219	20	necrotizing	necrotize	VERB
fnp-2627	219	21	myopathies	myopathy	NOUN
fnp-2627	219	22	:	:	PUNCT
fnp-2627	219	23	myofiber	myofiber	VERB
fnp-2627	219	24	atrophy	atrophy	NOUN
fnp-2627	219	25	and	and	CCONJ
fnp-2627	219	26	impairment	impairment	NOUN
fnp-2627	219	27	of	of	ADP
fnp-2627	219	28	muscle	muscle	NOUN
fnp-2627	219	29	regeneration	regeneration	NOUN
fnp-2627	219	30	in	in	ADP
fnp-2627	219	31	necrotizing	necrotize	VERB
fnp-2627	219	32	autoimmune	autoimmune	ADJ
fnp-2627	219	33	myopathies	myopathy	NOUN
fnp-2627	219	34	.	.	PUNCT
fnp-2627	220	1	ann	ann	PROPN
fnp-2627	220	2	neurol	neurol	PROPN
fnp-2627	220	3	81	81	NUM
fnp-2627	220	4	,	,	PUNCT
fnp-2627	220	5	538	538	NUM
fnp-2627	220	6	-	-	SYM
fnp-2627	220	7	548	548	NUM
fnp-2627	220	8	.	.	PUNCT
fnp-2627	221	1	bergua	bergua	NOUN
fnp-2627	221	2	,	,	PUNCT
fnp-2627	221	3	c.	c.	PROPN
fnp-2627	221	4	,	,	PUNCT
fnp-2627	221	5	chiavelli	chiavelli	PROPN
fnp-2627	221	6	,	,	PUNCT
fnp-2627	221	7	h.	h.	PROPN
fnp-2627	221	8	,	,	PUNCT
fnp-2627	221	9	allenbach	allenbach	ADV
fnp-2627	221	10	,	,	PUNCT
fnp-2627	221	11	y.	y.	PROPN
fnp-2627	221	12	,	,	PUNCT
fnp-2627	221	13	arouche	arouche	PROPN
fnp-2627	221	14	-	-	PUNCT
fnp-2627	221	15	delaperche	delaperche	PROPN
fnp-2627	221	16	,	,	PUNCT
fnp-2627	221	17	l.	l.	PROPN
fnp-2627	221	18	,	,	PUNCT
fnp-2627	221	19	arnoult	arnoult	PROPN
fnp-2627	221	20	,	,	PUNCT
fnp-2627	221	21	c.	c.	NOUN
fnp-2627	221	22	,	,	PUNCT
fnp-2627	221	23	bourdenet	bourdenet	NOUN
fnp-2627	221	24	,	,	PUNCT
fnp-2627	221	25	g.	g.	PROPN
fnp-2627	221	26	,	,	PUNCT
fnp-2627	221	27	jean	jean	PROPN
fnp-2627	221	28	,	,	PUNCT
fnp-2627	221	29	l.	l.	PROPN
fnp-2627	221	30	,	,	PUNCT
fnp-2627	221	31	zoubairi	zoubairi	PROPN
fnp-2627	221	32	,	,	PUNCT
fnp-2627	221	33	r.	r.	PROPN
fnp-2627	221	34	,	,	PUNCT
fnp-2627	221	35	guerout	guerout	PROPN
fnp-2627	221	36	,	,	PUNCT
fnp-2627	221	37	n.	n.	NOUN
fnp-2627	221	38	,	,	PUNCT
fnp-2627	221	39	mahler	mahler	PROPN
fnp-2627	221	40	,	,	PUNCT
fnp-2627	221	41	m.	m.	NOUN
fnp-2627	221	42	,	,	PUNCT
fnp-2627	221	43	et	et	PROPN
fnp-2627	221	44	al	al	PROPN
fnp-2627	221	45	.	.	PROPN
fnp-2627	221	46	(	(	PUNCT
fnp-2627	221	47	2019	2019	NUM
fnp-2627	221	48	)	)	PUNCT
fnp-2627	221	49	.	.	PUNCT
fnp-2627	222	1	in	in	ADP
fnp-2627	222	2	vivo	vivo	ADJ
fnp-2627	222	3	pathogenicity	pathogenicity	NOUN
fnp-2627	222	4	of	of	ADP
fnp-2627	222	5	igg	igg	PROPN
fnp-2627	222	6	from	from	ADP
fnp-2627	222	7	patients	patient	NOUN
fnp-2627	222	8	with	with	ADP
fnp-2627	222	9	anti	anti	ADJ
fnp-2627	222	10	-	-	ADJ
fnp-2627	222	11	srp	srp	ADJ
fnp-2627	222	12	or	or	CCONJ
fnp-2627	222	13	anti	anti	ADJ
fnp-2627	222	14	-	-	ADJ
fnp-2627	222	15	hmgcr	hmgcr	ADJ
fnp-2627	222	16	autoantibodies	autoantibody	NOUN
fnp-2627	222	17	in	in	ADP
fnp-2627	222	18	immune	immune	NOUN
fnp-2627	222	19	-	-	PUNCT
fnp-2627	222	20	mediated	mediate	VERB
fnp-2627	222	21	necrotising	necrotise	VERB
fnp-2627	222	22	myopathy	myopathy	NOUN
fnp-2627	222	23	.	.	PUNCT
fnp-2627	223	1	ann	ann	PROPN
fnp-2627	223	2	rheum	rheum	PROPN
fnp-2627	223	3	dis	dis	PROPN
fnp-2627	223	4	78	78	NUM
fnp-2627	223	5	,	,	PUNCT
fnp-2627	223	6	131	131	NUM
fnp-2627	223	7	-	-	SYM
fnp-2627	223	8	139	139	NUM
fnp-2627	223	9	.	.	PUNCT
fnp-2627	224	1	betteridge	betteridge	PROPN
fnp-2627	224	2	,	,	PUNCT
fnp-2627	224	3	z.	z.	PROPN
fnp-2627	224	4	,	,	PUNCT
fnp-2627	224	5	tansley	tansley	NOUN
fnp-2627	224	6	,	,	PUNCT
fnp-2627	224	7	s.	s.	PROPN
fnp-2627	224	8	,	,	PUNCT
fnp-2627	224	9	shaddick	shaddick	PROPN
fnp-2627	224	10	,	,	PUNCT
fnp-2627	224	11	g.	g.	PROPN
fnp-2627	224	12	,	,	PUNCT
fnp-2627	224	13	chinoy	chinoy	PROPN
fnp-2627	224	14	,	,	PUNCT
fnp-2627	224	15	h.	h.	PROPN
fnp-2627	224	16	,	,	PUNCT
fnp-2627	224	17	cooper	cooper	PROPN
fnp-2627	224	18	,	,	PUNCT
fnp-2627	224	19	r.g	r.g	PROPN
fnp-2627	224	20	.	.	PROPN
fnp-2627	224	21	,	,	PUNCT
fnp-2627	224	22	new	new	PROPN
fnp-2627	224	23	,	,	PUNCT
fnp-2627	224	24	r.p	r.p	PROPN
fnp-2627	224	25	.	.	PROPN
fnp-2627	224	26	,	,	PUNCT
fnp-2627	224	27	lilleker	lilleker	PROPN
fnp-2627	224	28	,	,	PUNCT
fnp-2627	224	29	j.b	j.b	PROPN
fnp-2627	224	30	.	.	PROPN
fnp-2627	224	31	,	,	PUNCT
fnp-2627	224	32	vencovsky	vencovsky	PROPN
fnp-2627	224	33	,	,	PUNCT
fnp-2627	224	34	j.	j.	PROPN
fnp-2627	224	35	,	,	PUNCT
fnp-2627	224	36	chazarain	chazarain	VERB
fnp-2627	224	37	,	,	PUNCT
fnp-2627	224	38	l.	l.	PROPN
fnp-2627	224	39	,	,	PUNCT
fnp-2627	224	40	danko	danko	PROPN
fnp-2627	224	41	,	,	PUNCT
fnp-2627	224	42	k.	k.	PROPN
fnp-2627	224	43	,	,	PUNCT
fnp-2627	224	44	et	et	PROPN
fnp-2627	224	45	al	al	PROPN
fnp-2627	224	46	.	.	PROPN
fnp-2627	225	1	(	(	PUNCT
fnp-2627	225	2	2019	2019	NUM
fnp-2627	225	3	)	)	PUNCT
fnp-2627	225	4	.	.	PUNCT
fnp-2627	226	1	frequency	frequency	NOUN
fnp-2627	226	2	,	,	PUNCT
fnp-2627	226	3	mutual	mutual	ADJ
fnp-2627	226	4	exclusivity	exclusivity	NOUN
fnp-2627	226	5	and	and	CCONJ
fnp-2627	226	6	clinical	clinical	ADJ
fnp-2627	226	7	associations	association	NOUN
fnp-2627	226	8	of	of	ADP
fnp-2627	226	9	myositis	myositis	NOUN
fnp-2627	226	10	autoantibodies	autoantibody	NOUN
fnp-2627	226	11	in	in	ADP
fnp-2627	226	12	a	a	DET
fnp-2627	226	13	combined	combine	VERB
fnp-2627	226	14	european	european	ADJ
fnp-2627	226	15	cohort	cohort	NOUN
fnp-2627	226	16	of	of	ADP
fnp-2627	226	17	idiopathic	idiopathic	ADJ
fnp-2627	226	18	inflammatory	inflammatory	ADJ
fnp-2627	226	19	myopathy	myopathy	ADJ
fnp-2627	226	20	patients	patient	NOUN
fnp-2627	226	21	.	.	PUNCT
fnp-2627	227	1	j	j	PROPN
fnp-2627	227	2	autoimmun	autoimmun	PROPN
fnp-2627	227	3	101	101	NUM
fnp-2627	227	4	,	,	PUNCT
fnp-2627	227	5	48	48	NUM
fnp-2627	227	6	-	-	SYM
fnp-2627	227	7	55	55	NUM
fnp-2627	227	8	.	.	PUNCT
fnp-2627	228	1	cummings	cummings	PROPN
fnp-2627	228	2	,	,	PUNCT
fnp-2627	228	3	b.b	b.b	PROPN
fnp-2627	228	4	.	.	PROPN
fnp-2627	228	5	,	,	PUNCT
fnp-2627	228	6	marshall	marshall	PROPN
fnp-2627	228	7	,	,	PUNCT
fnp-2627	228	8	j.l	j.l	PROPN
fnp-2627	228	9	.	.	PROPN
fnp-2627	228	10	,	,	PUNCT
fnp-2627	228	11	tukiainen	tukiainen	PROPN
fnp-2627	228	12	,	,	PUNCT
fnp-2627	228	13	t.	t.	PROPN
fnp-2627	228	14	,	,	PUNCT
fnp-2627	228	15	lek	lek	PROPN
fnp-2627	228	16	,	,	PUNCT
fnp-2627	228	17	m.	m.	NOUN
fnp-2627	228	18	,	,	PUNCT
fnp-2627	228	19	donkervoort	donkervoort	NOUN
fnp-2627	228	20	,	,	PUNCT
fnp-2627	228	21	s.	s.	PROPN
fnp-2627	228	22	,	,	PUNCT
fnp-2627	228	23	foley	foley	PROPN
fnp-2627	228	24	,	,	PUNCT
fnp-2627	228	25	a.r	a.r	PROPN
fnp-2627	228	26	.	.	PROPN
fnp-2627	228	27	,	,	PUNCT
fnp-2627	228	28	bolduc	bolduc	PROPN
fnp-2627	228	29	,	,	PUNCT
fnp-2627	228	30	v.	v.	PROPN
fnp-2627	228	31	,	,	PUNCT
fnp-2627	228	32	waddell	waddell	PROPN
fnp-2627	228	33	,	,	PUNCT
fnp-2627	228	34	l.b	l.b	PROPN
fnp-2627	228	35	.	.	PROPN
fnp-2627	228	36	,	,	PUNCT
fnp-2627	228	37	sandaradura	sandaradura	PROPN
fnp-2627	228	38	,	,	PUNCT
fnp-2627	228	39	s.a	s.a	PROPN
fnp-2627	228	40	.	.	PROPN
fnp-2627	228	41	,	,	PUNCT
fnp-2627	228	42	o'grady	o'grady	PROPN
fnp-2627	228	43	,	,	PUNCT
fnp-2627	228	44	g.l	g.l	PROPN
fnp-2627	228	45	.	.	PROPN
fnp-2627	228	46	,	,	PUNCT
fnp-2627	228	47	et	et	PROPN
fnp-2627	228	48	al	al	PROPN
fnp-2627	228	49	.	.	PUNCT
fnp-2627	228	50	(	(	PUNCT
fnp-2627	228	51	2017	2017	NUM
fnp-2627	228	52	)	)	PUNCT
fnp-2627	228	53	.	.	PUNCT
fnp-2627	229	1	improving	improve	VERB
fnp-2627	229	2	genetic	genetic	ADJ
fnp-2627	229	3	diagnosis	diagnosis	NOUN
fnp-2627	229	4	in	in	ADP
fnp-2627	229	5	mendelian	mendelian	ADJ
fnp-2627	229	6	disease	disease	NOUN
fnp-2627	229	7	with	with	ADP
fnp-2627	229	8	transcriptome	transcriptome	ADJ
fnp-2627	229	9	sequencing	sequencing	NOUN
fnp-2627	229	10	.	.	PUNCT
fnp-2627	230	1	sci	sci	PROPN
fnp-2627	230	2	transl	transl	PROPN
fnp-2627	230	3	med	me	VERB
fnp-2627	230	4	9	9	NUM
fnp-2627	230	5	.	.	PUNCT
fnp-2627	231	1	dabbous	dabbous	ADJ
fnp-2627	231	2	,	,	PUNCT
fnp-2627	231	3	o.	o.	PROPN
fnp-2627	231	4	,	,	PUNCT
fnp-2627	231	5	maru	maru	PROPN
fnp-2627	231	6	,	,	PUNCT
fnp-2627	231	7	b.	b.	PROPN
fnp-2627	231	8	,	,	PUNCT
fnp-2627	231	9	jansen	jansen	PROPN
fnp-2627	231	10	,	,	PUNCT
fnp-2627	231	11	j.p	j.p	PROPN
fnp-2627	231	12	.	.	PROPN
fnp-2627	231	13	,	,	PUNCT
fnp-2627	231	14	lorenzi	lorenzi	ADJ
fnp-2627	231	15	,	,	PUNCT
fnp-2627	231	16	m.	m.	NOUN
fnp-2627	231	17	,	,	PUNCT
fnp-2627	231	18	cloutier	cloutier	NOUN
fnp-2627	231	19	,	,	PUNCT
fnp-2627	231	20	m.	m.	NOUN
fnp-2627	231	21	,	,	PUNCT
fnp-2627	231	22	guerin	guerin	PROPN
fnp-2627	231	23	,	,	PUNCT
fnp-2627	231	24	a.	a.	PROPN
fnp-2627	231	25	,	,	PUNCT
fnp-2627	231	26	pivneva	pivneva	PROPN
fnp-2627	231	27	,	,	PUNCT
fnp-2627	231	28	i.	i.	PROPN
fnp-2627	231	29	,	,	PUNCT
fnp-2627	231	30	wu	wu	PROPN
fnp-2627	231	31	,	,	PUNCT
fnp-2627	231	32	e.q	e.q	PROPN
fnp-2627	231	33	.	.	PROPN
fnp-2627	231	34	,	,	PUNCT
fnp-2627	231	35	arjunji	arjunji	PROPN
fnp-2627	231	36	,	,	PUNCT
fnp-2627	231	37	r.	r.	PROPN
fnp-2627	231	38	,	,	PUNCT
fnp-2627	231	39	feltner	feltner	NOUN
fnp-2627	231	40	,	,	PUNCT
fnp-2627	231	41	d.	d.	PROPN
fnp-2627	231	42	,	,	PUNCT
fnp-2627	231	43	et	et	PROPN
fnp-2627	231	44	al	al	PROPN
fnp-2627	231	45	.	.	PROPN
fnp-2627	232	1	(	(	PUNCT
fnp-2627	232	2	2019	2019	NUM
fnp-2627	232	3	)	)	PUNCT
fnp-2627	232	4	.	.	PUNCT
fnp-2627	233	1	survival	survival	NOUN
fnp-2627	233	2	,	,	PUNCT
fnp-2627	233	3	motor	motor	NOUN
fnp-2627	233	4	function	function	NOUN
fnp-2627	233	5	,	,	PUNCT
fnp-2627	233	6	and	and	CCONJ
fnp-2627	233	7	motor	motor	NOUN
fnp-2627	233	8	milestones	milestone	NOUN
fnp-2627	233	9	:	:	PUNCT
fnp-2627	233	10	comparison	comparison	NOUN
fnp-2627	233	11	of	of	ADP
fnp-2627	233	12	avxs-101	avxs-101	NOUN
fnp-2627	233	13	relative	relative	ADJ
fnp-2627	233	14	to	to	PART
fnp-2627	233	15	nusinersen	nusinersen	VERB
fnp-2627	233	16	for	for	ADP
fnp-2627	233	17	the	the	DET
fnp-2627	233	18	treatment	treatment	NOUN
fnp-2627	233	19	of	of	ADP
fnp-2627	233	20	infants	infant	NOUN
fnp-2627	233	21	with	with	ADP
fnp-2627	233	22	spinal	spinal	ADJ
fnp-2627	233	23	muscular	muscular	ADJ
fnp-2627	233	24	atrophy	atrophy	NOUN
fnp-2627	233	25	type	type	NOUN
fnp-2627	233	26	1	1	NUM
fnp-2627	233	27	.	.	PUNCT
fnp-2627	234	1	adv	adv	PROPN
fnp-2627	234	2	ther	ther	VERB
fnp-2627	234	3	36	36	NUM
fnp-2627	234	4	,	,	PUNCT
fnp-2627	234	5	1164	1164	NUM
fnp-2627	234	6	-	-	SYM
fnp-2627	234	7	1176	1176	NUM
fnp-2627	234	8	.	.	PUNCT
fnp-2627	235	1	dangouloff	dangouloff	PROPN
fnp-2627	235	2	,	,	PUNCT
fnp-2627	235	3	t.	t.	PROPN
fnp-2627	235	4	,	,	PUNCT
fnp-2627	235	5	burghes	burghe	NOUN
fnp-2627	235	6	,	,	PUNCT
fnp-2627	235	7	a.	a.	NOUN
fnp-2627	235	8	,	,	PUNCT
fnp-2627	235	9	tizzano	tizzano	NOUN
fnp-2627	235	10	,	,	PUNCT
fnp-2627	235	11	e.f	e.f	PROPN
fnp-2627	235	12	.	.	PROPN
fnp-2627	235	13	,	,	PUNCT
fnp-2627	235	14	servais	servais	PROPN
fnp-2627	235	15	,	,	PUNCT
fnp-2627	235	16	l.	l.	PROPN
fnp-2627	235	17	,	,	PUNCT
fnp-2627	235	18	and	and	CCONJ
fnp-2627	235	19	group	group	NOUN
fnp-2627	235	20	,	,	PUNCT
fnp-2627	235	21	n.s.s	n.s.	NOUN
fnp-2627	235	22	.	.	PUNCT
fnp-2627	236	1	(	(	PUNCT
fnp-2627	236	2	2019	2019	NUM
fnp-2627	236	3	)	)	PUNCT
fnp-2627	236	4	.	.	PUNCT
fnp-2627	237	1	244th	244th	PROPN
fnp-2627	237	2	enmc	enmc	VERB
fnp-2627	237	3	international	international	ADJ
fnp-2627	237	4	workshop	workshop	NOUN
fnp-2627	237	5	:	:	PUNCT
fnp-2627	237	6	newborn	newborn	ADJ
fnp-2627	237	7	screening	screening	NOUN
fnp-2627	237	8	in	in	ADP
fnp-2627	237	9	spinal	spinal	ADJ
fnp-2627	237	10	muscular	muscular	ADJ
fnp-2627	237	11	atrophy	atrophy	NOUN
fnp-2627	237	12	may	may	AUX
fnp-2627	237	13	10	10	NUM
fnp-2627	237	14	-	-	SYM
fnp-2627	237	15	12	12	NUM
fnp-2627	237	16	,	,	PUNCT
fnp-2627	237	17	2019	2019	NUM
fnp-2627	237	18	,	,	PUNCT
fnp-2627	237	19	hoofdorp	hoofdorp	PROPN
fnp-2627	237	20	,	,	PUNCT
fnp-2627	237	21	the	the	DET
fnp-2627	237	22	netherlands	netherlands	PROPN
fnp-2627	237	23	.	.	PUNCT
fnp-2627	238	1	neuromuscul	neuromuscul	PROPN
fnp-2627	238	2	disord	disord	PROPN
fnp-2627	238	3	,	,	PUNCT
fnp-2627	238	4	epub	epub	NOUN
fnp-2627	238	5	ahead	ahead	ADV
fnp-2627	238	6	of	of	ADP
fnp-2627	238	7	print	print	NOUN
fnp-2627	238	8	.	.	PUNCT
fnp-2627	239	1	de	de	PROPN
fnp-2627	239	2	ridder	ridder	PROPN
fnp-2627	239	3	,	,	PUNCT
fnp-2627	239	4	w.	w.	PROPN
fnp-2627	239	5	,	,	PUNCT
fnp-2627	239	6	nelson	nelson	PROPN
fnp-2627	239	7	,	,	PUNCT
fnp-2627	239	8	i.	i.	PROPN
fnp-2627	239	9	,	,	PUNCT
fnp-2627	239	10	asselbergh	asselbergh	PROPN
fnp-2627	239	11	,	,	PUNCT
fnp-2627	239	12	b.	b.	PROPN
fnp-2627	239	13	,	,	PUNCT
fnp-2627	239	14	de	de	PROPN
fnp-2627	239	15	paepe	paepe	PROPN
fnp-2627	239	16	,	,	PUNCT
fnp-2627	239	17	b.	b.	PROPN
fnp-2627	239	18	,	,	PUNCT
fnp-2627	239	19	beuvin	beuvin	NOUN
fnp-2627	239	20	,	,	PUNCT
fnp-2627	239	21	m.	m.	NOUN
fnp-2627	239	22	,	,	PUNCT
fnp-2627	239	23	ben	ben	PROPN
fnp-2627	239	24	yaou	yaou	PROPN
fnp-2627	239	25	,	,	PUNCT
fnp-2627	239	26	r.	r.	PROPN
fnp-2627	239	27	,	,	PUNCT
fnp-2627	239	28	masson	masson	PROPN
fnp-2627	239	29	,	,	PUNCT
fnp-2627	239	30	c.	c.	PROPN
fnp-2627	239	31	,	,	PUNCT
fnp-2627	239	32	boland	boland	NOUN
fnp-2627	239	33	,	,	PUNCT
fnp-2627	239	34	a.	a.	PROPN
fnp-2627	239	35	,	,	PUNCT
fnp-2627	239	36	deleuze	deleuze	PROPN
fnp-2627	239	37	,	,	PUNCT
fnp-2627	239	38	j.f	j.f	PROPN
fnp-2627	239	39	.	.	PROPN
fnp-2627	239	40	,	,	PUNCT
fnp-2627	239	41	maisonobe	maisonobe	PROPN
fnp-2627	239	42	,	,	PUNCT
fnp-2627	239	43	t.	t.	PROPN
fnp-2627	239	44	,	,	PUNCT
fnp-2627	239	45	et	et	PROPN
fnp-2627	239	46	al	al	PROPN
fnp-2627	239	47	.	.	PROPN
fnp-2627	239	48	(	(	PUNCT
fnp-2627	239	49	2019	2019	NUM
fnp-2627	239	50	)	)	PUNCT
fnp-2627	239	51	.	.	PUNCT
fnp-2627	240	1	muscular	muscular	ADJ
fnp-2627	240	2	dystrophy	dystrophy	NOUN
fnp-2627	240	3	with	with	ADP
fnp-2627	240	4	arrhythmia	arrhythmia	NOUN
fnp-2627	240	5	caused	cause	VERB
fnp-2627	240	6	by	by	ADP
fnp-2627	240	7	loss	loss	NOUN
fnp-2627	240	8	-	-	PUNCT
fnp-2627	240	9	of	of	ADP
fnp-2627	240	10	-	-	PUNCT
fnp-2627	240	11	function	function	NOUN
fnp-2627	240	12	mutations	mutation	NOUN
fnp-2627	240	13	in	in	ADP
fnp-2627	240	14	bves	bve	NOUN
fnp-2627	240	15	.	.	PUNCT
fnp-2627	241	1	neurol	neurol	PROPN
fnp-2627	241	2	genet	genet	PROPN
fnp-2627	241	3	5	5	NUM
fnp-2627	241	4	,	,	PUNCT
fnp-2627	241	5	e321	e321	PROPN
fnp-2627	241	6	.	.	PUNCT
fnp-2627	241	7	de	de	X
fnp-2627	241	8	vivo	vivo	PROPN
fnp-2627	241	9	,	,	PUNCT
fnp-2627	241	10	d.c	d.c	PROPN
fnp-2627	241	11	.	.	PROPN
fnp-2627	241	12	,	,	PUNCT
fnp-2627	241	13	bertini	bertini	PROPN
fnp-2627	241	14	,	,	PUNCT
fnp-2627	241	15	e.	e.	PROPN
fnp-2627	241	16	,	,	PUNCT
fnp-2627	241	17	swoboda	swoboda	PROPN
fnp-2627	241	18	,	,	PUNCT
fnp-2627	241	19	k.j	k.j	PROPN
fnp-2627	241	20	.	.	PROPN
fnp-2627	241	21	,	,	PUNCT
fnp-2627	241	22	hwu	hwu	PROPN
fnp-2627	241	23	,	,	PUNCT
fnp-2627	241	24	w.l	w.l	PROPN
fnp-2627	241	25	.	.	PROPN
fnp-2627	241	26	,	,	PUNCT
fnp-2627	241	27	crawford	crawford	PROPN
fnp-2627	241	28	,	,	PUNCT
fnp-2627	241	29	t.o	t.o	PROPN
fnp-2627	241	30	.	.	PROPN
fnp-2627	241	31	,	,	PUNCT
fnp-2627	241	32	finkel	finkel	PROPN
fnp-2627	241	33	,	,	PUNCT
fnp-2627	241	34	r.s	r.s	PROPN
fnp-2627	241	35	.	.	PROPN
fnp-2627	241	36	,	,	PUNCT
fnp-2627	241	37	kirschner	kirschner	PROPN
fnp-2627	241	38	,	,	PUNCT
fnp-2627	241	39	j.	j.	PROPN
fnp-2627	241	40	,	,	PUNCT
fnp-2627	241	41	kuntz	kuntz	PROPN
fnp-2627	241	42	,	,	PUNCT
fnp-2627	241	43	n.l	n.l	PROPN
fnp-2627	241	44	.	.	PROPN
fnp-2627	241	45	,	,	PUNCT
fnp-2627	241	46	parsons	parsons	PROPN
fnp-2627	241	47	,	,	PUNCT
fnp-2627	241	48	j.a	j.a	PROPN
fnp-2627	241	49	.	.	PROPN
fnp-2627	241	50	,	,	PUNCT
fnp-2627	241	51	ryan	ryan	PROPN
fnp-2627	241	52	,	,	PUNCT
fnp-2627	241	53	m.m	m.m	PROPN
fnp-2627	241	54	.	.	PROPN
fnp-2627	241	55	,	,	PUNCT
fnp-2627	241	56	et	et	PROPN
fnp-2627	241	57	al	al	PROPN
fnp-2627	241	58	.	.	PROPN
fnp-2627	242	1	(	(	PUNCT
fnp-2627	242	2	2019	2019	NUM
fnp-2627	242	3	)	)	PUNCT
fnp-2627	242	4	.	.	PUNCT
fnp-2627	243	1	nusinersen	nusinersen	PROPN
fnp-2627	243	2	initiated	initiate	VERB
fnp-2627	243	3	in	in	ADP
fnp-2627	243	4	infants	infant	NOUN
fnp-2627	243	5	during	during	ADP
fnp-2627	243	6	the	the	DET
fnp-2627	243	7	presymptomatic	presymptomatic	ADJ
fnp-2627	243	8	stage	stage	NOUN
fnp-2627	243	9	of	of	ADP
fnp-2627	243	10	spinal	spinal	ADJ
fnp-2627	243	11	muscular	muscular	ADJ
fnp-2627	243	12	atrophy	atrophy	NOUN
fnp-2627	243	13	:	:	PUNCT
fnp-2627	243	14	interim	interim	ADJ
fnp-2627	243	15	efficacy	efficacy	NOUN
fnp-2627	243	16	and	and	CCONJ
fnp-2627	243	17	safety	safety	NOUN
fnp-2627	243	18	results	result	NOUN
fnp-2627	243	19	from	from	ADP
fnp-2627	243	20	the	the	DET
fnp-2627	243	21	phase	phase	NOUN
fnp-2627	243	22	2	2	NUM
fnp-2627	243	23	nurture	nurture	NOUN
fnp-2627	243	24	study	study	NOUN
fnp-2627	243	25	.	.	PUNCT
fnp-2627	244	1	neuromuscul	neuromuscul	PROPN
fnp-2627	244	2	disord	disord	PROPN
fnp-2627	244	3	29	29	NUM
fnp-2627	244	4	,	,	PUNCT
fnp-2627	244	5	842	842	NUM
fnp-2627	244	6	-	-	SYM
fnp-2627	244	7	856	856	NUM
fnp-2627	244	8	.	.	PUNCT
fnp-2627	245	1	de	de	PROPN
fnp-2627	245	2	winter	winter	NOUN
fnp-2627	245	3	,	,	PUNCT
fnp-2627	245	4	j.m	j.m	PROPN
fnp-2627	245	5	.	.	PROPN
fnp-2627	245	6	,	,	PUNCT
fnp-2627	245	7	molenaar	molenaar	PROPN
fnp-2627	245	8	,	,	PUNCT
fnp-2627	245	9	j.p	j.p	PROPN
fnp-2627	245	10	.	.	PROPN
fnp-2627	245	11	,	,	PUNCT
fnp-2627	245	12	yuen	yuen	PROPN
fnp-2627	245	13	,	,	PUNCT
fnp-2627	245	14	m.	m.	NOUN
fnp-2627	245	15	,	,	PUNCT
fnp-2627	245	16	van	van	PROPN
fnp-2627	245	17	der	der	PROPN
fnp-2627	245	18	pijl	pijl	PROPN
fnp-2627	245	19	,	,	PUNCT
fnp-2627	245	20	r.	r.	PROPN
fnp-2627	245	21	,	,	PUNCT
fnp-2627	245	22	shen	shen	PROPN
fnp-2627	245	23	,	,	PUNCT
fnp-2627	245	24	s.	s.	PROPN
fnp-2627	245	25	,	,	PUNCT
fnp-2627	245	26	conijn	conijn	PROPN
fnp-2627	245	27	,	,	PUNCT
fnp-2627	245	28	s.	s.	PROPN
fnp-2627	245	29	,	,	PUNCT
fnp-2627	245	30	van	van	PROPN
fnp-2627	245	31	de	de	PROPN
fnp-2627	245	32	locht	locht	PROPN
fnp-2627	245	33	,	,	PUNCT
fnp-2627	245	34	m.	m.	NOUN
fnp-2627	245	35	,	,	PUNCT
fnp-2627	245	36	willigenburg	willigenburg	NOUN
fnp-2627	245	37	,	,	PUNCT
fnp-2627	245	38	m.	m.	NOUN
fnp-2627	245	39	,	,	PUNCT
fnp-2627	245	40	bogaards	bogaard	NOUN
fnp-2627	245	41	,	,	PUNCT
fnp-2627	245	42	s.j	s.j	PROPN
fnp-2627	245	43	.	.	PROPN
fnp-2627	245	44	,	,	PUNCT
fnp-2627	245	45	van	van	PROPN
fnp-2627	245	46	kleef	kleef	PROPN
fnp-2627	245	47	,	,	PUNCT
fnp-2627	245	48	e.s	e.s	PROPN
fnp-2627	245	49	.	.	PROPN
fnp-2627	245	50	,	,	PUNCT
fnp-2627	245	51	et	et	PROPN
fnp-2627	245	52	al	al	PROPN
fnp-2627	245	53	.	.	PROPN
fnp-2627	246	1	(	(	PUNCT
fnp-2627	246	2	2020	2020	NUM
fnp-2627	246	3	)	)	PUNCT
fnp-2627	246	4	.	.	PUNCT
fnp-2627	247	1	kbtbd13	kbtbd13	PROPN
fnp-2627	247	2	is	be	AUX
fnp-2627	247	3	an	an	DET
fnp-2627	247	4	actin	actin	NOUN
fnp-2627	247	5	-	-	PUNCT
fnp-2627	247	6	binding	bind	VERB
fnp-2627	247	7	protein	protein	NOUN
fnp-2627	247	8	that	that	PRON
fnp-2627	247	9	modulates	modulate	VERB
fnp-2627	247	10	muscle	muscle	NOUN
fnp-2627	247	11	kinetics	kinetic	NOUN
fnp-2627	247	12	.	.	PUNCT
fnp-2627	248	1	j	j	PROPN
fnp-2627	248	2	clin	clin	PROPN
fnp-2627	248	3	invest	invest	PROPN
fnp-2627	248	4	,	,	PUNCT
fnp-2627	248	5	epub	epub	NOUN
fnp-2627	248	6	ahead	ahead	ADV
fnp-2627	248	7	of	of	ADP
fnp-2627	248	8	print	print	NOUN
fnp-2627	248	9	.	.	PUNCT
fnp-2627	249	1	dyda	dyda	PROPN
fnp-2627	249	2	,	,	PUNCT
fnp-2627	249	3	a.	a.	NOUN
fnp-2627	249	4	,	,	PUNCT
fnp-2627	249	5	stelzer	stelzer	NOUN
fnp-2627	249	6	-	-	PUNCT
fnp-2627	249	7	braid	braid	NOUN
fnp-2627	249	8	,	,	PUNCT
fnp-2627	249	9	s.	s.	PROPN
fnp-2627	249	10	,	,	PUNCT
fnp-2627	249	11	adam	adam	PROPN
fnp-2627	249	12	,	,	PUNCT
fnp-2627	249	13	d.	d.	PROPN
fnp-2627	249	14	,	,	PUNCT
fnp-2627	249	15	chughtai	chughtai	PROPN
fnp-2627	249	16	,	,	PUNCT
fnp-2627	249	17	a.a	a.a	PROPN
fnp-2627	249	18	.	.	PROPN
fnp-2627	249	19	,	,	PUNCT
fnp-2627	249	20	and	and	CCONJ
fnp-2627	249	21	macintyre	macintyre	PROPN
fnp-2627	249	22	,	,	PUNCT
fnp-2627	249	23	c.r	c.r	PROPN
fnp-2627	249	24	.	.	PROPN
fnp-2627	249	25	(	(	PUNCT
fnp-2627	249	26	2018	2018	NUM
fnp-2627	249	27	)	)	PUNCT
fnp-2627	249	28	.	.	PUNCT
fnp-2627	250	1	the	the	DET
fnp-2627	250	2	association	association	NOUN
fnp-2627	250	3	between	between	ADP
fnp-2627	250	4	acute	acute	ADJ
fnp-2627	250	5	flaccid	flaccid	ADJ
fnp-2627	250	6	myelitis	myelitis	NOUN
fnp-2627	250	7	(	(	PUNCT
fnp-2627	250	8	afm	afm	PROPN
fnp-2627	250	9	)	)	PUNCT
fnp-2627	250	10	and	and	CCONJ
fnp-2627	250	11	enterovirus	enterovirus	NOUN
fnp-2627	250	12	d68	d68	NOUN
fnp-2627	250	13	(	(	PUNCT
fnp-2627	250	14	ev	ev	NOUN
fnp-2627	250	15	-	-	PUNCT
fnp-2627	250	16	d68	d68	NOUN
fnp-2627	250	17	)	)	PUNCT
fnp-2627	250	18	what	what	PRON
fnp-2627	250	19	is	be	AUX
fnp-2627	250	20	the	the	DET
fnp-2627	250	21	evidence	evidence	NOUN
fnp-2627	250	22	for	for	ADP
fnp-2627	250	23	causation	causation	NOUN
fnp-2627	250	24	?	?	PUNCT
fnp-2627	251	1	euro	euro	NOUN
fnp-2627	251	2	surveill	surveill	NOUN
fnp-2627	251	3	23	23	NUM
fnp-2627	251	4	.	.	PUNCT
fnp-2627	252	1	dzangue	dzangue	NOUN
fnp-2627	252	2	-	-	PUNCT
fnp-2627	252	3	tchoupou	tchoupou	NOUN
fnp-2627	252	4	,	,	PUNCT
fnp-2627	252	5	g.	g.	PROPN
fnp-2627	252	6	,	,	PUNCT
fnp-2627	252	7	mariampillai	mariampillai	NOUN
fnp-2627	252	8	,	,	PUNCT
fnp-2627	252	9	k.	k.	PROPN
fnp-2627	252	10	,	,	PUNCT
fnp-2627	252	11	bolko	bolko	PROPN
fnp-2627	252	12	,	,	PUNCT
fnp-2627	252	13	l.	l.	PROPN
fnp-2627	252	14	,	,	PUNCT
fnp-2627	252	15	amelin	amelin	PROPN
fnp-2627	252	16	,	,	PUNCT
fnp-2627	252	17	d.	d.	PROPN
fnp-2627	252	18	,	,	PUNCT
fnp-2627	252	19	mauhin	mauhin	PROPN
fnp-2627	252	20	,	,	PUNCT
fnp-2627	252	21	w.	w.	PROPN
fnp-2627	252	22	,	,	PUNCT
fnp-2627	252	23	corneau	corneau	PROPN
fnp-2627	252	24	,	,	PUNCT
fnp-2627	252	25	a.	a.	NOUN
fnp-2627	252	26	,	,	PUNCT
fnp-2627	252	27	blanc	blanc	NOUN
fnp-2627	252	28	,	,	PUNCT
fnp-2627	252	29	c.	c.	PROPN
fnp-2627	252	30	,	,	PUNCT
fnp-2627	252	31	allenbach	allenbach	ADV
fnp-2627	252	32	,	,	PUNCT
fnp-2627	252	33	y.	y.	PROPN
fnp-2627	252	34	,	,	PUNCT
fnp-2627	252	35	and	and	CCONJ
fnp-2627	252	36	benveniste	benveniste	VERB
fnp-2627	252	37	,	,	PUNCT
fnp-2627	252	38	o.	o.	NOUN
fnp-2627	252	39	(	(	PUNCT
fnp-2627	252	40	2019	2019	NUM
fnp-2627	252	41	)	)	PUNCT
fnp-2627	252	42	.	.	PUNCT
fnp-2627	253	1	cd8+t	cd8+t	NOUN
fnp-2627	253	2	-	-	PUNCT
fnp-2627	253	3	bet+	bet+	PROPN
fnp-2627	253	4	cells	cell	NOUN
fnp-2627	253	5	as	as	ADP
fnp-2627	253	6	a	a	DET
fnp-2627	253	7	predominant	predominant	ADJ
fnp-2627	253	8	biomarker	biomarker	NOUN
fnp-2627	253	9	for	for	ADP
fnp-2627	253	10	inclusion	inclusion	NOUN
fnp-2627	253	11	body	body	NOUN
fnp-2627	253	12	myositis	myositis	NOUN
fnp-2627	253	13	.	.	PUNCT
fnp-2627	254	1	autoimmun	autoimmun	PROPN
fnp-2627	254	2	rev	rev	VERB
fnp-2627	254	3	18	18	NUM
fnp-2627	254	4	,	,	PUNCT
fnp-2627	254	5	325	325	NUM
fnp-2627	254	6	-	-	SYM
fnp-2627	254	7	333	333	NUM
fnp-2627	254	8	.	.	PUNCT
fnp-2627	255	1	fischer	fischer	PROPN
fnp-2627	255	2	,	,	PUNCT
fnp-2627	255	3	n.	n.	NOUN
fnp-2627	255	4	,	,	PUNCT
fnp-2627	255	5	preusse	preusse	NOUN
fnp-2627	255	6	,	,	PUNCT
fnp-2627	255	7	c.	c.	PROPN
fnp-2627	255	8	,	,	PUNCT
fnp-2627	255	9	radke	radke	PROPN
fnp-2627	255	10	,	,	PUNCT
fnp-2627	255	11	j.	j.	PROPN
fnp-2627	255	12	,	,	PUNCT
fnp-2627	255	13	pehl	pehl	PROPN
fnp-2627	255	14	,	,	PUNCT
fnp-2627	255	15	d.	d.	PROPN
fnp-2627	255	16	,	,	PUNCT
fnp-2627	255	17	allenbach	allenbach	ADV
fnp-2627	255	18	,	,	PUNCT
fnp-2627	255	19	y.	y.	PROPN
fnp-2627	255	20	,	,	PUNCT
fnp-2627	255	21	schneider	schneider	PROPN
fnp-2627	255	22	,	,	PUNCT
fnp-2627	255	23	u.	u.	PROPN
fnp-2627	255	24	,	,	PUNCT
fnp-2627	255	25	feist	feist	PROPN
fnp-2627	255	26	,	,	PUNCT
fnp-2627	255	27	e.	e.	PROPN
fnp-2627	255	28	,	,	PUNCT
fnp-2627	255	29	von	von	PROPN
fnp-2627	255	30	casteleyn	casteleyn	PROPN
fnp-2627	255	31	,	,	PUNCT
fnp-2627	255	32	v.	v.	PROPN
fnp-2627	255	33	,	,	PUNCT
fnp-2627	255	34	hahn	hahn	PROPN
fnp-2627	255	35	,	,	PUNCT
fnp-2627	255	36	k.	k.	PROPN
fnp-2627	255	37	,	,	PUNCT
fnp-2627	255	38	ruck	ruck	NOUN
fnp-2627	255	39	,	,	PUNCT
fnp-2627	255	40	t.	t.	PROPN
fnp-2627	255	41	,	,	PUNCT
fnp-2627	255	42	et	et	PROPN
fnp-2627	255	43	al	al	PROPN
fnp-2627	255	44	.	.	PROPN
fnp-2627	255	45	(	(	PUNCT
fnp-2627	255	46	2019	2019	NUM
fnp-2627	255	47	)	)	PUNCT
fnp-2627	255	48	.	.	PUNCT
fnp-2627	256	1	sequestosome-1	sequestosome-1	NUM
fnp-2627	256	2	(	(	PUNCT
fnp-2627	256	3	p62	p62	NOUN
fnp-2627	256	4	)	)	PUNCT
fnp-2627	256	5	expression	expression	NOUN
fnp-2627	256	6	reveals	reveal	VERB
fnp-2627	256	7	chaperone	chaperone	NOUN
fnp-2627	256	8	-	-	PUNCT
fnp-2627	256	9	assisted	assist	VERB
fnp-2627	256	10	selective	selective	ADJ
fnp-2627	256	11	autophagy	autophagy	NOUN
fnp-2627	256	12	in	in	ADP
fnp-2627	256	13	immune	immune	NOUN
fnp-2627	256	14	-	-	PUNCT
fnp-2627	256	15	mediated	mediate	VERB
fnp-2627	256	16	necrotizing	necrotizing	NOUN
fnp-2627	256	17	myopathies	myopathy	NOUN
fnp-2627	256	18	.	.	PUNCT
fnp-2627	257	1	brain	brain	NOUN
fnp-2627	257	2	pathol	pathol	NOUN
fnp-2627	257	3	,	,	PUNCT
fnp-2627	257	4	epub	epub	NOUN
fnp-2627	257	5	ahead	ahead	ADV
fnp-2627	257	6	of	of	ADP
fnp-2627	257	7	print	print	NOUN
fnp-2627	257	8	.	.	PUNCT
fnp-2627	258	1	gonorazky	gonorazky	PROPN
fnp-2627	258	2	,	,	PUNCT
fnp-2627	258	3	h.d	h.d	PROPN
fnp-2627	258	4	.	.	PROPN
fnp-2627	258	5	,	,	PUNCT
fnp-2627	258	6	naumenko	naumenko	PROPN
fnp-2627	258	7	,	,	PUNCT
fnp-2627	258	8	s.	s.	PROPN
fnp-2627	258	9	,	,	PUNCT
fnp-2627	258	10	ramani	ramani	PROPN
fnp-2627	258	11	,	,	PUNCT
fnp-2627	258	12	a.k	a.k	PROPN
fnp-2627	258	13	.	.	PROPN
fnp-2627	258	14	,	,	PUNCT
fnp-2627	258	15	nelakuditi	nelakuditi	PROPN
fnp-2627	258	16	,	,	PUNCT
fnp-2627	258	17	v.	v.	PROPN
fnp-2627	258	18	,	,	PUNCT
fnp-2627	258	19	mashouri	mashouri	PROPN
fnp-2627	258	20	,	,	PUNCT
fnp-2627	258	21	p.	p.	PROPN
fnp-2627	258	22	,	,	PUNCT
fnp-2627	258	23	wang	wang	PROPN
fnp-2627	258	24	,	,	PUNCT
fnp-2627	258	25	p.	p.	PROPN
fnp-2627	258	26	,	,	PUNCT
fnp-2627	258	27	kao	kao	PROPN
fnp-2627	258	28	,	,	PUNCT
fnp-2627	258	29	d.	d.	PROPN
fnp-2627	258	30	,	,	PUNCT
fnp-2627	258	31	ohri	ohri	PROPN
fnp-2627	258	32	,	,	PUNCT
fnp-2627	258	33	k.	k.	PROPN
fnp-2627	258	34	,	,	PUNCT
fnp-2627	258	35	viththiyapaskaran	viththiyapaskaran	PROPN
fnp-2627	258	36	,	,	PUNCT
fnp-2627	258	37	s.	s.	PROPN
fnp-2627	258	38	,	,	PUNCT
fnp-2627	258	39	tarnopolsky	tarnopolsky	PROPN
fnp-2627	258	40	,	,	PUNCT
fnp-2627	258	41	m.a	m.a	PROPN
fnp-2627	258	42	.	.	PROPN
fnp-2627	258	43	,	,	PUNCT
fnp-2627	258	44	et	et	PROPN
fnp-2627	258	45	al	al	PROPN
fnp-2627	258	46	.	.	PROPN
fnp-2627	258	47	(	(	PUNCT
fnp-2627	258	48	2019	2019	NUM
fnp-2627	258	49	)	)	PUNCT
fnp-2627	258	50	.	.	PUNCT
fnp-2627	259	1	expanding	expand	VERB
fnp-2627	259	2	the	the	DET
fnp-2627	259	3	boundaries	boundary	NOUN
fnp-2627	259	4	of	of	ADP
fnp-2627	259	5	rna	rna	NOUN
fnp-2627	259	6	sequencing	sequence	VERB
fnp-2627	259	7	as	as	ADP
fnp-2627	259	8	a	a	DET
fnp-2627	259	9	diagnostic	diagnostic	ADJ
fnp-2627	259	10	tool	tool	NOUN
fnp-2627	259	11	for	for	ADP
fnp-2627	259	12	rare	rare	ADJ
fnp-2627	259	13	mendelian	mendelian	ADJ
fnp-2627	259	14	disease	disease	NOUN
fnp-2627	259	15	.	.	PUNCT
fnp-2627	260	1	am	be	AUX
fnp-2627	260	2	j	j	PROPN
fnp-2627	260	3	hum	hum	PROPN
fnp-2627	260	4	genet	genet	PROPN
fnp-2627	260	5	104	104	NUM
fnp-2627	260	6	,	,	PUNCT
fnp-2627	260	7	466	466	NUM
fnp-2627	260	8	-	-	SYM
fnp-2627	260	9	483	483	NUM
fnp-2627	260	10	.	.	PUNCT
fnp-2627	261	1	greenberg	greenberg	PROPN
fnp-2627	261	2	,	,	PUNCT
fnp-2627	261	3	s.a	s.a	PROPN
fnp-2627	261	4	.	.	PROPN
fnp-2627	261	5	,	,	PUNCT
fnp-2627	261	6	pinkus	pinku	NOUN
fnp-2627	261	7	,	,	PUNCT
fnp-2627	261	8	j.l	j.l	PROPN
fnp-2627	261	9	.	.	PROPN
fnp-2627	261	10	,	,	PUNCT
fnp-2627	261	11	kong	kong	PROPN
fnp-2627	261	12	,	,	PUNCT
fnp-2627	261	13	s.w	s.w	PROPN
fnp-2627	261	14	.	.	PROPN
fnp-2627	261	15	,	,	PUNCT
fnp-2627	261	16	baecher	baecher	PROPN
fnp-2627	261	17	-	-	PUNCT
fnp-2627	261	18	allan	allan	PROPN
fnp-2627	261	19	,	,	PUNCT
fnp-2627	261	20	c.	c.	PROPN
fnp-2627	261	21	,	,	PUNCT
fnp-2627	261	22	amato	amato	PROPN
fnp-2627	261	23	,	,	PUNCT
fnp-2627	261	24	a.a	a.a	PROPN
fnp-2627	261	25	.	.	PROPN
fnp-2627	261	26	,	,	PUNCT
fnp-2627	261	27	and	and	CCONJ
fnp-2627	261	28	dorfman	dorfman	PROPN
fnp-2627	261	29	,	,	PUNCT
fnp-2627	261	30	d.m	d.m	PROPN
fnp-2627	261	31	.	.	PUNCT
fnp-2627	261	32	(	(	PUNCT
fnp-2627	261	33	2019	2019	NUM
fnp-2627	261	34	)	)	PUNCT
fnp-2627	261	35	.	.	PUNCT
fnp-2627	262	1	highly	highly	ADV
fnp-2627	262	2	differentiated	differentiate	VERB
fnp-2627	262	3	cytotoxic	cytotoxic	ADJ
fnp-2627	262	4	t	t	NOUN
fnp-2627	262	5	cells	cell	NOUN
fnp-2627	262	6	in	in	ADP
fnp-2627	262	7	inclusion	inclusion	NOUN
fnp-2627	262	8	body	body	NOUN
fnp-2627	262	9	myositis	myositis	NOUN
fnp-2627	262	10	.	.	PUNCT
fnp-2627	263	1	brain	brain	PROPN
fnp-2627	263	2	142	142	NUM
fnp-2627	263	3	,	,	PUNCT
fnp-2627	263	4	2590	2590	NUM
fnp-2627	263	5	-	-	SYM
fnp-2627	263	6	2604	2604	NUM
fnp-2627	263	7	.	.	PUNCT
fnp-2627	264	1	hixon	hixon	PROPN
fnp-2627	264	2	,	,	PUNCT
fnp-2627	264	3	a.m.	a.m.	ADV
fnp-2627	264	4	,	,	PUNCT
fnp-2627	264	5	yu	yu	PROPN
fnp-2627	264	6	,	,	PUNCT
fnp-2627	264	7	g.	g.	PROPN
fnp-2627	264	8	,	,	PUNCT
fnp-2627	264	9	leser	leser	PROPN
fnp-2627	264	10	,	,	PUNCT
fnp-2627	264	11	j.s	j.s	PROPN
fnp-2627	264	12	.	.	PROPN
fnp-2627	264	13	,	,	PUNCT
fnp-2627	264	14	yagi	yagi	PROPN
fnp-2627	264	15	,	,	PUNCT
fnp-2627	264	16	s.	s.	PROPN
fnp-2627	264	17	,	,	PUNCT
fnp-2627	264	18	clarke	clarke	PROPN
fnp-2627	264	19	,	,	PUNCT
fnp-2627	264	20	p.	p.	PROPN
fnp-2627	264	21	,	,	PUNCT
fnp-2627	264	22	chiu	chiu	PROPN
fnp-2627	264	23	,	,	PUNCT
fnp-2627	264	24	c.y	c.y	PROPN
fnp-2627	264	25	.	.	PROPN
fnp-2627	264	26	,	,	PUNCT
fnp-2627	264	27	and	and	CCONJ
fnp-2627	264	28	tyler	tyler	PROPN
fnp-2627	264	29	,	,	PUNCT
fnp-2627	264	30	k.l	k.l	PROPN
fnp-2627	264	31	.	.	PROPN
fnp-2627	264	32	(	(	PUNCT
fnp-2627	264	33	2017	2017	NUM
fnp-2627	264	34	)	)	PUNCT
fnp-2627	264	35	.	.	PUNCT
fnp-2627	265	1	a	a	DET
fnp-2627	265	2	mouse	mouse	NOUN
fnp-2627	265	3	model	model	NOUN
fnp-2627	265	4	of	of	ADP
fnp-2627	265	5	paralytic	paralytic	ADJ
fnp-2627	265	6	myelitis	myelitis	NOUN
fnp-2627	265	7	caused	cause	VERB
fnp-2627	265	8	by	by	ADP
fnp-2627	265	9	enterovirus	enterovirus	NOUN
fnp-2627	265	10	d68	d68	NOUN
fnp-2627	265	11	.	.	PUNCT
fnp-2627	266	1	plos	plos	PROPN
fnp-2627	266	2	pathog	pathog	VERB
fnp-2627	266	3	13	13	NUM
fnp-2627	266	4	,	,	PUNCT
fnp-2627	266	5	e1006199	e1006199	PROPN
fnp-2627	266	6	.	.	PUNCT
fnp-2627	267	1	hwang	hwang	PROPN
fnp-2627	267	2	,	,	PUNCT
fnp-2627	267	3	j.	j.	PROPN
fnp-2627	267	4	,	,	PUNCT
fnp-2627	267	5	and	and	CCONJ
fnp-2627	267	6	yokota	yokota	NOUN
fnp-2627	267	7	,	,	PUNCT
fnp-2627	267	8	t.	t.	PROPN
fnp-2627	267	9	(	(	PUNCT
fnp-2627	267	10	2019	2019	NUM
fnp-2627	267	11	)	)	PUNCT
fnp-2627	267	12	.	.	PUNCT
fnp-2627	268	1	recent	recent	ADJ
fnp-2627	268	2	advancements	advancement	NOUN
fnp-2627	268	3	in	in	ADP
fnp-2627	268	4	exon	exon	NOUN
fnp-2627	268	5	-	-	PUNCT
fnp-2627	268	6	skipping	skip	VERB
fnp-2627	268	7	therapies	therapy	NOUN
fnp-2627	268	8	using	use	VERB
fnp-2627	268	9	antisense	antisense	NOUN
fnp-2627	268	10	oligonucleotides	oligonucleotide	NOUN
fnp-2627	268	11	and	and	CCONJ
fnp-2627	268	12	genome	genome	NOUN
fnp-2627	268	13	editing	editing	NOUN
fnp-2627	268	14	for	for	ADP
fnp-2627	268	15	the	the	DET
fnp-2627	268	16	treatment	treatment	NOUN
fnp-2627	268	17	of	of	ADP
fnp-2627	268	18	various	various	ADJ
fnp-2627	268	19	muscular	muscular	ADJ
fnp-2627	268	20	dystrophies	dystrophy	NOUN
fnp-2627	268	21	.	.	PUNCT
fnp-2627	269	1	expert	expert	PROPN
fnp-2627	269	2	rev	rev	PROPN
fnp-2627	269	3	mol	mol	ADP
fnp-2627	269	4	med	med	PROPN
fnp-2627	269	5	21	21	NUM
fnp-2627	269	6	,	,	PUNCT
fnp-2627	269	7	e5	e5	PROPN
fnp-2627	269	8	.	.	PUNCT
fnp-2627	270	1	johansen	johansen	PROPN
fnp-2627	270	2	,	,	PUNCT
fnp-2627	270	3	a.	a.	PROPN
fnp-2627	270	4	,	,	PUNCT
fnp-2627	270	5	christensen	christensen	PROPN
fnp-2627	270	6	,	,	PUNCT
fnp-2627	270	7	s.j	s.j	PROPN
fnp-2627	270	8	.	.	PROPN
fnp-2627	270	9	,	,	PUNCT
fnp-2627	270	10	scheie	scheie	PROPN
fnp-2627	270	11	,	,	PUNCT
fnp-2627	270	12	d.	d.	PROPN
fnp-2627	270	13	,	,	PUNCT
fnp-2627	270	14	hojgaard	hojgaard	NOUN
fnp-2627	270	15	,	,	PUNCT
fnp-2627	270	16	j.l.s	j.l.s	NOUN
fnp-2627	270	17	.	.	PUNCT
fnp-2627	270	18	,	,	PUNCT
fnp-2627	270	19	and	and	CCONJ
fnp-2627	270	20	kondziella	kondziella	NOUN
fnp-2627	270	21	,	,	PUNCT
fnp-2627	270	22	d.	d.	PROPN
fnp-2627	270	23	(	(	PUNCT
fnp-2627	270	24	2019	2019	NUM
fnp-2627	270	25	)	)	PUNCT
fnp-2627	270	26	.	.	PUNCT
fnp-2627	271	1	neuromuscular	neuromuscular	ADJ
fnp-2627	271	2	adverse	adverse	ADJ
fnp-2627	271	3	events	event	NOUN
fnp-2627	271	4	associated	associate	VERB
fnp-2627	271	5	with	with	ADP
fnp-2627	271	6	anti	anti	ADJ
fnp-2627	271	7	-	-	ADJ
fnp-2627	271	8	pd-1	pd-1	ADJ
fnp-2627	271	9	monoclonal	monoclonal	NOUN
fnp-2627	271	10	antibodies	antibodie	VERB
fnp-2627	271	11	:	:	PUNCT
fnp-2627	271	12	systematic	systematic	ADJ
fnp-2627	271	13	review	review	NOUN
fnp-2627	271	14	.	.	PUNCT
fnp-2627	272	1	neurology	neurology	NOUN
fnp-2627	272	2	92	92	NUM
fnp-2627	272	3	,	,	PUNCT
fnp-2627	272	4	663	663	NUM
fnp-2627	272	5	-	-	SYM
fnp-2627	272	6	674	674	NUM
fnp-2627	272	7	.	.	PUNCT
fnp-2627	273	1	kabeya	kabeya	PROPN
fnp-2627	273	2	,	,	PUNCT
fnp-2627	273	3	y.	y.	PROPN
fnp-2627	273	4	,	,	PUNCT
fnp-2627	273	5	iwamori	iwamori	NOUN
fnp-2627	273	6	,	,	PUNCT
fnp-2627	273	7	t.	t.	PROPN
fnp-2627	273	8	,	,	PUNCT
fnp-2627	273	9	yonezawa	yonezawa	PROPN
fnp-2627	273	10	,	,	PUNCT
fnp-2627	273	11	s.	s.	PROPN
fnp-2627	273	12	,	,	PUNCT
fnp-2627	273	13	takeuchi	takeuchi	PROPN
fnp-2627	273	14	,	,	PUNCT
fnp-2627	273	15	y.	y.	PROPN
fnp-2627	273	16	,	,	PUNCT
fnp-2627	273	17	nakano	nakano	PROPN
fnp-2627	273	18	,	,	PUNCT
fnp-2627	273	19	h.	h.	PROPN
fnp-2627	273	20	,	,	PUNCT
fnp-2627	273	21	nagisa	nagisa	PROPN
fnp-2627	273	22	,	,	PUNCT
fnp-2627	273	23	y.	y.	PROPN
fnp-2627	273	24	,	,	PUNCT
fnp-2627	273	25	okubo	okubo	ADJ
fnp-2627	273	26	,	,	PUNCT
fnp-2627	273	27	m.	m.	NOUN
fnp-2627	273	28	,	,	PUNCT
fnp-2627	273	29	inoue	inoue	PROPN
fnp-2627	273	30	,	,	PUNCT
fnp-2627	273	31	m.	m.	NOUN
fnp-2627	273	32	,	,	PUNCT
fnp-2627	273	33	tokumasu	tokumasu	VERB
fnp-2627	273	34	,	,	PUNCT
fnp-2627	273	35	r.	r.	PROPN
fnp-2627	273	36	,	,	PUNCT
fnp-2627	273	37	ozawa	ozawa	PROPN
fnp-2627	273	38	,	,	PUNCT
fnp-2627	273	39	i.	i.	PROPN
fnp-2627	273	40	,	,	PUNCT
fnp-2627	273	41	et	et	PROPN
fnp-2627	273	42	al	al	PROPN
fnp-2627	273	43	.	.	PROPN
fnp-2627	273	44	(	(	PUNCT
fnp-2627	273	45	2019	2019	NUM
fnp-2627	273	46	)	)	PUNCT
fnp-2627	273	47	.	.	PUNCT
fnp-2627	274	1	ai	ai	VERB
fnp-2627	274	2	-	-	PUNCT
fnp-2627	274	3	based	base	VERB
fnp-2627	274	4	muscle	muscle	NOUN
fnp-2627	274	5	histopathologist	histopathologist	NOUN
fnp-2627	274	6	can	can	AUX
fnp-2627	274	7	differentiate	differentiate	VERB
fnp-2627	274	8	major	major	ADJ
fnp-2627	274	9	muscular	muscular	ADJ
fnp-2627	274	10	dystrophies	dystrophy	NOUN
fnp-2627	274	11	better	well	ADV
fnp-2627	274	12	than	than	ADP
fnp-2627	274	13	human	human	PROPN
fnp-2627	274	14	.	.	PUNCT
fnp-2627	275	1	neuromusc	neuromusc	PROPN
fnp-2627	275	2	disord	disord	PROPN
fnp-2627	275	3	29	29	NUM
fnp-2627	275	4	,	,	PUNCT
fnp-2627	275	5	s126	s126	PROPN
fnp-2627	275	6	-	-	PUNCT
fnp-2627	275	7	127	127	NUM
fnp-2627	275	8	.	.	PUNCT
fnp-2627	276	1	(	(	PUNCT
fnp-2627	276	2	abstract	abstract	ADJ
fnp-2627	276	3	)	)	PUNCT
fnp-2627	276	4	knauss	knauss	PROPN
fnp-2627	276	5	,	,	PUNCT
fnp-2627	276	6	s.	s.	PROPN
fnp-2627	276	7	,	,	PUNCT
fnp-2627	276	8	preusse	preusse	NOUN
fnp-2627	276	9	,	,	PUNCT
fnp-2627	276	10	c.	c.	PROPN
fnp-2627	276	11	,	,	PUNCT
fnp-2627	276	12	allenbach	allenbach	ADV
fnp-2627	276	13	,	,	PUNCT
fnp-2627	276	14	y.	y.	PROPN
fnp-2627	276	15	,	,	PUNCT
fnp-2627	276	16	leonard	leonard	PROPN
fnp-2627	276	17	-	-	PUNCT
fnp-2627	276	18	louis	louis	PROPN
fnp-2627	276	19	,	,	PUNCT
fnp-2627	276	20	s.	s.	PROPN
fnp-2627	276	21	,	,	PUNCT
fnp-2627	276	22	touat	touat	PROPN
fnp-2627	276	23	,	,	PUNCT
fnp-2627	276	24	m.	m.	NOUN
fnp-2627	276	25	,	,	PUNCT
fnp-2627	276	26	fischer	fischer	PROPN
fnp-2627	276	27	,	,	PUNCT
fnp-2627	276	28	n.	n.	NOUN
fnp-2627	276	29	,	,	PUNCT
fnp-2627	276	30	radbruch	radbruch	PROPN
fnp-2627	276	31	,	,	PUNCT
fnp-2627	276	32	h.	h.	PROPN
fnp-2627	276	33	,	,	PUNCT
fnp-2627	276	34	mothes	mothe	VERB
fnp-2627	276	35	,	,	PUNCT
fnp-2627	276	36	r.	r.	PROPN
fnp-2627	276	37	,	,	PUNCT
fnp-2627	276	38	matyash	matyash	NOUN
fnp-2627	276	39	,	,	PUNCT
fnp-2627	276	40	v.	v.	ADP
fnp-2627	276	41	,	,	PUNCT
fnp-2627	276	42	bohmerle	bohmerle	PROPN
fnp-2627	276	43	,	,	PUNCT
fnp-2627	276	44	w.	w.	PROPN
fnp-2627	276	45	,	,	PUNCT
fnp-2627	276	46	et	et	PROPN
fnp-2627	276	47	al	al	PROPN
fnp-2627	276	48	.	.	PROPN
fnp-2627	277	1	(	(	PUNCT
fnp-2627	277	2	2019	2019	NUM
fnp-2627	277	3	)	)	PUNCT
fnp-2627	277	4	.	.	PUNCT
fnp-2627	278	1	pd1	pd1	VERB
fnp-2627	278	2	pathway	pathway	NOUN
fnp-2627	278	3	in	in	ADP
fnp-2627	278	4	immune	immune	NOUN
fnp-2627	278	5	-	-	PUNCT
fnp-2627	278	6	mediated	mediate	VERB
fnp-2627	278	7	myopathies	myopathy	NOUN
fnp-2627	278	8	:	:	PUNCT
fnp-2627	278	9	pathogenesis	pathogenesis	NOUN
fnp-2627	278	10	of	of	ADP
fnp-2627	278	11	dysfunctional	dysfunctional	ADJ
fnp-2627	278	12	t	t	PROPN
fnp-2627	278	13	cells	cell	NOUN
fnp-2627	278	14	revisited	revisit	VERB
fnp-2627	278	15	.	.	PUNCT
fnp-2627	279	1	neurol	neurol	PROPN
fnp-2627	279	2	neuroimmunol	neuroimmunol	PROPN
fnp-2627	279	3	neuroinflamm	neuroinflamm	PROPN
fnp-2627	279	4	6	6	NUM
fnp-2627	279	5	,	,	PUNCT
fnp-2627	279	6	e558	e558	PROPN
fnp-2627	279	7	.	.	PUNCT
fnp-2627	280	1	lornage	lornage	NOUN
fnp-2627	280	2	,	,	PUNCT
fnp-2627	280	3	x.	x.	NOUN
fnp-2627	280	4	,	,	PUNCT
fnp-2627	280	5	schartner	schartner	NOUN
fnp-2627	280	6	,	,	PUNCT
fnp-2627	280	7	v.	v.	ADV
fnp-2627	280	8	,	,	PUNCT
fnp-2627	280	9	balbueno	balbueno	NOUN
fnp-2627	280	10	,	,	PUNCT
fnp-2627	280	11	i.	i.	PROPN
fnp-2627	280	12	,	,	PUNCT
fnp-2627	280	13	biancalana	biancalana	PROPN
fnp-2627	280	14	,	,	PUNCT
fnp-2627	280	15	v.	v.	PROPN
fnp-2627	280	16	,	,	PUNCT
fnp-2627	280	17	willis	willis	PROPN
fnp-2627	280	18	,	,	PUNCT
fnp-2627	280	19	t.	t.	PROPN
fnp-2627	280	20	,	,	PUNCT
fnp-2627	280	21	echaniz	echaniz	NOUN
fnp-2627	280	22	-	-	PUNCT
fnp-2627	280	23	laguna	laguna	PROPN
fnp-2627	280	24	,	,	PUNCT
fnp-2627	280	25	a.	a.	PROPN
fnp-2627	280	26	,	,	PUNCT
fnp-2627	280	27	scheidecker	scheidecker	PROPN
fnp-2627	280	28	,	,	PUNCT
fnp-2627	280	29	s.	s.	PROPN
fnp-2627	280	30	,	,	PUNCT
fnp-2627	280	31	quinlivan	quinlivan	PROPN
fnp-2627	280	32	,	,	PUNCT
fnp-2627	280	33	r.	r.	PROPN
fnp-2627	280	34	,	,	PUNCT
fnp-2627	280	35	fardeau	fardeau	PROPN
fnp-2627	280	36	,	,	PUNCT
fnp-2627	280	37	m.	m.	NOUN
fnp-2627	280	38	,	,	PUNCT
fnp-2627	280	39	malfatti	malfatti	PROPN
fnp-2627	280	40	,	,	PUNCT
fnp-2627	280	41	e.	e.	PROPN
fnp-2627	280	42	,	,	PUNCT
fnp-2627	280	43	et	et	PROPN
fnp-2627	280	44	al	al	PROPN
fnp-2627	280	45	.	.	PROPN
fnp-2627	280	46	(	(	PUNCT
fnp-2627	280	47	2019	2019	NUM
fnp-2627	280	48	)	)	PUNCT
fnp-2627	280	49	.	.	PUNCT
fnp-2627	281	1	clinical	clinical	ADJ
fnp-2627	281	2	,	,	PUNCT
fnp-2627	281	3	histological	histological	ADJ
fnp-2627	281	4	,	,	PUNCT
fnp-2627	281	5	and	and	CCONJ
fnp-2627	281	6	genetic	genetic	ADJ
fnp-2627	281	7	characterization	characterization	NOUN
fnp-2627	281	8	of	of	ADP
fnp-2627	281	9	pyroxd1	pyroxd1	NOUN
fnp-2627	281	10	-	-	PUNCT
fnp-2627	281	11	related	relate	VERB
fnp-2627	281	12	myopathy	myopathy	ADJ
fnp-2627	281	13	.	.	PUNCT
fnp-2627	282	1	acta	acta	PROPN
fnp-2627	282	2	neuropathol	neuropathol	PROPN
fnp-2627	282	3	commun	commun	PROPN
fnp-2627	282	4	7	7	NUM
fnp-2627	282	5	,	,	PUNCT
fnp-2627	282	6	138	138	NUM
fnp-2627	282	7	.	.	PUNCT
fnp-2627	283	1	margeta	margeta	NOUN
fnp-2627	283	2	,	,	PUNCT
fnp-2627	283	3	m.	m.	NOUN
fnp-2627	283	4	(	(	PUNCT
fnp-2627	283	5	2019	2019	NUM
fnp-2627	283	6	)	)	PUNCT
fnp-2627	283	7	.	.	PUNCT
fnp-2627	284	1	autophagy	autophagy	ADJ
fnp-2627	284	2	defects	defect	NOUN
fnp-2627	284	3	in	in	ADP
fnp-2627	284	4	skeletal	skeletal	ADJ
fnp-2627	284	5	myopathies	myopathy	NOUN
fnp-2627	284	6	.	.	PUNCT
fnp-2627	285	1	annu	annu	PROPN
fnp-2627	285	2	rev	rev	PROPN
fnp-2627	285	3	pathol	pathol	PROPN
fnp-2627	285	4	,	,	PUNCT
fnp-2627	285	5	epub	epub	NOUN
fnp-2627	285	6	ahead	ahead	ADV
fnp-2627	285	7	of	of	ADP
fnp-2627	285	8	print	print	NOUN
fnp-2627	285	9	.	.	PUNCT
fnp-2627	286	1	messacar	messacar	NOUN
fnp-2627	286	2	,	,	PUNCT
fnp-2627	286	3	k.	k.	PROPN
fnp-2627	286	4	,	,	PUNCT
fnp-2627	286	5	asturias	asturias	PROPN
fnp-2627	286	6	,	,	PUNCT
fnp-2627	286	7	e.j	e.j	PROPN
fnp-2627	286	8	.	.	PROPN
fnp-2627	286	9	,	,	PUNCT
fnp-2627	286	10	hixon	hixon	PROPN
fnp-2627	286	11	,	,	PUNCT
fnp-2627	286	12	a.m.	a.m.	ADV
fnp-2627	286	13	,	,	PUNCT
fnp-2627	286	14	van	van	PROPN
fnp-2627	286	15	leer	leer	PROPN
fnp-2627	286	16	-	-	PUNCT
fnp-2627	286	17	buter	buter	NOUN
fnp-2627	286	18	,	,	PUNCT
fnp-2627	286	19	c.	c.	PROPN
fnp-2627	286	20	,	,	PUNCT
fnp-2627	286	21	niesters	niester	NOUN
fnp-2627	286	22	,	,	PUNCT
fnp-2627	286	23	h.g.m	h.g.m	INTJ
fnp-2627	286	24	.	.	PUNCT
fnp-2627	286	25	,	,	PUNCT
fnp-2627	286	26	tyler	tyler	PROPN
fnp-2627	286	27	,	,	PUNCT
fnp-2627	286	28	k.l	k.l	PROPN
fnp-2627	286	29	.	.	PROPN
fnp-2627	286	30	,	,	PUNCT
fnp-2627	286	31	abzug	abzug	PROPN
fnp-2627	286	32	,	,	PUNCT
fnp-2627	286	33	m.j	m.j	PROPN
fnp-2627	286	34	.	.	PROPN
fnp-2627	286	35	,	,	PUNCT
fnp-2627	286	36	and	and	CCONJ
fnp-2627	286	37	dominguez	dominguez	PROPN
fnp-2627	286	38	,	,	PUNCT
fnp-2627	286	39	s.r	s.r	PROPN
fnp-2627	286	40	.	.	PROPN
fnp-2627	286	41	(	(	PUNCT
fnp-2627	286	42	2018	2018	NUM
fnp-2627	286	43	)	)	PUNCT
fnp-2627	286	44	.	.	PUNCT
fnp-2627	287	1	enterovirus	enterovirus	NOUN
fnp-2627	287	2	d68	d68	NOUN
fnp-2627	287	3	and	and	CCONJ
fnp-2627	287	4	acute	acute	ADJ
fnp-2627	287	5	flaccid	flaccid	ADJ
fnp-2627	287	6	myelitis	myelitis	NOUN
fnp-2627	287	7	-	-	PUNCT
fnp-2627	287	8	evaluating	evaluate	VERB
fnp-2627	287	9	the	the	DET
fnp-2627	287	10	evidence	evidence	NOUN
fnp-2627	287	11	for	for	ADP
fnp-2627	287	12	causality	causality	NOUN
fnp-2627	287	13	.	.	PUNCT
fnp-2627	288	1	lancet	lancet	PROPN
fnp-2627	288	2	infect	infect	PROPN
fnp-2627	288	3	dis	dis	PROPN
fnp-2627	288	4	18	18	NUM
fnp-2627	288	5	,	,	PUNCT
fnp-2627	288	6	e239	e239	PROPN
fnp-2627	288	7	-	-	PUNCT
fnp-2627	288	8	e247	e247	PROPN
fnp-2627	288	9	.	.	PUNCT
fnp-2627	289	1	mohn	mohn	PROPN
fnp-2627	289	2	,	,	PUNCT
fnp-2627	289	3	n.	n.	NOUN
fnp-2627	289	4	,	,	PUNCT
fnp-2627	289	5	beutel	beutel	NOUN
fnp-2627	289	6	,	,	PUNCT
fnp-2627	289	7	g.	g.	PROPN
fnp-2627	289	8	,	,	PUNCT
fnp-2627	289	9	gutzmer	gutzmer	NOUN
fnp-2627	289	10	,	,	PUNCT
fnp-2627	289	11	r.	r.	PROPN
fnp-2627	289	12	,	,	PUNCT
fnp-2627	289	13	ivanyi	ivanyi	PROPN
fnp-2627	289	14	,	,	PUNCT
fnp-2627	289	15	p.	p.	NOUN
fnp-2627	289	16	,	,	PUNCT
fnp-2627	289	17	satzger	satzger	NOUN
fnp-2627	289	18	,	,	PUNCT
fnp-2627	289	19	i.	i.	PROPN
fnp-2627	289	20	,	,	PUNCT
fnp-2627	289	21	and	and	CCONJ
fnp-2627	289	22	skripuletz	skripuletz	VERB
fnp-2627	289	23	,	,	PUNCT
fnp-2627	289	24	t.	t.	PROPN
fnp-2627	289	25	(	(	PUNCT
fnp-2627	289	26	2019	2019	NUM
fnp-2627	289	27	)	)	PUNCT
fnp-2627	289	28	.	.	PUNCT
fnp-2627	290	1	neurological	neurological	ADJ
fnp-2627	290	2	immune	immune	ADJ
fnp-2627	290	3	related	relate	VERB
fnp-2627	290	4	adverse	adverse	ADJ
fnp-2627	290	5	events	event	NOUN
fnp-2627	290	6	associated	associate	VERB
fnp-2627	290	7	with	with	ADP
fnp-2627	290	8	nivolumab	nivolumab	NOUN
fnp-2627	290	9	,	,	PUNCT
fnp-2627	290	10	ipilimumab	ipilimumab	ADV
fnp-2627	290	11	,	,	PUNCT
fnp-2627	290	12	and	and	CCONJ
fnp-2627	290	13	pembrolizumab	pembrolizumab	NOUN
fnp-2627	290	14	therapy	therapy	NOUN
fnp-2627	290	15	-	-	PUNCT
fnp-2627	290	16	review	review	NOUN
fnp-2627	290	17	of	of	ADP
fnp-2627	290	18	the	the	DET
fnp-2627	290	19	literature	literature	NOUN
fnp-2627	290	20	and	and	CCONJ
fnp-2627	290	21	future	future	ADJ
fnp-2627	290	22	outlook	outlook	NOUN
fnp-2627	290	23	.	.	PUNCT
fnp-2627	291	1	j	j	PROPN
fnp-2627	291	2	clin	clin	PROPN
fnp-2627	291	3	med	me	VERB
fnp-2627	291	4	8	8	NUM
fnp-2627	291	5	,	,	PUNCT
fnp-2627	291	6	epub	epub	NOUN
fnp-2627	291	7	ahead	ahead	ADV
fnp-2627	291	8	of	of	ADP
fnp-2627	291	9	print	print	NOUN
fnp-2627	291	10	.	.	PUNCT
fnp-2627	292	1	montagnese	montagnese	NOUN
fnp-2627	292	2	,	,	PUNCT
fnp-2627	292	3	f.	f.	PROPN
fnp-2627	292	4	,	,	PUNCT
fnp-2627	292	5	babacic	babacic	ADV
fnp-2627	292	6	,	,	PUNCT
fnp-2627	292	7	h.	h.	NOUN
fnp-2627	292	8	,	,	PUNCT
fnp-2627	292	9	eichhorn	eichhorn	ADJ
fnp-2627	292	10	,	,	PUNCT
fnp-2627	292	11	p.	p.	NOUN
fnp-2627	292	12	,	,	PUNCT
fnp-2627	292	13	and	and	CCONJ
fnp-2627	292	14	schoser	schoser	NOUN
fnp-2627	292	15	,	,	PUNCT
fnp-2627	292	16	b.	b.	PROPN
fnp-2627	292	17	(	(	PUNCT
fnp-2627	292	18	2019	2019	NUM
fnp-2627	292	19	)	)	PUNCT
fnp-2627	292	20	.	.	PUNCT
fnp-2627	293	1	evaluating	evaluate	VERB
fnp-2627	293	2	the	the	DET
fnp-2627	293	3	diagnostic	diagnostic	ADJ
fnp-2627	293	4	utility	utility	NOUN
fnp-2627	293	5	of	of	ADP
fnp-2627	293	6	new	new	ADJ
fnp-2627	293	7	line	line	NOUN
fnp-2627	293	8	immunoassays	immunoassay	NOUN
fnp-2627	293	9	for	for	ADP
fnp-2627	293	10	myositis	myositis	NOUN
fnp-2627	293	11	antibodies	antibodie	VERB
fnp-2627	293	12	in	in	ADP
fnp-2627	293	13	clinical	clinical	ADJ
fnp-2627	293	14	practice	practice	NOUN
fnp-2627	293	15	:	:	PUNCT
fnp-2627	293	16	a	a	DET
fnp-2627	293	17	retrospective	retrospective	ADJ
fnp-2627	293	18	study	study	NOUN
fnp-2627	293	19	.	.	PUNCT
fnp-2627	294	1	j	j	PROPN
fnp-2627	294	2	neurol	neurol	PROPN
fnp-2627	294	3	266	266	NUM
fnp-2627	294	4	,	,	PUNCT
fnp-2627	294	5	1358	1358	NUM
fnp-2627	294	6	-	-	SYM
fnp-2627	294	7	1366	1366	NUM
fnp-2627	294	8	.	.	PUNCT
fnp-2627	295	1	olive	olive	NOUN
fnp-2627	295	2	,	,	PUNCT
fnp-2627	295	3	m.	m.	NOUN
fnp-2627	295	4	,	,	PUNCT
fnp-2627	295	5	engvall	engvall	PROPN
fnp-2627	295	6	,	,	PUNCT
fnp-2627	295	7	m.	m.	NOUN
fnp-2627	295	8	,	,	PUNCT
fnp-2627	295	9	ravenscroft	ravenscroft	NOUN
fnp-2627	295	10	,	,	PUNCT
fnp-2627	295	11	g.	g.	PROPN
fnp-2627	295	12	,	,	PUNCT
fnp-2627	295	13	cabrera	cabrera	NOUN
fnp-2627	295	14	-	-	PUNCT
fnp-2627	295	15	serrano	serrano	PROPN
fnp-2627	295	16	,	,	PUNCT
fnp-2627	295	17	m.	m.	NOUN
fnp-2627	295	18	,	,	PUNCT
fnp-2627	295	19	jiao	jiao	PROPN
fnp-2627	295	20	,	,	PUNCT
fnp-2627	295	21	h.	h.	PROPN
fnp-2627	295	22	,	,	PUNCT
fnp-2627	295	23	bortolotti	bortolotti	PROPN
fnp-2627	295	24	,	,	PUNCT
fnp-2627	295	25	c.a	c.a	PROPN
fnp-2627	295	26	.	.	PROPN
fnp-2627	295	27	,	,	PUNCT
fnp-2627	295	28	pignataro	pignataro	NOUN
fnp-2627	295	29	,	,	PUNCT
fnp-2627	295	30	m.	m.	NOUN
fnp-2627	295	31	,	,	PUNCT
fnp-2627	295	32	lambrughi	lambrughi	PROPN
fnp-2627	295	33	,	,	PUNCT
fnp-2627	295	34	m.	m.	NOUN
fnp-2627	295	35	,	,	PUNCT
fnp-2627	295	36	jiang	jiang	PROPN
fnp-2627	295	37	,	,	PUNCT
fnp-2627	295	38	h.	h.	PROPN
fnp-2627	295	39	,	,	PUNCT
fnp-2627	295	40	forrest	forrest	PROPN
fnp-2627	295	41	,	,	PUNCT
fnp-2627	295	42	a.r.r	a.r.r	ADV
fnp-2627	295	43	.	.	PUNCT
fnp-2627	295	44	,	,	PUNCT
fnp-2627	295	45	et	et	PROPN
fnp-2627	295	46	al	al	PROPN
fnp-2627	295	47	.	.	PROPN
fnp-2627	295	48	(	(	PUNCT
fnp-2627	295	49	2019	2019	NUM
fnp-2627	295	50	)	)	PUNCT
fnp-2627	295	51	.	.	PUNCT
fnp-2627	296	1	myoglobinopathy	myoglobinopathy	ADJ
fnp-2627	296	2	is	be	AUX
fnp-2627	296	3	an	an	DET
fnp-2627	296	4	adult	adult	NOUN
fnp-2627	296	5	-	-	PUNCT
fnp-2627	296	6	onset	onset	NOUN
fnp-2627	296	7	autosomal	autosomal	ADJ
fnp-2627	296	8	dominant	dominant	ADJ
fnp-2627	296	9	myopathy	myopathy	ADJ
fnp-2627	296	10	with	with	ADP
fnp-2627	296	11	characteristic	characteristic	ADJ
fnp-2627	296	12	sarcoplasmic	sarcoplasmic	ADJ
fnp-2627	296	13	inclusions	inclusion	NOUN
fnp-2627	296	14	.	.	PUNCT
fnp-2627	297	1	nat	nat	PROPN
fnp-2627	297	2	commun	commun	PROPN
fnp-2627	297	3	10	10	NUM
fnp-2627	297	4	,	,	PUNCT
fnp-2627	297	5	1396	1396	NUM
fnp-2627	297	6	.	.	PUNCT
fnp-2627	298	1	pinal	pinal	PROPN
fnp-2627	298	2	-	-	PUNCT
fnp-2627	298	3	fernandez	fernandez	PROPN
fnp-2627	298	4	,	,	PUNCT
fnp-2627	298	5	i.	i.	NOUN
fnp-2627	298	6	,	,	PUNCT
fnp-2627	298	7	casal	casal	PROPN
fnp-2627	298	8	-	-	PUNCT
fnp-2627	298	9	dominguez	dominguez	NOUN
fnp-2627	298	10	,	,	PUNCT
fnp-2627	298	11	m.	m.	NOUN
fnp-2627	298	12	,	,	PUNCT
fnp-2627	298	13	derfoul	derfoul	PROPN
fnp-2627	298	14	,	,	PUNCT
fnp-2627	298	15	a.	a.	PROPN
fnp-2627	298	16	,	,	PUNCT
fnp-2627	298	17	pak	pak	PROPN
fnp-2627	298	18	,	,	PUNCT
fnp-2627	298	19	k.	k.	PROPN
fnp-2627	298	20	,	,	PUNCT
fnp-2627	298	21	plotz	plotz	PROPN
fnp-2627	298	22	,	,	PUNCT
fnp-2627	298	23	p.	p.	PROPN
fnp-2627	298	24	,	,	PUNCT
fnp-2627	298	25	miller	miller	PROPN
fnp-2627	298	26	,	,	PUNCT
fnp-2627	298	27	f.w	f.w	PROPN
fnp-2627	298	28	.	.	PROPN
fnp-2627	298	29	,	,	PUNCT
fnp-2627	298	30	milisenda	milisenda	ADV
fnp-2627	298	31	,	,	PUNCT
fnp-2627	298	32	j.c	j.c	PROPN
fnp-2627	298	33	.	.	PROPN
fnp-2627	298	34	,	,	PUNCT
fnp-2627	298	35	grau	grau	PROPN
fnp-2627	298	36	-	-	PUNCT
fnp-2627	298	37	junyent	junyent	PROPN
fnp-2627	298	38	,	,	PUNCT
fnp-2627	298	39	j.m	j.m	PROPN
fnp-2627	298	40	.	.	PROPN
fnp-2627	298	41	,	,	PUNCT
fnp-2627	298	42	selva	selva	PROPN
fnp-2627	298	43	-	-	PUNCT
fnp-2627	298	44	o'callaghan	o'callaghan	PROPN
fnp-2627	298	45	,	,	PUNCT
fnp-2627	298	46	a.	a.	NOUN
fnp-2627	298	47	,	,	PUNCT
fnp-2627	298	48	paik	paik	NOUN
fnp-2627	298	49	,	,	PUNCT
fnp-2627	298	50	j.	j.	PROPN
fnp-2627	298	51	,	,	PUNCT
fnp-2627	298	52	et	et	PROPN
fnp-2627	298	53	al	al	PROPN
fnp-2627	298	54	.	.	PROPN
fnp-2627	298	55	(	(	PUNCT
fnp-2627	298	56	2019	2019	NUM
fnp-2627	298	57	)	)	PUNCT
fnp-2627	298	58	.	.	PUNCT
fnp-2627	299	1	identification	identification	NOUN
fnp-2627	299	2	of	of	ADP
fnp-2627	299	3	distinctive	distinctive	ADJ
fnp-2627	299	4	interferon	interferon	ADJ
fnp-2627	299	5	gene	gene	NOUN
fnp-2627	299	6	signatures	signature	NOUN
fnp-2627	299	7	in	in	ADP
fnp-2627	299	8	different	different	ADJ
fnp-2627	299	9	types	type	NOUN
fnp-2627	299	10	of	of	ADP
fnp-2627	299	11	myositis	myositis	PROPN
fnp-2627	299	12	.	.	PUNCT
fnp-2627	300	1	neurology	neurology	NOUN
fnp-2627	300	2	93	93	NUM
fnp-2627	300	3	,	,	PUNCT
fnp-2627	300	4	e1193	e1193	NOUN
fnp-2627	300	5	-	-	PUNCT
fnp-2627	300	6	e1204	e1204	NOUN
fnp-2627	300	7	.	.	PUNCT
fnp-2627	301	1	psimaras	psimaras	PROPN
fnp-2627	301	2	,	,	PUNCT
fnp-2627	301	3	d.	d.	PROPN
fnp-2627	301	4	,	,	PUNCT
fnp-2627	301	5	velasco	velasco	PROPN
fnp-2627	301	6	,	,	PUNCT
fnp-2627	301	7	r.	r.	PROPN
fnp-2627	301	8	,	,	PUNCT
fnp-2627	301	9	birzu	birzu	PROPN
fnp-2627	301	10	,	,	PUNCT
fnp-2627	301	11	c.	c.	NOUN
fnp-2627	301	12	,	,	PUNCT
fnp-2627	301	13	tamburin	tamburin	PROPN
fnp-2627	301	14	,	,	PUNCT
fnp-2627	301	15	s.	s.	PROPN
fnp-2627	301	16	,	,	PUNCT
fnp-2627	301	17	lustberg	lustberg	PROPN
fnp-2627	301	18	,	,	PUNCT
fnp-2627	301	19	m.	m.	NOUN
fnp-2627	301	20	,	,	PUNCT
fnp-2627	301	21	bruna	bruna	PROPN
fnp-2627	301	22	,	,	PUNCT
fnp-2627	301	23	j.	j.	PROPN
fnp-2627	301	24	,	,	PUNCT
fnp-2627	301	25	and	and	CCONJ
fnp-2627	301	26	argyriou	argyriou	PROPN
fnp-2627	301	27	,	,	PUNCT
fnp-2627	301	28	a.a	a.a	PROPN
fnp-2627	301	29	.	.	PROPN
fnp-2627	301	30	(	(	PUNCT
fnp-2627	301	31	2019	2019	NUM
fnp-2627	301	32	)	)	PUNCT
fnp-2627	301	33	.	.	PUNCT
fnp-2627	302	1	immune	immune	ADJ
fnp-2627	302	2	checkpoint	checkpoint	NOUN
fnp-2627	302	3	inhibitors	inhibitor	NOUN
fnp-2627	302	4	-	-	PUNCT
fnp-2627	302	5	induced	induce	VERB
fnp-2627	302	6	neuromuscular	neuromuscular	ADJ
fnp-2627	302	7	toxicity	toxicity	NOUN
fnp-2627	302	8	:	:	PUNCT
fnp-2627	302	9	from	from	ADP
fnp-2627	302	10	pathogenesis	pathogenesis	NOUN
fnp-2627	302	11	to	to	ADP
fnp-2627	302	12	treatment	treatment	NOUN
fnp-2627	302	13	.	.	PUNCT
fnp-2627	303	1	j	j	PROPN
fnp-2627	303	2	peripher	peripher	PROPN
fnp-2627	303	3	nerv	nerv	PROPN
fnp-2627	303	4	syst	syst	PROPN
fnp-2627	303	5	24	24	NUM
fnp-2627	304	1	suppl	suppl	ADJ
fnp-2627	304	2	2	2	NUM
fnp-2627	304	3	,	,	PUNCT
fnp-2627	304	4	s74	s74	NOUN
fnp-2627	304	5	-	-	PUNCT
fnp-2627	304	6	s85	s85	NOUN
fnp-2627	304	7	.	.	PUNCT
fnp-2627	304	8	ramos	ramos	PROPN
fnp-2627	304	9	,	,	PUNCT
fnp-2627	304	10	d.m	d.m	PROPN
fnp-2627	304	11	.	.	PROPN
fnp-2627	304	12	,	,	PUNCT
fnp-2627	304	13	d'ydewalle	d'ydewalle	PROPN
fnp-2627	304	14	,	,	PUNCT
fnp-2627	304	15	c.	c.	PROPN
fnp-2627	304	16	,	,	PUNCT
fnp-2627	304	17	gabbeta	gabbeta	NOUN
fnp-2627	304	18	,	,	PUNCT
fnp-2627	304	19	v.	v.	ADV
fnp-2627	304	20	,	,	PUNCT
fnp-2627	304	21	dakka	dakka	PROPN
fnp-2627	304	22	,	,	PUNCT
fnp-2627	304	23	a.	a.	PROPN
fnp-2627	304	24	,	,	PUNCT
fnp-2627	304	25	klein	klein	PROPN
fnp-2627	304	26	,	,	PUNCT
fnp-2627	304	27	s.k	s.k	PROPN
fnp-2627	304	28	.	.	PROPN
fnp-2627	304	29	,	,	PUNCT
fnp-2627	304	30	norris	norris	PROPN
fnp-2627	304	31	,	,	PUNCT
fnp-2627	304	32	d.a	d.a	PROPN
fnp-2627	304	33	.	.	PROPN
fnp-2627	304	34	,	,	PUNCT
fnp-2627	304	35	matson	matson	PROPN
fnp-2627	304	36	,	,	PUNCT
fnp-2627	304	37	j.	j.	PROPN
fnp-2627	304	38	,	,	PUNCT
fnp-2627	304	39	taylor	taylor	PROPN
fnp-2627	304	40	,	,	PUNCT
fnp-2627	304	41	s.j	s.j	PROPN
fnp-2627	304	42	.	.	PROPN
fnp-2627	304	43	,	,	PUNCT
fnp-2627	304	44	zaworski	zaworski	PROPN
fnp-2627	304	45	,	,	PUNCT
fnp-2627	304	46	p.g	p.g	PROPN
fnp-2627	304	47	.	.	PROPN
fnp-2627	304	48	,	,	PUNCT
fnp-2627	304	49	prior	prior	ADV
fnp-2627	304	50	,	,	PUNCT
fnp-2627	304	51	t.w	t.w	PROPN
fnp-2627	304	52	.	.	PROPN
fnp-2627	304	53	,	,	PUNCT
fnp-2627	304	54	et	et	PROPN
fnp-2627	304	55	al	al	PROPN
fnp-2627	304	56	.	.	PROPN
fnp-2627	304	57	(	(	PUNCT
fnp-2627	304	58	2019	2019	NUM
fnp-2627	304	59	)	)	PUNCT
fnp-2627	304	60	.	.	PUNCT
fnp-2627	305	1	age	age	NOUN
fnp-2627	305	2	-	-	PUNCT
fnp-2627	305	3	dependent	dependent	ADJ
fnp-2627	305	4	smn	smn	NOUN
fnp-2627	305	5	expression	expression	NOUN
fnp-2627	305	6	in	in	ADP
fnp-2627	305	7	disease	disease	NOUN
fnp-2627	305	8	-	-	PUNCT
fnp-2627	305	9	relevant	relevant	ADJ
fnp-2627	305	10	tissue	tissue	NOUN
fnp-2627	305	11	and	and	CCONJ
fnp-2627	305	12	implications	implication	NOUN
fnp-2627	305	13	for	for	ADP
fnp-2627	305	14	sma	sma	NOUN
fnp-2627	305	15	treatment	treatment	NOUN
fnp-2627	305	16	.	.	PUNCT
fnp-2627	306	1	j	j	PROPN
fnp-2627	306	2	clin	clin	PROPN
fnp-2627	306	3	invest	invest	VERB
fnp-2627	306	4	129	129	NUM
fnp-2627	306	5	,	,	PUNCT
fnp-2627	306	6	4817	4817	NUM
fnp-2627	306	7	-	-	SYM
fnp-2627	306	8	4831	4831	NUM
fnp-2627	306	9	.	.	PUNCT
fnp-2627	307	1	reyes	reyes	PROPN
fnp-2627	307	2	-	-	PUNCT
fnp-2627	307	3	fernandez	fernandez	PROPN
fnp-2627	307	4	,	,	PUNCT
fnp-2627	307	5	p.c	p.c	PROPN
fnp-2627	307	6	.	.	PROPN
fnp-2627	307	7	,	,	PUNCT
fnp-2627	307	8	periou	periou	PROPN
fnp-2627	307	9	,	,	PUNCT
fnp-2627	307	10	b.	b.	PROPN
fnp-2627	307	11	,	,	PUNCT
fnp-2627	307	12	decrouy	decrouy	PROPN
fnp-2627	307	13	,	,	PUNCT
fnp-2627	307	14	x.	x.	NOUN
fnp-2627	307	15	,	,	PUNCT
fnp-2627	307	16	relaix	relaix	PROPN
fnp-2627	307	17	,	,	PUNCT
fnp-2627	307	18	f.	f.	PROPN
fnp-2627	307	19	,	,	PUNCT
fnp-2627	307	20	and	and	CCONJ
fnp-2627	307	21	authier	authier	NOUN
fnp-2627	307	22	,	,	PUNCT
fnp-2627	307	23	f.j	f.j	PROPN
fnp-2627	307	24	.	.	PROPN
fnp-2627	307	25	(	(	PUNCT
fnp-2627	307	26	2019	2019	NUM
fnp-2627	307	27	)	)	PUNCT
fnp-2627	307	28	.	.	PUNCT
fnp-2627	308	1	automated	automate	VERB
fnp-2627	308	2	image	image	NOUN
fnp-2627	308	3	-	-	PUNCT
fnp-2627	308	4	analysis	analysis	NOUN
fnp-2627	308	5	method	method	NOUN
fnp-2627	308	6	for	for	ADP
fnp-2627	308	7	the	the	DET
fnp-2627	308	8	quantification	quantification	NOUN
fnp-2627	308	9	of	of	ADP
fnp-2627	308	10	fiber	fiber	NOUN
fnp-2627	308	11	morphometry	morphometry	NOUN
fnp-2627	308	12	and	and	CCONJ
fnp-2627	308	13	fiber	fiber	NOUN
fnp-2627	308	14	type	type	NOUN
fnp-2627	308	15	population	population	NOUN
fnp-2627	308	16	in	in	ADP
fnp-2627	308	17	human	human	ADJ
fnp-2627	308	18	skeletal	skeletal	ADJ
fnp-2627	308	19	muscle	muscle	NOUN
fnp-2627	308	20	.	.	PUNCT
fnp-2627	309	1	skelet	skelet	PROPN
fnp-2627	309	2	muscle	muscle	NOUN
fnp-2627	309	3	9	9	NUM
fnp-2627	309	4	,	,	PUNCT
fnp-2627	309	5	15	15	NUM
fnp-2627	309	6	.	.	PUNCT
fnp-2627	310	1	rigolet	rigolet	NOUN
fnp-2627	310	2	,	,	PUNCT
fnp-2627	310	3	m.	m.	NOUN
fnp-2627	310	4	,	,	PUNCT
fnp-2627	310	5	hou	hou	PROPN
fnp-2627	310	6	,	,	PUNCT
fnp-2627	310	7	c.	c.	PROPN
fnp-2627	310	8	,	,	PUNCT
fnp-2627	310	9	baba	baba	PROPN
fnp-2627	310	10	amer	amer	PROPN
fnp-2627	310	11	,	,	PUNCT
fnp-2627	310	12	y.	y.	PROPN
fnp-2627	310	13	,	,	PUNCT
fnp-2627	310	14	aouizerate	aouizerate	ADJ
fnp-2627	310	15	,	,	PUNCT
fnp-2627	310	16	j.	j.	PROPN
fnp-2627	310	17	,	,	PUNCT
fnp-2627	310	18	periou	periou	PROPN
fnp-2627	310	19	,	,	PUNCT
fnp-2627	310	20	b.	b.	PROPN
fnp-2627	310	21	,	,	PUNCT
fnp-2627	310	22	gherardi	gherardi	PROPN
fnp-2627	310	23	,	,	PUNCT
fnp-2627	310	24	r.k	r.k	PROPN
fnp-2627	310	25	.	.	PROPN
fnp-2627	310	26	,	,	PUNCT
fnp-2627	310	27	lafuste	lafuste	PROPN
fnp-2627	310	28	,	,	PUNCT
fnp-2627	310	29	p.	p.	NOUN
fnp-2627	310	30	,	,	PUNCT
fnp-2627	310	31	and	and	CCONJ
fnp-2627	310	32	authier	authier	NOUN
fnp-2627	310	33	,	,	PUNCT
fnp-2627	310	34	f.j	f.j	PROPN
fnp-2627	310	35	.	.	PROPN
fnp-2627	310	36	(	(	PUNCT
fnp-2627	310	37	2019	2019	NUM
fnp-2627	310	38	)	)	PUNCT
fnp-2627	310	39	.	.	PUNCT
fnp-2627	311	1	distinct	distinct	ADJ
fnp-2627	311	2	interferon	interferon	ADJ
fnp-2627	311	3	signatures	signature	NOUN
fnp-2627	311	4	stratify	stratify	VERB
fnp-2627	311	5	inflammatory	inflammatory	ADJ
fnp-2627	311	6	and	and	CCONJ
fnp-2627	311	7	dysimmune	dysimmune	NOUN
fnp-2627	311	8	myopathies	myopathy	NOUN
fnp-2627	311	9	.	.	PUNCT
fnp-2627	312	1	rmd	rmd	PROPN
fnp-2627	312	2	open	open	VERB
fnp-2627	312	3	5	5	NUM
fnp-2627	312	4	,	,	PUNCT
fnp-2627	312	5	e000811	e000811	PROPN
fnp-2627	312	6	.	.	PUNCT
fnp-2627	313	1	ross	ross	PROPN
fnp-2627	313	2	,	,	PUNCT
fnp-2627	313	3	j.a	j.a	PROPN
fnp-2627	313	4	.	.	PROPN
fnp-2627	313	5	,	,	PUNCT
fnp-2627	313	6	levy	levy	NOUN
fnp-2627	313	7	,	,	PUNCT
fnp-2627	313	8	y.	y.	NOUN
fnp-2627	313	9	,	,	PUNCT
fnp-2627	313	10	ripolone	ripolone	NOUN
fnp-2627	313	11	,	,	PUNCT
fnp-2627	313	12	m.	m.	NOUN
fnp-2627	313	13	,	,	PUNCT
fnp-2627	313	14	kolb	kolb	PROPN
fnp-2627	313	15	,	,	PUNCT
fnp-2627	313	16	j.s	j.s	PROPN
fnp-2627	313	17	.	.	PROPN
fnp-2627	313	18	,	,	PUNCT
fnp-2627	313	19	turmaine	turmaine	ADJ
fnp-2627	313	20	,	,	PUNCT
fnp-2627	313	21	m.	m.	NOUN
fnp-2627	313	22	,	,	PUNCT
fnp-2627	313	23	holt	holt	PROPN
fnp-2627	313	24	,	,	PUNCT
fnp-2627	313	25	m.	m.	NOUN
fnp-2627	313	26	,	,	PUNCT
fnp-2627	313	27	lindqvist	lindqvist	NOUN
fnp-2627	313	28	,	,	PUNCT
fnp-2627	313	29	j.	j.	PROPN
fnp-2627	313	30	,	,	PUNCT
fnp-2627	313	31	claeys	claeys	PROPN
fnp-2627	313	32	,	,	PUNCT
fnp-2627	313	33	k.g	k.g	PROPN
fnp-2627	313	34	.	.	PROPN
fnp-2627	313	35	,	,	PUNCT
fnp-2627	313	36	weis	weis	PROPN
fnp-2627	313	37	,	,	PUNCT
fnp-2627	313	38	j.	j.	PROPN
fnp-2627	313	39	,	,	PUNCT
fnp-2627	313	40	monforte	monforte	NOUN
fnp-2627	313	41	,	,	PUNCT
fnp-2627	313	42	m.	m.	NOUN
fnp-2627	313	43	,	,	PUNCT
fnp-2627	313	44	et	et	PROPN
fnp-2627	313	45	al	al	PROPN
fnp-2627	313	46	.	.	PROPN
fnp-2627	313	47	(	(	PUNCT
fnp-2627	313	48	2019	2019	NUM
fnp-2627	313	49	)	)	PUNCT
fnp-2627	313	50	.	.	PUNCT
fnp-2627	314	1	impairments	impairment	NOUN
fnp-2627	314	2	in	in	ADP
fnp-2627	314	3	contractility	contractility	NOUN
fnp-2627	314	4	and	and	CCONJ
fnp-2627	314	5	cytoskeletal	cytoskeletal	ADJ
fnp-2627	314	6	organisation	organisation	NOUN
fnp-2627	314	7	cause	cause	VERB
fnp-2627	314	8	nuclear	nuclear	ADJ
fnp-2627	314	9	defects	defect	NOUN
fnp-2627	314	10	in	in	ADP
fnp-2627	314	11	nemaline	nemaline	ADJ
fnp-2627	314	12	myopathy	myopathy	ADJ
fnp-2627	314	13	.	.	PUNCT
fnp-2627	315	1	acta	acta	PROPN
fnp-2627	315	2	neuropathol	neuropathol	PROPN
fnp-2627	315	3	138	138	NUM
fnp-2627	315	4	,	,	PUNCT
fnp-2627	315	5	477	477	NUM
fnp-2627	315	6	-	-	SYM
fnp-2627	315	7	495	495	NUM
fnp-2627	315	8	.	.	PUNCT
fnp-2627	316	1	schubert	schubert	PROPN
fnp-2627	316	2	,	,	PUNCT
fnp-2627	316	3	r.d	r.d	PROPN
fnp-2627	316	4	.	.	PROPN
fnp-2627	316	5	,	,	PUNCT
fnp-2627	316	6	hawes	hawes	PROPN
fnp-2627	316	7	,	,	PUNCT
fnp-2627	316	8	i.a	i.a	PROPN
fnp-2627	316	9	.	.	PROPN
fnp-2627	316	10	,	,	PUNCT
fnp-2627	316	11	ramachandran	ramachandran	PROPN
fnp-2627	316	12	,	,	PUNCT
fnp-2627	316	13	p.s	p.s	PROPN
fnp-2627	316	14	.	.	PROPN
fnp-2627	316	15	,	,	PUNCT
fnp-2627	316	16	ramesh	ramesh	PROPN
fnp-2627	316	17	,	,	PUNCT
fnp-2627	316	18	a.	a.	PROPN
fnp-2627	316	19	,	,	PUNCT
fnp-2627	316	20	crawford	crawford	PROPN
fnp-2627	316	21	,	,	PUNCT
fnp-2627	316	22	e.d	e.d	PROPN
fnp-2627	316	23	.	.	PROPN
fnp-2627	316	24	,	,	PUNCT
fnp-2627	316	25	pak	pak	PROPN
fnp-2627	316	26	,	,	PUNCT
fnp-2627	316	27	j.e	j.e	PROPN
fnp-2627	316	28	.	.	PROPN
fnp-2627	316	29	,	,	PUNCT
fnp-2627	316	30	wu	wu	PROPN
fnp-2627	316	31	,	,	PUNCT
fnp-2627	316	32	w.	w.	PROPN
fnp-2627	316	33	,	,	PUNCT
fnp-2627	316	34	cheung	cheung	PROPN
fnp-2627	316	35	,	,	PUNCT
fnp-2627	316	36	c.k	c.k	PROPN
fnp-2627	316	37	.	.	PROPN
fnp-2627	316	38	,	,	PUNCT
fnp-2627	316	39	o'donovan	o'donovan	PROPN
fnp-2627	316	40	,	,	PUNCT
fnp-2627	316	41	b.d	b.d	PROPN
fnp-2627	316	42	.	.	PROPN
fnp-2627	316	43	,	,	PUNCT
fnp-2627	316	44	tato	tato	PROPN
fnp-2627	316	45	,	,	PUNCT
fnp-2627	316	46	c.m	c.m	PROPN
fnp-2627	316	47	.	.	PROPN
fnp-2627	316	48	,	,	PUNCT
fnp-2627	316	49	et	et	PROPN
fnp-2627	316	50	al	al	PROPN
fnp-2627	316	51	.	.	PROPN
fnp-2627	316	52	(	(	PUNCT
fnp-2627	316	53	2019	2019	NUM
fnp-2627	316	54	)	)	PUNCT
fnp-2627	316	55	.	.	PUNCT
fnp-2627	317	1	pan	pan	ADJ
fnp-2627	317	2	-	-	ADJ
fnp-2627	317	3	viral	viral	ADJ
fnp-2627	317	4	serology	serology	NOUN
fnp-2627	317	5	implicates	implicate	VERB
fnp-2627	317	6	enteroviruses	enterovirus	NOUN
fnp-2627	317	7	in	in	ADP
fnp-2627	317	8	acute	acute	ADJ
fnp-2627	317	9	flaccid	flaccid	ADJ
fnp-2627	317	10	myelitis	myelitis	NOUN
fnp-2627	317	11	.	.	PUNCT
fnp-2627	318	1	nat	nat	PROPN
fnp-2627	318	2	med	me	VERB
fnp-2627	318	3	25	25	NUM
fnp-2627	318	4	,	,	PUNCT
fnp-2627	318	5	1748	1748	NUM
fnp-2627	318	6	-	-	SYM
fnp-2627	318	7	1752	1752	NUM
fnp-2627	318	8	.	.	PUNCT
fnp-2627	319	1	sloan	sloan	PROPN
fnp-2627	319	2	,	,	PUNCT
fnp-2627	319	3	e.a	e.a	PROPN
fnp-2627	319	4	.	.	PROPN
fnp-2627	319	5	,	,	PUNCT
fnp-2627	319	6	sampognaro	sampognaro	PROPN
fnp-2627	319	7	,	,	PUNCT
fnp-2627	319	8	p.j	p.j	PROPN
fnp-2627	319	9	.	.	PROPN
fnp-2627	319	10	,	,	PUNCT
fnp-2627	319	11	junn	junn	PROPN
fnp-2627	319	12	,	,	PUNCT
fnp-2627	319	13	j.c	j.c	PROPN
fnp-2627	319	14	.	.	PROPN
fnp-2627	319	15	,	,	PUNCT
fnp-2627	319	16	chin	chin	PROPN
fnp-2627	319	17	,	,	PUNCT
fnp-2627	319	18	c.	c.	PROPN
fnp-2627	319	19	,	,	PUNCT
fnp-2627	319	20	jacques	jacques	PROPN
fnp-2627	319	21	,	,	PUNCT
fnp-2627	319	22	l.	l.	PROPN
fnp-2627	319	23	,	,	PUNCT
fnp-2627	319	24	ramachandran	ramachandran	PROPN
fnp-2627	319	25	,	,	PUNCT
fnp-2627	319	26	p.s	p.s	PROPN
fnp-2627	319	27	.	.	PROPN
fnp-2627	319	28	,	,	PUNCT
fnp-2627	319	29	derisi	derisi	VERB
fnp-2627	319	30	,	,	PUNCT
fnp-2627	319	31	j.l	j.l	PROPN
fnp-2627	319	32	.	.	PROPN
fnp-2627	319	33	,	,	PUNCT
fnp-2627	319	34	wilson	wilson	PROPN
fnp-2627	319	35	,	,	PUNCT
fnp-2627	319	36	m.r	m.r	PROPN
fnp-2627	319	37	.	.	PROPN
fnp-2627	319	38	,	,	PUNCT
fnp-2627	319	39	kriegstein	kriegstein	PROPN
fnp-2627	319	40	,	,	PUNCT
fnp-2627	319	41	a.r	a.r	PROPN
fnp-2627	319	42	.	.	PROPN
fnp-2627	319	43	,	,	PUNCT
fnp-2627	319	44	bollen	bollen	PROPN
fnp-2627	319	45	,	,	PUNCT
fnp-2627	319	46	a.w	a.w	PROPN
fnp-2627	319	47	.	.	PROPN
fnp-2627	319	48	,	,	PUNCT
fnp-2627	319	49	et	et	PROPN
fnp-2627	319	50	al	al	PROPN
fnp-2627	319	51	.	.	PROPN
fnp-2627	320	1	(	(	PUNCT
fnp-2627	320	2	2019	2019	NUM
fnp-2627	320	3	)	)	PUNCT
fnp-2627	320	4	.	.	PUNCT
fnp-2627	321	1	neuroglial	neuroglial	ADJ
fnp-2627	321	2	stem	stem	NOUN
fnp-2627	321	3	cell	cell	NOUN
fnp-2627	321	4	-	-	PUNCT
fnp-2627	321	5	derived	derive	VERB
fnp-2627	321	6	inflammatory	inflammatory	ADJ
fnp-2627	321	7	pseudotumor	pseudotumor	NOUN
fnp-2627	321	8	(	(	PUNCT
fnp-2627	321	9	n	n	CCONJ
fnp-2627	321	10	-	-	PUNCT
fnp-2627	321	11	scipt	scipt	NOUN
fnp-2627	321	12	):	):	PUNCT
fnp-2627	321	13	clinicopathologic	clinicopathologic	ADJ
fnp-2627	321	14	characterization	characterization	NOUN
fnp-2627	321	15	of	of	ADP
fnp-2627	321	16	a	a	DET
fnp-2627	321	17	novel	novel	ADJ
fnp-2627	321	18	lesion	lesion	NOUN
fnp-2627	321	19	of	of	ADP
fnp-2627	321	20	the	the	DET
fnp-2627	321	21	lumbosacral	lumbosacral	ADJ
fnp-2627	321	22	spinal	spinal	NOUN
fnp-2627	321	23	cord	cord	NOUN
fnp-2627	321	24	and	and	CCONJ
fnp-2627	321	25	nerve	nerve	NOUN
fnp-2627	321	26	roots	root	NOUN
fnp-2627	321	27	following	follow	VERB
fnp-2627	321	28	intrathecal	intrathecal	ADJ
fnp-2627	321	29	allogeneic	allogeneic	ADJ
fnp-2627	321	30	stem	stem	NOUN
fnp-2627	321	31	cell	cell	NOUN
fnp-2627	321	32	intervention	intervention	NOUN
fnp-2627	321	33	.	.	PUNCT
fnp-2627	322	1	acta	acta	PROPN
fnp-2627	322	2	neuropathol	neuropathol	PROPN
fnp-2627	322	3	138	138	NUM
fnp-2627	322	4	,	,	PUNCT
fnp-2627	322	5	1103	1103	NUM
fnp-2627	322	6	-	-	SYM
fnp-2627	322	7	1106	1106	NUM
fnp-2627	322	8	.	.	PUNCT
fnp-2627	323	1	tanboon	tanboon	PROPN
fnp-2627	323	2	,	,	PUNCT
fnp-2627	323	3	j.	j.	PROPN
fnp-2627	323	4	,	,	PUNCT
fnp-2627	323	5	and	and	CCONJ
fnp-2627	323	6	nishino	nishino	PROPN
fnp-2627	323	7	,	,	PUNCT
fnp-2627	323	8	i.	i.	PROPN
fnp-2627	323	9	(	(	PUNCT
fnp-2627	323	10	2019	2019	NUM
fnp-2627	323	11	)	)	PUNCT
fnp-2627	323	12	.	.	PUNCT
fnp-2627	324	1	classification	classification	NOUN
fnp-2627	324	2	of	of	ADP
fnp-2627	324	3	idiopathic	idiopathic	ADJ
fnp-2627	324	4	inflammatory	inflammatory	ADJ
fnp-2627	324	5	myopathies	myopathy	NOUN
fnp-2627	324	6	:	:	PUNCT
fnp-2627	324	7	pathology	pathology	NOUN
fnp-2627	324	8	perspectives	perspective	NOUN
fnp-2627	324	9	.	.	PUNCT
fnp-2627	325	1	curr	curr	PROPN
fnp-2627	325	2	opin	opin	PROPN
fnp-2627	325	3	neurol	neurol	NOUN
fnp-2627	325	4	32	32	NUM
fnp-2627	325	5	,	,	PUNCT
fnp-2627	325	6	704	704	NUM
fnp-2627	325	7	-	-	SYM
fnp-2627	325	8	714	714	NUM
fnp-2627	325	9	.	.	PUNCT
fnp-2627	326	1	touat	touat	PROPN
fnp-2627	326	2	,	,	PUNCT
fnp-2627	326	3	m.	m.	NOUN
fnp-2627	326	4	,	,	PUNCT
fnp-2627	326	5	maisonobe	maisonobe	PROPN
fnp-2627	326	6	,	,	PUNCT
fnp-2627	326	7	t.	t.	PROPN
fnp-2627	326	8	,	,	PUNCT
fnp-2627	326	9	knauss	knauss	PROPN
fnp-2627	326	10	,	,	PUNCT
fnp-2627	326	11	s.	s.	PROPN
fnp-2627	326	12	,	,	PUNCT
fnp-2627	326	13	ben	ben	PROPN
fnp-2627	326	14	hadj	hadj	PROPN
fnp-2627	326	15	salem	salem	PROPN
fnp-2627	326	16	,	,	PUNCT
fnp-2627	326	17	o.	o.	PROPN
fnp-2627	326	18	,	,	PUNCT
fnp-2627	326	19	hervier	hervier	PROPN
fnp-2627	326	20	,	,	PUNCT
fnp-2627	326	21	b.	b.	PROPN
fnp-2627	326	22	,	,	PUNCT
fnp-2627	326	23	aure	aure	PROPN
fnp-2627	326	24	,	,	PUNCT
fnp-2627	326	25	k.	k.	PROPN
fnp-2627	326	26	,	,	PUNCT
fnp-2627	326	27	szwebel	szwebel	PROPN
fnp-2627	326	28	,	,	PUNCT
fnp-2627	326	29	t.a	t.a	PROPN
fnp-2627	326	30	.	.	PROPN
fnp-2627	326	31	,	,	PUNCT
fnp-2627	326	32	kramkimel	kramkimel	PROPN
fnp-2627	326	33	,	,	PUNCT
fnp-2627	326	34	n.	n.	NOUN
fnp-2627	326	35	,	,	PUNCT
fnp-2627	326	36	lethrosne	lethrosne	NOUN
fnp-2627	326	37	,	,	PUNCT
fnp-2627	326	38	c.	c.	PROPN
fnp-2627	326	39	,	,	PUNCT
fnp-2627	326	40	bruch	bruch	PROPN
fnp-2627	326	41	,	,	PUNCT
fnp-2627	326	42	j.f	j.f	PROPN
fnp-2627	326	43	.	.	PROPN
fnp-2627	326	44	,	,	PUNCT
fnp-2627	326	45	et	et	PROPN
fnp-2627	326	46	al	al	PROPN
fnp-2627	326	47	.	.	PUNCT
fnp-2627	326	48	(	(	PUNCT
fnp-2627	326	49	2018	2018	NUM
fnp-2627	326	50	)	)	PUNCT
fnp-2627	326	51	.	.	PUNCT
fnp-2627	327	1	immune	immune	ADJ
fnp-2627	327	2	checkpoint	checkpoint	NOUN
fnp-2627	327	3	inhibitor	inhibitor	NOUN
fnp-2627	327	4	-	-	PUNCT
fnp-2627	327	5	related	relate	VERB
fnp-2627	327	6	myositis	myositis	NOUN
fnp-2627	327	7	and	and	CCONJ
fnp-2627	327	8	myocarditis	myocarditis	NOUN
fnp-2627	327	9	in	in	ADP
fnp-2627	327	10	patients	patient	NOUN
fnp-2627	327	11	with	with	ADP
fnp-2627	327	12	cancer	cancer	NOUN
fnp-2627	327	13	.	.	PUNCT
fnp-2627	328	1	neurology	neurology	NOUN
fnp-2627	328	2	91	91	NUM
fnp-2627	328	3	,	,	PUNCT
fnp-2627	328	4	e985	e985	PROPN
fnp-2627	328	5	-	-	PUNCT
fnp-2627	328	6	e994	e994	PROPN
fnp-2627	328	7	.	.	PUNCT
fnp-2627	328	8	vill	vill	NOUN
fnp-2627	328	9	,	,	PUNCT
fnp-2627	328	10	k.	k.	PROPN
fnp-2627	328	11	,	,	PUNCT
fnp-2627	328	12	kolbel	kolbel	PROPN
fnp-2627	328	13	,	,	PUNCT
fnp-2627	328	14	h.	h.	PROPN
fnp-2627	328	15	,	,	PUNCT
fnp-2627	328	16	schwartz	schwartz	PROPN
fnp-2627	328	17	,	,	PUNCT
fnp-2627	328	18	o.	o.	PROPN
fnp-2627	328	19	,	,	PUNCT
fnp-2627	328	20	blaschek	blaschek	NOUN
fnp-2627	328	21	,	,	PUNCT
fnp-2627	328	22	a.	a.	NOUN
fnp-2627	328	23	,	,	PUNCT
fnp-2627	328	24	olgemoller	olgemoller	NOUN
fnp-2627	328	25	,	,	PUNCT
fnp-2627	328	26	b.	b.	PROPN
fnp-2627	328	27	,	,	PUNCT
fnp-2627	328	28	harms	harm	NOUN
fnp-2627	328	29	,	,	PUNCT
fnp-2627	328	30	e.	e.	PROPN
fnp-2627	328	31	,	,	PUNCT
fnp-2627	328	32	burggraf	burggraf	PROPN
fnp-2627	328	33	,	,	PUNCT
fnp-2627	328	34	s.	s.	PROPN
fnp-2627	328	35	,	,	PUNCT
fnp-2627	328	36	roschinger	roschinger	NOUN
fnp-2627	328	37	,	,	PUNCT
fnp-2627	328	38	w.	w.	PROPN
fnp-2627	328	39	,	,	PUNCT
fnp-2627	328	40	durner	durner	NOUN
fnp-2627	328	41	,	,	PUNCT
fnp-2627	328	42	j.	j.	PROPN
fnp-2627	328	43	,	,	PUNCT
fnp-2627	328	44	glaser	glaser	PROPN
fnp-2627	328	45	,	,	PUNCT
fnp-2627	328	46	d.	d.	PROPN
fnp-2627	328	47	,	,	PUNCT
fnp-2627	328	48	et	et	PROPN
fnp-2627	328	49	al	al	PROPN
fnp-2627	328	50	.	.	PROPN
fnp-2627	329	1	(	(	PUNCT
fnp-2627	329	2	2019	2019	NUM
fnp-2627	329	3	)	)	PUNCT
fnp-2627	329	4	.	.	PUNCT
fnp-2627	330	1	one	one	NUM
fnp-2627	330	2	year	year	NOUN
fnp-2627	330	3	of	of	ADP
fnp-2627	330	4	newborn	newborn	ADJ
fnp-2627	330	5	screening	screening	NOUN
fnp-2627	330	6	for	for	ADP
fnp-2627	330	7	sma	sma	NOUN
fnp-2627	330	8	results	result	NOUN
fnp-2627	330	9	of	of	ADP
fnp-2627	330	10	a	a	DET
fnp-2627	330	11	german	german	ADJ
fnp-2627	330	12	pilot	pilot	NOUN
fnp-2627	330	13	project	project	NOUN
fnp-2627	330	14	.	.	PUNCT
fnp-2627	331	1	j	j	PROPN
fnp-2627	331	2	neuromuscul	neuromuscul	PROPN
fnp-2627	331	3	dis	dis	PROPN
fnp-2627	331	4	6	6	NUM
fnp-2627	331	5	,	,	PUNCT
fnp-2627	331	6	503	503	NUM
fnp-2627	331	7	-	-	SYM
fnp-2627	331	8	515	515	NUM
fnp-2627	331	9	.	.	PUNCT
fnp-2627	332	1	villar	villar	ADJ
fnp-2627	332	2	-	-	PUNCT
fnp-2627	332	3	quiles	quile	NOUN
fnp-2627	332	4	,	,	PUNCT
fnp-2627	332	5	r.n	r.n	PROPN
fnp-2627	332	6	.	.	PROPN
fnp-2627	332	7	,	,	PUNCT
fnp-2627	332	8	catervi	catervi	PROPN
fnp-2627	332	9	,	,	PUNCT
fnp-2627	332	10	f.	f.	PROPN
fnp-2627	332	11	,	,	PUNCT
fnp-2627	332	12	cabet	cabet	PROPN
fnp-2627	332	13	,	,	PUNCT
fnp-2627	332	14	e.	e.	PROPN
fnp-2627	332	15	,	,	PUNCT
fnp-2627	332	16	juntas	juntas	PROPN
fnp-2627	332	17	-	-	PUNCT
fnp-2627	332	18	morales	morale	NOUN
fnp-2627	332	19	,	,	PUNCT
fnp-2627	332	20	r.	r.	PROPN
fnp-2627	332	21	,	,	PUNCT
fnp-2627	332	22	genetti	genetti	PROPN
fnp-2627	332	23	,	,	PUNCT
fnp-2627	332	24	c.a	c.a	PROPN
fnp-2627	332	25	.	.	PROPN
fnp-2627	332	26	,	,	PUNCT
fnp-2627	332	27	gidaro	gidaro	NOUN
fnp-2627	332	28	,	,	PUNCT
fnp-2627	332	29	t.	t.	PROPN
fnp-2627	332	30	,	,	PUNCT
fnp-2627	332	31	koparir	koparir	PROPN
fnp-2627	332	32	,	,	PUNCT
fnp-2627	332	33	a.	a.	NOUN
fnp-2627	332	34	,	,	PUNCT
fnp-2627	332	35	yuksel	yuksel	ADJ
fnp-2627	332	36	,	,	PUNCT
fnp-2627	332	37	a.	a.	PROPN
fnp-2627	332	38	,	,	PUNCT
fnp-2627	332	39	coppens	coppen	NOUN
fnp-2627	332	40	,	,	PUNCT
fnp-2627	332	41	s.	s.	PROPN
fnp-2627	332	42	,	,	PUNCT
fnp-2627	332	43	deconinck	deconinck	NOUN
fnp-2627	332	44	,	,	PUNCT
fnp-2627	332	45	n.	n.	NOUN
fnp-2627	332	46	,	,	PUNCT
fnp-2627	332	47	et	et	PROPN
fnp-2627	332	48	al	al	PROPN
fnp-2627	332	49	.	.	PROPN
fnp-2627	332	50	(	(	PUNCT
fnp-2627	332	51	2019	2019	NUM
fnp-2627	332	52	)	)	PUNCT
fnp-2627	332	53	.	.	PUNCT
fnp-2627	333	1	asc-1	asc-1	PUNCT
fnp-2627	333	2	is	be	AUX
fnp-2627	333	3	a	a	DET
fnp-2627	333	4	cell	cell	NOUN
fnp-2627	333	5	cycle	cycle	NOUN
fnp-2627	333	6	regulator	regulator	NOUN
fnp-2627	333	7	associated	associate	VERB
fnp-2627	333	8	with	with	ADP
fnp-2627	333	9	severe	severe	ADJ
fnp-2627	333	10	and	and	CCONJ
fnp-2627	333	11	mild	mild	ADJ
fnp-2627	333	12	forms	form	NOUN
fnp-2627	333	13	of	of	ADP
fnp-2627	333	14	myopathy	myopathy	ADJ
fnp-2627	333	15	.	.	PUNCT
fnp-2627	334	1	ann	ann	PROPN
fnp-2627	334	2	neurol	neurol	PROPN
fnp-2627	334	3	,	,	PUNCT
fnp-2627	334	4	epub	epub	NOUN
fnp-2627	334	5	ahead	ahead	ADV
fnp-2627	334	6	of	of	ADP
fnp-2627	334	7	print	print	NOUN
fnp-2627	334	8	.	.	PUNCT
fnp-2627	335	1	vissing	visse	VERB
fnp-2627	335	2	,	,	PUNCT
fnp-2627	335	3	j.	j.	PROPN
fnp-2627	335	4	,	,	PUNCT
fnp-2627	335	5	johnson	johnson	PROPN
fnp-2627	335	6	,	,	PUNCT
fnp-2627	335	7	k.	k.	PROPN
fnp-2627	335	8	,	,	PUNCT
fnp-2627	335	9	topf	topf	VERB
fnp-2627	335	10	,	,	PUNCT
fnp-2627	335	11	a.	a.	NOUN
fnp-2627	335	12	,	,	PUNCT
fnp-2627	335	13	nafissi	nafissi	ADJ
fnp-2627	335	14	,	,	PUNCT
fnp-2627	335	15	s.	s.	PROPN
fnp-2627	335	16	,	,	PUNCT
fnp-2627	335	17	diaz	diaz	PROPN
fnp-2627	335	18	-	-	PUNCT
fnp-2627	335	19	manera	manera	PROPN
fnp-2627	335	20	,	,	PUNCT
fnp-2627	335	21	j.	j.	PROPN
fnp-2627	335	22	,	,	PUNCT
fnp-2627	335	23	french	french	PROPN
fnp-2627	335	24	,	,	PUNCT
fnp-2627	335	25	v.m	v.m	PROPN
fnp-2627	335	26	.	.	PROPN
fnp-2627	335	27	,	,	PUNCT
fnp-2627	335	28	schindler	schindler	PROPN
fnp-2627	335	29	,	,	PUNCT
fnp-2627	335	30	r.f	r.f	PROPN
fnp-2627	335	31	.	.	PROPN
fnp-2627	335	32	,	,	PUNCT
fnp-2627	335	33	sarathchandra	sarathchandra	PROPN
fnp-2627	335	34	,	,	PUNCT
fnp-2627	335	35	p.	p.	PROPN
fnp-2627	335	36	,	,	PUNCT
fnp-2627	335	37	lokken	lokken	PROPN
fnp-2627	335	38	,	,	PUNCT
fnp-2627	335	39	n.	n.	NOUN
fnp-2627	335	40	,	,	PUNCT
fnp-2627	335	41	rinne	rinne	PROPN
fnp-2627	335	42	,	,	PUNCT
fnp-2627	335	43	s.	s.	PROPN
fnp-2627	335	44	,	,	PUNCT
fnp-2627	335	45	et	et	PROPN
fnp-2627	335	46	al	al	PROPN
fnp-2627	335	47	.	.	PROPN
fnp-2627	336	1	(	(	PUNCT
fnp-2627	336	2	2019	2019	NUM
fnp-2627	336	3	)	)	PUNCT
fnp-2627	336	4	.	.	PUNCT
fnp-2627	337	1	popdc3	popdc3	NOUN
fnp-2627	337	2	gene	gene	NOUN
fnp-2627	337	3	variants	variant	NOUN
fnp-2627	337	4	associate	associate	VERB
fnp-2627	337	5	with	with	ADP
fnp-2627	337	6	a	a	DET
fnp-2627	337	7	new	new	ADJ
fnp-2627	337	8	form	form	NOUN
fnp-2627	337	9	of	of	ADP
fnp-2627	337	10	limb	limb	NOUN
fnp-2627	337	11	girdle	girdle	NOUN
fnp-2627	337	12	muscular	muscular	ADJ
fnp-2627	337	13	dystrophy	dystrophy	NOUN
fnp-2627	337	14	.	.	PUNCT
fnp-2627	338	1	ann	ann	PROPN
fnp-2627	338	2	neurol	neurol	PROPN
fnp-2627	338	3	86	86	NUM
fnp-2627	338	4	,	,	PUNCT
fnp-2627	338	5	832	832	NUM
fnp-2627	338	6	-	-	SYM
fnp-2627	338	7	843	843	NUM
fnp-2627	338	8	.	.	PUNCT
fnp-2627	339	1	vita	vita	PROPN
fnp-2627	339	2	,	,	PUNCT
fnp-2627	339	3	g.	g.	PROPN
fnp-2627	339	4	,	,	PUNCT
fnp-2627	339	5	vita	vita	PROPN
fnp-2627	339	6	,	,	PUNCT
fnp-2627	339	7	g.l	g.l	PROPN
fnp-2627	339	8	.	.	PROPN
fnp-2627	339	9	,	,	PUNCT
fnp-2627	339	10	musumeci	musumeci	PROPN
fnp-2627	339	11	,	,	PUNCT
fnp-2627	339	12	o.	o.	PROPN
fnp-2627	339	13	,	,	PUNCT
fnp-2627	339	14	rodolico	rodolico	PROPN
fnp-2627	339	15	,	,	PUNCT
fnp-2627	339	16	c.	c.	PROPN
fnp-2627	339	17	,	,	PUNCT
fnp-2627	339	18	and	and	CCONJ
fnp-2627	339	19	messina	messina	PROPN
fnp-2627	339	20	,	,	PUNCT
fnp-2627	339	21	s.	s.	PROPN
fnp-2627	339	22	(	(	PUNCT
fnp-2627	339	23	2019	2019	NUM
fnp-2627	339	24	)	)	PUNCT
fnp-2627	339	25	.	.	PUNCT
fnp-2627	340	1	genetic	genetic	ADJ
fnp-2627	340	2	neuromuscular	neuromuscular	ADJ
fnp-2627	340	3	disorders	disorder	NOUN
fnp-2627	340	4	:	:	PUNCT
fnp-2627	340	5	living	live	VERB
fnp-2627	340	6	the	the	DET
fnp-2627	340	7	era	era	NOUN
fnp-2627	340	8	of	of	ADP
fnp-2627	340	9	a	a	DET
fnp-2627	340	10	therapeutic	therapeutic	ADJ
fnp-2627	340	11	revolution	revolution	NOUN
fnp-2627	340	12	.	.	PUNCT
fnp-2627	341	1	part	part	NOUN
fnp-2627	341	2	2	2	NUM
fnp-2627	341	3	:	:	PUNCT
fnp-2627	341	4	diseases	disease	NOUN
fnp-2627	341	5	of	of	ADP
fnp-2627	341	6	motor	motor	NOUN
fnp-2627	341	7	neuron	neuron	NOUN
fnp-2627	341	8	and	and	CCONJ
fnp-2627	341	9	skeletal	skeletal	ADJ
fnp-2627	341	10	muscle	muscle	NOUN
fnp-2627	341	11	.	.	PUNCT
fnp-2627	342	1	neurol	neurol	PROPN
fnp-2627	342	2	sci	sci	PROPN
fnp-2627	342	3	40	40	NUM
fnp-2627	342	4	,	,	PUNCT
fnp-2627	342	5	671	671	NUM
fnp-2627	342	6	-	-	SYM
fnp-2627	342	7	681	681	NUM
fnp-2627	342	8	.	.	PUNCT
fnp-2627	343	1	copyright	copyright	NOUN
fnp-2627	343	2	:	:	PUNCT
fnp-2627	343	3	©	©	PROPN
fnp-2627	343	4	2020	2020	NUM
fnp-2627	343	5	the	the	DET
fnp-2627	343	6	author(s	author(s	NOUN
fnp-2627	343	7	)	)	PUNCT
fnp-2627	343	8	.	.	PUNCT
fnp-2627	344	1	this	this	PRON
fnp-2627	344	2	is	be	AUX
fnp-2627	344	3	an	an	DET
fnp-2627	344	4	open	open	ADJ
fnp-2627	344	5	access	access	NOUN
fnp-2627	344	6	article	article	NOUN
fnp-2627	344	7	distributed	distribute	VERB
fnp-2627	344	8	under	under	ADP
fnp-2627	344	9	the	the	DET
fnp-2627	344	10	terms	term	NOUN
fnp-2627	344	11	of	of	ADP
fnp-2627	344	12	the	the	DET
fnp-2627	344	13	creative	creative	ADJ
fnp-2627	344	14	commons	common	NOUN
fnp-2627	344	15	attribution	attribution	NOUN
fnp-2627	344	16	4.0	4.0	NUM
fnp-2627	344	17	international	international	ADJ
fnp-2627	344	18	license	license	NOUN
fnp-2627	344	19	(	(	PUNCT
fnp-2627	344	20	https://creativecommons.org/licenses/by/4.0/	https://creativecommons.org/licenses/by/4.0/	PROPN
fnp-2627	344	21	)	)	PUNCT
fnp-2627	344	22	,	,	PUNCT
fnp-2627	344	23	which	which	PRON
fnp-2627	344	24	permits	permit	VERB
fnp-2627	344	25	unrestricted	unrestricted	ADJ
fnp-2627	344	26	use	use	NOUN
fnp-2627	344	27	,	,	PUNCT
fnp-2627	344	28	distribution	distribution	NOUN
fnp-2627	344	29	,	,	PUNCT
fnp-2627	344	30	and	and	CCONJ
fnp-2627	344	31	reproduction	reproduction	NOUN
fnp-2627	344	32	in	in	ADP
fnp-2627	344	33	any	any	DET
fnp-2627	344	34	medium	medium	NOUN
fnp-2627	344	35	,	,	PUNCT
fnp-2627	344	36	provided	provide	VERB
fnp-2627	344	37	the	the	DET
fnp-2627	344	38	original	original	ADJ
fnp-2627	344	39	author	author	NOUN
fnp-2627	344	40	and	and	CCONJ
fnp-2627	344	41	source	source	NOUN
fnp-2627	344	42	are	be	AUX
fnp-2627	344	43	credited	credit	VERB
fnp-2627	344	44	,	,	PUNCT
fnp-2627	344	45	a	a	DET
fnp-2627	344	46	link	link	NOUN
fnp-2627	344	47	to	to	ADP
fnp-2627	344	48	the	the	DET
fnp-2627	344	49	creative	creative	ADJ
fnp-2627	344	50	commons	common	NOUN
fnp-2627	344	51	license	license	NOUN
fnp-2627	344	52	is	be	AUX
fnp-2627	344	53	provided	provide	VERB
fnp-2627	344	54	,	,	PUNCT
fnp-2627	344	55	and	and	CCONJ
fnp-2627	344	56	any	any	DET
fnp-2627	344	57	changes	change	NOUN
fnp-2627	344	58	are	be	AUX
fnp-2627	344	59	indicated	indicate	VERB
fnp-2627	344	60	.	.	PUNCT
fnp-2627	345	1	the	the	DET
fnp-2627	345	2	creative	creative	ADJ
fnp-2627	345	3	commons	common	NOUN
fnp-2627	345	4	public	public	ADJ
fnp-2627	345	5	domain	domain	NOUN
fnp-2627	345	6	dedication	dedication	NOUN
fnp-2627	345	7	waiver	waiver	NOUN
fnp-2627	345	8	(	(	PUNCT
fnp-2627	345	9	https://creativecommons.org/publicdomain/zero/1.0/	https://creativecommons.org/publicdomain/zero/1.0/	PROPN
fnp-2627	345	10	)	)	PUNCT
fnp-2627	345	11	applies	apply	VERB
fnp-2627	345	12	to	to	ADP
fnp-2627	345	13	the	the	DET
fnp-2627	345	14	data	datum	NOUN
fnp-2627	345	15	made	make	VERB
fnp-2627	345	16	available	available	ADJ
fnp-2627	345	17	in	in	ADP
fnp-2627	345	18	this	this	DET
fnp-2627	345	19	article	article	NOUN
fnp-2627	345	20	,	,	PUNCT
fnp-2627	345	21	unless	unless	SCONJ
fnp-2627	345	22	otherwise	otherwise	ADV
fnp-2627	345	23	stated	state	VERB
fnp-2627	345	24	.	.	PUNCT